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Abstract 
Secretory phospholipase A2 group (sPLA2) enzymes hydrolyze the sn-2 ester bond of 
phospholipids, producing lysophospholipids and free fatty acids. SPLA2s have been 
identified as biomarkers of atherosclerosis in observational and animal studies.  
The aim of this study was to identify functional variants in PLA2G2A and, to a lesser extent, 
PLA2G5 and PLA2G10 (sPLA2 encoding genes). These variants could then serve as tools 
to examine their contribution to sPLA2-activity, since this is a composite measure of sPLA2-
IIA,-V and –X, and associations with CHD risk/CHD traits.   
Two PLA2G2A SNPs were identified as being associated with sPLA2-IIA mass/sPLA2 
activity. Luciferase assays, EMSA and RNA expression were used to examine their allelic 
differences. Rs3767221G showed ∼55% lower luciferase activity compared to rs3767221T 
(p = 1.22×10-35), and stronger EMSA binding of a nuclear protein compared to the T-allele. 
For rs11573156 C >G there were no luciferase or EMSA allelic differences. For rs11573156 
there was no differential allelic lymphocyte cDNA expression for exons 5-6, but G-allele 
carriers (n = 7) showed a trend to lower exon 1-2 expression versus CC individuals. In the 
ASAP study (n = 223), a SNP acting as a proxy for rs11573156 (r2 = 0.91) on the expression 
array showed allelic difference of ∼25% in liver expression of total PLA2G2A (1.67×10-17). 
However, exon 2 specific expression was greatly reduced (4.5×10-5) compared to exons 3-6 
(10-10 to 10-20), implying allele-specific exon 2 skipping as the functional basis of rs11573156 
association. Rs11573156 was used as a genetic tool in a large Mendelian randomisation 
(MR) collaboration to establish the causality of sPLA2-IIA for CHD. While the sPLA2-IIA 
mass was strongly associated with CHD events, rs11573156 was not associated with 
outcome.  Similar approaches were taken for studying PLA2G5 and PLA2G10, using eQTL 
data and smaller meta-analyses. 
Both PLA2G2A SNPs are functional. Using rs11573156 as a genetic instrument, MR 
suggested that sPLA2-IIA is not causally associated with CHD. Based on initial meta-
analyses, neither PLA2G5 nor PLA2G10 appeared to be associated significantly with sPLA2 
activity in cardiovascular related tissues. This conclusion is consistent with the outcome of 
the recent Phase III trial for the sPLA2 inhibitor varespladib, which was terminated due to 
lack of efficacy since the drug was shown to be having no significant effect on the reduction 
of secondary cardiovascular events. 
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CHAPTER 1 
INTRODUCTION 
1. Cardiovascular disease: A Worldwide Problem
Cardiovascular disease is an umbrella term for all diseases of the heart and vascular 
system, including coronary heart disease (CHD) and stroke. It is a well reported and 
supported fact that cardiovascular diseases are currently the number one cause of mortality 
globally, since CVDs are now one of the biggest medical problems in low income 
(developing economy) countries (Figure 1.1) as well as in high income (developed economy) 
countries (Figure 1.2) (WHO; Media Centre, 
http://www.who.int/mediacentre/factsheets/fs317/en/). In 2008 a World Health Organisation 
(WHO) study showed that 17.3 million deaths worldwide could be attributed to CVDs, and a 
third of these were specifically identified as being caused by CHD (WHO; Media Centre, 
http://www.who.int/mediacentre/factsheets/fs317/en/). 
In order to reduce the high mortality rates attributed to CHD it is important to consider 
all that we currently know about the disease, its prevention and its treatment and then to 
attempt to find novel contributing factors that could be used to improve on this current 
knowledge. This chapter will introduce what is already known about CHD and its known risk 
factors and then discuss what is known about the novel risk factor, secretory phospholipase 
A2. The purpose of the rest of the thesis is to investigate what is currently unknown about 
secretory phospholipase activity, expression and the true causality of its association with 
CHD.  
1.1. Coronary Heart Disease and Atherosclerosis 
Coronary heart disease (also known as coronary artery disease) is defined by a 
stenosis of the vessels that supply blood and oxygen to the heart, leading to tissue necrosis 
and cardiac events such as myocardial infarction. Stenosis is usually caused by an 
accumulation of plaque in the arteries. This is commonly known as atherosclerosis. When 
atherosclerosis occurs in the coronary arteries it can lead to CHD and is the underlying 
cause of CHD in most instances. The plaque is mostly composed of fatty material, 
leukocytes and other cell debris (which is explained in more detail in 1.2.2) and the build-up 
of plaque causes the walls of the coronary arteries to stiffen and narrow, preventing blood 
from flowing efficiently (Weber and Noels 2011). 
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Figure 1.1. Graphic to show the top 10 causes of mortality in low income countries in 2008. Graphic 
and data according to the World Health Organisation- Heart disease is the biggest cause of death 
(www.who.int)  
Figure 1.2. Graphic to show the top 10 causes of mortality in high income countries in 2008. Graphic 
and data according to the World Health Organisation- Heart disease is the biggest cause of death 
(www.who.int)  
World Health Organisation 10 Leading Causes of Death (2008) Low Income Countries 
World Health Organisation 10 Leading Causes of Death (2008) High Income Countries 
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reprinted with permission.
reprinted with permission.
1.2. Pathology of Atherosclerosis 
1.2.1. The Morphology of a Normal Artery 
Atherosclerosis is a disease of the arteries. Therefore in order to understand the 
development of an atherosclerotic plaque it is important to first examine the structure of a 
normal artery.  A normal artery is composed of several distinct layers surrounding the lumen, 
each incorporating different cell types (Figure 1.3.). The inner layer of the artery is the intima. 
The intima is separated from the lumen by a thin layer of endothelial cells known as the 
endothelium and on the peripheral boundary by a sheet of elastic fibres known as the 
internal elastic lamina. The intima is a relatively thin layer (the normal intima size has been 
exaggerated for better visualisation in Figure 1.3) comprised of extracellular matrix 
connective tissues, a composition largely made up of collagen fibres and proteoglycans, 
which often have a role in the trapping and stability of proteins within the layer. The middle 
layer, or media, is composed entirely of smooth muscle cells, which maintain local blood 
pressure and control the volume of the vessel. This layer is thicker in arteries than it is in 
veins as arteries are carrying blood pumped away from the heart towards the organs and 
must therefore be able to stand the higher pressure. The outer layer of the normal artery is 
the adventitia. This is a mixture of connective tissues, fibroblasts and smooth muscle cells 
(Lusis 2000).   
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Figure 1.3. The morphology of the normal artery (Lusis 2000). The size of the intima has been 
exaggerated for better visualization. The adventitia is the outermost layer composed of connective 
tissue, fibroblasts and smooth muscle cells. The middle layer is the media and is made up of smooth 
muscle cells. The media contributes to blood pressure regulation. The inner layer is the intima, which 
contains an internal elastic lamina and is lined at the innermost boundary by a thin layer of epithelial 
cells, which are joined by tight junctions, which help to regulate what passes from the lumen into the 
arterial wall and vice versa. Blood flows through the centre of the vessel in the lumen. 
1.2.2. Development of Atherosclerosis 
Atherosclerosis is a multifactorial disease that progresses over multiple stages and is 
defined by an accumulation of lipid and fibrous matter in the large arteries. Onset of 
atherosclerosis is triggered by several complex signal cascades including the inflammatory 
pathway, endothelial function, platelet activation, lipid metabolism and oxidative stress. 
These pathways operate independently of one another, but also have the ability to ‘cross-
talk,’ providing positive feedback for each other and driving plaque formation (Davies and 
Woolf 1993; Tegos, Kalodiki et al. 2001; Mudau, Genis et al. 2012). These pathways and 
their regulatory mechanisms are discussed below. The family of secretory phospholipase 
A2s are thought to increase the risk of atherosclerosis as part of an inflammatory cascade as 
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well as by contributing to the disruption of the lipoprotein metabolism pathway (1.5.7), 
though it is debatable whether these actions are causal for atherogenesis or as a result of it. 
The Step-Wise Progression of an Atherosclerotic Plaque 
There are four main stages of atherosclerotic plaque progression; Initiation, LDL 
modification and accumulation, foam cell formation and necrotic core formation leading to 
plaque rupture. These stages are described in detail below (Ross 1999).  
Plaque Initiation by Endothelial Dysfunction 
The endothelium plays a major role in the regulation of vascular homeostasis. The 
endothelium has several important functions including balancing vasoconstriction and 
vasodilation and the homeostasis of smooth muscle cell proliferation and migration. It also 
plays a role in fibrinolysis and thrombogenesis (Cannon 1998; Mudau, Genis et al. 2012).  
Endothelium dysfunction usually refers to an interruption in the synthesis or release 
of nitric oxide (NO) which is constitutively synthesised by the endothelium and has a wide 
range of biological properties that make it the ideal mechanism by which the endothelium 
can control both vascular homeostasis and anti-thrombosis of platelets (Cannon 1998; 
Mudau, Genis et al. 2012). Disruption of any of the endothelial functions can trigger 
processes that are directly related to an increase in atherosclerosis. Thus, disruption to the 
endothelium is likely to induce the onset of atherosclerosis (Sitia, Tomasoni et al. 2010).  
There are several chemical and mechanical changes within the blood flow in the 
vessel that can contribute to atherosclerosis development by endothelial dysfunction (1.3) 
(Sitia, Tomasoni et al. 2010), including an increase in low density lipoprotein (LDL) 
cholesterol, LDL modifications, hypertension, diabetes, the introduction of free radicals 
through cigarette smoking, genetic variations, increased homocysteine concentrations and 
infection. All of these potential causes have the ability to elicit an inflammatory response and 
the ‘injury’ to the endothelium promotes atherogenesis since the endothelium becomes more 
adhesive for leukocytes and platelets, more permeable and produces further growth factors 
and cytokines, which are known procoagulant molecules and important regulators of 
inflammation (Luscher and Barton 1997; Ross 1999; Sitia, Tomasoni et al. 2010).  
Since endothelial dysfunction tends to induce an inflammatory response and the 
onset of atherosclerosis, atherosclerosis is considered to be an inflammatory disease (Libby 
1995; Hansson 2009) and this is apparent at the initiation of plaque development. Increased 
inflammatory mediators are produced by endothelial injury as well as increased platelet and 
leukocyte aggregation. Platelets secrete chemokines and cytokines, which are known 
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inflammatory mediators and can be activated by secretions from the vascular wall, creating 
feedback loops that can interfere with normal vascular regulation (Lusis 2000; Langer and 
Gawaz 2008; Zhang 2008). This inflammatory activation of endothelial cells leads to 
proatherogenic cells and proinflammatory mediators such as intracellular and vascular cell 
adhesion molecules, IL1-β, TNF-α and the acute phase protein C-reactive protein (CRP) to 
be recruited and secreted (Lusis 2000; Langer and Gawaz 2008; Zhang 2008). Additional 
inflammatory mediators, such as sPLA2, may also be involved in the regulation of these 
signal cascades. If prolonged, this inflammatory activation of endothelial cells (leading to 
proatherogenic cells and proinflammatory mediators) will initiate the development of 
cholesterol-rich macrophages, known as foam cells, which is a primary stage of plaque 
formation (Lusis 2000; Langer and Gawaz 2008; Zhang 2008) and continues throughout the 
development of the plaque. The earliest atherosclerotic lesions can be seen to develop in 
humans within the first decade of life. At this point the lesions are known as ‘fatty streaks’ 
and are not yet of clinical relevance. These early fatty streaks are distinguished by high 
smooth muscle cell proliferation and migration towards the intima as well as increased 
collagen synthesis (Figure 1.4A) and they appear subendothelially (Zhang 2008). 
Development of the Plaque: LDL Accumulation and Modification 
Low density lipoprotein (LDL) is the major transporter of cholesterol in humans and 
delivers cholesterol to the peripheral cells of the body (Steinberg 1987). In circulation, LDL 
has the ability to diffuse passively through endothelial cell tight junctions into the intima. 
Normally these LDL particles are metabolised and do not to accumulate in the vessel wall 
(Brown and Goldstein 1986; Brown and Goldstein 1997; Lusis, Mar et al. 2004). However, 
when there is an unusually high level of LDL in the circulation or endothelial dysfunction 
increases LDL permeability, both transportation and retention of LDL in the vessel wall seem 
to increase (Lusis 2000). LDL retention in the intima is further increased by LDL 
modifications including oxidation (Berliner and Heinecke 1996; Badimon, Storey et al. 2011). 
The increase in modified LDL and inflammatory mediators attracts monocytes to first adhere 
to the endothelium in these areas and then traverse the vessel wall to enter the intima 
(Figure 1.4B) (Pentikainen, Oorni et al. 2000; Hansson 2009). 
Foam Cell Formation 
Once monocytes are induced to enter the vessel wall by the increase in modified LDL 
and inflammatory mediators they then differentiate into macrophages, which form foam cells 
by cellular uptake of atherogenic lipoproteins. These lipoproteins are classified as different 
chemical modifications of ApoB containing lipoproteins, such as lipoprotein(a), small dense 
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LDL (sd-LDL), oxidised LDL (ox-LDL) and enzymatically modified LDL (Orso, Grandl et al. 
2011). 
 Macrophages are classified as foam cells when they are engorged with lipid 
droplets, which has been shown experimentally to be due to enzyme modified LDL loading 
of macrophages and, additionally, ox-LDL loading of macrophages. This forms lipid laden 
foam cells and these foam cells play an important role in the synthesis and progression of 
atherosclerotic plaques (Orso, Grandl et al. 2011). Secretory phospholipases have been 
shown previously to interact with LDL to produce enzyme modified LDL (sd-LDL) (Hurt-
Camejo, Camejo et al. 2001). Some secretory phospholipases have also been shown to 
have an increased affinity for ox-LDL binding, resulting in further modifications to LDL 
particles (Wootton, Arora et al. 2007; Blache, Gautier et al. 2012). Therefore secretory 
phospholipases appear to be strong candidates to play a role in atherosclerosis progression 
(1.5.7).     
Plaque progression: Necrotic Core Formation and Plaque Rupture 
Initially the vessel copes with the formation of an atherosclerotic plaque by 
remodelling itself. Arteries can expand outwards while maintaining the size of the lumen 
(Figure 1.4C). However this is a finite process and eventually the plaque will grow big 
enough to encroach upon the lumen and block circulation (Libby 1995). 
As atherosclerotic plaques increase in size they form fibrous caps (Ross 1999; 
Businaro, Tagliani et al. 2012), separating the plaque from the lumen. The larger plaques 
induce growth factor release from leukocytes and platelets (Ross 1999; Businaro, Tagliani et 
al. 2012), which stimulate smooth muscle cell proliferation and these cells form a fibrous cap 
over the plaque. The core of the lesion now includes foam cells, leukocytes and other cell 
debris- caused by a combination of necrosis and apoptosis (Ross 1999; Businaro, Tagliani 
et al. 2012). Mature plaques can be considered stable and unstable (Ross 1999; Businaro, 
Tagliani et al. 2012). Stable plaques are identified by their thick fibrous caps, making it 
unlikely that a rupture will occur and spill atherosclerotic matter into the vessel. Unstable 
plaques have thinner fibrous caps and are more prone to rupture. Plaque rupture releases 
tissue fragments including clot-promoting and platelet activating factors (Figure 1.4D). Post-
rupture thrombosis ensues and clots further narrow the vessel, reducing the flow of 
oxygenated blood able to flow through the vessel, thus increasing the likelihood of cardiac 
tissue death and a cardiac event. Additionally, each plaque develops its own micro-vessel 
network and haemorrhaging and clotting of these micro-vessels may contribute to vessel 
narrowing (Borissoff, Spronk et al. 2011). The process of atherosclerotic plaque formation to 
thrombus is shown below (Figure 1.4 a, b, c and d, taken from (Ross 1999)). 
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Figure 1.4. Atherosclerotic Plaque Progression (Reproduced with permission from Ross et al. 1999, 
NEJM, copyright Massachusetts Medical Society). a) Leukocyte and monocyte cells migrate from the 
lumen into the intima, forming a fatty streak. b) Foam cell formation by the uptake of LDL cholesterol/
modified-LDL/ox-LDL by macrophages, as well as smooth muscle cell stimulation and migration, T 
cell activation, platelet aggregation and the adherence and migration of leukocytes cause the lesion 
to increase in size and protrude into the vessel. c) Apoptosis and necrosis promote the formation of 
the necrotic core. Foam cells continue to form and the proliferation of smooth muscle cells forms the 
fibrous cap. d) If the fibrous cap thins the plaque will rupture inducing platelet activating factor and a 
thrombus forms, occluding the vessel and preventing blood flow. Secretory phospholipases are 
inflammatory enzymes and may contribute to plaque progression by contributing to the induction of 
leukocyte migration (a) and by foam cell formation by the modification of LDL particles (b). 
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1.3. Predicting the Risk of CHD 
1.3.1. Some known and Emerging Risk Factors of CHD 
CHD is a complex multivariate disease and a number of elements combine to trigger 
its onset. These elements are known as CHD risk factors and the concept of predicting the 
risk of CHD in an individual has evolved from numerous epidemiological studies of these 
factors over the past 50 years or so. One of the best known epidemiological studies is the 
Framingham Heart Study. In the 1960s the Framingham Heart Study showed several risk 
factors were key independent predictors of CHD and these included age, cigarette smoking, 
hypertension, increased LDL-cholesterol and decreased high density lipoprotein (HDL) 
cholesterol. Independent risk factors in combination provide a comprehensive risk profile for 
each individual. In the decades that followed the first Framingham results many other 
independent CHD risk factors have been established (Table 1.1) and subsequent studies 
have also identified a number of emerging risk factors that may have the potential to 
independently affect CHD risk. For example, a recent study used an in-depth proteomics 
platform on 800 women with CHD and 800 women with stroke who are enrolled in the 
Women’s Health Institute study. The outcome was the identification of the protein B2M as a 
potential risk marker for CHD (Prentice, Paczesny et al. 2010).  
Over the years there have also been many suspected risk factors that have been 
proved not to be independently contributing to the onset of CHD. These factors tend to be 
markers of CHD or a known independent risk factor for CHD rather than being directly 
causal (Graham 2006). 
Known causal risk factors can be genetic or environmental and both types interact to 
increase the risk of CHD. Independent risk factors and their pathways are excellent targets 
for the treatment and prevention of CHD. However, current available treatments have not 
reduced CHD mortality rates significantly enough and it is therefore necessary to continue 
investigating other contributing risk factors.  
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*Secretory phospholipase A2 is the factor under investigation for this thesis.
Table 1.1. An overview of some of the known and predicted risk factors for CHD. If evidence has 
proved causality or not for a risk factor it has been indicated with a tick for ‘causal’ or a cross for ‘non-
causal’ followed by a reference for evidence in each case. Those risk factors with no tick or cross are 
still currently under investigation. 
Risk Factor 
(Biological) Confirmed? Evidence 
Environment Related 
Diet F.B. Hu, International Encyclopaedia 
of Public Health; pages 181-190 
Smoking 
Leif Erhardt. Atherosclerosis: 2009; 
205, p23-32 
Lack of Exercise/Obesity (Duscha, Slentz et al. 2005) 
Gender Lloyd-Jones, DM; Larson, MG et al. 
LANCET: 1999; 353(9147) 89-92 
Lipids: 
Low density lipoprotein Brown & Goldstein, Science 1986, 
Martin et al. Med Clin North Am, 
1996(1): 13-26 
High density lipoprotein 
  (Inverse) 
Lewington S, Whitlock G, Clarke R, 
et al. Lancet. 2007; 370: 1829–1839 
Triglycerides Triglyceride Coronary Disease Genetics, 
Emerging Risk Factors et al. Lancet 
2010:  375(9726): 1634-1639 
Haemostasis/Thrombosis: 
Fibrinogen 
Reinhart WH. Vascular Medicine 
2003; 8(3), 211-216 
von Willebrand Factor 
Tissue plasminogen activator 
D-Dimer 
Plasminogen activator inhibitor 1 
Bart De Taeye, L Harris Smith, 
Douglas E Vaughan.  Current 
Opinions in Pharmacology., 2005; 
5(2) 149-154 
Oxidative Stress/Others: 
Homocysteine 
Veeranna V, Zalawadiya SK, Niraj A 
et al. J Am Coll Cardiol. 2011 Aug 
30;58(10):1025-33. 
Lipoprotein-associated phospholipase A2 The Lp-PLA2 Studies Collaboration, 
Lancet. 2010 May 1; 375(9725): 
1536–1544. 
Myeloperoxidase 
Family History Hawe E, Talmud PJ, Miller GJ, 
Humphries SE; Ann Hum Genet. 
2003 Mar;67(Pt 2):97-106. 
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1.3.2. Environmental Risk Factors 
 An example of an environmental risk factor for the progression of atherosclerosis is 
diet, since this is the source of exogenous cholesterol (1.4.5). In excess this cholesterol will 
cause a build-up of foam cells. Cholesterol, modified cholesterol particles and inflammatory 
cells, such as macrophages induce foam cell formation by accumulating in the artery along 
with calcium and fibrous tissue. Increased triglycerides in the diet can also exaggerate these 
plaque forming effects  (Bhupathiraju and Tucker 2011).  
Cigarette smoking is another highly publicised and well researched environmental 
risk factor for CHD as well as ischemic stroke, many cancers and other vascular diseases 
(Doll and Hill 1966; Ockene and Miller 1997). Smoking is strongly associated to risk of CHD 
and is one of the single most modifiable factors that, if ceased, can significantly reduce CHD 
risk (Gordon, Kannel et al. 1974). There are more than 250 by-products of smoking and 
these can affect CHD risk in different ways. For example, products of tobacco smoke are 
known to lead to increased endothelial dysfunction and activation of adhesion molecules, 
required for monocyte and platelet attachment (Lu and Creager 2004). Damage to the lining 
of the vessels caused by smoking increases the risk of atherosclerosis by narrowing the 
lumen. Some of the potential pathways thought to be mediated by cigarette smoking include; 
the deposition of free radicals directly from the smoke and the activation of endogenous 
sources of free radicals, such as uncoupled nitrous oxide synthase (NOS) and NADPH 
oxidase, which increases oxidative stress. Cigarette smoke also induces the activation of 
inflammatory mediators such as neutrophils, monocytes, platelets and T-cells, which in turn 
causes an increase in cytokines. Overall these interactions can cause inflammatory mediator 
activation (which may include inducing secretory phospholipase expression, though this 
theory would require experimental validation), vasomotor dysfunction, increased pro-
thrombotic and decreased fibrinolytic factors, an increase in leukocyte and platelet 
activation, increased lipid peroxidation and smooth muscle cell proliferation (Ambrose and 
Barua 2004).  
1.3.3. Factors with a Strong Genetic Component. 
Due to the complex nature of CHD and its underlying cause (atherosclerosis), many 
different biological processes are involved. Considering this, it is likely that in different 
individuals and in different populations, variations within the genes coding for the multiple 
implicated mechanisms contributing to CHD will have an impact on CHD risk. Evidence for 
this is seen in large scale investigations into the many ‘candidate genes’ and genetic loci 
identified as being involved in processes related to atherosclerosis (Yang 2012). These 
include genes related to inflammation (Humphries, Luong et al. 2001), lipid metabolism 
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(Lusis 2012) and thrombosis (Kathiresan, Yang et al. 2006). The volume of data produced 
about these associations is vast and too much to summarise completely here. However the 
potential role of genetics in atherosclerosis is discussed below. 
A family history of CHD is a strong independent risk factor for future CHD events 
(Hawe, Talmud et al. 2003) in both men and women (Boer, Feskens et al. 1999), especially 
in the case of early onset CHD (Pohjola-Sintonen, Rissanen et al. 1998). This has been 
supported by evidence from several observational studies (Pohjola-Sintonen, Rissanen et al. 
1998; Boer, Feskens et al. 1999; Hawe, Talmud et al. 2003) as well as twin studies 
comparing CHD risk between sets of monozygotic and dizygotic twins. Many heritable 
genetic factors have been identified and studied (Willer, Sanna et al. 2008) and more 
potential genetic traits are currently being discovered and investigated, such as those of the 
PLA2 genes, which are explored in this thesis. The sum of these genetic risks will give a 
strong indication of CHD susceptibility. Family history reflects the combination of heritable 
genetic factors and environmental factors. Environmental factors can enhance or supress 
the effects of genetic variants dependent on lifestyle choices and socio-economic status.  
The independent association of cardiovascular disease with hypertension has been 
known for some time and a meta-analysis of over a million people and 61 prospective 
studies confirms this association (Lewington, Clarke et al. 2002). The mechanisms by which 
hypertension increases the risk of these cardiovascular diseases include decreased NO, 
increased oxidative stress and changes in the renin angiotensin aldosterone system (RAAS) 
(Mason 2011). These pathways are regulated by gene interactions and this has been 
verified in gene studies. There have been several genetic variations identified as being 
involved in the RAAS system that have been studied in conjunction with their effects on CHD 
risk and show strong, independent associations (Jones, Dhamrait et al. 2003).  
Genetic studies like these help to identify potential pathways to stimulate or inhibit in 
order to prevent or treat CHD and similar research could be applied to novel biomarkers 
such as secretory phospholipase A2s. 
Inflammatory Markers of Atherosclerosis 
Since atherosclerosis is considered an inflammatory disorder, the inflammatory 
pathway plays a crucial role in atherogenesis and atherosclerotic plaque maintenance by the 
recruitment of inflammatory cells and mediators, such as monocyte- derived macrophages 
and T-lymphocytes, into the arterial intima (Figures 1.4B and 1.4C). Both epidemiological 
and clinical studies have validated a strong association between inflammatory markers 
related to the inflammatory cascades known to induce and maintain atherogenesis and CHD 
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events (Kuller and Meilahn 1996), (Willerson and Ridker 2004). Inflammatory markers are 
also potentially involved in disease progression and secondary events. Many inflammatory 
markers have been the subject of recent studies to identify associations with CHD events, 
for example, interleukins 6 and 18 (IL-6 and IL-18) the soluble CD-40 ligand, CRP, 
lipoprotein-associated phospholipase A2 (Lp-PLA2) and secretory phospholipase A2 
(sPLA2) (Corson 2009). Genetic studies of several of these and additional inflammatory 
markers have identified some polymorphisms associated with CHD (Andreotti, Porto et al. 
2002). Secretory phospholipase A2 is the inflammatory marker that is the focus of the 
following chapters of this thesis (1.5). 
 Despite the association between inflammation and atherosclerosis, the evidence for 
anti-inflammatories having a positive effect on coronary heart disease risk is mixed. For 
example, a study of the anti-inflammatory properties of statins has shown that their anti-
inflammatory effect seems to contribute to the overall CHD risk reduction that is reported 
(Jain and Ridker 2005) (although the majority of this effect is attributed to the lipid lowering 
effect of statins) (Jain and Ridker 2005). Contrary to this, an observational study of non-
aspirin, non-steroidal anti-inflammatory drugs (NANSAID) provided evidence to suggest that 
there is no cardio-protective effect provided by these drugs and they are therefore not good 
candidates to aid the prevention of CHD (Ray, Stein et al. 2002).This evidence is partly 
contradicted by a prospective case-control NANSAID study, which shows a reduction in the 
risk of MI for patients using NANSAIDs without aspirin. However this study further concludes 
NANSAIDs offer no further cardio-protection to patients already taking aspirin and 
recommends that further studies should be carried out (Kimmel, Berlin et al. 2004). Overall, 
the evidence from these studies suggests that new anti-inflammatory compounds need to be 
assessed on their individual properties and associations with atherosclerosis/CHD as well as 
in combination with known drugs to assess their true benefits. 
Diabetes and Glucose Control as a CHD Risk Factor 
Diabetes has a strong genetic component and there has been a steady interest in the 
study of the positive association between diabetes and coronary heart disease for some time 
(Ali, Narayan et al. 2010). The pre-dominant form of diabetes is Type 2 diabetes (T2D). 
Results from the Framingham Heart Study showed strong evidence that individuals with 
diabetes have a two to four fold increase in risk of coronary heart disease when compared 
with non-diabetics (Kannel and McGee 1979). Further to this, results are presented from a 
study by Moss et al. that show risk of mortality from cardiovascular diseases is higher in 
diabetics compared to a non-diabetic group (Moss, Klein et al. 1991). A first incident of a 
cardiovascular event, such as myocardial infarction (MI), is known to significantly increase 
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the risk of a second event, with the 10 year risk of CHD in a man increasing from 3.8% to 
approximately 20% (Pekkanen, Linn et al. 1990; Rosengren, Hagman et al. 1997). A study of 
patients with T2D with no previous coronary heart disease revealed that their risk of CHD 
was as high as a comparative group of non-diabetics with a previous cardiovascular event 
(Haffner, Lehto et al. 1998). 
 This strong association between CHD mortality rates and diabetes may indicate that 
the two diseases share common precursors; excess inflammation, insulin resistance and 
visceral adiposity and mechanistic processes such as renal dysfunction and oxidative stress 
are thought to be common to both diseases (Ali, Narayan et al. 2010). This may also mean 
that there is some cross-over between the genetic regulation of these diseases too (Singh, 
Singh et al. 2007). There has been some speculation that secretory phospholipases may 
play a role in Type II diabetes onset and/or progression and, if so, whether this association is 
a result of a causal role in atherosclerosis or due to a direct association with diabetes. These 
ideas require experimental verification (Rosenson and Hurt-Camejo 2012).   
1.4. Lipoprotein Metabolism 
 A significant body of evidence confirms that lipid abnormalities are central to the 
development of CHD and its associated disorders (Lusis 2000; Pentikainen, Oorni et al. 
2000). Lipid metabolism plays a key role in lipid regulation and therefore CHD initiation and 
progression (Davies and Woolf 1993; Aulchenko, Ripatti et al. 2009). 
Lipids are required in the body for cell membrane formation, hormone synthesis and 
bile acid production and the major classes of lipid are; cholesterol, triglycerides (TG) and 
phospholipids. Due to the hydrophobic nature of lipids they are not soluble in blood and must 
be packaged into lipid/protein complexes known as lipoproteins to allow them to travel 
efficiently in the circulation. (Nichols 1969; Lin, Mousa et al. 2010). 
1.4.1. Structure of Lipoproteins 
 Figure 1.5 illustrates a typical lipoprotein. The major common lipoprotein complexes 
are chylomicrons, very low density lipoproteins (VLDL), intermediate density lipoproteins 
(IDL), LDL and HDL.(Nichols 1969; Lin, Mousa et al. 2010). These five major classes of 
lipoprotein are based on size and density and include several subclasses. The largest class 
are the chylomicrons (CM), which are synthesised in the intestine and are approximately 75-
1200nm in diameter and have a density of less than 0.95g/ml. The second largest class is 
very low density lipoprotein (VLDL), which are synthesised in the liver with a mean diameter 
of 30-80nm and a density of 0.95-1.006g/ml. These two classes of lipoprotein are classified 
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as triglyceride rich and the catabolism of either group synthesises another class of 
lipoprotein, chylomicron remnants or intermediate density lipoprotein (IDL), which have a 
mean diameter of 25-35nm and a density of 1.006-1.019g/ml (Nichols 1969; Freedman, 
Otvos et al. 1998; Carmena, Duriez et al. 2004). Low density lipoprotein (LDL) is the next 
largest lipoprotein with a mean diameter of 18-25nm and is a product of VLDL catabolism in 
the liver. There are subclasses of LDL with different densities. These include; LDL I, which is 
1.02-1.03g/ml, LDL II is 1.03-1.04g/ml and LDL III, which is 1.04-1.06g/ml (Freedman, Otvos 
et al. 1998; Carmena, Duriez et al. 2004). The smallest lipoprotein is high density lipoprotein 
(HDL), which is synthesised in the liver and intestine. These particles have a mean diameter 
of 5-12nm and are split subclasses including, HDL 2, which is 1.063-1.125g/ml and HDL 3, 
which is 1.125-1.210g/ml (Freedman, Otvos et al. 1998; Carmena, Duriez et al. 2004). 
Together LDL and HDL are classified as cholesterol ester and phospholipid-rich lipoproteins 
(Nichols 1969).     
Figure 1.5. A circulating plasma lipoprotein. Lipoprotein particles are composed of phospholipids, free 
cholesterol, cholesteryl esters, TG and proteins from a class called apolipoproteins, which includes 
Apo A-I, A-II, A-IV, A-V, B48, B100, C-I, C-II, C-III and E (see 1.4.2.)  Each lipoprotein contains core 
triglycerides and cholesteryl esters. A phospholipid surface layer with interspersed cholesterol and 
one or more apolipoproteins.  
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1.4.2. Phospholipids 
The major groups of phospholipids are; glycerophospholipids and sphingolipids (van 
Meer, Voelker et al. 2008). Glycerophospholipids are considered the most abundant and are 
present in virtually all mammalian cell membranes (van Meer, Voelker et al. 2008). There are 
at least 10 different structures that are defined by the structure of their head groups 
(Hermansson, Hokynar et al. 2011). The major classes in mammalian cells are; 
phosphatidylcholine (PC), phosphatidylethanolamines (PE), phosphatidylinositols (PI), 
phosphatidylserines (PS) and cardiolipins (CL).  
1.4.3. Metabolism of Lipoproteins 
Three major pathways work to control lipoprotein metabolism (Figure 1.6). Each 
pathway works independently, but all three are connected in such a way that interference 
with one upsets the homeostasis and will ultimately affect the other pathways too. The three 
pathways are: the transport of dietary (exogenous) fat, the transport of hepatic (endogenous) 
fat and reverse cholesterol transport (Kwiterovich 2000).  
Figure 1.6. Lipoprotein Metabolism. An overview of the lipoprotein metabolism process illustrating 
both the endogenous (formed in the liver) and exogenous (dietary intake) pathways of lipid/lipoprotein 
synthesis as well as the removal of lipoproteins from circulation back to the liver for processing, by the 
reverse cholesterol transport pathway. ABCA1 = ATP-binding cassette transporter. ABCG1 = ATP-
binding cassette transporter sub-family G. SR-B1= scavenger receptor B1. PLTP= phospholipase 
transporter protein. CETP= cholesterol ester transfer protein. LDL= low density lipoprotein. HDL= high 
density lipoprotein. LDLR= LDL receptor. LCAT = Lecithin-cholesterol acyltransferase. Schematic 
reprinted with permission from (Rader and Daugherty 2008). 
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Transport of Dietary Fat 
Dietary fat is absorbed by the intestine, where cholesterol and fatty acids are re-
esterified to form triglycerides and cholesteryl esters. These are packaged with ApoB-48, 
phospholipids, unesterified cholesterol and several further apolipoproteins into nascent 
chylomicrons (CM). These are transported to the Golgi apparatus through vesicles and next 
released to the lymph for transportation into the blood circulation. Once in the circulation the 
CMs exchange apolipoproteins with HDL including; ApoE, ApoC-I, ApoC-II, ApoC-III and 
ApoA-V. The enzyme lipoprotein lipase (LPL) hydrolyses the core triglycerides into free fatty 
acids and glycerol when activated by ApoC-II (Eisenberg and Levy 1975; Eisenberg 1984). 
The CM is then broken down into to CM remnants (Kwiterovich 2000; Kindel, Lee et al. 
2010) and these CM remnants are taken up via the LDL receptor (LDLR) and the LDLR 
related protein with ApoE as the ligand. The majority are taken up in this way by the liver 
parenchymal cells (Brown and Goldstein 1986; Beisiegel, Weber et al. 1989; Krieger and 
Herz 1994). Interruption to this pathway leading to a reduction in CM clearance may result in 
elevated TG levels (post-prandial) and this is a recognized feature of CAD patients (Patsch, 
Miesenbock et al. 1992; Yu and Cooper 2001). 
Transport of Endogenous Fat 
A process that occurs in the liver is the synthesis and secretion of VLDL particles and 
this process incorporates ApoB-100 rather than ApoB-48. VLDL is triglyceride rich and once 
secreted into the plasma the triglyceride in VLDL is catabolised by the lipoprotein lipase 
enzyme and its ApoC-II co-factor into free fatty acids and glycerol. The breakdown of the TG 
produces smaller VLDL remnants and eventually IDL. IDL particles are taken back up into 
the liver via the interaction of ApoE and LDLR.  Further hydrolysis of triglycerides by the 
hepatic lipase enzyme leads to the production of LDL and small dense LDL particles. The 
LDL particles are removed from the circulation either by cells requiring cholesterol or by the 
liver when there is an excess, by the interaction of ApoB-100 with the LDLR. However, if 
LDL is oxidised it can also enter the macrophage through the scavenger receptors CD36 
and SR-A (Kwiterovich 2000).  
Reverse Cholesterol Transport and the Role of HDL 
The phrase ‘reverse cholesterol transport’ (RCT) was first coined by Glomset in 1968 
(Glomset 1968) and describes the process by which cholesterol is transported from non-
hepatic, peripheral cells, including macrophages, back to the liver for processing and 
excretion in the bile and faeces. HDL is the lipoprotein associated with this process. It 
acquires free cholesterol from the peripheral, non-hepatic tissues by either passive diffusion 
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or interaction with either the SR-BI receptor or the ABCA1 transporter. The ABCA1 
transporter system is considered the most efficient pathway. It is responsible for around half 
the cholesterol efflux from macrophages to HDL (Moreno, Sanz et al. 2009). HDL particles 
are the densest due to their high protein:cholesterol ratio and their most abundant proteins 
are ApoA-I and ApoA-II. When newly secreted HDL is poorly lipidated and acquires free 
cholesterol from the peripheral cells via ABCA1. The free cholesterol is then esterified by 
lecithin-cholesterol acyltransferase (LCAT), with ApoA-I as a co-factor (Fielding and Fielding 
1995). Mature HDL cholesterol particles also transfer esterified cholesterol to other ApoB 
containing lipoproteins, in exchange for TGs, by the cholesteryl ester transporter protein 
(CETP), which can then be taken up by the liver via the LDL or LRP receptors and increases 
the efficiency of the RCT system. By removing cholesterol from peripheral tissues (especially 
macrophages) in this manner, HDL and the RCT system have been shown to have an 
inverse relationship to CAD risk and increased HDL cholesterol has been shown to reduce 
the risk of CVD (Moreno, Sanz et al. 2009). Despite the seemingly positive research showing 
low HDL to be a potentially causal risk factor for CVD, recent research has challenged the 
concept that raising plasma HDL will lower the risk of myocardial infarction (Voight, Peloso et 
al. 2012). 
1.4.4. Lipoprotein Metabolism as a CHD Risk Factor 
Since an early step in atherogenesis is the accumulation of lipoprotein particles and 
their aggregates in the arterial intima, lipoprotein metabolism is a key process in the initiation 
and progress of atherosclerosis and several of the most significant CHD risk factors are 
associated with this process (Lusis, Mar et al. 2004). Generally, increased LDL/modified LDL 
(predominantly sd-LDL particles) and triglycerides in combination with reduced HDL are 
thought to be representative of an atherosclerotic lipid profile. However, despite increased 
TG being cited as part of this atherosclerotic risk profile, it is not clear whether it is 
independently associated with CHD, or merely a marker for the disease (Sarwar, Danesh et 
al. 2007; Kawakami, Osaka et al. 2008; Triglyceride Coronary Disease Genetics, Emerging 
Risk Factors et al. 2010; Libby, Ridker et al. 2011).  
There are many enzymes, cellular receptors and ligands involved in the metabolism 
and clearance of lipoprotein particles (Packard, Caslake et al. 2000) and over the last few 
years studies have identified genes associated with lipoproteins, lipoprotein metabolism and 
lipoprotein modification to be excellent ‘candidate genes’ with the potential to alter the 
balance of lipid metabolism and, therefore, CHD risk (Willer, Sanna et al. 2008; Aulchenko, 
Ripatti et al. 2009; Interleukin-6 Receptor Mendelian Randomisation Analysis, Hingorani et 
al. 2012). One group of genes associated with lipoprotein modification and metabolism are 
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the genes coding for the secretory phospholipase A2 enzymes. Secretory phospholipase A2 
enzymes play a significant role in the modification of lipoproteins and the speed at which 
they are cleared from the vessel. Their role in lipid metabolism has led to the question of 
what effect these enzymes may have on the risk of CHD (1.5.7). 
1.5. The Secretory Phospholipase A2 Family 
 Having described the process of atherosclerosis and some of the associated risk 
factors above, a good candidate to investigate as a novel CHD risk factor has emerged as 
the sPLA2 enzyme family. These enzymes are involved in both the inflammatory pathway 
and in lipoprotein metabolism as described in detail below. 
 Secretory phospholipase A2 (sPLA2) is a structurally heterogeneous family of 
proteins belonging to the PLA2 superfamily. This superfamily comprises 15 groups also 
including; cystolic, calcium independent (iPLA2) and platelet-activating (PAF) acetyl 
hydrolase/oxidized lipid lipoprotein associated phospholipase A2 (LpPLA2) (Burke and 
Dennis 2009). There are approximately 30 PLA2 enzymes split between these groups and 
around a third of these are considered sPLA2 enzymes (Murakami, Taketomi et al. 2011). 
Regarding cardiovascular disease, both iPLA2 and cystolic PLA2 are thought to contribute 
indirectly through the production of various lipid mediators in different cell types (Mallat, 
Lambeau et al. 2010). However, a more direct role has been attributed to both sPLA2 and 
Lp-PLA2 due to the additional ability of these enzymes to bind to and hydrolyse the 
phospholipid moieties of lipoproteins (Mallat, Lambeau et al. 2010). Secretory PLA2 
enzymes have the ability to bind and hydrolyse the phospholipid components of both 
unmodified lipoproteins and oxidized-LDL (ox-LDL), whereas LpPLA2 specifically hydrolyses 
ox-LDL and does not affect unmodified lipoproteins (Mallat, Lambeau et al. 2010). 
The sPLA2 enzymes are secreted by various mammalian cells and tissues in a lipid-
free state. The sPLA2 family is identified by the common ability to catalyse the hydrolysis of 
the middle (sn-2) ester bond of glycerophospholipids (Figure 1.7)  in lipoproteins and in 
some cases, cell membranes, producing non-esterified free fatty acids (NEFAs) and 
lysophospholipids, which are pre-cursors of pro-inflammatory lipid mediators, including 
arachidonic acid derived eicosanoids such as prostaglandins and leukotrienes (Six and 
Dennis 2000; Lambeau and Gelb 2008) (Figure 1.8). They can also act as secondary 
messengers in intracellular inflammatory pathways (Hurt-Camejo, Camejo et al. 2000). For 
example it has been suggested by analysis of data from animal studies that sPLA2s 
including IIA, V and X could stimulate inflammatory pathways by binding to murine, specific 
membrane receptors (including the M-type receptor, which is expressed by neutrophils, 
monocytes and macrophages) and that both normal and catalytically inactive sPLA2s can 
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induce the production of cytokines and chemokines, inducing further inflammation (Mallat, 
Lambeau et al. 2010). Secretory PLA2s are secreted and require variable µM-order Ca2+ 
which binds a common calcium peptide loop and interacts with surrounding water molecules 
for catalysis (Lambeau and Gelb 2008). It is therefore reasonable to suggest that the primary 
target phospholipids for sPLA2 are extracellular.  
Secretory phospholipases can act through either an autocrine or a paracrine pathway 
(Jaulmes, Janvier et al. 2005; Murakami, Taketomi et al. 2011) to release arachidonic acid, 
an important pre-cursor of lipid mediators, or a variety of saturated, monounsaturated and 
polyunsaturated fatty acids such as eicosapentaenoic acid and docosahexaenoic acid 
(Murakami, Taketomi et al. 2011). These products are, conversely to arachidonic acid, pre-
cursors of anti-inflammatory lipid mediators, suggesting that there is a small anti-
inflammatory element to sPLA2 actions in addition to the overwhelming evidence for the 
overall pro-inflammatory status of sPLA2. The accompanying lysophospholipid product may 
be, for example, lysophosphatidylcholine or lysophosphatidic acid which have various 
bioactivities (Murakami, Taketomi et al. 2011).       
Figure 1.7. The site of action for sPLA2. Secretory phospholipase A2 acts to catalyse the hydrolysis of 
the Sn-2 ester bond of phospholipids. This reaction produces a lysophospholipid and a free fatty acid. 
Hydrolysis of this particular bond distinguishes PLA2 from the other phospholipases.  
O- 
X 
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Figure 1.8. This figure represents the potential outcomes of sPLA2 hydrolysis of cell surface 
phospholipids. The enzyme acts on phospholipids to produce lysophospholipids (Lyso-PL) and non-
esterified free fatty acids (NEFA) such as arachidonic acid (AA). As well as these products having 
independent proinflammatory activity, AA is a precursor of pro-inflammatory lipid mediators such as 
the AA-derived eicosanoids; leukotrienes, thromboxanes and prostaglandins, all of which lead to 
increased inflammation. 
The secretory phospholipases are also disulphide-rich enzymes with molecular 
weights ranging between ~14 and 16kDa, with the exception of sPLA2-III, which has a 
molecular weight of ~55kDa. Human sPLA2 proteins are generally well conserved, and 
share homologs with mouse sPLA2 proteins (Lambeau and Gelb 2008). Secretory PLA2s 
can be induced by inflammatory signals, such as tumour necrosis factor (TNF) and 
interleukin-1 (Il-1) (Hurt-Camejo, Camejo et al. 2001; Jaulmes, Thierry et al. 2006) and have 
been shown to be inhibited by growth factors such as transforming growth factor β 
(Vervoordeldonk, Schalkwijk et al. 1996). To date, 11 sPLA2s have been identified in 
(Phospholipid) 
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mammals; IB, IIA, IIC, IID, IIE, IIF, III, V, X, XIIA and XIIB (Murakami, Taketomi et al. 2011). 
The oldest sPLA2 isoenzyme appears to be IB, whose orthologues are found in C.elegans 
and then, slightly later, sPLA2-X which appeared in amphibians (Lambeau and Gelb 2008). 
Both of the DNA structures for these sPLA2 groups have encoded an N-terminal propeptide, 
but at later stages evolutionary pressure saw the emergence of sPLA2 group II, which were 
encoding sPLA2 enzymes without an N-terminal propeptide. This group first appeared in 
snakes. The most recently formed isoform is sPLA2-V, which is also considered the simplest 
isoform and was found in mammals (Murakami, Taketomi et al. 2011). The secretory PLA2 
groups are shown below in Figure 1.9. 
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Figure 1.9. A schematic of the different secretory phospholipase A2 isoforms and their roles in the 
body and in disease; assessed by knockouts (red), transgenic models (blue) or both (green). All 
enzymes contain a conserved catalytic histidine-aspartate dyad and a Ca2+ binding loop. Group IB 
contains a unique pancreatic loop, which is thought to be a redundant structure conserved by this 
group. Group II is characterized by the absence of an N-terminal propeptide (which exists in groups IB 
and X) and the presence of cysteine49-cysteine within the C terminal extension. Group IIC has a 
unique insertion with an extra disulphide bond and is absent in humans. sPLA2-V is most similar to 
Group II, but lacks the group II-specific disulphide and C-terminal extension. sPLA2-X has both group I 
and II properties. This schematic is reprinted with permission from (Murakami, Taketomi et al. 2011)). 
Human groups IIA, V and X share a common three dimensional structure and the 
catalytic mechanism of sPLA2 involves several key features. The common structure of the 
active site includes an Aspartate-Histidine catalytic dyad (Figure 1.10), unique to the sPLA2 
family, and the previously described peptide loop bound Ca2+ ion (Lambeau and Gelb 2008). 
Secretory PLA2 enzymes are water soluble, unlike their preferred substrates, phospholipids, 
whose hydrophobic tails prevent them from water dissolution (unless in a conformation such 
as a lipoprotein). In order for phospholipids to become water soluble, a second, interfacial 
binding site has been determined by previous experimental analysis in addition to the active 
site which allows the enzyme to bind to the intracellular surface of the phospholipid 
substrate, significantly improving the binding ability of the substrate to the active site 
C = Additional disulphide 
bond 
H= His/Asp catalytic dyad 
L= Leu replaces His 
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(Lambeau and Gelb 2008). Differences in the binding abilities of human sPLA2 groups to 
different phospholipids occur due to their diverse side-chains of sPLA2 enzymes, which 
create distinctive charges associated with each sPLA2 group. These differences in charge 
dictate the ability of each group to interact with anionic and/or zwitterionic substrates. For 
example, phosphatidylcholine is zwitterionic whereas phosphatidylglycerol and 
phosphatidylserine are anionic (Lambeau and Gelb 2008). 
Figure 1.10. This figure shows the Aspartate-Histidine catalytic dyad active site of secretory 
phospholipase A2 Group IIA in green. This catalytic dyad is specific to the sPLA2 family of enzymes. 
The figure shows the interfacial binding surface from the front (A) and back (B). Lysine (cationic 
residues) are shown in blue and the crystal structure is taken from (Wery, Schevitz et al. 1991; Birts, 
Barton et al. 2010). The ability of sPLA2 enzymes to interact with different lipoproteins effectively 
depends on differences in enzyme conformation. For example the sPLA2-IIA has less tryptophan 
residues than sPLA2-V or sPLA2-X and tryptophan has been shown to increase the binding ability of 
sPLA2 to PC rich phospholipids. Reprinted with permission from (Lambeau and Gelb 2008). 
A previous study (Sawada, Murakami et al. 1999) showed that there are different 
profiles of sPLA2 isoenzyme expression and one form of the enzyme may partially 
compensate for the loss/lack of another (Sawada, Murakami et al. 1999). However, there are 
catabolic differences between each isoenzyme regarding phospholipid hydrolysis, and 
therefore their interactions with lipoproteins (Lambeau and Gelb 2008). 
Secretory PLA2-IIA shows the weakest hydrolysing effect towards the surface 
phospholipids of lipoproteins comparatively. This has previously been attributed to the fact 
that wild type sPLA2-IIA has less ability to hydrolyse the major lipoprotein membrane 
phospholipid, PC compared to sPLA2-V and X. The presence of increased tryptophan 
residues occurring naturally in sPLA2-V and X compared to sPLA2-IIA has been cited as a 
reason why there is a difference in the hydrolysis between these sPLA2s (Hurt-Camejo, 
Camejo et al. 2001; Bezzine, Bollinger et al. 2002). The suggested mechanism by which 
A B 
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sPLA2-V and X can hydrolyse PC is by preferentially binding these tryptophan residues to 
the interfacial region of PC-rich phospholipid bilayers (Pruzanski, Lambeau et al. 2005). A 
previous study examining this relationship used sPLA2-IIA proteins modified with additional 
tryptophan residues. Results showed sPLA2-IIA proteins modified with extra tryptophan 
residues at position 3 or 31 had an increased ability to hydrolyse PC molecules. Significantly 
the tryptophan residues at these positions improve sPLA2-IIA hydrolysis of PC-rich 
membranes in a way that is highly comparable with the action of sPLA2-V (Beers, Buckland 
et al. 2003). It is unknown how much of each sPLA2 enzyme is bound to lipoprotein 
phospholipids at any one time. The binding abilities of each of the sPLA2 enzymes, groups 
IIA, V and X, to common phospholipids is shown below (Table 1.2).  
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Structural Features Enzymatic Properties 
Molecula
r Mass, 
kDa 
Active 
Site 
PE 
Hydrolysis 
PC 
Hydrolysis 
PAF 
Hydrolysis 
oxPL 
Hydrolysis 
Proteoglycan 
Binding 
Foam Cell 
Formation 
sPLA2-IIA 13.9 His/Asp +++ +/− − ?† +++ + 
sPLA2-V 13.8 His/Asp +++ +++ − ?† ++ ++ 
sPLA2-X 13.6 His/Asp +++ +++ ++ ?† − ++ 
PE = phosphatidylethanolamine; PC = phosphatidylcholine, PAF=platelet activating factor 
Phosphatidylcholine and phosphatidylethanolamine are differentially hydrolysed by sPLA2s.  
sPLA2-X has a unique capacity to hydrolyse PAF. 
On the basis of studies with pancreatic and snake venom sPLA2s, their activity on oxidized phosphatidylcholine may be 
weaker than on nonoxidized phosphatidylcholine. 
 sPLA2-IIA and -V, but not -X, show high affinity for heparan sulphate proteoglycans. 
LDLs modified by sPLA2-IIA, -V, and -X are efficiently internalized by macrophages to induce the accumulation of cellular 
cholesterol ester and formation of foam cells. 
?† Detailed analysis of the enzymatic properties of human sPLA2s toward ox-PLs has not been performed. 
Table 1.2. Shows the structural features and enzymatic properties of secretory phospholipase A2 
groups IIA, V and X. The three enzymes share a similar molecular weight and an identical His/Asp 
active site. However, each enzyme has a differential binding ability to different substrates. This is 
probably due to the subtle structural differences between them, such as additional tryptophan 
residues on sPLA2-V and X and the improved interfacial binding of these enzymes, which increases 
the ability of these enzymes to bind to zwitterionic phospholipids in comparison to sPLA2-IIA. The 
high proteoglycan binding ability of sPLA2-IIA and, to a lesser extent sPLA2-V improves the binding 
ability of these enzymes to common lipoprotein surface phospholipids. Increased potency of sPLA2-V 
and X for PC and PE (compared to sPLA2-IIA) leads to increased LDL modifications and a higher risk 
of foam cell formation (from Mallat et al. 2010).  
In this thesis the enzymes focused on are; sPLA2-IIA, sPLA2-V and sPLA2-X as 
there is evidence to suggest an association between these enzymes and atherosclerosis 
(1.5.7). 
1.5.1. Secretory phospholipase A2 Group IIA (sPLA2-IIA) 
The common amino acid sequence for the sPLA2-IIA protein is shown in Figure 1.11. 
Secretory PLA2-IIA is probably the most researched and understood of the sPLA2 enzymes. 
It is expressed in and secreted by cells of numerous mammalian tissues including the 
ovaries, heart, liver and prostate and has been identified in many cell types, including 
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macrophages (Kimura-Matsumoto, Ishikawa et al. 2008), as well as extracellularly in the 
circulation (Menschikowski, Hagelgans et al. 2006). The initial isolation of sPLA2-IIA was 
from human rheumatoid arthritis synovial fluid (Wery, Schevitz et al. 1991; Masuda, 
Murakami et al. 2005), then later in the serum of patients with severe inflammatory disorders 
such as sepsis and septic shock (Pruzanski, Vadas et al. 1985; Waydhas, Nast-Kolb et al. 
1989). The correlation of enzyme levels with the severity of the patients’ inflammatory 
disorder suggests that sPLA2-IIA has a mediating role to play in the inflammatory pathway 
by responding to inflammatory cytokines and lipolysaccharides (Menschikowski, Hagelgans 
et al. 2006). A cationic motif (common to sPLA2-IIA and V) allows the enzyme to bind 
strongly to proteoglycans in the vessel wall (Murakami, Kudo et al. 1989), improving the 
longevity of the enzymes within the vessel and thus increasing its potential for activity. This 
is known as the heparan sulphate proteoglycan (HSPG) binding pathway (Figure 1.12). 
1.5.2. Secretory phospholipase A2 Group V (sPLA2-V) 
The common amino acid sequence for the sPLA2-V protein is shown in Figure 1.11. 
Secretory PLA2-V is secreted at the subcellular level. It is observed to be most frequently 
expressed in heart, placenta, macrophages and in lung and other respiratory tissues 
(http://www.genwaybio.com/product_info.php?products_id=45346).  
Secretory PLA2-V is structurally similar to sPLA2-IIA and has been implicated in 
inflammation as an important component of the cyclooxygenase-2-dependent prostaglandin 
production pathway on the nuclear envelopes of cells (Balsinde, Shinohara et al. 1999; Kim, 
Kim et al. 2002). Secretory PLA2-V also plays a role in the arachidonic acid pathway and is 
considered to be a more potent hydrolyser of lipoproteins than sPLA2-IIA (Lambeau and 
Gelb 2008). This is probably due to the increased ability of sPLA2-V to catalyse the 
phospholipids most commonly associated with lipoprotein surface layers; PC and PE. 
Secretory PLA2-V can hydrolyse both of these with potent effect (Murakami, Kambe et al. 
1999; Oestvang, Anthonsen et al. 2003).  
Since it has been shown to have a particular efficacy for PC hydrolysis, sPLA2-V is 
thought to contribute to the hydrolysis of the PC content on HDL surfaces, altering the HDL 
apolipoprotein A (Apo-A) complex and impeding the reverse cholesterol transport pathway, 
thus increasing the risk of atherosclerosis (Saiga, Morioka et al. 2001). In fact, sPLA2-V is 
thought to be more potent towards HDL compared to LDL, due to the increased 
sphingomyelin found in LDL, which prevents the action of sPLA2s (Murakami and Kudo 
2003). 
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Previously published data (Sawada, Murakami et al. 1999) suggest that when 
sPLA2-V is co-transfected with cyclooxygenase (COX)-2 (but not COX-1) into human 
embryonic kidney (HEK) 293 cells it significantly increases the interleukin-1-dependent 
prostaglandin E2 generation over a 24 hour period of culture. Additionally, rat mastocytoma 
RBL-2H3 cells overexpressing sPLA2-V showed increased immunoglobin E-dependent 
prostaglandin D2 generation and accelerated β-hexosaminidase exocytosis. These results 
suggest that, like sPLA2-IIA, sPLA2-V acts as a regulator of inflammation-associated cellular 
responses and though sPLA2-IIA and sPLA2-V appear to work through different pathways 
(Sawada, Murakami et al. 1999), this is further evidence that there could be some 
complementary behaviour between them, which may go some way to explaining why strains 
of mice that are sPLA2-IIA deficient can live normally for an average life-span (Sawada, 
Murakami et al. 1999). 
The sPLA2-V enzymes have the capability of proteoglycan binding and use the 
HSPG pathway to interact with phospholipids in the same way as sPLA2-IIA (Lambeau and 
Gelb 2008). However, sPLA2-V has increased interfacial binding capability compared to 
sPLA2-IIA and thus can also act directly on the phospholipid outer layer of lipoproteins. This 
is known as the external plasma membrane pathway (Figure 1.12) (Lambeau and Gelb 
2008). 
1.5.3. Secretory phospholipase A2 Group X (sPLA2-X) 
The common amino acid sequence for the sPLA2-X protein is shown below in Figure 
1.11. Human sPLA2-X is expressed in various tissues including thymus, spleen, leukocytes, 
colon and lung tissue. The presence of sPLA2-X in these organs suggests it could be 
involved in immunity, including inflammation (Gora, Lambeau et al. 2006). 
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sPLA2 Protein Coding Sequences 
PLA2G2A Translation (144 aa): 
MKTLLLLAVIMIFGLLQAHGNLVNFHRMIKLTTGKEAALSYGFYGCHCGVGGRGSPKDATDRCCVTHDCC 
YKRLEKRGCGTKFLSYKFSNSGSRITCAKQDSCRSQLCECDKAAATCFARNKTTYNKKYQYYSNKHCRGS 
TPRC 
PLA2G5 Translation (138 aa):  
MKGLLPLAWFLACSVPAVQGGLLDLKSMIEKVTGKNALTNYGFYGCYCGWGGRGTPKDGTDWCCWAHDHC 
YGRLEEKGCNIRTQSYKYRFAWGVVTCEPGPFCHVNLCACDRKLVYCLKRNLRSYNPQYQYFPNILCS 
PLA2G10 Translation (165 aa): 
MGPLPVCLPIMLLLLLPSLLLLLLLPGPGSGEASRILRVHRRGILELAGTVGCVGPRTPIAYMKYGCFCG 
LGGHGQPRDAIDWCCHGHDCCYTRAEEAGCSPKTERYSWQCVNQSVLCGPAENKCQELLCKCDQEIANCL 
AQTEYNLKYLFYPQFLCEPDSPKCD 
Figure 1.11 The protein coding sequences for each of the sPLA2 enzymes: sPLA2-IIA, sPLA2-V and 
sPLA2-X. In comparison, each protein has a different length amino acid sequence and the lack of 
significant homology between sequences suggests that each protein has independent actions and 
none of these three sPLA2 enzymes are redundant in normal physiology (adapted from 
http://www.ncbi.nlm.nih.gov/CCDS/ http://www.ncbi.nlm.nih.gov/CCDS/,  
http://www.ncbi.nlm.nih.gov/CCDS/ http://www.ncbi.nlm.nih.gov/CCDS/ and 
http://www.ncbi.nlm.nih.gov/CCDS/ http://www.ncbi.nlm.nih.gov/CCDS/). 
sPLA2-X has the most potent hydrolytic effects on lipoproteins compared to other 
sPLA2 enzymes (Hurt-Camejo, Camejo et al. 2000). Secretory PLA2-X is a very effective 
stimulator of the arachidonic acid pathway (Henderson, Chi et al. 2007) and its activity and 
high affinity for hydrolysing phospholipids, especially those found in HDL particles to produce 
arachidonic acid, can be regulated by sphingomyelin and ceramide activity (Oestvang, 
Anthonsen et al. 2003; Singh, Gesquiere et al. 2007). Increased sphingomyelin was shown 
to inhibit sPLA2-X activity and to decrease the amount of arachidonic acid produced by 
sPLA2-X hydrolysis of PC in HDL (Singh and Subbaiah 2007). Conversely, when there is an 
abundance of ceramide in the environment sPLA2-X activity is increased and there is a 
significant increase in arachidonic acid as a product of PC hydrolysis by sPLA2-X, especially 
regarding HDL (Singh and Subbaiah 2007). Secretory PLA2-X has a preferential affinity for 
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HDL hydrolysis due to its high PC content (Ishimoto, Yamada et al. 2003; Karabina, 
Brocheriou et al. 2006). 
sPLA2-X lacks the cationic motif that allows both group IIA and V to interact with 
proteoglycans. It is therefore thought that sPLA2-X uses the external plasma membrane 
pathway (Figure 1.12) to induce the majority of its cellular arachidonic acid release (Bezzine, 
Bollinger et al. 2002; Pruzanski, Lambeau et al. 2007) and it has been shown to have a 
strong ability to elicit arachidonic acid production when added exogenously to adherent 
mammalian cells- something which neither group IIA or V can do (Bezzine, Koduri et al. 
2000; Pruzanski, Lambeau et al. 2007).  
Figure 1.12 The Heparan sulphate pathway (used by sPLA2-IIA and sPLA2-V) and the Plasma 
Membrane Pathway (Used by sPLA2-V and X) Reprinted with permission from (Kudo and Murakami 
2002). The figure shows most of the enzymes in the sPLA2 cluster, sPLA2-IIA, IID, IIE and V are 
internalised to the intracellular membrane via the Heparan sulphate pathway where they interact with 
intracellular membrane phospholipids to produce arachidonic acid. sPLA2-IIF interacts with internal 
membrane microdomain phospholipids directly to produce arachidonic acid. Both sPLA2-V and 
sPLA2-X use the external plasma membrane pathway to interact directly with the external plasma 
membrane phospholipids to produce arachidonic acid.  
Secretory PLA2-X expression also appears to be activated under inflammatory 
conditions (Curfs, Ghesquiere et al. 2008). Unlike sPLA2-IIA and V it is also induced by high 
levels of platelet activating factor (PAF) and plays a role in PAF hydrolysis and regulation 
(Karabina, Gora et al. 2010). The preferential, precision hydrolysis of PC is what makes 
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sPLA2-X one of the most potent of the sPLA2 enzymes regarding lipoprotein modification in 
vitro. The selective hydrolysis of PC by sPLA2-X produces a large amount of unsaturated 
fatty acids and lysoPC (Saiga, Morioka et al. 2001). The enzyme is particularly active when 
hydrolysing PC on lipoprotein particles and in the outer leaflet of intact cell plasma 
membranes (Saiga, Morioka et al. 2001). Since HDL is a preferential substrate for sPLA2-X 
hydrolysis, modifications of HDL due to sPLA2-X hydrolysis means that it is less able to 
regulate cholesterol efflux, which impedes the reverse cholesterol transport pathway from 
the arteries to the liver, allowing macrophages to build up and accumulate as foam cells 
(1.4.5) (Saiga, Morioka et al. 2001). 
Since sPLA2-X does not have significant HSPG binding, it is not retained by 
proteoglycan binding in the extracellular matrix of atherosclerotic plaques, however, this may 
not be necessary for sPLA2-X to contribute to sPLA2 activity due to its increased potency, 
dependent on whether there are significant levels of sPLA2-X produced. Despite the 
increased efficiency of sPLA2-X towards hydrolysis of PC in LDL particles, it has been 
shown that sPLA2-X-treated LDL particles do not aggregate as sPLA2-IIA modified particles 
are known to do (Gora, Perret et al. 2009), which is likely due to the additional tryptophan 
residues found in sPLA2-X compared with sPLA2-IIA and their composition (Gora, Perret et 
al. 2009). However, these sPLA2-X modified particles are efficiently incorporated into 
macrophages (Curfs, Ghesquiere et al. 2008), increasing the formation and accumulation of 
foam cells. Immunohistochemistry has detected sPLA2-X in foam cell lesions the arterial 
intima and in the smooth muscle cells of the medial layer of the artery wall in Apoe deficient 
mice on an atherosclerotic diet (Hanasaki, Yamada et al. 2002; Murakami and Kudo 2003). 
This data implicating sPLA2-X in atherosclerosis has been supported by a study designed to 
detect sPLA2-X in human atherosclerotic lesions from human samples taken from the media 
and intima (Karabina, Brocheriou et al. 2006) which used double immunohistochemical 
staining to show that sPLA2-X resides in the atherosclerotic plaque. While there is some 
evidence to suggest that sPLA2-X may be involved in atherosclerosis, sPLA2-X is not 
normally expressed in the heart (Masuda, Murakami et al. 2005). In addition to its expression 
in immune/inflammatory organs and cells, sPLA2-X is expressed most readily in the 
digestive organs and in the testis. However, it is its expression in blood leukocytes which 
may explain its presence in the atherosclerotic plaque, since leukocytes are recruited during 
the inflammatory process of atherogenesis (Kudo and Murakami 2002). 
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1.5.4. The Genetics of Secretory Phospholipase A2s 
The genes that control the production of sPLA2 A2s are among the PLA2 family of 
genes. Specifically, sPLA2-IIA, V and X are encoded for by PLA2G2A, PLA2G5 and 
PLA2G10, respectively.  
PLA2G2A and PLA2G5 are tightly linked and transcribed in opposite directions, 
mapping to chromosome 1p34-p36.1 and only 90Kb apart (Tischfield, Xia et al. 1996). In 
addition, the genes PLA2G2D, PLA2GE and PLA2GF are all found in a cluster with 
PLA2G2A and PLA2G5 (Figure 1.13), which could indicate control of all these genes by 
common promoter elements (Ghesquiere, Gijbels et al. 2005), although this has yet to be 
proven, since there is no experimental evidence of the precise length of the PLA2 promoter 
regions. The percentage of identical amino acids of each gene compared to PLA2G2A is 
shown in Figure 1.13. PLA2G5 is often co-expressed with PLA2G2A in mammalian species 
in a tissue specific pattern (Tischfield, Xia et al. 1996). There is no observed recombination 
between the two genes, suggesting they are often inherited together (Tischfield, Xia et al. 
1996). 
Figure 1.13 Taken from Wootton et al. 2006. Chromosome 1 p34-36, the PLA2 gene cluster. 
PLA2G2A and PLA2G5 are transcribed in different directions and are ~90Kb apart. The percentage 
value above each gene is indicative of the amount of identical amino acids compared to PLA2G2A. 
The sPLA2-X coding gene, PLA2G10 but lies on chromosome 16 at 16p13.1-p12 in a 
gene dense region (Figure 1.14) (Cupillard, Koumanov et al. 1997). In comparison to 
PLA2G2A the PLA2G10 gene shows only 25% identical amino acid sequence 
(Ensembl.org). 
Chromosome 1p34-36 
100%49% 45% 46% 26% 
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Figure 1.14. PLA2G10 mapped to its location on chromosome 16, a gene dense region including 
PARN, BFAR, LOC642778 and LOC100652777. PLA2G10 is reverse transcribed as indicated by the 
black arrow. (http://www.ncbi.nlm.nih.gov/gene/8399). 
 
1.5.5. Measuring sPLA2 Mass and sPLA2 Activity 
 An assay that determines enzyme mass will quantify the amount of enzyme present 
in a sample matrix (e.g. plasma or synovial fluid), whereas an assay that determines enzyme 
activity is a measure of the ability of an enzyme to catalyse a specific reaction. 
 Regarding the enzymes sPLA2-IIA, V and X, development of assays to measure the 
mass and activity of enzyme has yet to be fully achieved. There is an assay available to 
measure sPLA2-IIA mass. This is an enzyme-linked immunoabsorbant assay (ELISA), with 
an sPLA2-IIA specific monoclonal antibody to directly measure the amount of sPLA2-IIA 
specific antigen in a sample (Koenig, Vossen et al. 2009). This assay is specific for sPLA2-
IIA and has been shown to have no cross-over with other known sPLA2 enzymes (Cayman 
Chemical Co., Ann Arbor, MI, USA), despite similarities in structure with other group II 
enzymes such as sPLA2-IID, IIE and IIF (Figure 1.9). To date no such assays have been 
developed to measure either sPLA2-V or sPLA2-X in the same way. It is unclear why no 
similar assays have been developed for sPLA2-V and X but this may be due to the fact that 
sPLA2-IIA was the enzyme initially discovered and was of interest to scientists before any 
more recently discovered isoenzymes including groups V and X. In any case it is surprising 
that there still appears to be no effort to produce assays for the measurement of sPLA2-V 
and X that are synonymous with the current sPLA2-IIA assay. 
The assay commonly used to measure sPLA2 activity is problematic since the 
measure of activity obtained includes the individual activity contributions of sPLA2-IIA, 
sPLA2-V and sPLA2-X. There is currently no assay that can detect each individual input, 
thus veiling the true value of each of the enzymes’ activity. The assay in question is a 
selective fluorometric assay, where the active enzyme is determined by the production of an 
increased fluorescent signal (Koenig, Vossen et al. 2009). However, if assays are developed 
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to measure the individual activity of each enzyme we are still left with the issue of the 
complexity and precision of the term ‘activity.’ Measuring the biological activity of any 
enzyme by an assay using an artificial substrate is only an imperfect model of the substrate 
formed. Both the sPLA2-IIA mass and the sPLA2 activity assays are used for taking in vitro 
measurements. 
1.5.6. Biological Functions of the sPLA2 Family  
As previously described, sPLA2 is expressed in response to signals from an 
inflammatory cascade (1.5.1-1.5.3). Some examples of the inflammatory markers known to 
initiate expression of each enzyme include several cytokines, growth factors and 
transcription factors. The presence of each enzyme is in a cell and tissue specific manner 
(Peilot, Rosengren et al. 2000; Menschikowski, Hagelgans et al. 2008). A prolonged 
inflammatory response drives prolonged PLA2 gene activation. It is thought that the chief 
role of sPLA2 enzymes in vivo is as part of the hosts defence mechanism against bacterial, 
viral and parasitic infection (Lambeau and Gelb 2008). Previous studies have shown that 
sPLA2 is active against both gram positive and gram negative bacteria. Secretory PLA2-IIA 
was shown to work together with a bactericidal/permeability increasing protein (BPI) to 
breakdown Gram-negative bacteria such as Escherichia coli. The BPI disturbs the surface 
lipopolysaccharide coat of the E.coli, allowing the sPLA2-IIA enzyme to efficiently interact 
with and break down the cell wall.  
Secretory PLA2-IIA was then shown to be most potent against Gram positive 
bacteria such as Staphyloccus aureus, Streptococcus pyogenes and Listeria 
monocytogenes (Lambeau and Gelb 2008). No co-enzyme activity is required in this case 
and the sPLA2-IIA enzyme can act directly on the Gram-positive bacteria cell wall in order to 
break it down. The physiological properties of sPLA2-IIA are such that the protein is 
extremely basic and cationic. This charge allows the enzyme to form strong electrostatic 
interactions with the acidic Gram-positive bacteria surface before binding of the substrate to 
the active site causes the hydrolysis of the phospholipid membrane (Buckland and Wilton 
2000; Lambeau and Gelb 2008).  
 Other sPLA2 groups exhibit antibacterial activity and a previous study has ranked 
them in order of potency against Gram-positive activity in vitro; group 
IIA>X>V>XII>IIE>IB/IIF (Koduri, Gronroos et al. 2002). Additionally sPLA2-V was identified 
as present in the phagosome of macrophages, regulating phagocytosis, suggesting it plays a 
role in the killing of ingested bacteria (Balestrieri, Hsu et al. 2006). 
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Antiviral and anti-parasitic roles for sPLA2 groups are less well studied, though it has 
been shown that sPLA2-X can help to inhibit infection by the human immunodeficiency virus 
(Fenard, Lambeau et al. 2001; Kim, Chakrabarti et al. 2007)  and sPLA2-V and X have been 
shown to resist adenoviral infection in mammalian cells (Mitsuishi, Masuda et al. 2006). 
Finally sPLA2-IB can block red blood cell infection by the malaria parasite, Plasmodium 
falciparum (Deregnaucourt and Schrevel 2000; Lambeau and Gelb 2008).  
1.5.7. sPLA2s in Disease 
Table 1.3 summarises the known and suspected contributions to disease (Pruzanski, 
Keystone et al. 1988; Henderson, Oslund et al. 2011; Murakami, Taketomi et al. 2011). It 
appears that each enzyme is expressed differentially depending on the disorder and in some 
instances all three of the sPLA2 enzymes of interest appear to be associated with a disease 
(though this is largely based on in vitro studies and therefore requires further investigation). 
This raises the question of whether one or more of these enzymes are redundant or whether 
differential expression and behaviour of each enzyme contributes to disease. Should the 
latter be the case then it is also important to explore what the contribution of each enzyme is. 
As has been discussed previously (1.1) CHD is the most significant cause of global mortality 
and thus it is of great importance to identify causal risk factors associated with this disease. I 
have therefore chosen to focus my thesis on the investigation of the role of sPLA2 enzymes 
in CHD, however it is important to also consider the role of these enzymes in other 
inflammatory disorders, such as rheumatoid arthritis/respiratory inflammation, and in known 
CHD related diseases such as Type II diabetes (as discussed below). This study will require 
an understanding of the interactions and contributions of each individual sPLA2 enzyme and 
this information may also be of use in researching the role of sPLA2 in other disorders.   
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Table 1.3. Highlights the diverse nature of sPLA2 enzyme activity in disease. The differential 
expression patterns of each enzyme and their distinct catalytic mechanisms suggest independent 
roles for each enzyme in several diseases. However, in the instance of rheumatoid arthritis, CHD and 
ARDs all three enzymes have been identified as having a potential association with these diseases. 
Whether one enzyme is more clinically significant than any other is currently an unanswered question. 
The evidence for most of these associations relies on in vitro data, observational data in small 
datasets or animal models and more research is required to confirm the existence and potential 
causality of these associations.  
sPLA2-IIA Role in Rheumatoid Arthritis 
sPLA2-IIA is considered to play a pro-inflammatory role in rheumatoid arthritis and 
studies have shown that sPLA2-IIA is highly expressed in synovial cells and chondrocytes in 
the joints of rheumatoid arthritis sufferers, but not in those of normal subjects (Seilhamer, 
Pruzanski et al. 1989; Pruzanski and Vadas 1991). This has led to the hypothesis that 
sPLA2-IIA plays an aggravating role in this autoimmune disease (Murakami, Taketomi et al. 
2011). Further support for this theory has come in more recent studies that have utilised the 
C57BL/6 mouse model, which has a natural frame-shift mutation for pla2g2a (Kennedy, 
Payette et al. 1995). The natural knockout mouse model strain has been used to look at the 
role of active sPLA2-IIA in inflammation (Ghesquiere, Gijbels et al. 2005) and also in 
atherosclerosis. These mice are excellent transgenic models for human sPLA2-IIA, as any 
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recorded changes in atherosclerosis attributed to sPLA2-IIA are due to the human transgene 
since there is no confounding by endogenous mouse sPLA2-IIA (Webb, Bostrom et al. 
2003). Regarding rheumatoid arthritis, these C57BL/6 mice were bred with BALB/c mice 
(which do not have a mutation for pla2g2a) and backcrossed with BALB/c mice. The 
resulting pla2g2a-/- BALB/c offspring were used to show that sPLA2-IIA plays a role in 
rheumatoid arthritis. This was revealed when arthritis was induced in pla2g2a+/+ BALB/c 
and pla2g2a-/- BALB/c mice using the K/BxN autoantibody and the levels of inflammatory 
arthritis were measured in both models. The pla2g2a-/- mice showed a significant reduction 
in arthritic inflammation compared to the pla2g2a+/+ models (Boilard, Lai et al. 2010). 
Additionally, PLA2G2A transgenic mice have been used with the same K/BxN autoantibody 
to induce arthritis and increased levels of inflammatory arthritis were seen in these models. It 
has not yet been confirmed whether sPLA2-IIA contributes to the synthesis of eicosanoids or 
acts through a different mechanism in inflamed joints (Murakami, Taketomi et al. 2011).  
sPLA2-IIA Role in Atherosclerosis and CHD 
Observational Data: sPLA2-IIA and Atherosclerosis 
Observational studies have been the chief source identifying a relationship between, 
higher sPLA2 mass and activity and risk of CHD and several studies report this. The first 
study recruited patients with CAD and sex-matched controls and measured their plasma 
sPLA2-IIA levels. The study identified the association between elevated PLA2 and increased 
atherosclerosis/CHD risk. It went on to specify the secretory family of phospholipases as a 
subgroup associated with this action (Kugiyama, Ota et al. 1999). Studies of the prospective 
nested case-control study, the European Prospective Investigation of Cancer (EPIC)-Norfolk 
cohort showed measures of sPLA2-IIA levels have a strong positive correlation with CRP 
levels and furthermore an independent association with both fatal and non-fatal CHD risk in 
men (Boekholdt, Keller et al. 2005). The Global Registry of Acute Coronary Events (GRACE) 
cohort, an observational cohort of acute coronary patients recruited soon after MI, gave 
results confirming a significant association of sPLA2-IIA levels with risk, as well as showing 
an association with measures of sPLA2 activity and major recurrent coronary events. The 
sPLA2 activity measures were a more accurate predictor of death (Mallat, Steg et al. 2005). 
The same group later used the EPIC study to show a significant association between sPLA2 
activity and incidents of CHD (Mallat, Benessiano et al. 2007). A further study examined 
sPLA2 levels and activity in the Langzeiterfolge der Kardiologischen Anschlussheil-
Behandlung (KAROLA) cohort of post myocardial infarction (MI) patients and showed 
significant associations between sPLA2 levels and activity with fatal and non-fatal MI and 
stroke (Koenig and Khuseyinova 2009). The association results from all these studies were 
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equally strong. Table 1.4 gives an overview of the outcome of these and several subsequent 
studies examining the association between sPLA2 and CHD risk. 
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 Table 1.4. Studies investigating the association of sPLA2-IIA mass and sPLA2 activity with cardiovascular event risk (Adapted from (Mallat, Lambeau et al. 
2010)) 
CI indicates confidence interval; OR, odds ratio; Q4, quartile 4; Q1, quartile 1; T3, tertile 3; T1, tertile 1; CABG, coronary artery bypass graft surgery; and HR, 
hazard ratio.  
Fully adjusted risk estimates are depicted for the primary end points.  
sPLA2 mass assay and sPLA2 activity assay: See 1.5.5  
Reference sPLA2 
Assay 
Study 
Design 
Population No. of Individuals Average 
Follow-Up, 
y 
Primary End Point(s) Risk Estimates (95% CI)* 
Boekholdt et al 
and Mallat et al 
Type IIA 
mass or 
total sPLA2 
activity 
Nested 
case-
control 
Apparently healthy men 
and women 
2209 Controls and 1105 
cases for mass; 1806 
controls and 991 cases 
for activity 
6 Fatal and nonfatal coronary 
heart disease 
OR 1.34 (1.02–1.71) Q4 vs Q1 with mass; 
OR 1.65 (1.27–2.12) with activity 
Kugiyama et al Type IIA 
mass 
Cohort Consecutive patients with 
angiographically proven 
stable CAD 
142 Patients (48 events) 2 Coronary death, MI, and 
coronary revascularization 
OR 3.3 (1.3–9.2) T3 vs T1 
Liu et al Type IIA 
mass 
Cohort Stable coronary patients 
undergoing PCI 
247 Patients (87 events) 2 Cardiac death, nonfatal MI, 
repeat angioplasty, or CABG 
due to recurrent angina 
OR 2.1 (1.4–7.0) for sPLA2 IIA mass >450 
ng/dL 
Koenig et al Type IIA 
mass or 
total sPLA2 
activity 
Cohort Coronary patients 30–70 y 
old within 3 wk to 3 mo 
after ACS or CABG 
1032 Patients (93 
events) 
4.1 Cardiovascular death, 
nonfatal MI, stroke 
HR 2.07 (1.17–3.66) T3 vs T1 with mass 
and 1.65 (0.96–2.84) with activity; HR 1.45 
(1.07–1.96) per unit increase with mass 
and 1.78 (1.03–3.11) per unit increase 
with activity  
O'Donoghue et 
al 
Total sPLA2 
activity 
Cohort Patients with stable CAD 3738 Patients 4.8 Cardiovascular death, MI, or 
stroke 
HR 1.49 (1.08–2.06) Q4 vs Q1 
Kugiyama et al Type IIA 
mass 
Cohort Patients with unstable 
angina 
52 Patients (28 events) 2 Coronary death, MI, CABG, 
PCI, or readmission 
OR 5.08 (1.4–18.6) for sPLA2 type IIA 
mass >246 ng/dL 
Mallat et al Type IIA 
mass or 
total sPLA2 
activity 
Cohort Patients with ACS 446 Patients (35 events) 0.54 Death or MI HR 3.08 (1.37–6.91) T3 vs T1–T2 with 
activity; HR 1.9 (0.96–3.6) with IIA mass in 
univariate analysis 
Simon et al Total sPLA2 
activity 
Cohort Patients with acute MI 1036 Patients (98 
events) 
0.5 Death, MI, or stroke HR 2.29 (1.28–4.12) T3 vs T1 
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Animal Models: sPLA2-IIA and Atherosclerosis 
The natural knockout mouse model strain for pla2g2a; C57BL/6 have also been used 
as a transgenic model for human PLA2G2A when studying sPLA2 association with CHD 
risk. Mice transgenic for PLA2G2A develop atherosclerosis and when macrophages from 
these mice are transplanted into atherosclerosis-prone knockout mice (either low density 
receptor Ldlr-/- or Apolipoprotein E (Apoe) -/- models) atherosclerosis is enhanced (Webb, 
Bostrom et al. 2003; Boyanovsky, Zack et al. 2009). Specifically, in data from transgenic 
mice (again strain C57BL/6) over-expressing human sPLA2-IIA it was observed that the 
enzyme functions in the aorta by altering the conformation of LDL particles, allowing them to 
aggregate more easily and enhancing their ability to bind to proteoglycans. More specifically 
it was identified that the apolipoprotein-B100 (ApoB) component of LDL particle was 
conformationally changed. ApoB has two active sites, designated A and B (among 8 total 
active sites for proteoglycan binding). Both sites are activated in the presence of sPLA2-IIA 
and the effects combine to increase proteoglycan binding ability and decreased LDL 
receptor affinity. However, it has been suggested that it is the conformational change 
undergone by the site B that causes the greatest enhancement of LDL affinity for 
proteoglycan binding (Flood, Gustafsson et al. 2004). This has been supported by in vitro 
studies (Eckey, Menschikowski et al. 1997; Jaross, Eckey et al. 2002).  
Suggested sPLA2-IIA Pathway to Atherosclerosis 
When sPLA2 enzymes hydrolyse the sn-2 ester bond of phospholipids they release a 
lyso-phospholipid and a non-esterified free fatty acid (NEFA). Release of the NEFA 
arachidonic acid (AA) is a key step as a precursor in the production of eicosanoids such as 
leukotrienes, thromboxanes and prostaglandins (Figure 1.8). It therefore promotes these 
pro-inflammatory lipid mediators which aid the initiation and maintenance of prolonged 
inflammatory responses in the body, and are implicated in the development of 
atherosclerosis (Figure 1.16) (Lambeau and Gelb 2008; Leonarduzzi, Gamba et al. 2011). 
  Studies show that sPLA2-IIA is present in both normal and atherosclerotic arteries, 
in the circulation and within the vessel wall (Figure 1.16) (Lambeau and Gelb 2008). It is 
thought to be the most abundant of the three groups of sPLA2 associated with CHD (Mallat, 
Lambeau et al. 2010) but it is the least potent towards the PC rich phospholipid outer layers 
of lipoproteins (Lambeau and Gelb 2008; Rosenson and Hurt-Camejo 2012). Though its 
potency for unmodified LDL is lower compared to sPLA2-V and sPLA2-X , it does have a 
better affinity for ox-LDL (Lambeau and Gelb 2008; Rosenson and Hurt-Camejo 2012) and 
its ability to bind strongly to proteoglycans in the extra cellular matrix of smooth muscle cells 
in the vessel wall, creates an excellent anchor for the longer time it requires to hydrolyse PC 
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effectively (Murakami, Kudo et al. 1989). As previously discussed, this lack of affinity for PC 
is probably due to the lack of tryptophan residues compared to sPLA2-V and X, which gives 
rise to the highly negative charge of sPLA2-IIA enzymes, giving them a very high affinity for 
binding anionic phospholipid vesicles, but not zwitterionic phospholipid vesicles (Lambeau 
and Gelb 2008).  
 sPLA2-IIA expression can be activated by the combined synergistic binding of cAMP 
and IL-1β, or by reactive oxygen species (ROS), such as those produced from the NADPH 
pathway in endothelial cells (Jensen, Sheng et al. 2009) triggering the initiation of PLA2G2A 
transcription (Antonio, Brouillet et al. 2002). In the circulation, hydrolysis of the LDL by 
sPLA2-IIA modifies the LDL particles generating sd-LDL, which can then transverse the 
endothelial cell layer of the artery wall  into the intima, where they are further modified (Hurt-
Camejo, Camejo et al. 2000). This modification increases the propensity of the particles to 
aggregate and bind to proteoglycans, resulting in aggregation of sd-LDL in the intima. The 
proinflammatory products released by the sPLA2 hydrolysis of phospholipids stimulate 
monocytes to enter the intima via the endothelial cell wall where they become macrophages 
and phagocytose sd-LDL and other sPLA2 modified lipoprotein fragments. This leads to 
foam cell formation and increased atherosclerotic plaque size (Figure 1.16) (Hurt-Camejo, 
Camejo et al. 2000). 
sPLA2-IIA further modifies LDL in the arterial wall by inducing a conformational 
change of the ApoB complex in LDL particles, which exposes an extra proteoglycan binding 
site, promoting the internal aggregation of LDL particles (Tietge, Pratico et al. 2005). This 
modified LDL is also more susceptible to lipid peroxidation, forming oxidised lipoproteins that 
bind more tightly to extracellular proteoglycans, increasing atherosclerosis (Tietge, Pratico et 
al. 2005). The increased levels of foam cells and sPLA2-IIA also appear to contribute to 
higher oxidative stress within the vessels, increasing inflammatory cytokine expression and 
therefore further sPLA2-IIA expression in the smooth muscle cells (Tietge, Pratico et al. 
2005; Blache, Gautier et al. 2012). The prolonged inflammatory effect also induces smooth 
muscle cell proliferation, which was cited earlier as a contributing factor to the progression of 
atherosclerosis (Figure 1.4). 
sPLA2-V in Arthritis and Respiratory Disease 
An effect of knocking out pla2g5 in mice (pla2g5-/-) leads to an increase K/BxN 
autoantibody-induced arthritis (Masuda, Murakami et al. 2005). This is probably due to the 
reduction in the clearance of the pathogenic immune complex by macrophages in inflamed 
joints in the absence of pla2g5 (Boilard, Lai et al. 2010). This is validated by a study showing 
that systemic administration of recombinant sPLA2-V protein promotes the arthritic response 
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by facilitating the phagocytic uptake of the immune complex by macrophages (Murakami, 
Taketomi et al. 2011). The pro and anti-inflammatory actions attributed to sPLA2-IIA and 
sPLA2-V in arthritis are different. This is the likely reason for the ineffectiveness of a 
combined inhibitor for both sPLA2-IIA and V to combat arthritis, and suggests that drugs 
specific for each enzyme may be of more use (Murakami, Taketomi et al. 2011). 
Regarding respiratory disorders, an association was first noted in 2006 when the first 
sPLA2 transgenic mice were developed- a pla2g5 transgenic model. These mice were 
observed to die soon after birth and the early death was attributed to acute respiratory 
distress syndrome (ARDS), which is bought on by the abnormal hydrolysis of pulmonary 
surfactant phospholipids. Pulmonary surfactant is produced by alveolar type II epithelial cells 
and is essential for maintaining alveolar stability. Destruction of surfactant lipids by high 
levels of sPLA2-V can cause loss of alveolar stability and impairment of gas exchange 
(Ohtsuki, Taketomi et al. 2006). Secretory PLA2-V has been shown to be expressed in the 
bronchial endothelium and alveolar macrophages and over expression of this enzyme is 
associated with patients with severe pneumonia (Masuda, Murakami et al. 2005; Munoz, 
Meliton et al. 2007). Further studies have utilised both PLA2G5 transgenic mouse models 
and pla2g5-/- mouse models and the resulting data indicates that sPLA2-V is involved in 
both acute and chronic respiratory disorders, by increasing airway inflammation and 
increased hydrolysis of pulmonary surfactant lipids (Munoz, Meliton et al. 2007; Munoz, 
Meliton et al. 2009). 
sPLA2-V in Atherosclerosis and CHD 
Like sPLA2-IIA, sPLA2-V is present in both the normal artery and in the 
atherosclerotic vessel in an in vitro study (Masuda, Murakami et al. 2005). Some studies 
have failed to find evidence of significant sPLA2-V activity or levels in atherosclerotic lesions, 
suggesting that this protein has a less important role to play in CAD than sPLA2-IIA 
(Ishimoto, Yamada et al. 2003). These results are disputed in studies using 
immunohistochemistry that showed that sPLA2-V is present in the smooth muscle cell 
associated atherosclerotic lesions of mice and humans as well as in the areas around foam 
cells (Rosengren, Peilot et al. 2006; Bostrom, Boyanovsky et al. 2007). This suggests that 
the contribution of sPLA2-V to atherosclerosis may be localised to the intima of the vessel 
wall, probably altering lipoprotein/proteoglycan interactions at the surface of macrophages 
and increasing the deposition of collagen (Bostrom, Boyanovsky et al. 2007). 
 Unlike sPLA2-IIA, both sPLA2-V and X have been shown to be at least 20-fold more 
efficient in hydrolysing PC, including that seen in LDL and HDL phospholipid outer layers, 
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due to their high affinity for both anionic and zwitterionic phospholipid vesicles (Lambeau 
and Gelb 2008). 
     As previously mentioned, sPLA2-V has a strong effect on HDL. Secretory PLA2-V 
has been shown to preferably bind to the outer layer of PC in HDL as a substrate, altering 
the HDL apolipoprotein A (Apo-A) complex and impeding the reverse cholesterol transport 
pathway (1.4.5) to increase the risk of atherosclerosis (Ishimoto, Yamada et al. 2003).  
 A study using C57BL/6 mice to create pla2g5 knockouts from embryonic stem cells 
that had been transfected with a linearized gene targeting construct, monitored zymosan-
induced inflammatory products made in the cells of the wild type (shown to be at high levels) 
versus the cells of C57BL/6 pla2gv-/- mice (shown to be at low levels) and suggested that 
sPLA2-V has a role in eicosanoid generation regulation in response to an acute innate 
response of the immune system. This eicosanoid regulation is thought to be in the induced 
arachidonic acid pathway. Further findings confirmed sPLA2-V promotes the atherogenic 
process by both liberating potent pro-inflammatory lipid mediators and by modifying LDL to 
pro-atherogenic LDL (Satake, Diaz et al. 2004).  
A likely conclusion is therefore that sPLA2-V does play a role in CHD, but that it acts 
in a different way to sPLA2-IIA and seems to adopt elements of activity similar to both 
sPLA2-IIA and X, which have very different actions and activity (Webb, Bostrom et al. 2003; 
Rosengren, Peilot et al. 2006). However it is important to interpret these results with caution 
since they are mostly based on in vitro assays. 
sPLA2-X in Respiratory Disease 
 Like sPLA2-V, sPLA2-X has been shown to play a pathological role in respiratory 
diseases such as ARDs and asthma. It is thought to contribute to airway injury through the 
hydrolysis of pulmonary surfactant lipids, such as PC, in the same way as sPLA2-V (Curfs, 
Ghesquiere et al. 2008). Studies have also acknowledged the expression of sPLA2-X in the 
airway epithelial cells of both mice and humans (Masuda, Murakami et al. 2005; Hallstrand, 
Chi et al. 2007). PLA2G10 transgenic mouse models and knockout (pla2g10-/-) mouse 
models have been used since 2007 (Henderson, Chi et al. 2007; Curfs, Ghesquiere et al. 
2008) to confirm this pathologic effect of sPLA2-X. The use of sPLA2 inhibitors has been 
shown to improve the condition of ARDS models (Furue, Mikawa et al. 2001; Touqui and 
Alaoui-El-Azher 2001).  
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sPLA2-X in Atherosclerosis and CHD 
Unlike sPLA2-IIA and sPLA2-V, sPLA2-X is not seen in the healthy human artery, but 
it has been shown to be present in atherosclerotic plaques by immunohistochemistry 
(Kimura-Matsumoto, Ishikawa et al. 2008). As previously highlighted, it is the most potent of 
the three enzymes for hydrolysing PC and like sPLA2-V it has a high affinity for both anionic 
and zwitterionic phospholipid vesicles (Lambeau and Gelb 2008).  
 Treating cells with sPLA2-X induces an increase in the negative charge of LDL 
without the excessive modification linked with oxidation (Hanasaki, Yamada et al. 2002). 
This process of lowering the charge of LDL particles suggests that sPLA2-X treatment is a 
very efficient way to complete the prerequisite step required for LDL to promote the 
formation of foam cells (usually this occurs due to oxidation) and this promotes the 
pathogenesis of atherosclerotic lesions (Ishimoto, Yamada et al. 2003; Boyanovsky, van der 
Westhuyzen et al. 2005). 
Watanabe heritable hyperlipidemic (WHHL) rabbits were used to show that sPLA2-X 
(as well as sPLA2-V) unlike some other sPLA2 groups, including IIA, can induce lypolytic 
modification of HDL (Ishimoto, Yamada et al. 2003). As previously discussed, this reduces 
the ability of HDL to initiate cellular cholesterol efflux from macrophages containing high lipid 
levels (1.4.5). The study used immunohistochemical analysis to look at WHHL rabbit arterial 
intima, and observed that there is a significant expression of sPLA2-X in foam cell lesions 
there (Ishimoto, Yamada et al. 2003). The PLA2G10 transgenic mouse model and the 
knockout pla2g10 mouse model used previously to study the role of sPLA2-X in respiratory 
disorders (Henderson, Chi et al. 2007) have not currently been used to look at CHD risk. 
1.5.8. An Overview of sPLA2 Actions 
 Secretory phospholipase A2s have been associated with several biological 
processes and human diseases and the most significant of these have been discussed 
above. Figure 1.15 has been adapted from a recent review and is a useful schematic tool for 
presenting an overview of these processes (Murakami, Taketomi et al. 2011). Figure 1.15 is 
also a good illustration of the many unanswered questions that remain about in vivo sPLA2 
actions, several of which are addressed in this thesis. 
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Figure 1.15. A schematic representation of sPLA2 pathways. This figure represents the known and 
suspected biological pathways, processes and diseases that sPLA2 isoforms have been linked with. 
The figure also indicates how we have not yet comprehensively identified which of the sPLA2 
isoforms contributes to which processes, by what mechanisms and with what outcomes. Reprinted 
with permission from (Murakami, Taketomi et al. 2011).    
Summary of the sPLA2 Association with CHD Based on Current Data 
The identification of elevated sPLA2-IIA in the serum of rheumatoid arthritis patients 
(Seilhamer, Pruzanski et al. 1989) raised the question of the role of this enzyme in the 
inflammatory pathway. Atherosclerosis, which is often the initial stage of CHD, is considered 
to be an inflammatory disorder, leading researchers to consider the role of the supposed 
inflammatory biomarker, sPLA2-IIA, in the onset of CHD. Later, sPLA2-V and sPLA2-X were 
identified as additional potential causal risk factors of CHD. The literature to date has 
established that all three enzymes exist in the human atherosclerotic plaque (Karabina, 
Brocheriou et al. 2006; Rosenson and Gelb 2009). However, only sPLA2-IIA and sPLA2-V 
were shown to be present in the normal human artery (Karabina, Brocheriou et al. 2006). It 
has also been confirmed in observational studies that increased sPLA2-IIA levels are 
significantly associated with primary CHD, as has sPLA2-activity (Koenig and Khuseyinova 
2009). Additionally, serum measurements of both sPLA2-IIA levels and sPLA2 activity have 
been shown in observational studies to be associated with secondary events (Lind, Simon et 
al. 2012). There are however, some remaining questions, which are to be explored in this 
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thesis. For example, the observational, in vitro and in vivo data confirm a significant 
association between sPLA2 enzymes and CHD, probably through the previously established 
sPLA2/atherosclerosis pathway (summarised below in Figure 1.16). However, we do not 
know whether this association is causal or whether sPLA2 is merely a marker of 
atherosclerosis, induced by the onset of disease. In addition there are no known assays to 
measure sPLA2-V and sPLA2-X mass individually in the serum as we have seen for sPLA2-
IIA and there is no assay to measure individual serum activity measures of any of the three 
enzymes since the current assay is a composite measure of all three enzyme contributions 
(Mallat, Benessiano et al. 2007). This is problematic since we cannot be sure of which 
enzyme is the most effective. The group IIA enzyme is thought to be the most abundant 
(Mallat, Lambeau et al. 2010), but the group V and X enzymes are more potent so it is 
impossible to know which is the most effective without individual activity measures. 
 Figure 1.16 depicts the pathways through which previous research has suggested 
that sPLA2 enzymes contribute to atherosclerosis. It is not known whether these actions are 
causal for atherosclerosis onset or merely a disease/risk-factor induced marker. 
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 Figure 1.16. Secretory phospholipase interaction with lipoproteins is thought to increase the risk of 
atherosclerosis. SPLA2 enzymes are induced as part of the inflammatory pathway, which is known to 
initiate atherosclerosis. However, we do not know whether this pathway is part of the initial causal 
inflammatory response that induces atherosclerosis, or whether it is a secondary inflammatory 
response induced by plaque formation or an increase in a known causal biomarker. Secretory 
phospholipase A2 group IIA (green) is expressed in both the circulation and in the intima. It is thought 
to be the most abundant of the sPLA2 enzymes, but the least potent towards PC rich lipoproteins. It 
acts with weak effect on LDL-cholesterol in the circulation and in the extracellular matrix where is has 
the ability to bind to proteoglycans and modifies LDL to sd-LDL. It acts with slightly more potent effect 
on modified LDL (for example ox-LDL). Group V sPLA2 (purple) acts on LDL/LDL modified particles in 
the intima via interactions with proteoglycans in the extracellular matrix and directly on the surface 
phospholipids of LDL in the intima. Group V sPLA2 also acts on HDL/HDL-modified particles in the 
intima. As with sPLA2-V, sPLA2-X (orange) acts directly on the surface phospholipids on both 
LDL/LDL-modified and HDL/HDL –modified particles in the intima, however it cannot interact with 
proteoglycans to hydrolyse LDL surface phospholipids in the extracellular matrix. SPLA2-V and X are 
the most potent hydrolysers of lipoproteins such as LDL and HDL, which are high in PC. Modified 
lipoproteins remain in the intima and have an increased ability to bind to proteoglycans in the extra 
cellular matrix and to aggregate together. Further products of sPLA2 hydrolysis include elevated lyso-
phospholipid, free fatty acids, cytokines and increased sPLA2 enzymes. These products induce 
monocytes to move into the intima and become macrophages. The macrophages begin to 
phagocytose the modified lipoprotein aggregates and eventually become foam cells, which form the 
beginnings of atherosclerotic plaques. The increased inflammatory products act to increase sPLA2 
enzyme production. 
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 The pathways via which sPLA2 enzymes are thought to contribute to atherosclerosis 
do not confirm or refute the causality of sPLA2 in the onset of atherosclerosis. Since the 
enzymes are induced by various inflammatory markers there is currently no definitive 
evidence that sPLA2 enzymes are part of the inflammatory cascade that initiate 
atherogenesis or as part of a secondary cascade induced by the onset of the disease. The 
causality of sPLA2 enzymes in the process of atherogenesis is an important question to 
address to understand the value of sPLA2s as a candidate drug target for CHD.  
1.6. Varespladib: An sPLA2 Inhibitor Under Trial 
 Inhibitor drug compounds are often designed based on observational and early 
animal studies where data has indicated that blocking the pathway of a biomarker of interest 
will be beneficial regarding a disease outcome. An example of a class of drugs that were 
trialled in this way, with generally excellent outcomes in the reduction of disease versus 
potential side-effects, is statins. One of the early statin compounds is simvastatin, an 
inhibitor of HMG-CoA reductase that leads to a decrease of LDL-cholesterol, which was 
tested to evaluate its suitability for combating death by CHD in a large scale randomised 
control trial (RCT); The Scandinavian Simvastatin Survival Study (4S) (Kjekshus and 
Pedersen 1995). This trial showed that lowering LDL-cholesterol by inhibiting the HMG-CoA 
reductase pathway leads to a reduction in death by CHD. The trial was based on 4,444 
patients with angina pectoris or previous myocardial infarction and serum cholesterol levels 
of 213-310mg/dl while being treated with a lipid-lowering diet. Participants were randomly 
and blindly allocated to treatment with simvastatin or placebo with a follow-up over 5.4 years. 
The trial showed that simvastatin was associated with a risk reduction of 34% (P=0.0001) 
with major coronary events. The data showed how important drug inhibitors can be in the 
prevention and treatment of disease (Kjekshus and Pedersen 1995). This trial clearly 
confirmed that the relationship between LDL-cholesterol and CHD was a causal one. 
However, it has also been shown that inhibition of biomarkers that look potentially 
important in the causality of disease can have either unforeseen side-effects or can even be 
proved not to be causal. For example; Lp-PLA2 was identified as a potential therapeutic 
target for reducing the risk of CHD since observational studies showed a significant 
association between Lp-PLA2 activity and increased CHD risk (Kleber, Wolfert et al. 2011). 
Darespladib is an Lp-PLA2 inhibitory compound designed to decrease the risk of CHD. 
Animal studies and Phase I clinical trials proved the inhibitory effects of the drug on Lp-PLA2 
activity (Garcia-Garcia and Serruys 2009). However, no significant reduction in CHD risk 
was seen. Additionally, a study investigating genetic variants significantly associated with 
Lp-PLA2 activity examined the SNP rs1051931 (A379V), which was shown to be the SNP 
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with the strongest association to Lp-PLA2 activity. The VV genotypes showed 7.2% higher 
activity compared to AA genotypes. This SNP was not shown to be independently 
associated with CHD risk, suggesting that Lp-PLA2 does not play a causal role in CHD and 
therefore inhibition of this enzyme is unlikely to decrease CHD risk (Casas, Ninio et al. 
2010). Varespladib is a drug currently under development and comes from the same class of 
drugs as darespladib, but rather than inhibiting Lp-PLA2, it is a specific inhibitor of sPLA2, 
the novel biomarker explored during this thesis. Over 40 structural classes of sPLA2 
inhibitors exist and all but a few lack potency against sPLA2 action with 50% or more 
inhibitory concentration (IC50) value (Lambeau and Gelb 2008). Among the known inhibitors 
being developed is a class of sPLA2 inhibitors known as indoles, including varespladib the 
first in class to inhibit secretory phospholipases (Lambeau and Gelb 2008). At the beginning 
of my research, secondary trials for this drug were in their infancy, increasing the interest 
and validity of my research.  
1.6.1. Varespladib Structure and Production 
Varespladib (A-002) is an orally delivered drug that was being developed by Anthera 
Pharmaceuticals (http://www.anthera.com/) in a Phase III trial as specific inhibitor of sPLA2-
IIA, V and X (Nicholls, Cavender et al. 2011), hypothesising that inhibition of these enzymes 
will significantly reduce the risk of CHD. 
 The molecule was first identified by a high throughput screen to obtain lead 
compounds of interest for sPLA2 inhibition based on structure (Schevitz, Bach et al. 1995; 
Lambeau and Gelb 2008). Varespladib is a broad sPLA2-inhibitor with IC50 values in the 
nanomolar range. Studies show that these indole compounds contain amide carbonyl and 
carboxylate groups that act as direct ligands to the active calcium site (including the unique 
catalytic dyad comprising aspartic acid (Asp) and histidine (His)) of sPLA2 (Mihelich and 
Schevitz 1999; Smart, Pan et al. 2004; Lambeau and Gelb 2008). The chemical structure for 
varespladib is shown below in Figure 1.17.   
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Figure 1.17. The chemical structure of varespladib (Reprinted with permission from (Lambeau 
and Gelb 2008)). Varespladib is a specific sPLA2 inhibitor drug, which was trialled as a drug for 
the prevention of secondary cardiovascular events. 
Phase I and II trials provided some evidence that the drug may be of use for 
secondary prevention of major adverse coronary events such as myocardial infarction 
(Rosenson, Hislop et al. 2010; Rosenson, Elliott et al. 2011) and it was being trialled on a 
large ACS cohort in the Phase III trial, Vascular Inflammation Suppression to Treat Acute 
Coronary Syndrome (VISTA-16) (Nicholls, Cavender et al. 2011).  
Phase I trials studied the effects of varespladib methyl on Apoe knockout strain of 
atherosclerosis prone mice. The Apoe -/- mice used in these studies had a C57BL/6J 
background, where a frame-shift mutation causes the loss of sPLA2-IIA production. 
Varespladib was shown to reduce atherosclerosis in these mice by 48-52% at a dose of 30 
and 90mg/kg twice a day for 16 weeks, suggesting that varespladib was a potentially useful 
anti-atherosclerosis treatment and that may inhibit sPLA2-V and sPLA2-X (since sPLA2-IIA 
is not present), which implies that these isoenzymes may have additional significant effects 
towards atherosclerosis (Rosenson, Fraser et al. 2010). Total plasma cholesterol was also 
reduced by around 22% to 24%. Experiments in Apoe accelerated atherosclerosis and 
aneurysm models, administering a dose of 30mg/Kg twice a day, showed a similar reduction 
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of atherosclerosis and total elimination of any aneurysm formation (Rosenson, Fraser et al. 
2010). An additional study investigated the effects of a combination therapy of varespladib 
methyl and pravastatin in the Apoe-/- model (Shaposhnik, Wang et al. 2009). The results 
were interpreted to show a synergistic action between pravastatin and varespladib to reduce 
atherosclerosis, with the additional benefit that varespladib appeared to alter the structure of 
the lesion to a less mature version with a larger and more stable fibrous cap, thus reducing 
the likelihood of plaque rupture. In this instance the plasma LDL-cholesterol levels were 
unaltered by varespladib, but the results did show a 40% increase in HDL and an 80% 
increase in plasma paraoxonase (PON) levels, both of which are considered cardioprotective 
(Gordon, Probstfield et al. 1989; Assmann, Schulte et al. 1996; Shih, Xia et al. 2000; Hase, 
Tanaka et al. 2002). 
 High-fat, high-cholesterol diets fed to guinea pig models induced atherosclerosis 
(Leite, Vaishnav et al. 2009). Varespladib was introduced at 150mg/Kg per day and 
significantly reduced measures of IL-2, IL-10 and IL-12 as well as reducing cholesterol 
accumulation in aortic tissues by 26.5%. No significant effects were observed on plasma 
cholesterol levels. Atherosclerosis measured by severity score was decreased by 24% and 
when measured by digital imaging was reduced by 37%, though neither result was 
statistically significant. It was also acknowledged that varespladib decreased hepatic 
lipidosis (fatty liver) by around a third (Leite, Vaishnav et al. 2009).   
Phase II trial in humans were named Phospholipase Levels and Serological Markers 
of Atherosclerosis (PLASMA) I and II, Fewer Recurrent Acute coronary events with Near-
term Cardiovascular Inflammatory Suppression (FRANCIS) and the sPLA2 Inhibition to 
Decrease Enzyme Release after Pre-Cutaneous Intervention (SPIDER-PCI) trial (Rosenson, 
Fraser et al. 2010; Rosenson, Hislop et al. 2010). PLASMA I was a randomised, double-
blind, placebo-controlled parallel arm dose-ranging study (Rosenson, Fraser et al. 2010). 
Doses were administered twice a day at 50, 100, 250 and 500mg per day in 393 patients 
with stable CHD for 8 weeks (Rosenson, Hislop et al. 2009). There was a dose-dependent, 
significant reduction of sPLA2-IIA levels with varespladib (69.2-95.8%, P=0.0001). 
Comparison measures of sPLA2 activity could not be taken due to the enzyme mass in 
treated patients falling below the threshold necessary for sPLA2 activity measures. 
Varespladib treatment also appeared to modify LDL particles from small to large, 
significantly reducing the total LDL-cholesterol compared to placebo as well as decreasing 
ox-LDL and high-sensitivity CRP (Rosenson, Hislop et al. 2009).    
PLASMA-II was a randomised and placebo controlled trial where doses of 250mg 
and 500mg were administered to 135 stable CHD patients once a day for 8 weeks 
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(Rosenson, Elliott et al. 2011). The outcomes of this trial were very similar to those of 
PLASMA-I. A significant reduction in sPLA2-IIA levels was seen in a dose dependent 
manner. Reductions of 73.4% with 250mg and 84.4% with 500mg were observed. 
Additionally, LDL-cholesterol was reduced by 12-18% with a shift from smaller to larger 
particles appearing to drive this reduction and decreased ox-LDL and high-sensitivity CRP 
levels were also observed (Rosenson, Elliott et al. 2011). 
Based on evidence from these trials and previous in vivo and observational data, it 
appeared that sPLA2 acted through the inflammatory pathway to affect secondary coronary 
event incidence, and was unlikely to have an effect on primary cardiac event incidence. For 
this reason, varespladib was considered to be a drug that could be effective as a treatment 
for acute coronary syndrome (ACS) patients, who suffer from increased inflammation post-
event, as well as an increased risk of a second cardiac event (Blake and Ridker 2003). 
Varespladib was considered as an intervention to reduce inflammation and thus also 
significantly reduce the likelihood of a secondary major adverse coronary event (MACE), 
such as myocardial infarction, unstable angina or stroke.   
The FRANCIS trial was set up to observe the effect of varespladib on sPLA2-IIA 
levels in patients with acute coronary syndrome (ACS) as sPLA2-IIA was thought to be 
predictive for future events in this group (Rosenson, Hislop et al. 2010). There were 624 
patients enrolled in the trial, all of whom were already being treated with 80mg/day of 
atorvastatin. The patients were randomised to either a 500mg/day dose of varespladib or a 
placebo for a minimum of 6 months. Varespladib was shown to significantly reduce sPLA2-
IIA levels along with LDL-cholesterol and inflammatory biomarkers. A positive trend was 
seen for the reduction of unstable angina and myocardial infarction (Rosenson, Hislop et al. 
2010). 
The SPIDER-PCI trial included 144 patients randomised to either 500mg per day of 
orally administered varespladib or a placebo 3-5 days before an elective percutaneous 
coronary intervention (PCI) and then for 5 days following the operation. Results showed that 
while varespladib significantly reduced sPLA2-IIA levels, no other effects were seen for 
relevant biomarkers (Dzavik, Lavi et al. 2010).  
Despite some positive evidence in Phase I and II trials there were still many 
questions to be answered as to how effective this drug is at lowering secondary CHD risk, 
especially in comparison to treatments already in place. At the start of my studies for this 
thesis, the phase III VISTA-16 trial was in progress. This was a time consuming and 
expensive trial designed based on phase I and II results. I hope to show how the use of 
genetics earlier on in the drug development process can add valuable data to the suitability 
80 
 
of an enzyme as a drug target- in this case examining the causality of sPLA2 enzymes for 
CHD. This process may save time and resources for drug companies. 
1.7. Genetic Variations and Disease 
 The Human Genome Project was completed in 2003 (International Human Genome 
Sequencing 2004) and findings showed approximately 3.3 billion DNA base pairs along with 
around 23,000 protein-coding genes. This was far less than previously expected. It is 
estimated that around 1.5% of the genome is protein coding and the remainder is made up 
of non-coding ribonucleic acid (RNA) genes, introns, regulatory sequences and ‘junk’ DNA 
(International Human Genome Sequencing 2004). There has been an abundance of data 
available regarding the variation of the genome (Sachidanandam, Weissman et al. 2001) 
and a great many human DNA sequence variations have been identified due to advances in 
sequencing technology, which have increased both the speed and efficiency of sequencing. 
Every genome has around 4 million DNA sequence variants and several different types of 
variant exist. Some of the most common and important DNA variations are known as single 
nucleotide polymorphisms (SNPs). There are thought to be approximately 3 million SNPs 
within the human genome. There are also structural variations such as copy number variants 
(CNVs) that cover a wide number of nucleotides.  
 More recently the Encyclopedia of DNA Elements (ENCODE) project has examined 
the non-protein coding regions of the genome (Consortium, Bernstein et al. 2012). This 
project aimed to identify the functions of these regions, which make up the vast majority of 
the human genome. Systematic mapping of the various regions of transcription, transcription 
factor association, chromatin structure and histone modification was undertaken. The results 
suggested that over 80% of the genome can now be assigned a biochemical function. Many 
of these regions have subsequently been identified as candidate regulatory elements and 
are physically associated with each other and expressed genes and this gives researchers 
fresh insight into the mechanisms of gene regulation. The statistical correspondence of 
these newly identified elements with sequence variants was often significant and will aid the 
interpretation of these variations. The advances made by this project provide new insight s 
into the organization and regulation of our genes and genome and is an excellent resource 
for future studies (Consortium, Bernstein et al. 2012). 
 Genetic variations have been shown to have a strong biological and clinical impact. 
Complex common disorders are often due to many intricate interactions between a large 
number of genetic variants and environmental factors. Each factor contributes a small effect 
which can often be clinically insignificant. However, some SNPs contribute a much larger 
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effect size and can even have clinical significance which could lead to an improvement in 
treatment, early diagnosis or risk stratification (Marian 2010). 
For this thesis it was important to identify SNPs that played a functional role in 
sPLA2-IIA to use as viable genetic instruments in a large scale meta-analysis. By attempting 
to identify functional SNPs that showed differential effects on sPLA2-IIA mass and/or activity 
and the pathways they worked through, it would be possible to confidently predict that any 
associations with either CHD or CHD biomarkers seen with these variants would be truly due 
to changes in sPLA2-IIA levels or sPLA2 activity. The use of tagging-SNP (tSNP) analysis of 
PLA2G2A demonstrated a strong association of serum levels of sPLA2-IIA and PLA2G2A 
variants (Wootton, Drenos et al. 2006). Results also showed levels of sPLA2-IIA were 
negatively correlated with total antioxidant status and low HDL cholesterol in men 
(independent of CRP) and in women levels of sPLA2-IIA mass were correlated with CAD 
status. These results highlighted for the first time the relationship between genetics, elevated 
sPLA2-IIA levels and CAD (Wootton, Drenos et al. 2006). 
1.7.1. Genome-Wide Association Scans 
 Rather than focusing on a small candidate gene area to identify possible clinically 
relevant variations, a genome wide association scan (GWAS) study will scan the whole 
genome to detect all variations included in the array. It is a hypothesis free, unbiased 
approach allowing a comprehensive, genome wide survey. The limitations of such studies 
include the need for very large sample sizes, to avoid multiple testing errors (Suh and Vijg 
2005) and should a disease associated variant occur at a low frequency it will often be 
undetected by GWAS. It is also relatively expensive to carry out. 
1.7.2. Indirect/Direct Candidate Gene Approach 
 This is an alternative approach to GWAS that utilizes the indirect/direct candidate 
gene pathway, based on prior knowledge of the disease phenotype and genetic studies in 
model organisms or genetic location studies (Tabor, Risch et al. 2002). Pre-defined tagging-
SNPs (tSNPs) that exist across a gene or region of interest are utilised in indirect candidate 
association studies. Tagging-SNPs are variants that have been shown to occur in high 
linkage disequilibrium (LD). This means that the likelihood of a combination of variations or 
genetic markers occurring more or less frequently in a population compared to what would 
be expected by chance, i.e. there is little recombination between these alleles. Tagging-
SNPs can therefore be used to analyse large areas of a gene, since one tSNP is able to 
represent all SNPs in high LD with it across the gene. High LD is considered to be calculated 
at >90%. LD can be represented by either a D’ or an R2 value. The D’ value is a 
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measurement of LD between two variants that does not take into account the frequencies of 
each variant. Therefore two SNPs may be in high D’ but one allele occurs at a much higher 
frequency in a population that the other. A more precise LD measurement is R2, which does 
take into account allele frequency and therefore means that a high value not only suggests 
that two variants are often inherited together in a population, but additionally that they occur 
at a similar frequency in that population. Studies using tSNPs are used to investigate the 
genetic aetiology of complex diseases such as CHD. This approach was used to identify the 
tagging SNPs associated with the PLA2 genes.    
A previous study has identified tagging-SNPs for PLA2G2A (Wootton, Drenos et al. 
2006). Any significant associations between biomarkers and a tSNP can reasonably be 
assumed to occur with all tagged SNPs. Therefore tSNPs allow us to potentially interpret the 
effects of SNPs capturing the majority of the variance of a gene of interest in a cost and 
time-effective manner. However, once a significant association between a tSNP and a 
biomarker has been identified the question is raised about which SNP is the true functional 
variant, the tSNP or a tagged variant(s)? Knowledge of which SNP is functional can be 
important when attempting to assess the biological mechanism through which the variant 
acts, potentially helping to identify new drug targets. It also provides useful genetic tools for 
large scale observational studies. For the PLA2G2A gene, the six identified tSNPs captured 
92% of the variation of PLA2G2A (Wootton, Drenos et al. 2006). These tSNPs were 
genotyped in a cohort of patients with type 2 diabetes (the UDACS cohort- See 2.5) and their 
association with sPLA2-IIA mass and lipid traits was explored. Baseline measurements for 
sPLA2-IIA levels were taken in UDACS samples with and without CAD; 3.08ng/ml in 
samples without CAD (n=383) and 3.45ng/ml in patients with CAD (n=136). Additional 
baseline characteristics for this study are defined in 2.5 Table 2.6 and Table 2.7. Two tSNPs 
showed strong association with sPLA2 mass. For rs11573156 C>G in the 5’UTR  of 
PLA2G2A (which is potentially part of the PLA2G2A promoter) (Figure 1.18), compared to 
the common CC genotype, the G homozygotes had 2.16ng/ml higher sPLA2-IIA levels (P= 
1.9x10-14) from 2.59ng/ml (CC) to 4.75ng/ml (GG).The second variant, rs3767221 A>C in the 
3’UTR (Figure 1.18), showed the opposite effect with the rare homozygotes having 
significantly lower (1.77ng/ml) sPLA2-IIA mass (P=2.5x10-10) compared to the common A 
variant homozygotes from 3.94ng/ml (AA) to 2.17ng/ml (CC) (Wootton, Drenos et al. 2006).  
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 Figure 1.18. A Schematic Representation PLA2G2A and SNPs of Interest. This figure represents a 
map of the human PLA2G2A gene and our SNPs of interest, rs11573156 C>G and rs3767221A>C. 
Coding exons are shown as hatched blocks, non-coding exons are shown as empty blocks. The gene 
is reverse transcribed and this schematic is based on the Ensembl transcript; Transcript: 
ENST00000400520. This transcript relates to Gene: ENSG00000188257 and Protein: 
ENSP00000383364  (Based on data from Ensembl.org). Data from PharmGKB predicts that the 
5’UTR, including untranslated exon1 (54bp), untranslated exon 2 (110bp), the untranslated portion of 
exon 3 (105bp) and the additional untranslated sequence = 1638bp. The translated portion of exon 3 
= 39bp, intron 1= 208bp, exon 4 = 144bp, intron 2 = 257bp, exon 5 = 106bp, intron 3 = 2,170bp, exon 
6 translated = 142bp, exon 6 untranslated =2,66bp and the 3’UTR = 263bp.  
 
Additionally, our lab had previously identified seven tagging SNPs (Wootton, Arora et 
al. 2007), spanning the gene PLA2G5 (Figure 1.19 Table 1.5) were analysed in a cohort of 
Type II diabetes patients (UDACS). From these original 7 tSNPs, four SNPs were selected 
for further analysis on the basis of positive associations with sPLA2 mass and LDL 
cholesterol from univariate analysis in this study (Wootton, Arora et al. 2007).  
 
 
 
 
 
 
 
 
4.97Kb 
Chr1: 20306932 Chr1: 20301924 
Chr1: 20306146 
Chr1: 20301781 
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Figure 1.19. A schematic of the PLA2G5 gene and the 7 tSNPs originally identified (Wootton, Arora et 
al. 2007). Schematic reprinted from (Wootton, Arora et al. 2007). The UTR regions were defined in 
data from the Ensembl Genome browser as; 5’UTR= Chr1:20,396,451-20,396,700 and 3’UTR= 
Chr1:20,417,622-20,417,911. The region spanned here is from the upstream 5’UTR SNP rs11573185 
to downstream 3’UTR SNP rs622450, since these were the most extremely located previously 
identified tSNPs; Chr1: 20,395,401-20,419,340. 
SNPs and minor allele frequency of the PLA2G5 tSNPs in UDACS 
rs number Minor allele frequency (95% CI) 
rs11573185 0.45 (0.43-0.48) 
rs2148911 0.07 (0.05-0.08) 
rs11573191 0.18 (0.16-0.19) 
rs640022 0.15 (0.13-0.16) 
rs11573203 0.28 (0.26-0.30) 
rs11573248 0.36 (0.34-0.39) 
rs622450 0.14 (0.12-0.15) 
 
Table 1.5. The seven PLA2G5 tSNPs originally identified by Wootton et al. and their minor allele 
frequencies (Wootton, Arora et al. 2007). 
 
 Genetic variations in PLA2G10 have been utilised in only a few studies to assess the 
potential contribution of sPLA2-X to overall sPLA2 activity. However, the increased potency 
of sPLA2-X compared to sPLA2-IIA and even sPLA2-V (Ishimoto, Yamada et al. 2003) 
suggests that it could have a more significant effect on total sPLA2 activity, dependent on 
sufficient expression in a tissue of interest and therefore suggests further studies using a 
genetic approach would be valid. 
We identified 10 tagging-SNPs in PLA2G10 using the STRAM algorithm (Burkett, 
Ghadessi et al. 2005). Five of these tSNPs occurred at frequencies <5% and were not 
rs2148911 
rs11573191 
rs640022 
rs11573203 
rs11573248 
rs622450 
rs11573185 
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studied further and an additional three of these tSNPs were analysed in additional cohorts. 
An additional SNP, the C-SNP rs4003228 (R38C) had been reported by Gora et al (Gora, 
Perret et al. 2009), and was included in our study despite the low reported MAF (3%).    
A previous study (Gora, Perret et al. 2009) analysed and identified several potential 
SNPs of interest within the PLA2G10 gene in two cohorts; SIPLAC, a nested case control 
study of MI based on the trends and determinants in cardiovascular disease project registers 
recruited from samples in Belfast and Glasgow (n=312) and AtheroGene, a cohort of CAD 
patients recruited from the Department of Medicine II of the Johannes Gutenberg University 
Mainz and the Bundeswehrzentralkrankenhaus Koblenz at the occasion of a diagnostic 
coronary angiography (n=1,303). A priori inclusion criterion was the presence of a diameter 
stenosis >30% in at least one major coronary artery. Patients in this study were followed up 
for a median period of 6.2 years (Gora, Perret et al. 2009).  
In functional work (Gora, Perret et al. 2009) rs4003228 (R38C) was identified as the 
SNP with the most potential to affect the contribution of sPLA2-X to sPLA2 activity. The SNP 
was not shown to affect the risk of CHD in the combined AtheroGene and SIPLAC data, 
however this was potentially due to the lower MAF of this SNP (3%).  Data from the R38C 
functional experiments (Gora, Perret et al. 2009) suggested that R38C may play a role in 
controlling sPLA2-X activity. This substitution leads to an odd number of cysteines in the 
sPLA2-X protein, which could result in misfolding, mistargeting and subsequent protein 
degradation. Fluorescence immunocytochemistry experiments were carried out in COS-7 
cells which were transiently transfected with both R38C wild-type and rare sPLA2-X cDNA. 
Both forms of the protein were shown to be expressed in the endoplasmic reticulum and 
Golgi compartments. Analysis of the expression patterns and activity of both forms of the 
protein showed that the presence of the rare allele lowered the amount of sPLA2 protein 
produced by COS-7 cells, preventing its efficient secretion and it had low or no activity. 
These results suggested that the rs4003228 may have a potential impact on sPLA2-X 
activity (Gora, Perret et al. 2009).   
A second SNP, rs36072688 T>C, was also shown to have a potential to effect the 
risk of future cardiovascular events, but only in the AtheroGene study and not in a case-
control cohort. This SNP is located in the 5’UTR of PLA2G10 and requires further research. 
1.7.3. Mendelian Randomisation  
 There are many potential biases that can affect observational epidemiological 
studies. These include reverse causation and confounding and any of these biases can 
interfere with study outcomes and prevent a robust identification of causal associations. 
There have been several examples of randomised control trials (RCT) examining an 
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intervention that has been assessed as potentially causal in observational and/or animal 
studies and yet produced a different outcome from the RCT of a drug based intervention. For 
example, observational data has shown the potential causality of the Hedgehog pathway in 
pancreatic cancer development (Thayer, di Magliano et al. 2003), leading to the 
development of the drug IPI-926, to be co-administered with the known pancreatic cancer 
drug, gemcitabine. Results from murine studies have previously indicated that co-
administration of the drug IPI-926, a Hedgehog cellular signalling pathway inhibitor, with 
gemcitabine can help to stabilize the disease (Olive, Jacobetz et al. 2009). Randomised 
control trials, while being the gold standard for determining causality are expensive and time 
consuming. They can also be risky, since causality cannot be proven by observational and 
animal data alone. In the case of IPI-926 the drug company Infinity Pharmaceuticals, which 
owns rights to the compound, previously announced that it was ending trials of the drug for 
pancreatic cancer due to poor preliminary results in 122 patients with previously untreated 
metastatic pancreatic cancer. However, it is still unclear whether the Hedgehog pathway 
plays a causal role in pancreatic cancer or is a marker for the disease; is the drug ineffective 
or is the biomarker not causal? A method that could help to answer this question without the 
need for developing another molecule to trial is Mendelian randomisation. 
 Mendelian randomisation is a technique that takes advantage of natural genetic 
randomisation during conception. The random allocation of alleles at conception, lends itself 
to the likelihood that all other traits, besides the one you are investigating, are evenly 
distributed between the genotype groups, similar to the blind allocation of intervention and 
placebo in an RCT. Therefore the alleles are not affected by reverse causation. These 
germline genetic variants can act as proxy for environmentally modifiable biomarkers by 
acting as a genetic instrument for these biomarkers in observational studies. By separating 
individuals by genotype as either homozygous for common variant, homozygous for the rare 
allele or heterozygous and analysing changes to a biomarker and disease outcomes in each 
genetic group, it can be determined whether a particular genotype for a biomarker-affecting 
variant is more or less likely to be at risk for a disease without reverse causation. Regarding 
confounding, the nature of this technique is such that the observational outcomes for 
confounding factors are calculated at the same time as the associations for the potentially 
causal biomarker. If the genetic variation has no effect on any other biomarker besides the 
disease outcome it is strong evidence that any association with a disease can be attributed 
to the biomarker of interest. Mendelian randomisation can therefore be considered naturally 
analogous for randomised control trials (Figure 1.20), but at a fraction of the cost and time 
(Hingorani and Humphries 2005; Lawlor, Harbord et al. 2008). 
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Figure 1.20. Mendelian Randomisation is Analogous for an RCT. This figure shows the parallels 
between a randomised control trial (RCT) and the use of Mendelian randomisation in conjunction with 
an epidemiological observational study. Reprinted from: (Hingorani and Humphries 2005). 
 
 An excellent example of how Mendelian randomisation has been used to great 
success was after the recent termination of a Phase III trial for the CETP inhibitor, 
torcetrapib (Barter, Caulfield et al. 2007). Torcetrapib was a first in class inhibitor of CETP, 
which is known to increase HDL levels. The trial was halted prematurely in 2006 due to an 
unexpected increase in blood pressure and cardiovascular events associated with the drug 
(Barter, Caulfield et al. 2007). This was despite positive results from a Phase II trial (Jensen 
and Hampton 2007). What was unclear was whether this increase in blood pressure was 
due to an off-target effect of the drug or as a direct result of CETP inhibition. It was essential 
to investigate this since other novel CETP inhibitors were already being produced. Should 
CETP inhibition raise blood pressure then it would be unethical to use any CETP inhibitor to 
raise HDL in patients with a high risk of CHD. However, if the increase in blood pressure 
could be attributed to an off-target effect of torcetrapib specifically then it would be very 
worthwhile to continue with research into other CETP inhibitor drugs. It would be costly and 
morally questionable to attempt to trial another CETP inhibitor without first knowing whether 
it was likely to endanger patients. By employing Mendelian randomisation to compare a 
group with naturally decreased CETP activity with a group with normal CETP activity, one 
could conclude whether lower CETP is naturally associated with an increase in blood 
Factor-lowering therapy 
Factor-lower Factor-higher Factor-lower Factor-higher 
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pressure (Sofat, Hingorani et al. 2010). If not then it would be a reasonable conclusion that it 
is an off target effect of torcetrapib specifically. A large Mendelian randomisation study was 
carried out using CETP genetic variants which mimicked the effects of torcetrapib by 
inhibiting CETP and increasing HDL levels. A total of 67,687 individuals from genetic studies 
and 17,911 from randomized trials were genotyped for these variants and their effects on 
several cardiovascular risk factors, including blood pressure, were compared (Sofat, 
Hingorani et al. 2010). These results were then matched with those of the torcetrapib trial. 
The study showed no significant differences in blood pressure associated with the genetic 
variant for lower CETP. This suggests that inhibition of the CETP pathway is still a valid 
research tool to treat those at a high risk of CHD since the increased blood pressure 
associated with torcetrapib appears to be an off-target of this drug only and a different class 
of drugs is unlikely to cause the same problem (Sofat, Hingorani et al. 2010).  
Additionally an MR study was carried out with the inflammatory marker, IL-6 where 
IL-6 polymorphisms have been used to assess the potential of IL-6 receptor blockers as an 
intervention for CHD (Interleukin-6 Receptor Mendelian Randomisation Analysis, Hingorani 
et al. 2012). The data showed favourable results regarding IL-6R inhibition as a mechanism 
for CHD prevention (Interleukin-6 Receptor Mendelian Randomisation Analysis, Hingorani et 
al. 2012). Conversely, recent MR results suggest that C-reactive protein inhibition is not a 
viable intervention to prevent CHD events (Collaboration, Wensley et al. 2011). Despite 
showing a strong independent association with CHD in observational studies, when selected 
CRP polymorphisms were analysed in an MR setting it was concluded that CRP is unlikely 
to play a causal role in the disease (Collaboration, Wensley et al. 2011). This was supported 
by several additional studies (Collaboration 2008; Elliott, Chambers et al. 2009) and provides 
researchers with strong evidence against developing CRP inhibitors with the intention of 
reducing CHD.  
1.8. Hypothesis 
 That secretory phospholipase A2 enzymes, sPLA2-IIA, sPLA2-V and sPLA2-X have 
a significant, independent effect on the risk of CHD. 
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1.9. Aims 
The following specific aims will be addressed to support the hypothesis outlined above 
i. To identify common genetic polymorphisms in PLA2G2A, PLA2G5 and PLA2G10 
that are associated with increased sPLA2-IIA levels and/or sPLA2 activity. 
 
ii. To examine the functionality of PLA2G2A common polymorphisms associated with 
sPLA2-IIA levels and activity in order to establish a biological mechanism and verify 
the polymorphisms’ suitability as genetic instruments for Mendelian Randomisation. 
 
iii. To genotype the genetic variants identified in aim (i) and verified in aim (ii) in a 
number of large prospective and case control studies. 
 
iv. To use the data generated in aim (iii) for PLA2G2A common polymorphisms in a 
large Mendelian Randomisation study to examine the association of sPLA2-IIA with 
CHD and a number of established CHD biomarkers and its likely contribution to 
sPLA2 activity measures. 
 
v. To use the data generated in aim (iii) for both PLA2G5 and PLA2G10 common 
polymorphisms to examine their potential association to CHD and CHD biomarkers 
and their potential contribution to sPLA2 activity measures.  
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CHAPTER 2 
MATERIALS AND METHODS 
 
 Please note: Gloves were used throughout for all methods. Filter tips were used and protective 
garments worn throughout where appropriate. All stocks and solutions were sterilised where necessary 
using standard conditions (121˚C for 1 hour).  
2.1. Commonly Used Reagents, Stocks, Products and Kits (alphabetical) 
Reagent/Stock/Kit: Supplier: Contains: 
Agarose Invitrogen (Life technologies), Carlsbad, California, USA 
(Catalogue №: 16500-500) UltraPure Agarose, 500g powder 
Ammonium Persulphate 
(APS) 
Severn Biotech (Worcester, UK), (Catalogue №: 20-3001-
25) 
 
25g Ammonium Persulphate 
(APS), >99% purity (228.2g/mol) 
Ampicillin Sigma-Aldrich (St. Louis, MO, USA (Catalogue №: A9518)  
Ampicillin sodium salt 
(C16H18N3NaO4S) 
Ampicillin solution made up with 
dH2O (50mg/ml) 
Annealing Buffer (10x) Made up in house 
0.2M Tris (pH 7.6) 
0.1M MgCl2 
0.5M NaCl 
Β-Galactosidase (β-Gal) 
Staining Kit 
Promega (Madison, Wisconsin, USA) (Catalogue №: E1081) 
 
β-Gal Staining plasmid    pSV-β-
Galactosidase Control Vector 
(20µg) 
Binding Buffer (10x) (EMSA) Made up in house 0.1M Tris 0.5M KCl pH 7.5 
Biotin-11-dUTP 
Thermo Scientific, Fermentas Molecular Biology Tools 
(ThermoFisher Scientific, Waltham, MA, USA), (Catalogue 
№: R0081) 
Biotin-11-dUTP (50nM) 
 
Buffer A (Nuclear Extract) Made up in house 
10mM HEPES, pH 7.9, 4ºC 
1.5mM MgCl2 
10mM KCl 
0.5mM dithiothreitol (DTT) 
(C4H10O2S2) 
Buffer C (Nuclear Extract) Made up in house 
20mM HEPES, pH 7.9, 4ºC 
25% v/v, Glycerol, 0.42M NaCl, 
1.5mM MgCl2, 0.2M EDTA, 0.5mM 
PMSF, 0.5mM DTT 
Cell Fixture Solution 
 
Made up in house 
10% Phosphate buffer solution 
(PBS) (10x), 5% Formalin (40% 
formaldehyde solution), 0.2% 
glutaraldehyde, dH2O 
Chloroform (≥99%) 
 
Sigma-Aldrich (St. Louis, MO, USA). (Catalogue No.: 
C2432-500ML). 
 
Chloroform (CHCl3) with amylenes 
as a stabilizer (Molecular weight: 
119.38) (500ml) 
 
Deoxyribonucleotide 
triphosphate (dNTP) Mix 
 
New England Biolabs (Ipswich, MA, USA), (Catalogue No.: 
NO447S). 
 
Deoxynucleotide Solution Mix, 
equimolar solution of dATP, dCTP, 
dGTP and dTTP (10mM per 
nucleotide triphosphate) 
Dimethyl sulfoxide (DMSO) 
(10x) 
 
Sigma-Aldrich (St. Louis, MO, USA) (Catalogue No.: D9170-
5VL). 
Dimethyl sulfoxide ((CH3)2SO) 
PCR reagent, 5ml 
DH5α Derived Competent 
E.Coli Cells 
 
New England BioLabs (Ipswich, MA, USA) (Catalogue No.: 
C2988J) 
 
NEB 5-alpha Competent E.Coli 
(Subcloning efficiency), 6 tubes 
(0.4ml/tube) 
DNA Ladder Invitrogen (Life technologies, Carlsbad, California, USA), (Catalogue No.: 10787-018). Plus DNA Ladder (1kb), 250µg 
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Dulbecco’s Modified Eagle 
Medium (DMEM) (Serum 
containing) 
PAA The Cell Culture Company (GE Healthcare, Pasching, 
Austria) (Catalogue No.: E15-810), 
PAA The Cell Culture Company (GE Healthcare, Pasching, 
Austria), (Catalogue No.: A15-151) 
DMEM with 4.5g/L glucose and L-
Glutamine 
10% Foetal bovine serum (Gold) 
Electrophoretic Mobility Shift 
Assay (EMSA) Detection Kit 
Thermo Scientific (ThermoFisher Scientific, Waltham, MA, 
USA), (Catalogue No.: 20148) 
LightShift Chemiluminescent 
EMSA Kit (100 reactions per 
kit) 
Ethidium Bromide Invitrogen (Life technologies, Carlsbad, California, USA), (Catalogue No.: 15585-011) 
UltraPure Ethidium Bromide 
solution (10mg/ml) 
Glycerol Made up in house 
50% v/v 
Glycerol (C3H8O3) 
dH2O 
Human hepatocellular 
carcinoma (Huh 7) Cell Line 
 
Health Protection Agency Culture Collections, (Catalogue 
No.: 01042712) 
Human hepatocellular carcinoma 
(Huh-7D12) cell line 
Hybond-N+ Membrane GE Healthcare (Thermo Fisher Scientific, Waltham, MA, 
USA). (Catalogue No.: GZRPN3050B). Hybond-N+ (300mmX3M) 
Isoamyl Alcohol (≥98%) Sigma-Aldrich (St.Louis, MO, USA), (Catalogue No.: 
W205702-1KG-K). 
Isoamyl 
(CH3)2CHCH2CH2OH) (Molecular 
weight: 88.15) 
Lipofectamine™ 2000 Invitrogen (Life technologies, Carlsbad, California, USA), 
(Catalogue No.: 11668-019) 
1.5ml Lipofectamine™ 2000 
Transfection Reagent (1mg/ml) 
Loading Buffer (6x) (Agarose 
gels) Made up in house 
10mM Tris-HCl (pH 7.6), 0.03% 
Bromophenol Blue, 0.03% Xylene 
Cyanol CFF, 60% glycerol 
(C3H8O3), 60mM, 
Ethylenediaminetetraacetic   
(EDTA) acid 
 
Loading Buffer (EMSA) Made up in house 
50% v/v: 10x Xylene Cyanol CFF 
loading buffer, 10x Bromophenol 
Blue loading buffer 
 
    Luciferase Assay Kit 
 
Made up in house 
50% v/v: 10x Xylene Cyanol CFF 
loading buffer, 10x Bromophenol 
Blue loading buffer 
Luria Bertani (LB)-Agar Made up in house 
Per 100ml: 1g Tryptone 
(C4H11NO3·HCl), 0.5g yeast 
extract, 1g sodium chloride 
(NaCl2), 0.1ml of 5M sodium 
hydroxide (NaOH), 1.5g Agar, 
99.9ml dH2O 
Luria Bertani (LB)-Medium Made up in house 
Per 100ml: 1g Tryptone 
(C4H11NO3HCl), 0.5g sodium 
chloride (NaCl), 0.5g yeast extract, 
0.2g glucose (C6H12O6), 100ml 
dH2O 
Lymphocyte Separation 
Solution 
PAA: The Cell Culture Company (GE Healthcare, Pasching, 
Austria). (Catalogue No.: J11-004). 
 
Lymphocyte Separation Medium 
LSM 1077 with Ficoll™ density 
gradient media (1,077g/ml) 
Magnesium Chloride (MgCl2) 
See Taq DNA Polymerase (Recombinant). MgCl2 is 
provided with this kit (Invitrogen (Life technologies, 
Carlsbad, California, USA), Catalogue No.: 10342-020) 
50mM MgCl2 
Maxiprep Kit Sigma-Aldrich (St. Louis, MO, USA), (Catalogue No.: NA0310-1KT). 
GenElute™ HP Plasmid Maxiprep 
Kit, used to isolate plasmid DNA 
up to 1.2mg (25x reaction kit) 
Micro Array Diagonal 
Gel Electrophoresis 
(MADGE) Gel (6%) 
Made up in house 
For 1 x 1.5mm gel: 12ml 30% 
polyacrylamide (37:5:1), 47ml 
dH2O, 3ml TBE (10x), 50µl 
TEMED, 500µl Ammonium 
Persulphate (APS) 10x) 
Miniprep Kit Qiagen (Hilden, Germany), (Catalogue No.: 27104). 
QIAprep Spin Miniprep Kit, for 
purification of up to 20µg molecular 
biology grade plasmid DNA (50x 
reaction kit) 
    NH4 Polmix Buffer (10x) Made up in house 
16mM [NH4]2SO4 
67mM Tris-HCL, pH8.4 
0.01% Tween 20 
2mM dATP, 2mM dTTP, 
2mM dGTP & 2mM dCTP 
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Opti-Mem® Gibco (Life technologies, Carlsbad, California, USA), (Catalogue No.: 31985-062) 
Opti-Mem (Opti-Minimal Essential 
Medium) (100ml) 
pGL3 Luciferase Reporter 
Vectors 
Promega (Madison, Wisconsin, USA), pGL3 
(Catalogue No.: E1751) 
(Catalogue No.: E1761) 
(Catalogue No.: E1741) 
Luciferase Reporter Vectors for 
quantitative analysis of potential 
regulatory factors of mammalian 
genes. pGL3-Basic vector (20µg) 
(Figure 2.1), pGL3-Promoter vector 
(20µg) (Figure 2.2), pGL3-Control 
vector (20µg), (Figure 2.3) 
Phosphate Buffer Saline 
(PBS) 
Gibco, (Catalogue No.: 18912014) 
 
100 solid tablets, each to be 
dissolved in 500ml dH2O (1x) 
Polyacrylamide 
Severn Biotech (Worcester, UK) (Catalogue No.: 20-2300-
10) (Catalogue No.: 20-2100-10) 
 
(30%) (19:1) 30% Acrylamide Gel 
solution Bis-Acrylamide (w/v) Ratio 
19:1 (concentrate) 
(30%) (37:5:1) 30% Acrylamide 
concentrate Bis-Acrylamide (w/v) 
Ratio 37:5:1 Protein Gel 
Primers 
Designed using the program Primer3 version 4.0 
(http://frodo.wi.mit.edu/primer3/). Primers synthesised by 
Eurofins MWG Operon (Ebersberg,Germany) 
All primers diluted to 100pmol/µl as 
standard. 
 
pRL-TK Renilla Luciferase 
Control Reporter Assay 
Promega (Madison, Wisconsin, USA), (Catalogue No.: 
E2241) 
 
pRL-TK Vector (20µg). An internal 
control reporter used in 
combination with an experimental 
reporter vector (e.g. pGL3 reporter 
vectors) to cotransfect mammalian 
cells. Used with the Dual 
Luciferase Reporter Assay 
Protease Inhibitor 
Thermo Scientific, Pierce Protein Research Products 
(ThermoFisher Scientific,Waltham, MA, USA) (Catalogue 
No.: 78410) 
2ml Protease Inhibitor Cocktail Kit 
(100x) 
 
pUC19 
 
New England Biolabs (Ipswich, MA, USA), (Catalogue No.: 
N3041L). 
pUC19, a commonly used plasmid 
cloning vector in E.coli 
(1,000µg/ml) 
Random Primers (d(N)6) 
Invitrogen, (Life technologies, Carlsbad, California, USA), 
(Catalogue No.: 48190-011) 
 
9 Units Random Primers 
(Hexamers) (3µg/µl in 3mM Tris-
HCl (pH 7.0), 0.2mM EDTA) 
Restriction Enzymes and 
buffers 
New England Biolabs (Ipswich, MA, USA) (Individual 
enzyme catalogue Numbers can be found at: 
http://www.neb.com/nebecomm/products/category1.asp) 
Known Restriction Endonucleases 
with relative consensus sequences 
and corresponding NEB Buffers (10x) 
Ribonuclease (RNase) H 
New England BioLabs (Ipswich, MA), (Catalogue No.: 
MO297S) 
 
250 units Ribonuclease H (RNase 
H) (5000U/ml) 
 
RNeasy Mini Kit 
 
Qiagen (Hilden, Germany). (Catalogue No.: 74104). 
RNeasy Mini Kit, for purification of 
up to 100µg total RNA from cells, 
tissues and Yeast (50 reaction kit) 
Saline Sodium Citrate (SSC) 
Buffer (20x) 
Made up in house 3M sodium chloride (NaCl2) 
0.3M sodium citrate dH2O 
Site Directed Mutagenesis Kit 
Stratagene (California, USA), QuikChange® (Catalogue No.: 
210518) 
 
Lightning Site-Directed 
Mutagenesis Kit 
Superscript III Reverse 
Transcription Kit 
Invitrogen, (Life technologies, Carlsbad, California, USA) 
(Catalogue No.: 18080-044) 
 
10,000 Units Superscript III 
Reverse Transcriptase (200U/µl) 
First Stand Buffer (5x) 
Dithiothreitol (DTT) 100mM 
T4 DNA Ligase New England BioLabs (Ipswich, MA, USA), (Catalogue No.: M0202S) T4 DNA Ligase kit 
Taq DNA Polymerase 
(Recombinant) 
Invitrogen (Life technologies, Carlsbad, California, USA) 
(Catalogue No.: 10342-020) 
 
Thermostable Thermus aquaticus 
(Taq) DNA Polymerase (500 units at 
5 U/µl). Amplifies products up to 5Kb. 
50mM MgCl2 
 
TaqMan ® SNP Genotyping 
Assays 
Applied Biosystems (Life technologies, Carlsbad, California, 
USA), (Part No.: 4351379).  
Table 2.2. Individual TaqMan ® SNP Genotyping Assay List 
Human Pre-Designed 
SNP Genotyping Assays (40x), 
small scale (Table 2.2) 
TaqMan ® (Genotyping) 
Universal PCR Master Mix 
Applied Biosystems (Life technologies, Carlsbad, California, 
USA), (Part No.: 4371355) 
 
TaqMan Genotyping Master Mix 
(2x) with AmpliTaq Gold DNA 
polymerase, 1- Pack (1x 10ml) 
93 
 
TaqMan ® Gene Expression 
Assays & Endogenous 
Controls 
Applied Biosystems (Life technologies, Carlsbad, California, 
USA), (Part No.: 4331182).  
Table 2.3. Individual TaqMan® Gene Expression Assay List 
Small Inventoried TaqMan Gene 
Expression or Endogenous Control 
Assay (20x) (Table 2.3) 
TaqMan® Gene Expression 
Master Mix 
Applied Biosystems (Life technologies, Carlsbad, California, 
USA), (Part No.: 4369016) 
TaqMan Gene Expression Master 
Mix (2x), 1-Pack (1x 5ml) 
Terminal Deoxynucleotidyl 
Transferase (TdT) 
Thermo Scientific, Fermentas Molecular Biology Tools 
(ThermoFisher Scientific, Waltham, MA, USA) (Catalogue 
No.: EP0161) 
 
500 Units Terminal 
Deoxynucleotidyl Transferase 
(TdT) enzyme (20U/µl) 
0.4ml TdT Reaction Buffer (5x) 
Tetramethylethylenediamine 
(TEMED) 
 
VWR International (Radnor, Pennsylvania, USA), (Catalogue 
No.: 443083G) 
 
TEMED (NNN’N’-
Tetramethylethylenediamine) 
Electran, (CH3)2NCH2CH2N(CH3)2, 
(116.21g/mol) 
Tris-Borate-EDTA (TBE) 
Buffer (10x) Fisher BioReagents, (product No.: BP13334) 4L PolyPac 
Trypsin Gibco (Life technologies, Carlsbad, California, USA), (Catalogue No.: 25200-056) 
0.25% Trypsin-EDTA (1x), phenol 
red 
Whatman Chromatography 
Paper 
Whatman (GE Healthcare) From Fisher Scientific (Thermo 
Fisher Scientific, Waltham, MA, USA), (Product Code: CJF-
240-070E) 
 
Whatman chromatography paper No 
3MM Chr electrophoresis and 
chromatography thick smooth 
surfaced 75mm, width 100m 
White Cell Culture Plates Appleton Woods (Appleton Woods Limited, Birmingham, UK), (Code: CC701, Alt Code: 3362) 
96 well plate, flat-well, sterile, 
with lid, Corning (100 pack) 
X- Galactosidase (X-gal) Made up in house 
10% Phosphate buffer solution (PBS) 
(10x), 10% Potassium ferricyanide 
(50mM), 10% Potassium ferrocyanide 
(50mM), 0.2% MgCl2 (1M), 2% X-Gal 
(20mg/ml) 
 
 
Table 2.1. Is a comprehensive list of commonly used reagents, stocks and kits. It includes details of the production 
company and what each kit contains or what each reagent/stock is made up from. 
 
            
Figure 2.1. The pGL3-Basic Luciferase Reporter Vector. This vector includes, 2 polylinker sites, the firefly and renilla 
luciferase (luc+) genes, a SV40 late poly(A) signal and the Ampr, ampicillin resistance region. 
(www.promega.com/~/media/Files/Resources/Protocols/Technical Manuals/0/pGL3 Luciferase Reporter Vectors 
Protocol.ashx) 
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Figure 2.2. The pGL3-Promoter Luciferase Reporter Vector. This vector includes, 2 polylinker sites an SV40 promoter, 
the firefly and renilla luciferase (luc+) genes, the SV40 late poly(A) signal and the Ampr, ampicillin resistance region. 
(www.promega.com/~/media/Files/Resources/Protocols/Technical Manuals/0/pGL3 Luciferase Reporter Vectors 
Protocol.ashx) 
Figure 2.3. pGL3-Control Vector. Contains an SV40 promoter and enhancer sequences that result in a strong 
expression of both the firefly and renilla luciferase (luc+) genes in many mammalian cell types. This plasmid is often 
used as a general check for transfection efficiency and as an internal standard for promoter and enhancer enzyme 
activities expressed by pGL3 recombinants www.promega.com/~/media/Files/Resources/Protocols/Technical 
Manuals/0/pGL3 Luciferase Reporter Vectors Protocol.ashx) 
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Table 2.2. Individual TaqMan ® SNP Genotyping Assay List 
 
 
 
 
Table 2.3. Individual TaqMan® Gene Expression Assay List  
2.2. Commonly Used Websites, Software and Services (alphabetical) 
Name: Company Details: Product Details: 
 
1000 Genomes 
Browser 
 
http://www.1000genomes.org/ensembl-browser 
1000 Genomes 2008-2012 
database. A deep catalogue of 
human genetic variation. 
 
Anthera 
Pharmaceuticals 
 
Anthera Pharmaceuticals (Hayward, CA. USA) http://www.anthera.com/ 
This company was developing 
varespladib methyl, a specific 
sPLA2 inhibitor. 
 
CLUSTALW 
 
Multiple Sequence Alignment by CLUSTALW 
(http://www.genome.jp/tools/clustalw/) 
Compares two FASTA sequences 
for alignment. It is often used to 
check the sequence of a DNA 
product compared to a known 
consensus sequence. 
Ensembl Genome 
Browser 
 
www.ensembl.org. 
International genome database 
project run by the Ensembl 
Scientific Advisory Board 
 
FinchTV 
 
PerkinElmer (Geospiza, Seattle, WA, USA) 
FinchTV Version 1.4 trace viewer 
software reads results from Source 
BioScience sequencing (See 
Sequencing DNA) and presents 
them as an electropherogram. This 
software also allows results to be 
read as a FASTA sequence in both 
forward and reverse orientations. 
 
Genesnap 
 
Syngene (Syngene UK, Cambridge UK) Genesnap software v6.04 
Software used in conjunction with 
Syngene Gel Documentation 
System to visualise and 
photograph gel electrophoresis 
products. 
 
International 
HapMap Project 
A partnership of scientists and funding agencies from Canada, China, 
Japan, Nigeria, the United Kingdom and the United States 
(http://www.hapmap.ncbi.nlm.nih.gov/). 
A public resource that helps to find 
genes associated with human 
disease and response to 
pharmaceuticals. 
Gene  SNP Assay Number Vic Probe  
Genotype 
Fam probe  
Genotype 
PLA2G2A rs11573156 PLA2C763G C G 
PLA2G2A rs3767221 PLA2T5128G T G 
PLA2G5 rs11573185 PLA2G5C100A C A 
PLA2G5 rs11573248 P5TAD12605 TA - 
PLA2G5 rs11573191 PLG5G1114A G A 
PLA2G5 rs11573203 PG5GDE3272 G - 
PLA2G10 rs72546339 PLG10C264A C A 
PLA2G10 rs72546340 PLG10G303C G C 
Gene  Target or 
Endogenous 
Control 
Exons Spanned Assay Number Reporter 
Dye 
PLA2G2A Target 1-2 Hs01044022_m1 FAM 
PLA2G2A Target 5-6 Hs00179898_m1 FAM 
ACTB Control N/A Hs99999903_m1 FAM 
GAPDH Control N/A Hs99999905_m1 FAM 
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MirBase MirBase The microRNA Database. Manchester University, Manchester 
UK. www.mirbase.org 
Algorithms from this website were 
used to predict miRNA binding in 
sequences of interest. 
MiRanda version 
4.0 
The European Bioinformatics Institute (EBI) (Wellcome Trust Genome 
Campus, Cambridgeshire, England) http://www.ebi.ac.uk/ 
Algorithms from this website were 
used to assess potential microRNA 
binding to sequences of interest. 
 
mirTar 
 
MicroRNA Target prediction (mirTar) (Institute of Bioinformatics National 
Chiao Tung University, Hsinchu, Taiwan). 
A tool to easily identify the 
biological functions and regulatory 
relationships between a group of 
known/putative miRNAs and 
protein coding genes and 
perspective on the information 
about miRNA targets on 
alternatively spliced transcripts. 
 
MatInspector 
Genomatix Software GmbH (Munich, Germany) 
www.genomatix.de/online_ 
Help/help_matinspector/matinspector_Help.html 
MatInspector. Database for 
transcription factor prediction. 
 
NEBCutter 
 
New England Biolabs (Ipswich, MA, USA). NEBCutter, version 2.0, 
http://www.neb.com/tools/index.aspx?req=nebcutter 
A tool used to identify natural 
cutting sites for Restriction 
Enzyme cutting in a sequence of 
interest (Vincze, T., Posfai, J. and 
Roberts, R.J. NEBcutter: a 
program to cleave DNA with 
restriction enzymes Nucleic Acids 
Res. 31: 3688-3691 (2003)). 
PharmGKB Pharmacogenomics. Knowledge. Implementation. (Stanford University 
USA) www.pharmkb.org 
Used to identify intron/exon 
boundaries and 5’UTR/3’UTR 
boundaries. 
PITA 
Segal Lab of Computational Biology (Weizmann Institute, Rehovot, 
76100, Israel) 
(http://genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html). 
MicroRNA target prediction 
algorithm. 
RegRNA A Regulatory RNA Motifs and Elements Finder (National Chiao Tung University, Taiwan) (http://regrna.mbc.nctu.edu.tw/). 
MicroRNA target prediction 
algorithm. 
REST-384 
Software 
Relative Expression Software Tool (REST)-384 (REST.gene-quantification.info). 
(Download at: (http://www.gene-quantification.de/download.html). 
Software designed to interpret 
gene expression data to compare 
genes and genotypes  
Restriction Enzyme 
Consensus 
Sequences 
New England Biolabs (Ipswich, MA, USA) 
(http://www.neb.com/nebecomm/EnzymeFinderSearchByRecombinant.asp). 
A catalogue of known restriction 
enzyme consensus sequences 
 
Sequence 
Detection System 
(SDS) v2.1 
 
Applied Biosystems (Life technologies, Carlsbad, California, USA) 
 
Sequence Detection System 
software version 2.4.1. High-
throughput gene expression and 
genotyping analysis software for 
use with the 7900HT Fast Real-
Time PCR System 
 
Sequencing DNA 
 
Where DNA sequences were to be verified, sequencing was carried out 
by Source BioScience, (London, UK) 
≥10µl DNA product (100ng/µl) was 
sent along with known primers 
(3.3pmol/µl) to be sequenced. 
Results are supplied as a file for 
use with FinchTV (See FinchTV) 
to be viewed as an 
electropherogram. 
 
SNAP Pairwise 
LD version 2.2. 
 
 
SNP Annotation and Proxy Search (BROAD Institute) 
http://www.broadinstitute.org/mpg/snap/ldsearchpw.php 
Input SNPs to calculate the LD 
between them using genotyping 
data from the 1000 Genomes 
Database and the International 
HapMap Project 
 
Tm Calculator 
 
Thermo Fisher Scientific, Waltham, MA, USA 
http://www.finnzymes.fi/tm_determination.html 
Finnzymes PCR & qPCR-products. 
Calculates optimum melting 
temperatures. 
 
UCSC Genome 
Browser 
The UCSC Genome Bioinformatics Group of UC Santa Cruz, California, 
USA http://genome.ucsc.edu/cgi-bin/hgGateway. Genome Reference Consortium 
 
WinGlow 
Software 
See Tropix TR717 Microplate Luminometer See Tropix TR717 Microplate Luminometer 
Table 2.4. A comprehensive overview of the software and bioinformatics databases used throughout this thesis. 
Includes company information and a brief description of use for each website. 
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 2.3. Commonly Used Laboratory Machines and equipment (alphabetical) 
Equipment: Company: Description: 
 
7900HT Fast Real-Time PCR 
System 
Applied Biosystems (Life 
technologies, Carlsbad, California, 
USA) (Catalogue No.: 4329001) 
7900HT Fast Real-Time PCR System with 384 Well 
Block Module 
Advanced Detection and 
Accurate Measurement (ADAM) 
Cell Counter 
Digital Bio Pharm (Cambridge, UK) 
(Catalogue No.: Adam-MC) 
Advanced Detection and Accurate Measurement 
(ADAM) Cell Counter 
Biomek® 2000 Laboratory 
Automation Workstation 
Beckman Coulter (High Wycombe, 
UK) 
Biomek 2000 Laboratory Automation Workstation and 
software 
Centrifuge (Up to 50ml) Qiagen (Hilden, Germany), Centrifuge 4-16 (Catalogue No.: 81325) Universal laboratory centrifuge with brushless rotor 
 
Centrifuge (Up to 200ml) 
Sorvall (DJB Labcare Ltd, 
Buckinghamshire, UK) 
Sorvall RC5 centrifuge with rotors SA-600 and SA-1500 
(Catalogue No. 74505) 
Finnpipette multichannel 
dispenser Life Sciences, Basingstoke, UK Finnpipette multichannel dispenser 
 
G-Strom Thermocycler 
 
G-Storm (Somerset, UK) 
G-Storm GS4 thermocycler, 4x 96 well temperature 
gradient blocks with optional heated lids, temperature 
range from 4ºC-99ºC 
 
Microcentrifuge 
 
Technico (ThermoFisher, Waltham, 
MA, USA) (Catalogue No.: TEC-150-
030N) 
Table top TEC-150-030N-Microcentrifuge Maxi; 
Including 18x 1 5/2ml rotor, pulse button, timer and 
continuous operation (Speed 1,000-14,000rpm 
(16,000g)) 
Single Channel Pipettes (P10, 
P20, P250, P1000) 
Gilson (Gilson Inc Middleton, WI, 
USA) 
Single channel pipettes sizes, P10, P20, P200 and 
P1000 
Spectrophotometer (NanoDrop 
8000) 
Thermo Scientific (ThermoFisher 
Scientific, Waltham, MA, USA) 
Microarray, Proteins & Labels (Catalogue No.: 
ND8000) 
 
Syngene Gel Documentation 
System 
 
Syngene UK (Cambridge UK), 
Allows for the visualisation and photographing of gel 
products after electrophoresis; Used in conjunction 
with Genesnap v604 software 
Tropix TR717 Microplate 
Luminometer 
Applied Biosystems (Life 
technologies, Carlsbad, California, 
USA) 
Tropix TR717 Microplate Luminometer; Includes 
WinGlow software for measurement and analysis of 
luciferase activity 
 
UV Stratalinker 2400 
Stratagene (Stratagene, California, 
USA) (Catalogue No.: 400075 (120V)) 
UV Stratalinker 2400; Used for membrane blotting, 
DNA nicking, Gene Mapping and RecA Screening 
 
Table 2.5. Displays a comprehensive overview of all instruments used throughout this thesis. Include company data 
and a brief overview of what each instrument is used for. 
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2.4. Standard Methods 
2.4.1. SNP Selection and Bioinformatics 
 Tagging SNPs for each PLA2 gene were identified as described in the Introduction 
(1.7.2). European populations were selected for without exception across all databases. 
Table 2.4 lists all of these bioinformatics tools, what they were used for and the web link to 
each one. The general parameters used per tool to research each gene/SNP are as follows: 
International HapMap Project: Choose the browser release #28 including phase 1, 2 
and 3. Type gene name or SNP rs number into the search box. Standard search parameters 
were kept and the ‘Download Decorated FASTA File’ Report & Analysis function was 
selected to view results. 
MatInspector: Consensus FASTA sequences were selected from the Ensembl 
Genome Browser and manually copied into the MatInspector tool. The software uses a large 
library of matrix descriptions for transcription factor binding sites, locating matches within the 
FASTA sequence and assigns a quality rating to each match. I selected each FASTA 
sequence to include either the common or rare variants of a SNP of interest for comparison 
to assess whether there was a possibility of differential TF binding between the alleles. The 
parameters selected for were as follows: Sequence added manually using ‘Your Sequence’ 
function. Homo Sapiens option selected for ‘search corresponding promoters’. ‘Transcription 
Factor Binding (weight matrices)’ selected for the library option. 
UCSC Genome Browser Bioinformatics Browser: From the main menu. The 
‘Assembly’ chosen was Mar. 2006 (NCBI36/hg18). The appropriate SNP or gene was 
selected for and the standard database parameters were applied on selection. These 
included Encode transcription factor binding prediction, DNA hypersensitivity prediction, 
spliced human expressed sequence tags (splice sites) and known SNPs.  
PITA, RegRNA and MiRTar were used to predict potential microRNA (miRNA) 
binding sites in the PLA2G2A 5’UTR. An mRNA consensus sequence was entered into each 
target prediction algorithm that includes searches outside of the 3’UTR. The PITA and 
miRbase algorithms were used to predict miRNA binding in the PLA2G2A 3’UTR. All 
predictions of putative miRNA binding sites were kindly carried out under the supervision of 
my colleague Dr Anastasia Kalea. The specific parameters used for each prediction are 
quoted where appropriate.   
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Analysing the sPLA2 Inhibitor, Varespladib 
Adhering to PRISMA guidance (Weber and Noels 2011), I conducted a systematic 
review of randomised trials that evaluated the effects of varespladib on sPLA2-IIA mass and 
other cardiovascular traits. The PubMed search parameters consisted of 
(“varespladib”[Substance Name] OR "varespladib methyl "[Substance Name] OR 
varespladib OR A002 OR LY333013). Studies in humans that were randomized trials 
comparing varespladib to placebo were selected for inclusion. Data was extracted and 
cross-checked by Dr Michael Holmes for agreement of its inclusion; discrepancies were 
resolved by consensus. Where possible, we harmonised variable units between studies. In 
the case where a conversion factor could not be identified, the standardized mean difference 
was used. 
2.4.2. DNA Standardisation and Determining DNA Concentration 
 All DNA used throughout this project had been previously standardised to either: 
2.5ng/µl, 5ng/µl, or 15ng/µl arrays. DNA concentration was determined throughout this 
thesis using the spectrophotometer, Nanodrop 8000. 
2.4.3. Primer Design 
 Oligonucleotide primers for were designed using the Primer3 primer design program 
v 0.4.0 (Table 2.4), which is freely available. The design of suitable primers for a sequence 
of interest is based on a number of factors including; the primer melting temperature, the GC 
content, 3’end stability, length, secondary structure and the ability for primer-dimer 
formation, which is undesirable. Primers that amplified poorly were redesigned.  
 For the Primer3 input: A sequence including the target was identified and isolated 
from the Ensembl Genome Browser and pasted into the ‘paste sequence’ box. ‘Pick left 
primer’ and ‘pick right primer’ options were selected. A sequence ID was chosen to 
recognise what purpose the primers were for. The target sequence was identified by 
indicating relevant anchor base number and any surrounding base pairs that make up the 
target sequence. ‘Excluded regions’ was left blank. All other parameters were kept as the 
parameters common to the original template.    
2.4.4. Polymerase Chain Reaction (PCR)  
 Polymerase Chain Reaction (PCR) is used to amplify DNA fragments of interest for 
an assortment of analytical techniques including genotyping, sequencing and cloning.                              
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        5-15ng of double stranded sample DNA was taken from a 96 well standardised array 
and was used in a standard 96 well PCR plate. DNA was transferred from array to plate 
using a Finnpipette multichannel dispenser. The plate was centrifuged at 1000rpm for 1 
minute to ensure that DNA was settled in the bottom of each well. 
A PCR reaction mix included MgCl2 (50mM), NH4+ buffer (10x), Taq DNA polymerase 
and a forward and reverse orientation primer (custom designed for the sequence of interest, 
usually to be around 20-30 base pairs). Once made up, this reaction mix was added to each 
DNA sample and a coat of 20µl mineral oil was added to each well to prevent evaporation. 
PCRs throughout this project were run on the G-Storm Thermocycler. Each reaction was 
optimised using test DNA samples across a gradient of MgCl2 and temperatures.  
A standard PCR has an initiation step then between 30-40 cycles of a denaturing 
step, an annealing step and an elongation step. The reaction concludes with a final step to 
ensure that all products are fully formed. The annealing temperature is based on the primer 
and product length. An accurate prediction of the annealing temperature for a primer is the 
melting temperature (Tm) minus 5. The Tm is based on the GC content and length of each 
primer. The annealing temperature can be calculated using the Finnzymes Tm Calculator. 
The timing of the elongation step is based on the length of the primers; approximately 
1Kb/minute (Lusis 2000). Each cycle results in an approximately two-fold replication, 
accumulating a large quantity of specific DNA. Should this method fail to provide a clean 
amplification, 5% dimethyl sulfoxide (DMSO) was added to act as a detergent to facilitate 
separation of double-stranded DNA and preventing non-specific primer binding. Specific 
PCR reaction volumes and steps are described throughout this chapter. 
2.4.5. Agarose Gel Electrophoresis 
 A standard 2% gel was effective for showing products in the range of 80-200bp. In 
order to visualize products of sizes outside this range the percentage of the gel was 
adjusted. A 1% gel was used to see products 500bp-1kb and a 0.5% gel to see 1-30kb.   
 For a standard 2% gel per 100ml: 2g agarose (Table 2.1), 10ml TBE (1x) + 0.01µg 
Ethidium Bromide (EtBr) (Table 2.1), 90ml dH2O. The agarose and water were added 
together and heated in a microwave on high power for 2 minutes. Then the TBE/EtBr was 
added to the mix which was immediately poured into a pre-assembled mould. A comb was 
added to form the wells. 
 Usually 2µl of agarose gel loading buffer (6x) was added to 10µl of DNA product. 3µl 
of Plus DNA Ladder (1kb) (Table 2.1) was loaded into one well of each gel in order to 
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determine fragment size. Typical gel electrophoresis was carried out at 100V for 45 minutes,                     
or as long as it took for the loading buffer to move down two thirds of the gel. Gels were 
analysed and photographed under UV illumination using the Syngene Gel Documentation 
System and Genesnap v6.04 software (Table 2.5). Standard parameters were maintained 
for image viewing with the exception of the image brightness and zoom, which were adjusted 
to optimum per gel.  
2.4.6. Genotyping 
2.4.6.1. TaqMan Genotyping  
 Each ABI TaqMan Genotyping Assay (40x) contains two target SNP specific primers 
to amplify the DNA sequence of interest (the ‘DNA template’) and two allele specific TaqMan 
MGB probes. Each allele specific probe has three main elements, a reporter dye at the 5’ 
end and a minor groove binder (MGB) and a non-fluorescent quencher (NFQ) at the 3’ end. 
There are two commonly used reporter dyes, VIC and FAM, and each allele is distinguished 
dependent on the reporter dye. The VIC dye is linked to the allele 1 probe and the FAM dye 
is linked to the allele 2 probe. The MGB is added in order to increase the melting 
temperature for a given probe length (Davies and Woolf 1993; Ross 1999; Tegos, Kalodiki et 
al. 2001), allowing shorter probes with an increased difference in melting temperature 
between matched and mismatched probes. Thus the addition of an MGB increases the 
efficiency of allelic discrimination. The NFQ does not fluoresce and will quench the 
fluorescent signal of any reporter dye linked to the 5’ end for as long as the probe remains 
intact. 
 ABI TaqMan Genotyping reactions were carried out in a 384 well plate format. DNA 
at 5ng was transferred from a standardized array, using the Biomek 2000 Laboratory 
Automation Workstation (Table 2.5), into a 384 well plate and centrifuged at 3000rpm for 1 
minute before being air dried. Each plate contained at least two no template control (NTC) 
wells.   
 The TaqMan genotyping reaction was carried out as per the TaqMan Genotyping 
mastermix manufacturers’ instructions. Each plate was centrifuged at 3000rpm for 1 minute 
and PCR reactions were carried out using the 7900HT Fast Real-Time PCR system (Table 
2.5). The standard PCR reaction conditions were as follows: 
AmpliTaq Gold Enzyme Activation 95ºC 10 minutes followed by 40 cycles of:  Denature 
92ºC 15 seconds and anneal/extend 60ºC 1 minute 
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 There were several phases that occurred during each PCR reaction (Figure 2.4); 
Each TaqMan MGB probe annealed to the specific complimentary sequence between the 
forward and reverse primer sites. At this point the probe was still intact and therefore the 
NFQ was still at close enough proximity to the reporter dye to quench its fluorescent signal.   
Next the AmpliTaq Gold DNA polymerase (a component of the TaqMan Universal Master 
Mix) extended the DNA template between the forward and reverse bound primers and 
caused the cleavage of the probe, specifically by cleaving only the probes that are 
hybridized to the target. The effect of cleavage was to separate the reporter dye from the 
NFQ, which caused an increase in fluorescence from the reporter dye. Generation of 
increased fluorescent signal by PCR amplification indicated which alleles were present in 
each the sample, with a significant increase in VIC dye signal correlated with homozygosity 
for allele 1, an increase in FAM dye signal correlated with homozygosity for allele 2 and a 
significant increase in both VIC and FAM signals correlated to Alleles 1 and 2 heterozygosity 
(http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocument
s/cms_039282.pdf). 
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Figure 2.4. A schematic of the process of TaqMan Assay genotyping using RT PCR. The resulting signal generation is specific to one SNP variant. Detection 
of signals from each sample allows one to genotype the sample as homozygous for the common variant, heterozygous or homozygous for the rare variant. 
(http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocuments/cms_039282.pdf).  
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 TaqMan Genotyping Signal Detection 
 Reaction runs and plate analysis were performed using the 7900HT Fast Real-Time 
PCR System (Table 2.5) with Sequence Detection System (SDS) v2.1 software (Table 2.4). 
Standard allelic discrimination was carried out using the SDS software which included an 
automatic threshold signal detector. A new document was opened for each 384 well plate.  
 The standard allelic discrimination program assigned genotypes automatically to a 
plate coordinate in a text output file and in the form of an allelic discrimination plot based on 
the fluorescent signal detected. The light source from the cycler excites the reporter dyes by 
fluorescence resonance energy transfer. VIC and FAM have significantly different excitation 
and emission wavelengths, which allows them to be differentially detected.  Each dot on the 
scatterplot represents one well of the plate (either a DNA sample or an NTC). An example of 
the scatterplot form of results is shown below (Figure 2.5). Undefinable samples are 
represented by an ‘X’. These samples did not reach the threshold fluorescent signal level to 
be defined as a particular genotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
105 
 
 Figure 2.5. Allelic Discrimination plot. This plot represents the results of genotyping PLA2G2A SNP 
rs11573156 C>G in part of the IMPROVE study. Samples with a significant VIC signal are called 
homozygous for the common allele C (red cluster). A sample with an even distribution of VIC and FAM 
signals will be called heterozygous (green cluster). Samples with a significant FAM signal are called 
homozygous for the rare allele G (blue cluster). No Template Controls (NTC) are represented by black 
squares and should display no signal. An ‘X’ indicates that the sample has not reached the threshold signal 
level for any group 
(http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocuments/cms_03928
2.pdf).  
 
TaqMan Genotyping PLA2G2A SNPs of interest 
 All but three of 28 studies used for the Mendelian randomisation analysis (see 2.5 
Table 2.6 and Table 2.7) directly genotyped rs11573156 by the genotyping methods 
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specifically associated with each study. Of the 3 exceptions, MedStar and Rotterdam 
imputed the SNP and GENDAR used a genotyped proxy. I genotyped the IMPROVE, TPT, 
CYPRUS, NPHSII and EAS studies using the TaqMan Genotyping Assay System and an 
rs11573156 specific assay (Table 2.2). 
 For rs3767221 all genotyping was undertaken using the TaqMan Genotyping Assay 
System and an rs3767221 specific assay (Table 2.2.). This SNP was genotyped previously 
in UDACS, EPIC-Norfolk, GRACE-France and NPHS-II. I genotyped this SNP in IMPROVE, 
the Edinburgh Artery Study and CYPRUS. All of these studies are detailed below in Table 
2.6 and Table 2.7. 
TaqMan Genotyping PLA2G5 SNPs of Interest  
 TaqMan genotyping assays for the PLA2G5 tSNPs rs11573185, rs11573191, 
rs11573203 and rs11573248 are defined in Table 2.2. These SNPs were genotyped in 
several studies (Table 2.6 and Table 2.7) as indicated in Table 2.8. Genotyping by the 
TaqMan method was carried out for all the non-MetaboChip studies. 
Genotyping PLA2G10 SNPs of Interest  
 The PLA2G10 tSNPs rs72546339 and rs72546340 were genotyped using specific 
TaqMan Assays (Table 2.2). The SNPs rs4003232 and rs4003228 were genotyped by 
restriction fragment length polymorphism (RFLP) as described below (2.4.6.2). I initially 
attempted to genotype these SNPs using a single PCR per SNP, but this did not produce 
very efficient results. Therefore, nested PCR reactions were set up for each SNP by myself 
and Jutta Palmen. 
In order to genotype rs4003228 the first reaction isolated a 2,869bp fragment and the 
second was a nested PCR amplification of a 220bp fragment.  
PCR 1: Forward primer: 5’GCGTGACCTGCCACACCTATG3’ 
            Reverse Primer: 5’TTCACTGGCCATGTTATCC3’ 
3µl of DNA (75ng) was transferred into a 96 well plate and centrifuged at 1000rpm for 
1 minute to ensure that the DNA sat in the bottom of the well. Added to the DNA per reaction 
was: MgCl2 0.75µl, DMSO (5%) 1.25µl, NH4+ 2.5µl, Forward primer 0.05µl, Reverse primer 
0.05µl, Taq polymerase 0.1µl, dH2O 17.3µl. 
The PCR Program carried out on the G-Storm Thermocycler (Table 2.5) was: 95ºC 4 
minutes, then 35 cycles of; 94ºC 45 seconds, 58ºC 45 seconds, 68ºC 3 minutes, and finally 
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one cycle of 72ºC 5 minutes. The product was diluted with dH2O 1:100 for use as DNA in the 
nested PCR. The PCR-product size was verified by electrophoresis on an agarose gel. 
For rs4003228 the restriction site for Bsa AI (YAC/GTR). Below is the 220bp 
PLA2G10 sequence fragment isolated by this PCR (taken from the Ensembl Genome 
Browser). The primers are highlighted in yellow. Blue lettering indicates exon 1 and red 
lettering indicates the restriction enzyme recognition site. The SNP of interest is highlighted 
blue. In this instance the enzyme will recognise the sequence and cut when the common 
allele is present but not the rare allele. 
14784686    ATTTCACAGATGAGGAAACCAAGGCCCAGAGAGGTTAAGAATTTGTCCAAGGTCACACAG            14784627 
14784626    CCAGGAAGTAGGATTCAAACCCAGACAGCCAGGCTGTAACACCTGGGCTCTTCTCAGGCT           14784567 
14784566    CATGCCCTTCCCAGGGGTCTGGGAAGCCCTGACCTGCAGCCTGTCACCTTTGTTTACCCC           14784507 
14784506    CCAGCCTCCAGGATATTAC/tGTGTGCACCGGCGTGGGATCCTGGAACTGGCAGGAACTGTG     14784447 
 
For the nested PCR 1µl of DNA was moved into a fresh 96 well plate and dried. 
Added to the DNA per reaction was: MgCl2 1.2µl, NH4+ 2µl, Forward primer 0.04µl, Reverse 
primer 0.04µl, Taq polymerase 0.04µl, dH2O 16.68µl. The PCR Program carried out on the 
G-Storm Thermocycler (Table 2.5) was: 98ºC 2 minutes, then 30 cycles of; 98ºC 15 
seconds, 63ºC 15 seconds, 68ºC 20 seconds and one final cycle of; 68ºC 2 minutes. 
  For RFLP: Per digestion reaction: Bsa AI 0.6µl, NEB Buffer 4 (10x) 1.3µl, dH2O 8.1µl, 
PCR-product 3µl was added to a fresh 96 well plate. The plate was sealed and centrifuged 
at 1000rpm for 1 minute. The plate was then incubated at 37ºC in a high humidity incubator 
for 16 hours. Agarose gel electrophoresis was used to check the product sizes and 
undigested PCR-product was used as a positive control in all instances. Expected product 
sizes are as follows; Homozygous common: 186+34, heterozygous: 220+186+34 and 
homozygous rare: 220.          
To genotype rs4003232 two PCR reactions were needed The first isolated a 2,869bp 
fragment and the second was a nested PCR amplification of a 216bp. The first fragment 
isolated is the same as the 2,869bp fragment for rs4003228 (above). 
 For rs4003232 a recognisable restriction enzyme site for Alu I (AG/CT) was 
identified. The 216bp fragment of the PLA2G10 sequence isolated by this PCR is shown 
below (taken from the Ensembl Genome Browser). The yellow highlight indicates the primers 
used. The red lettering indicates the restriction enzyme recognition site (Alu I) and the blue 
highlight indicates the SNP of interest. In this instance the restriction enzyme recognisable 
site includes the rare allele of the SNP of interest.  
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14784806    GTTGGGATTACAGGTGTGAGCCACTGAGCCCAGCCGGATTATAATAGCCTTTTCATGCAC            14784747 
14784746    CAGGGGCTTTATACTCATTATCTCATTTCATTCATATGAGTTGAAGTCAGTTTATCCCCC                14784687 
14784686    ATTTCACAGATGAGGAAACCAAGGCCCAGAGAGGTTAAGAATTTGTCCAAGGTCACACAG            14784627 
14784626    CCAGGAAGTAGGATTCAAACCCAGACAGC(C/t)AGGCTGTAACACCTGGGCTCTTCTCAGGCT   14784567 
14784566    CATGCCCTTCCCAGGGGTCTGGGAAGCCCTGACCTGCAGCCTGTCACCTTTGTTTACCCC           14784507 
 
1µl of DNA was added to each well of a fresh 96 well plate and dried. Added to the 
DNA per reaction was: MgCl2 1.2µl, NH4+ 2µl, Forward primer 0.04µl, Reverse primer 0.04µl, 
Taq polymerase 0.04µl, dH2O 16.68µl. The PCR Program carried out on the G-Storm 
Thermocycler was: 98ºC 2 minutes, then 30 cycles of; 98ºC 15 seconds, 63ºC 15 seconds, 
68ºC 20 seconds and finally one cycle of; 68ºC 2 minutes. 
For RFLP, per digestion reaction: Alu I 0.3µl, NEB Buffer 4 (10x) 1.3µl, dH2O 8.4µl, 
PCR-product 3µl. This was incubated at 37ºC in a high humidity incubator for 16 hours. 
Agarose gel electrophoresis was used to check the product sizes and undigested PCR-
product was used as a positive control in all instances. Expected product sizes; 
Homozygous common: 150+66, heterozygous: 216+150+66 and homozygous rare: 216.          
Micro Array Diagonal Gel Electrophoresis 
Digested products were analysed by Micro Array Diagonal Gel Electrophoresis 
(MADGE) (7.5% gel). MADGE gels are made up in house as described in Table 2.1. The 
resulting arrays are analysed by eye and cross checked by two people. Genotypes were 
identified as follows. When the genotype is homozygous for allele 1 and the restriction site is 
present for both alleles it shows as 2 bands of equal intensity. This product is fully digested 
by the restriction enzyme. The sum of the sizes of the two bands is equal to the full product 
size. When the genotype is homozygous for allele 2 and the restriction site is not present for 
either allele the result shows as 1 band equivalent to the full product size. When the 
genotype is heterozygous and the restriction site is present for one allele but not the other 
the results shows as 3 bands. The largest band has the highest intensity and is the size of 
the full product. Two less intense bands that total the sizes of the fully digested product. A 
typical MADGE analysis of the PLA2G10 SNP rs4003232 is shown below (Figure 2.6). 
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Figure 2.6. Shows restriction digested PCR samples run on a 7.5%, 96 well, MADGE gel. This gel 
represents the analysis of rs4003232 genotyped in samples from the EPIC-Norfolk study. The bands 
visible in each well recognize each sample as either: 11= homozygous for the variant with the 
restriction site, 22= homozygous for the variant with no restriction site or 12 as heterozygotes. The 
grid below the gel represents manually reported and cross checked results. 
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2.4.7. Luciferase Assay Analysis 
 The Dual-Luciferase Reporter Assay System is a genetic reporter system used to 
investigate eukaryotic gene expression. This assay has been used during this thesis for the 
purposes of comparing the luciferase expression generated by the different alleles of a SNP 
of interest in order to determine if there is a differential genotype effect. This can be 
achieved by creating DNA fragments containing each allele of the SNP of interest and 
inserting them into a pGL3-Luciferase Reporter Vector. The ‘dual’ system refers to the 
concurrent expression and measurement of two individual reporter enzymes in the same 
system. There was an experimental reporter enzyme and a co-transfected control reporter 
enzyme. The experimental enzyme was expressed based on the specific experimental 
conditions, whereas the control enzyme activity was measured as the internal baseline 
response and was used to normalize the experimental reporter activity, thus increasing the 
efficiency of the assay. There were several preparatory stages that must be completed 
before a luciferase assay is run.   
2.4.7.1. Isolating a DNA Fragment for Cloning into a pGL3-Luciferase Reporter Vector 
 The vector and fragment were accomplished by digestion of the PCR-product and 
the vector at the polylinker site with the appropriate restriction enzymes to synthesize 
compatible ‘sticky’ ends for cloning. These reactions were carried out as per restriction 
enzyme manufacturers’ instructions. Completion of each double digestion was verified by 
agarose gel electrophoresis. Undigested sample of the original PCR-product and undigested 
pGL3-Luciferase Reporter Vector DNA were used as controls. If the digestion was 
successful a single clean band that was demonstrably smaller than the original PCR-product 
would be visible when the gel was analysed 
(http://www.promega.com/~/media/Files/Resources/Protocols/Technical%20Manuals/0/pGL
3%20Luciferase%20Reporter%20Vectors%20Protocol.ashx).  
2.4.7.2. Ligation of Digested Vector and DNA Fragment (Insert) 
 To ligate the compatible ‘sticky’ ends of the vector polylinker site and insert, the T4 
DNA ligase kit was used. Each 20µl total reaction mix was set up and incubated on ice. 
Each component was added in the following specific order: 
50ng (0.025pmol) Vector DNA (3kb), then 50ng (0.076pmol) Insert DNA (1kb), then 2µl T4 
DNA Ligase Buffer (10x) (thawed and re-suspended at room temperature), then up to 19µl 
dH2O was added and finally 1µl T4 DNA Ligase. 
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 The reaction mix was gently pipetted up and down, briefly centrifuged and incubated 
at 16ºC overnight (http://www.neb.com/nebecomm/products/protocol658.asp).  
2.4.7.3. Transforming Vector/Insert Complex into Competent Cells 
 For rapid amplification of the vector/insert complex it was transformed into E.coli 
DH5α cells as follows: 50µl DH5α cells thawed on ice and added to 1-5µl ligated DNA (1-
10ng). This was mixed by gently pipetting up and down and incubated on ice for 30 minutes, 
while pre-warming 300µl LB Medium to 37ºC. Cells were heat shocked for 20 seconds in a 
42ºC water-bath. On removal from the water-bath the 300µl of pre-warmed LB was 
immediately added to the cell/DNA mix. The mix was then incubated on a shaker at 
37ºC/225rpm for 1hour and spread onto a fresh plate of LB agar + ampicillin (50mg/ml) 
(Table 2.1). Finally the plate was incubated at 37ºC for 16 hours. 
2.4.7.4. Amplification of Transformed Colonies and DNA Purification by Miniprep 
 A single colony was picked from each agarose plate and amplified in 5ml sterile LB 
medium and inoculated with 10µl of the antibiotic ampicillin (50mg/ml). The pGL3-Luciferase 
Reporter Vector (Figure 2.3) contains an ampicillin resistance gene. The culture was 
incubated on a shaker for 16 hours at 37ºC/225rpm.  Following amplification of the colony, 
glycerol stocks of the culture were made: 1ml of the culture was added to 1ml of glycerol 
(50%) and stored at -80ºC for future experiments. Plasmid DNA was purified using the 
QIAprep Spin Miniprep Kit purified up to 20µg of high-copy plasmid DNA from 1-5ml of E. 
coli culture. The bench protocol for the QIAprep Spin Miniprep Kit using a microcentrifuge as 
per manufacturers’ instructions. (www.qiagen.com/hb/qiaprepminiprep). 
Plasmid Design for rs11573156 C>G 
Previous studies have suggested that regulatory elements for PLA2G2A start 
occurring approximately 2.27Kb upstream of the translation start site (Cannon 1998), this is 
around 600bp upstream from the start of the suggested 5’UTR. Considering this, a 2.27Kb 
fragment upstream of the PLA2G2A translation start site (GRCh37.p5, chr1:20,305,406 to 
20,307,676) (Ensembl Genome Browser), including wild-type rs11573156 C, was amplified 
from a previously genotyped DNA sample of an individual homozygous for the C allele. The 
DNA used was from an in-house cohort known as the DRD study, a small, volunteer cohort 
of DNA taken from individuals working at the University College London Rayne Building or 
living in close proximity. The study is composed of males and females between the ages of 
19 and 65 years. 
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The primers used to create DNA fragments to insert into a plasmid for use in 
luciferase assays included two restriction endonuclease recognition sites (one forward and 
one reverse) to pair with the polylinker sites in the pGL3 vector (Figure 2.1). The primers 
included restriction endonuclease sites for NheI and HindIII and were as follows:  
Forward, 5’ CCCC GCTAGCTGATCTCTGCCTTCATCTTTGTATG  
Reverse, 5’CCCC AAGCTTCTGCTGGGTGGTCTCAACTTC.  
The PCR conditions were; 95˚C for 1 minute, then 30 cycles of 95˚C for 1 minute, 
68˚C for 1 minute and 72˚C for 1 minute, ending with 72˚C for 5 minutes. The amplified 
fragment was ligated into the pGL3-basic (Figure 2.1) vector upstream of the Luciferase 
(Luc) gene, using the HindIII and NheI polylinker sites and transformed into E.coli DH5α 
competent cells. 
Plasmid Design for rs3767221 A>C 
A 303bp fragment downstream of the PLA2G2A protein coding sequence 
(GRCh37.p5, chr1:20,301,598 to 20,301,873) (Ensembl Genome Browser) was identified to 
include rs3767221. As shown in Figure 1.18 the 3’UTR of PLA2G2A is ~263bp, therefore 
sequence of around 300bp was isolated since this would include the whole 3’UTR for 
PLA2G2A. The sequence was amplified using the primers, which included the restriction 
endonuclease sequences for BamHI and SalI:  
Forward 5’CGCGGATCCCATGCAGGAGGCACCAGTGTTATCTC 
Reverse 5’ACGCGTCGACGCATGAGAACAAACAGGGGTAGGGG 
Amplification of DNA was from two previously genotyped individual DRD samples; a 
sample homozygous for the wild-type allele (A) and a sample homozygous for the rare 
variant (C). The PCR conditions were; 98˚C for 2 minutes, then 30 cycles of 98˚C for 15 
seconds, 62˚C for 15 seconds and 72˚C for 1 minute, ending with 72˚C for 5 minutes.  
PCR fragments were ligated into a pGL3-Promoter expression vector (Figure 2.2), 
downstream of the Luc gene, using the BamHI and SalI polylinker sites. Constructs were 
transformed into DH5α competent E.coli. All products were sequenced for verification. 
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2.4.7.5. Verification of Amplification of the Correct DNA Sequence 
To verify that the correct plasmid DNA had been amplified, a portion of the miniprep 
product was digested with the appropriate restriction enzymes, as per the restriction enzyme 
manufacturers’ instruction. 
 To ensure that the sequence of the DNA was identical to the consensus sequence a 
sample of the miniprep solution was sent for sequencing. In 3 separate eppendorf tubes, 
10µl DNA (~100ng/µl) and two insert-flanking primers (33.3pmol per primer) were sent to 
Source BioScience UK. Sequencing results were sent as both a text file and an 
electropherogram, visible using FinchTV (Table 2.4). Where the software was unable to 
identify a base, the peaks of the sequence were checked by eye to identify whether there 
was a true error or not. The text file was then used to compare the sequenced DNA to the 
consensus sequence (Ensembl Genome Browser) with the online tool CLUSTALW to 
highlight discrepancies If a discrepancy is found to be a true mistake it was rectified using 
the Quikchange site-directed mutagenesis kit. 
To correct the sequence the kit used the supercoiled double-stranded DNA 
vector/insert complex and two synthetic oligonucleotide primers (one forward and one 
reverse) with the desired mutation. The DNA polymerase worked to extend the primers 
during a PCR and their incorporation synthesized mutated plasmids containing staggered 
nicks. Post-PCR the product was treated with Dpn I endonuclease, which is specific for 
methylated and hemimethylated DNA and digested the parental DNA template, selecting for 
the newly formed, corrected DNA sequence. This DNA was then transformed into XL1-Blue 
supercompetent cells, amplified and purified by miniprep as previously described 
(https://www.life-science-lab.org/.../ag-biochem-projekt2006).  
 Site directed mutagenesis was required to correct mistakes in the original, wild type 
rs11573156 (suspected) promoter fragment (which was used in luciferase assays) as shown 
below. The CLUSTAW tool (Table 2.4) was used to compare the Ensembl consensus 
sequence with the sequenced clone fragment text file (provided by Geneservice (Table 2.4)). 
A match is indicated by a star below each comparable allele. Where a gap occurs there was 
a mismatch in the sequence. A mismatch may represent a known polymorphism or a 
mistake. In the sequence below mistakes changed by site directed mutagenesis are 
highlighted in yellow and the corresponding primers are listed below the fragment. 
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Clone PLA2G2A promoter sequence: All mistakes corrected by SDM. 
>Ensemble<<               TGATCTCTGCCTTCATCTTTGTATGGCCTTCTCCCAGTGTGCCTGCCTGTCTCCAAATTT 
>Clone_PLA2G2A_full_seq<< TGATCTCTGCCTTCATCTTTGTATGGCCTTCTCCCAGTGTGCCTGCCTGTCTCCAAATTT 
                          ************************************************************ 
 
>Ensemble<<               CCCATTTTTGTAATGACATCTGTCATCTTGGATTAGGGCCCATCCTAGCTGCCCTAGTGA 
>Clone_PLA2G2A_full_seq<< CCCATTTTTGTAATGACATCTGTCATCTTGGATTAGGGCCCATCCTAGCTGCCCTAGTGA 
                          ************************************************************ 
 
>Ensemble<<               TCTCCTCTTAACTAATTATATCTGCAATGACCCTATTTTTAAATAAGATCACATTCTAAG 
>Clone_PLA2G2A_full_seq<< TCTCCTCTTAACTAATTATATCTGCAACGACCCTATTTTTAAATAAGATCACATTCTAAG 
                          *************************** ******************************** 
 
>Ensemble<<               GTACCGGGACTCCAACACAGGAACTGAGAGCAGGAAGGAGGACCACAGTCCAACCCCTTA 
>Clone_PLA2G2A_full_seq<< GTACCGGGACTCCAACACAGGAACTGAGAGCAGGAAGGAGGACCACAGTCCAACCCCTTA 
                          ************************************************************ 
 
>Ensemble<<               CACAGTCGAGCACTGGAGGTAAATGGTATTCTCGAGAGGAAAGCTGTTTGATGGCTCTTG 
>Clone_PLA2G2A_full_seq<< CACAGTCGAGCACTGGAGGTAAATGGTATTCTCGAGAGGAAAGCTGTTTGATGGCTCTTG 
                          ************************************************************ 
 
>Ensemble<<               GGATAGATTAGGTTATGCTCCAGCAACTGCCCATCTCAATTATCATCAGCTTAATACAAC 
>Clone_PLA2G2A_full_seq<< GGATAGATTAGGTTATGCTCCAGCAACTGCCCATCTCAATTATCATCAGCTTAATACAAC 
                          ************************************************************ 
 
>Ensemble<<               AAAAGTCTATTTCTCACTCACACTAAGACCCCTGTGAGCTGCAGGACTTTCTAGGACAAC 
>Clone_PLA2G2A_full_seq<< AAAAGTCTATTTCTCACTCACACTAAGACCCCTGTGAGCTGCAGGACTTTCTAGGACAAC 
                          ************************************************************ 
 
>Ensemble<<               TGTCTTCCGTGCCATGATTCTTACACCCCAGATTGCTTTCATCTTCTGGTTCTACCAGTG 
>Clone_PLA2G2A_full_seq<< TGTCTTCCGTGCCATGATTCTTACACCCCAGATTGCTTTCATCTTCTGGTTCTACCAGTG 
                          ************************************************************ 
 
>Ensemble<<               GGGCAGGGAAGGGCTGGGGAGTTGCATCTCATAGTCCCCTTGCTGGAGAAACCTGGAAGT 
>Clone_PLA2G2A_full_seq<< GGGCAGGGAAGGGCTGGGGAGTTGCATCTCATAGTCCCCTTGCTGGAGAAACCTGGAAGT 
                          ************************************************************ 
 
>Ensemble<<               GACCCTTCATACCAGTGCTCATGTTTTACCAGTCAGCAGCAGGGCCCTAGGTCTCCATCC 
>Clone_PLA2G2A_full_seq<< GACCCTTCATACCAGTGCTCATGTTTTACCAGTCAGCAGCAGGGCCCTAGGTCTCCATCC 
                          ************************************************************ 
 
>Ensemble<<               CTGCAAGGGGCTCTAGAGTGTAGGGAACAGATGGAATGTTCACAAGCACCACAGCCCCTG 
>Clone_PLA2G2A_full_seq<< CTGCAAGGGGCTCTAGAGTGTAGGGAACAGATGGAATGTTCACAAGCACCACAGCCCCTG 
                          ************************************************************ 
 
>Ensemble<<               CCACAGTGACTTTTTTAGGACTGGTATCGCAGAGTGTTTACTTAAGGCGGTGGAAGCTAA 
>Clone_PLA2G2A_full_seq<< CCACAGTGACTTTTTTAGGACTGGTATCGCAGAGTGTTTACTTAAGGCGGTGGAAGCTAA 
                          ************************************************************ 
                          Position 780 corrected g>a 
>Ensemble<<               ATTCTTAGCATGTGCTGGAGAGCAATGAAAAAGATATTTACTTTATGAATTAAAGCTGGA 
>Clone_PLA2G2A_full_seq<< ATTCTTAGCATGTGCTGGAGAGCAATGAAAAAGATATTTACTTTATGAATTAAAGCTGGA 
                          ************************************************************ 
 
>Ensemble<<               GTCAGTGTCAGCCCGAAGGCTGAAGGAAAAAGAGCAACAGATCCAGGGAGCATTCACCTG 
>Clone_PLA2G2A_full_seq<< GTCAGTGTCAGCCCGAAGGCTGAAGGAAAAAGAGCAACAGATCCAGGGAGCATTCACCTG 
                          ************************************************************ 
 
>Ensemble<<               CCCTGTCTCCAAACAGGTGAGGATGGGGAATAAAGTGAAGGCAGTGCTTTGGTGGGAACT 
>Clone_PLA2G2A_full_seq<< CCCTGTCTCCAAACAGGTGAGGATGGGGAATAAAGTGAAGGCAGTGCTTTGGTGGGAACT 
                          ************************************************************ 
 
>Ensemble<<               TCAAGGATAGCCTCTGGCTTTTTCCAGGTTTAGAAGCTCATATGAGACAGGGGTGGAGGA 
>Clone_PLA2G2A_full_seq<< TCAAGGATAGCCTCTGGCTTTTTCCAGGTTTAGAAGCTCATATGAGACAGGGGTGGAGGA 
                          ************************************************************ 
 
>Ensemble<<               AAAGAAGAAAGAAGAATAAGAAGAGAAAGTTGAGGCCCTGGCCCAAGTTAGTGGGAAGGG 
>Clone_PLA2G2A_full_seq<< AAAGAAGAAAGAAGAATAAGAAGAGAAAGTTGAGGCCCTGGCCCAAGTTAGTGGGAAGGG 
                          ************************************************************ 
 
>Ensemble<<               AAATCCACCCCCATTAAACTCTCTCCCTGGTGGACTGTGGGGTGCACACGTGAGGCCTGC 
>Clone_PLA2G2A_full_seq<< AAATCCACCCCCATTAAACTCTCTCCCTGGTGGACTGTGGGGTGCACACGTGAGGCCTGC 
                          ************************************************************ 
>Ensemble<<               ACAGGTGCTGGAACATGGTAGAGGCCCAGGACATACTTCCTGTGAATGAATGATTGAGCG 
>Clone_PLA2G2A_full_seq<< ACAGGTGCTGGAACATGGTAGAGGCCCAGGACATACTTCCTGTGAATGAATGATTGAGCG 
                          ************************************************************ 
 
>Ensemble<<               GCTGAATGAATGAGTACCACTAAAAGCCCTCTTTTCTATTCCCAAATGCCACATTGAGCA 
>Clone_PLA2G2A_full_seq<< GCTGAATGAATGAGTACCACTAAAAGCCCTCTTTTCTATTCCCAAATGCCACATTGAGCA 
                          ************************************************************ 
 
>Ensemble<<               GAAGGGAGCAATCCTTGCTCAGCAATTGGTAGTCCCTTTGGGTGTGCAAATGAGTCCACA 
>Clone_PLA2G2A_full_seq<< GAAGGGAGCAATCCTTGCTCAGCAATTGGTAGTCCCTTTGGGTGTGCAAATGAGTCCACA 
                          ************************************************************ 
 
>Ensemble<<               GCCTGCAACAGCAGACAGTCTCTGCCCCCCTTAGAGGCGATTGCAGGGAGGTGGCTGACC 
>Clone_PLA2G2A_full_seq<< GCCTGCAACAGCAGACAGTCTCTGCCCCCCTTAGAGGCGATTGCAGGGAGGTGGCTGACC 
                          ************************************************************ 
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                                                             Position 1369 corrected c>t 
>Ensemble<<               GTTGATCACACCCAGAGCTGGTTATGGGAATTTACTCCATGGAAAGACTGCAAAACTGCC 
>Clone_PLA2G2A_full_seq<< GTTGATCACACCCAGAGCTGGTTATGGGAATTTACTCCATGGAAAGACTGCAAAACTGCC 
                          ************************************************************ 
 
>Ensemble<<               TGAAATGTGTTTTGGCATCAGCTACTGACACGTAAGGTTTCCCAATCCTCAACTCTGTCC 
>Clone_PLA2G2A_full_seq<< TGAAATGTGTTTTGGCATCAGCTACTGACACGTAAGGTTTCCCAATCCTCAACTCTGTCC 
                          ************************************************************ 
 
>Ensemble<<               TGCCAGCTGATGAGGGGAAGGAAAGGGATTACCTAGGGGTATGGGCGACCAATCCTGAGT 
>Clone_PLA2G2A_full_seq<< TGCCAGCTGATGAGGGGAAGGAAAGGGATTACCTAGGGGTATGGGCGACCAATCCTGAGT 
                          ************************************************************ 
 
>Ensemble<<               CCACCAACTGACCACGCCCATCCCCAGCCTTGTGCCTCACCTACCCCCAACCTCCCAGAG 
>Clone_PLA2G2A_full_seq<< CCACCAACTGACCACGCCCATCCCCAGCCTTGTGCCTCACCTACCCCCAACCTCCCAGAG 
                          ************************************************************ 
 
>Ensemble<<               GGAGCAGCTATTTAAGGGGAGCAGGAGTGCAGAACAAACAAGACGGCCTGGGGATACAAC 
>Clone_PLA2G2A_full_seq<< GGAGCAGCTATTTAAGGGGAGCAGGAGTGCAGAACAAACAAGACGGCCTGGGGATACAAC 
                          ************************************************************ 
 
>Ensemble<<               TCTGGAGTCCTCTGAGAGGTAAAGAGCCAGCGAAGCTGATGTCCTGTCAAGAGCAGAATT 
>Clone_PLA2G2A_full_seq<< TCTGGAGTCCTCTGAGAGGTAAAGAGCCAGCGAAGCTGATGTCCTGTCAAGAGCAGAATT 
                          ************************************************************ 
 
>Ensemble<<               CCTGCTCATTCGCTGCCTTTGAGAGTGGCTGTGTTGTGCATGCATGTGCATGATTTGATA 
>Clone_PLA2G2A_full_seq<< CCTGCTCATTCGCTGCCTTTGAGAGTGGCTGTGTTGTGCATGCATGTGCATGATTTGATA 
                          ************************************************************ 
 
>Ensemble<<               TGTATGAGAGGGTGTGTGTGCATGAGTGTGTTGAGTGAGTATGTGAGTGTAGTGTAAGAG 
>Clone_PLA2G2A_full_seq<< TGTATGAGAGGGTGTGTGTGCATGAGTGTGTTGAGTGAGTATGTGAGTGTAGTGTAAGAG 
                          ************************************************************ 
                                            Known polymorphism 
>Ensemble<<               AGGATGTTGGCACTATCAGGTAAGTACGAGAGTGTGTGTATGTGGGCATAGGTGTGTTAA 
>Clone_PLA2G2A_full_seq<< AGGATGTTGGCACTATCAGGTAATTACGAGAGTGTGTGTATGTGGGCATAGGTGTGTTAA 
                          *********************** ************************************ 
 
>Ensemble<<               CATGTATGTGTTTGGGAACTTGTGTATGTGGAAGGGGTTAGAAGGCCTAGAAGAGAGAGG 
>Clone_PLA2G2A_full_seq<< CATGTATGTGTTTGGGAACTTGTGTATGTGGAAGGGGTTAGAAGGCCTAGAAGAGAGAGG 
                          ************************************************************ 
 
>Ensemble<<               TTGATGCTTTCATTCTGGAGGAAAATACTGAGGCCGAGCCTCCATGGGTGCCTTGGAGAC 
>Clone_PLA2G2A_full_seq<< TTGATGCTTTCATTCTGGAGGAAAATACTGAGGCCGAGCCTCCATGGGTGCCTTGGAGAC 
                          ************************************************************ 
 
>Ensemble<<               TCCAAGCCTTGAATCCAGTGTGGGGATATGCAAGCTATGTCTAGCGAGGGACACATCCTC 
>Clone_PLA2G2A_full_seq<< TCCAAGCCTTGAATCCAGTGTGGGGATATGCAAGCTATGTCTAGCGAGGGACACATCCTC 
                          ************************************************************ 
 
>Ensemble<<               TGACCTCAGGAACCTCCCAGGTAGTTGGGAGGAACCTGGTTCCAACCTCCCAAGAACTCT 
>Clone_PLA2G2A_full_seq<< TGACCTCAGGAACCTCCCAGGTAGTTGGGAGGAACCTGGTTCCAACCTCCCAAGAACTCT 
                          ************************************************************ 
                           
                                     position 2125 corrected c>t 
>Ensemble<<               CAGTCTGATGAGGTACAGGGGAGGTCTCATTAGTGTATCATGGGGTTCTCCACAGGTCTG 
>Clone_PLA2G2A_full_seq<< CAGTCTGATGAGGTACAGGGGAGGTCTCATTAGTGTATCATGGGGTTCTCCACAGGTCTG 
                          ************************************************************ 
 
>Ensemble<<               AGGGCCTGATGTGTGTGAAACCATTCTGCAGAGCTGGGAACGGGTCAGGAGGTGGTTGTG 
>Clone_PLA2G2A_full_seq<< AGGGCCTGATGTGTGTGAAACCATTCTGCAGAGCTGGGAACGGGTCAGGAGGTGGTTGTG 
                          ************************************************************ 
                                          Known repetition  
>Ensemble<<               TGTGTGTGTGTGTGTGTGTGTGTGCATTGCTGGAGGGCACTCCTTGTGTGCTCTGAGTGT 
>Clone_PLA2G2A_full_seq<< TGTGTGTGTGTGTGTGTGT----GCATTGCTGGAGGGCACTCCTTGTGTGCTCTGAGTGT 
                          *******************    ************************************* 
                                 Position 2300 corrected insert g 
>Ensemble<<               GACAGAGGAAGTCACCCTGGACTTAGGTTGGATGGGAGAGCATGTCTGTGTGTCTCAGAG 
>Clone_PLA2G2A_full_seq<< GACAGAGGAAGTCACCCTGGACTTAGGTTGGATGGGAGAGCATGTCTGTGTGTCTCAGAG 
                          ************************************************************ 
 
>Ensemble<<               CCACCAAGGAGGAGCAGGGGAGCGACGGCCGGGGCAGAAGTTGAGACCACCCAGCAG 
>Clone_PLA2G2A_full_seq<< CCACCAAGGAGGAGCAGGGGAGCGACGGCCGGGGCAGAAGTTGAGACCACCCAGCAG 
                          *********************************************************    
 
Primers for these site directed mutagenesis changes are shown below written stating 
the incorrect allele, the position of the allele and the corrected allele: 
G780A Forward: 5’ TTTATGAATTAAAGCTGGAGTGTCAGCCCGAAG 3’ 
G780A Reverse: 5’ CTTCGGGCTGACACTGACTCCAGCTTTAATTCATAAA 3’ 
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C1369T Forward: 5’AATTTACTCCATGGAAAGACTGCAAAACTGCCTGAAATGTG ’3 
C1369T Reverse: 5’ CACATTTCAGGCAGTTTTGCAGTCTTTCCATGGAGTAAATT ‘3 
 
C2125T Forward: 5’ TGAGGTACAGGGGAGGTCTCATTAGTGTATCATG ‘3 
C2125T Reverse: 5’ CATGATACACTAATGAGACCTCCCCTGTACCTCA ‘3 
 
Ins2300G Forward: 5’ AGAGGAAGTCACCCTGGACTTAGGTTGGATGGG ‘3   
Ins2300G Reverse: 5’ CCCATCCAACCTAAGTCCAGGGTGACTTCCTCT ‘3 
 
PLA2G2A rs11573156 Site Directed Mutagenesis to Introduce a Base 
Site directed mutagenesis was also used to deliberately introduce the rs11573156 G 
allele to the plasmid DNA insert sequence, for comparison to the wild-type sequence, under 
the following conditions: 
Forward primer: 5’CCTCCCAGAGGGAGGAGCTATTTAAGGGG 
Reverse primer: 5’CCCCTTAAATAGCTCCTCCCTCTGGGAGG 
 Primers were used at 125ng/µl. Each reaction included; 5µl Reaction Buffer (10x), 
1µl dNTPs, 1.5µl QuikSolution Reagent, 1µl Forward primer, 1µl Reverse primer, 1µl DNA 
(50ng/µl), 39.5µl dH2O, then add 1µl QuikChange Lightning Enzyme. The PCR conditions 
were as follows: 95ºC for 2 minutes, then 18 cycles of; 95ºC  for 20 seconds, 60ºC for 10 
seconds and 68ºC for 4.5 minutes (30 seconds/Kb plasmid length) followed by a final cycle 
of; 68ºC for 5 minutes. The PCR-product was then digested with 2µl DpnI and underwent 10 
minutes of incubation at 37ºC. The DpnI treated product was then re-transformed into XL1-
Blue supercompetent cells. 
2.4.7.6. Amplification of Re-grown Colonies and DNA Purification by Maxiprep 
 I used DNA at a concentration of 400ng/µl for luciferase assays. In order to achieve 
this concentration, more DNA was amplified and purified. The purification process was by 
maxiprep. This was achieved as follows: A glycerol stock of the cell culture was thawed on 
ice and a sample of cells was streaked onto a fresh LB agar plate (Table 2.1). The remaining 
cells were re-stored at -80ºC. 
The plate was incubated at 37ºC for 16 hours after which a fresh colony was picked 
and added to 150ml of sterile LB medium and inoculated with 300µl of ampicillin (100µg/ml). 
This was incubated on a shaker for a further 16hours at 37ºC/225rpm. Maxiprep reactions 
were carried out as according to the manufacturers’ guidelines. 
(http://www.sigmaaldrich.com/etc/medialib/docs/Sigma/Bulletin/na0300bul.Par.0001.File.tmp
/na0300bul.pdf).  
117 
 
2.4.7.7. Transfection of Purified Plasmid into a Human Cell Line. 
 Luciferase assay analysis was carried in order to measure the luciferase activity 
generated by the plasmid/insert complex. Human hepatocellular carcinoma cell line (Huh7 
cells) (Table 2.1) were incubated at 37ºC in DMEM (+10% FBS) (Table 2.1) and grown to 
95% confluency in a t-75 flask. Trypsin (0.25%) (Table 2.1), PBS (1x) and fresh DMEM were 
then pre-warmed to 37ºC. The Huh7 cells were washed with 10ml PBS (1x) after which the 
PBS and DMEM were drained. The cells were trypsinised with 3ml trypsin for 2 minutes at 
37ºC to remove cells from the flask wall. They were then immediately washed with 12ml 
fresh DMEM and transferred to a 15ml falcon tube. The cells were then centrifuged at 
1,000g for 5 minutes and the supernatant was discarded. The cell pellet was resuspended in 
12ml DMEM. The cell count was estimated using the Advanced Detection and Accurate 
Measurement (ADAM) cell counter.  
Cells were plated in a 96 well format. 100µl of the cell solution was added to each 
well (2x104 cells/100µl) and incubated at 37ºC for 24 hours. For each luciferase assay 
carried out in this thesis the plate would include one column containing the puc 19 plasmid, 
one containing pGL3-Basic plasmid, one containing pGL3-control plasmid and one 
containing β-Gal. Puc 19 is a plasmid that does not contain the luciferase (luc+) gene. pGL3-
Basic is a plasmid that contains both the Renilla and Firefly luc+ gene, but no promoter 
sequence. pGL3-Basic luciferase measurements were used to normalise all vector/insert 
plasmid measurements, so different DNA plasmids could be compared effectively within and 
between each plate. pGL3-Control is a plasmid that contains the luc+ gene and an internal 
promoter (the SV40 promoter) sequence, known to drive luciferase activity to high levels. 
This was used as a positive control for luciferase activity. β-Gal is an enzyme that catalyses 
the hydrolysis of β-galactosidase into monosaccharides. The β-Gal assay was used to 
detect transfection efficiency. Detection was by X-gal when X-gal was cleaved by active β-
Gal enzymes in this reaction it synthesized a blue product, easily identified by eye or under a 
light microscope.  
 For 1x 96 well plate, cells were transfected for luciferase assays as follows: A 
mastermix of 12µl of pRL-TK (10ng/µl) and 2,928µl of Opti-MEM was made and mixed by 
inverting 8-10 times. PRL-TK activated the renilla luciferase gene in the plasmid DNA. This 
measure was the co-transfected control reporter enzyme activity. 
 5µl of plasmid DNA (400ng/µl) and 245µl of the mastermix was added to an 
eppendorf tube, except in the case of puc plasmid DNA and β-Gal enzyme, which do not 
require the pRL-TK co-transfector as they have no luc+ genes. In this case 245µl of Opti-
MEM was added to each eppendorf tube. 
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 A lipid mastermix of 66µl of Lipofectamine 2000 (1mg/ml) was added to 3,243µl of 
Opti-MEM and mixed by inverting 8-10 times. The mix was then left to stand for 5 minutes. 
Lipofectamine 2000 is a transfection reagent that contains lipid subunits capable of forming 
liposomes in an aqueous environment, which trap the DNA plasmids and then fuse to the 
plasma membrane of the Huh7 cells and are engulfed. 250µl of lipid mix was added to each 
eppendorf tube to complete the transfection mix. Each transfection mix was left at room 
temperature for 20 minutes. 50µl of transfection mix was added to each well of the 96 well 
plate and the plate was incubated at 37ºC for 48 hours. 
2.4.7.8. Cell Lysis and β-Gal Assay 
 For the β-Gal assay, the medium was removed from the cells and washed with 100µl 
PBS (1x). 50µl of Fixture Solution per well was added and left at room temperature for 5 
minutes. The Fixture Solution was removed and the cells were washed twice with 100µl of 
PBS (1x). 50µl of Staining Solution was added to each well. 
 To lyse the cells in preparation for the luciferase assay the medium was removed 
from all wells and the cells were washed twice with PBS (1x). Then 20µl of Lysis Buffer (1x) 
was added to all wells and the plate was gently rocked for 15 minutes at room temperature. 
2.4.7.9. Luciferase Assay 
 The Dual-Luciferase Reporter Assay System sequentially measured the activity of 
both firefly and renilla luciferases from a single sample. The firefly was measured by the 
addition of Luciferase Assay Reagent II (LAR II) to generate a stabilized luminescent signal. 
After quantification of this luminescent signal this reaction was quenched and simultaneously 
the renilla reaction was initiated by the addition of the Stop & Glo Reagent to the same well. 
Stop & Glo also produced a stabilized signal from the renilla luciferase, which decayed over 
the course of the measurement.  
 The Dual-Luciferase Reporter Assays (Table 2.1) were run using the Tropix TR717 
Microplate Luminometer (Table 2.5) using WinGlow software (Table 2.4).  The machine 
injectors were set to dispense 100µl of LAR II and Stop & Glo respectively. All 
measurements were set for a 2 second delay and a 10 second read time. 10µl of lysed cells 
from each well were transferred by pipette to a white cell culture plate and placed into the 
Luminometer. LAR II was dispensed into the first well and the firefly luciferase activity was 
measured and recorded. Stop & Glo was dispensed and the renilla activity was measured 
and recorded. This process was repeated for each well.  
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 The resulting measurements were recorded using the WinGlow software (Table 2.4). 
The ratio of Firefly:renilla activities was used to effectively compare different samples and 
plates. 
2.4.8. LightShift Chemiluminescent Electrophoretic Mobility Shift Assay (EMSA) 
 The purpose of an electrophoretic mobility shift assay (EMSA) is to identify any 
specific protein complexes binding to a sequence of interest. Comparison of EMSA results 
for the genotypes of a SNP of interest can identify potential differential transcription factor, 
which may have a regulatory effect on the transcription of the gene of interest.  
 Throughout this thesis the chemiluminescent reaction is used, as opposed to the 
radiolabelled EMSA reaction. The chemiluminescent reaction works by detecting biotin 
labelled primers using the stabilized Streptavidin-Horseradish Peroxidase detection.  
As a control in each experiment, each set of biotin labelled primers was run 
alongside a reaction that had a 20x the same, unlabelled primers added to the reaction 
before the addition of the biotin labelled primers. As the unlabelled primers were added 
before the labelled primers, they annealed themselves to any specific protein-DNA binding 
sites, preventing the labelled primers from annealing there, thus ‘competing’ out the labelled 
primers. Non-specific binding would not be competed out by the specific, unlabelled primers. 
2.4.8.1. Designing, Biotin Labelling and Annealing Primers 
EMSA Probes for the Analysis of rs11573156 
 Forward and reverse primers were designed, as previously described, to be ~30 
base pairs in length. EMSA probes used for rs11573156 C>G were as follows: 
Forward wild type 5’-AACCTCCCAGAGGGAGCAGCTATTTAAGGGGAG-3’  
Reverse wild type 5’-CTCCCCTTAAATAGCTGCTCCCTCTGGGAGGTT-3’  
Forward rare variant 5’-AACCTCCCAGAGGGAGGAGCTATTTAAGGGGAG-3’ 
Reverse rare variant 5’-CTCCCCTTAAATAGCTCCTCCCTCTGGGAGGTT-3’ 
EMSA Probes for the Analysis of rs3767221 
 EMSA probes used for rs3767221 A>C were as follows: 
Forward wild type 5’-TGAGCTCAAGCAATCATTGCACTTCAGCCT-3’  
Reverse wild type 5’-AGGCTGAAGTGCAATGATTGCTTGAGCTCA-3’  
Forward rare 5’-TGAGCTCAAGCAATCCTTGCACTTCAGCCT -3’  
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Reverse rare 5’-AGGCTGAAGTGCAAGGATTGCTTGAGCTCA -3’ 
Each primer was diluted to 5µM for biotin labelling. For a standard 50µl biotin 
labelling reaction: 29.5µl dH2O, 10µl TdT Buffer (5x) (Table 2.1), 5µl biotin-11-dUTP (Table 
2.1), 0.5µl TdT (Table 2.1) and 5µl primer (5µM). 
 This mix was incubated at 37ºC for 90 minutes and then at 70ºC for 10 minutes to 
stop the reaction. An equal volume of chloroform:isoamyl alcohol (24:1) was added to extract 
TdT (50µl) and this mix was vortexed briefly and centrifuged at 13,000rpm for 2 minutes. 
The top (aqueous) layer was retained. 
  To anneal both the biotin labelled and unlabelled primer sets (forward and reverse) 
equal volumes of labelled forward and reverse primers (5µM), or unlabelled forward and 
reverse primers (100pMol/µl) were mixed together. 1/10th the total volume of annealing 
buffer (10x) was added and vortexed briefly. Primers then underwent an annealing reaction 
on the G-Storm thermocycler: 95ºC for 5 minutes, 70-95ºC (-1ºC/cycle) for 1 minute and 
then 4ºC HOLD. Primers were stored at -80ºC in 50µl aliquots.  
2.4.8.2. Nuclear Extraction 
 Mammalian eukaryotic cell nuclear extract contains protein-DNA complexes and 
were isolated from Huh7 cells grown to 95% confluency in a t-175 flask as follows: Cells 
were washed with 25ml PBS (1x) and trypsinised with 5ml trypsin (0.25%) at 37ºC for 3 
minutes. 30ml DMEM was added to the cells and the mix was transferred to a falcon tube 
and centrifuged at 4ºC for 5 minutes at 1000rpm. The supernatant was discarded. The cell 
pellet was resuspended in 5ml ice-cold Buffer A with 50µl of protease inhibitor (100x). This 
mix was incubated on ice for 10 minutes. The mix was then centrifuged at 4ºC for 5 minutes 
at 1000rpm. The supernatant was discarded. The cell pellet was resuspended in 2ml of ice-
cold Buffer A with 20µl of protease inhibitor (100x). The mix was then vortexed for 30 
seconds. This mix was centrifuged at 4ºC for 2 minutes at 13,000rpm. The supernatant was 
discarded. The cell pellet was resuspended in 800µl of ice-cold Buffer C with 16µl of 
protease inhibitor (100x). The mix was vortexed for 1 minute and incubated on ice for 10 
minutes. This vortex/incubation process was repeated 4 times in total. The mix was then 
centrifuged at 4ºC for 50 minutes at 13,000rpm. The supernatant was aliquoted into 50µl 
volumes and stored at -80ºC.  
2.4.8.3. Polyacrylamide Gel (6%) Preparation 
 Chemiluminescent EMSA reactions were run by gel electrophoresis on a 6% 
polyacrylamide gel (1x1.5mm). A frame was constructed to hold two clean glass panels with 
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a 1.5mm gap for the gel to be poured into. The gel was poured immediately into the gap 
between the glass panels and the dividing comb was placed into the top of the gel between 
the glass panels to create the well spaces. The gel was left to polymerise. 
Once polymerised, the comb was removed from the gel and the wells were washed 
with TBE (0.5x). Then 1µl of EMSA Loading Buffer was added into each well and the gel 
was moved to a cold room (4ºC). The gel was placed in a tank containing TBE (0.5x) and 
electrophoresed at 120V for 1 hour to ensure that everything was working.  
2.4.8.4. EMSA Binding Reaction and Gel Electrophoresis 
 There were two EMSA binding reactions, one for the competitor reactions and one 
for the non-competitor reactions. For both reactions: 2µl Binding buffer (10x) (Table 2.1), 1µl 
poly dIdC (Table 2.1), 0.5µl MgCl2 (50mM) (Table 2.1), 1.5µl Random primers (Table 2.1), 
3µl nuclear extract. Then for the competitor reactions the following was added: 6µl dH2O, 4µl 
unlabelled primers. The competitor reactions were incubated at 4ºC for 30 minutes. Then for 
non-competitor reactions 10µl dH2O was added and for both reactions 2µl biotin labelled 
primers was added and all reactions were then incubated at 25º for 50 minutes. 4µl of EMSA 
loading buffer was then added to each reaction and before loading into the pre-prepared gel 
and run at 120V for 5 hours. 
2.4.8.5. EMSA Blotting Membrane 
 Once gel electrophoresis was complete the protein was blotted onto a nylon 
membrane for the purposes of visualization. 4x pieces of Whatman paper were cut to ~15cm 
x 10cm, then a piece of Hybond-N+ membrane was also cut to the same dimensions. These 
were all soaked in SSC (10x) for 10 minutes. 
 A tank containing SSC (20x) with a Perspex block in the middle was assembled. 
Over this block 2 pieces of Whatman paper were layered so that the ends were submerged 
in the SSC. This served as the surface to layer the blotting membrane assembly onto and 
kept all the layers moist. Assembly included: 2 pieces of SSC soaked Whatman paper which 
the gel was laid on top of. The edges of the gel were then covered with Clingfilm. The 
Hybond-N+ membrane was layered next, ensuring that there were no air bubbles. Then 2 
pieces of SSC soaked Whatman paper were added and flattened with a roller to ensure 
there are no air bubbles. The layers were covered with a large stack of hand-towel tissues 
and a weight was added. This was left to blot over-night. The following morning the 
membrane was retrieved from the blotting assembly and cross linked using the UV 
Stratalinker 2400 at ~254nm for 3 minutes, making sure that the side of the membrane 
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closest to the gel was face up. This was done to fix the protein-DNA complexes to the 
membrane. 
 2.4.8.6. LightShift Chemiluminescent EMSA Detection System 
 The LightShift Chemiluminescent EMSA Kit (Table 2.1) was used to detect protein-
DNA complex binding. The manufacturers’ instructions were optimised as follows: 
 The blocking buffer and wash buffer (4x) were incubated at 37ºC until all the SDS in 
the solution was dissolved. The membrane was placed in a clean container and 30ml of 
blocking buffer was added. The container was rocked gently for 15 minutes. 75µl of 
stabilized Streptavidin-Horseradish Peroxidase was added to the buffer in the container and 
rocked for a further 15 minutes while 100ml of wash buffer dilution (1x) was prepared. The 
buffer/Streptavidin solution was decanted from the membrane. 20ml of wash buffer (1x) was 
added to the membrane and rocked gently for 5 minutes. This step was repeated 4 times in 
total. After decanting the last of the wash buffer the membrane was washed in 20ml of 
substrate equilibrium buffer for 5 minutes with gentle rocking. During this time 3ml of 
luminol/enhancer solution was combined with 3ml of stable peroxidase solution and 
decanted onto a clean glass plate. The membrane was then removed from the container and 
placed face down onto the solution on the glass plate, with no air bubbles, for 7 minutes. The 
membrane was briefly drip-dried and wrapped in Clingfilm, avoiding bubbles and wrinkles. It 
was then placed face up into a cassette for exposure to X-ray film. 
2.4.8.7. EMSA Visualisation  
 To visualize the protein-DNA complexes the membrane was taken into a dark room 
and exposed to X-ray film for variable time points. The film was developed according to the 
manufacturers’ instructions. 
2.4.9. TaqMan Gene Expression 
 TaqMan Gene Expression was used to measure the amount of mRNA expression 
associated with a target sequence. To do this, complementary DNA (cDNA) of known 
genotype must be synthesised from RNA taken from lymphocytes. 
2.4.9.1. RNA Extraction 
 10ml of whole blood was added to an equal volume of PBS (1x) (Table 2.1) and 
mixed by inversion. This blood/PBS mix was layered on top of 4ml Lymphocyte Separation 
solution (Table 2.1) and centrifuged at 2000rpm for 20 minutes. The resulting top layer 
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(plasma) was retained and added to 20ml PBS (1x) and centrifuged at 1000rpm for 5 
minutes. Lymphocyte RNA were isolated using the RNeasy Mini Kit. 
 For the purposes of rs11573156 CC comparison with rs11573156 CG/GG samples, 
lymphocytes were isolated from 12 samples of 10ml whole blood from an in house European 
cohort known as the DRD cohort.  
2.4.9.2. Complementary DNA (cDNA) Synthesis by Reverse Transcription  
All incubations were carried out on the G Storm Thermocycler. For each reaction the 
following mix was prepared: 1µg RNA in a 10µl solution (made up with dH2O), 2µl random 
primers (2 pMol) and 1µl dNTP (10mM). This mix was incubated at 65ºC for 5 minutes and 
then the following was added: 4µl First Strand Buffer and 2µl DTT (0.1M). This was 
incubated at 42ºC for 2 minutes and then 1µl Superscript III was added. After this addition 
the mix was incubated at 42ºC for 40 minutes and then at 70ºC for 15 minutes immediately 
after. Then 1µl ribonuclease (Rnase) H was added and the total mix was incubated at 37ºC 
for 10 minutes. Samples were labelled and stored at -20ºC. 
2.4.9.3. TaqMan Gene Expression Assays (20x) 
 TaqMan Gene Expression Assays (20x) are target protein-coding transcripts. All 
assays used throughout this thesis were of human species and are detailed in Table 2.3. 
The assays used for the work throughout this thesis were Inventoried or Made-to-Order. 
These assays were pre-designed and tested. They were either mass manufactured and 
stored as stock or manufactured at the time of order.  
TaqMan Endogenous Controls are a collection of predesigned assays for candidate 
control genes used in order to normalise for genotype specific differences in sample RNA. 
Endogenous controls were pre-run with all samples to determine the most appropriate 
control. The best endogenous controls show no difference in expression across all samples. 
Each TaqMan Gene Expression Assay (20x) and Endogenous Control contains two 
unlabelled primers (18µM per primer) and one 6-FAM reporter dye labelled TaqMan MGB 
probe (5µM). In both instances probes have a reporter dye attached to the 5’ end of the 
probe and a non-fluorescent quencher (NFQ) at the 3’ end.  
TaqMan Gene Expression Method Description and Conditions 
 ABI TaqMan Gene Expression reactions were carried out in a 384 well plate format. 
cDNA at 5ng/µl was transferred from a standardized array using the Biomek 2000 
Laboratory Automation Workstation (Table 2.5) into a 384 well plate and centrifuged at 
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3000rpm for 1 minute. Each plate contained at least two no template control (NTC) wells, 
containing no cDNA, to control for contamination. A standard curve was produced for each 
assay using a serial dilution of cDNA at 0.25ng, 0.5ng, 1ng, 2ng and 5ng.  
 TaqMan gene expression reactions were carried out as per the TaqMan Gene 
Expression Mastermix manufacturers’ instructions. Each plate was centrifuged at 3000rpm 
for 1 minute and PCR reactions were carried out using the 7900HT Fast Real-Time PCR 
system (Table 2.5). The standard PCR reaction conditions were as follows: Uracil-DNA 
Glycosylase (UDG) incubation at 50ºC 2 for minutes then AmpliTaq Gold UP Enzyme 
Activation at 95ºC for 10 minutes followed by 40 cycles of denaturing at 95ºC for 15 seconds 
each and finally annealing/Extension at 60ºC for 1 minute.  
 In a similar fashion to TaqMan Genotyping there are several phases that occurred 
during each PCR reaction for TaqMan Gene Expression (Figure 2.7). UDG was activated to 
prevent the re-amplification of carry over PCR-products. Each TaqMan MGB probe annealed 
to the specific complimentary sequence between the forward and reverse primer sites. At 
that point the probe was still intact and therefore the NFQ was still at close enough proximity 
to the reporter dye to quench its fluorescent signal. Next the AmpliTaq Gold DNA UP 
polymerase (a component of the TaqMan Gene Expression Master Mix) 5’ to 3’ activity along 
the DNA template between the forward and reverse bound primers specifically cleaved the 
probes that were hybridized to their target. The effect of cleavage was to separate the 
reporter dye from the NFQ, which caused an increase in fluorescence from the reporter dye 
and both probe fragments to become displaced from the target. Polymerization of the strand 
continued. The probes were blocked from the 3’end to prevent them from extending 
themselves during the PCR. During the PCR process the ROX passive reference acted as 
an internal reference for the normalization of the reporter dye signal, correcting for changes 
in concentration or volume. 
 The increase in fluorescent signal was only detected if the target sequence was 
complementary to the probe and amplified during PCR. This prevented non-specific 
amplification detection 
(http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocument
s/cms_039284.pdf).  
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Figure 2.7. The 5’ Nuclease Assay. Schematic to show the stages of a cycle of the TaqMan Gene 
Expression PCR . Reprinted from: 
(http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocuments/cms_0
39284.pdf).   
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TaqMan Gene Expression Signal Detection 
 Analysis was carried out using the 7900HT Fast Real-Time PCR System (Table 2.5) 
with Sequence Detection System (SDS) v2.1 software (Table 2.4). Each well was manually 
labelled using the SDS software to measure the correct assay. 
 A relative quantitation analysis was used for all plates. This compares a target 
against an internal standard (ROX) using the comparative threshold cycle (Ct) method. Ct is 
the PCR amplification cycle number where the signal associated with a sample first shows a 
significant exponential growth due to increased fluorescent signal detection with 
amplification. The lower the Ct, the higher the expression. In addition all measurements were 
also normalized to endogenous controls, which accounted for the quality of the cDNA used 
and any concentration variability. 
 Normalization was automatically calculated using the SDS relative quantitation 
function. This was achieved by dividing the emission intensity of the reporter gene by the 
ROX passive reference at two time points. The first is at the baseline (the early cycles of 
PCR before significant exponential growth) (Rn- value) and the second at 40 cycles - the 
PCR endpoint (Rn+ value).  The ∆Rn value is the difference between the Rn+ and Rn- values, 
which represents an accurate measurement of the magnitude of the signal generated by the 
PCR conditions (Figure 2.8).  
 The SDS software generated results as a set of amplification plots (Figure 2.9a) and 
a text file output. Plots can be manually viewed per sample or per assay (Figure 2.9b). This 
function allowed me to ensure that each assay had worked and to manually remove any 
anomalous results by discounting the relative well. Both baseline and threshold cycle values 
can be automatically calculated by the SDS software or set manually. For all assays carried 
out for rs11573156 I manually set the threshold to optimise the view of each set of results. 
The text output values were used to compare differences in expression by genotype. To 
achieve this, the text output values were sorted into genotype groups an input into the Rest-
384 software system (Table 2.4). This calculated the average difference in ∆Ct values 
between genotypes in the target sequence and between genotypes in the endogenous 
controls, taking into account the standard curve values 
(http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocument
s/cms_039284.pdf). 
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 Figure 2.8. TaqMan Gene Expression Schematic to show how each set of results are interpreted. 
Normalization using ROX showing Rn as a function of PCR amplification cycle number. This graph 
represents how ∆Rn is calculated and also indicates the point of significant exponential growth that 
determines ∆CT based on the increase in fluorescent signal detected with PCR amplification 
(http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocuments/cms_0
39284.pdf). 
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 Figure 2.9a. A Typical Amplification Curve. This graph represents a typical amplification curve and 
identifies the main phases of the run. Each line represents an individual sample and each colour 
represents a particular target or endogenous control assay 
(http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocuments/cms_0
39284.pdf). 
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Figure 2.9b. This is an example of a typical results plot for PLA2G2A TaqMan gene expression using 
the SDS software. Unlike Figure 2.9a, which represents the results for each assay (each shown in a 
different colour) this figure has been set to show the results for the PLA2G2A exon 1-2 assay only. 
This allows one to interpret whether the assay has worked and to manually remove any anomalous 
results. For example the sample that does not reach the threshold before 40 cycles is anomalous and 
was removed from the analysis. The threshold was manually set in order to best visualise the 
amplification curve.  
 
TaqMan Gene Expression Analysis for rs11573156 C>G 
The effect of rs11573156 C>G on mRNA levels was assessed using a TaqMan gene 
expression assay in a set of 12 Caucasian samples from the DRD cohort: 5 samples were 
homozygous for the common allele (CC), there were 4 heterozygous samples (CG) and the 
frequency of homozygosity of the minor G allele (0.0625) meant it was only possible to 
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identify three GG homozygous samples from this volunteer cohort. The samples were taken 
from a total of 67 previously genotyped DRD study participants using the TaqMan 
Genotyping protocol (2.6.1) and analysed using the relative quantitation (using comparative 
Ct) program on the ABI Prism 7900HT TaqMan machine (Table 2.5). Only 12 samples could 
be utilised due to a lack of remaining blood stocks for many of the study participants. 
RNA samples were isolated and reverse transcribed as described above for use with 
two TaqMan ABI inventoried gene expression assays (Table 2.3), Hs01044022_m1, 
spanning human PLA2G2A exon 1 and 2 and Hs00179898_m1, which spans exon 5 and 6. 
They were compared and normalised to the housekeeping genes Hs99999903_m1; ACTB 
(beta actin) and Hs99999905_m1; GAPDH. In all instances the housekeeping genes showed 
no difference in expression levels across all samples. Each sample was run in triplicate for 
each assay on the ABI Prism 7900HT Real Time PCR System. Results were analysed using 
the REST-384 Version 2 tool (Table 2.4).     
2.4.10. The Advanced Study of Aortic Pathology (ASAP) Gene Expression Analysis 
 The Advanced Study of Aortic Pathology (ASAP) is a cohort founded by Prof. Per 
Eriksson and his team at the Karolinska University Hospital in Stockholm. All analysis 
relating to this study was kindly carried out on my behalf by a member of the Karolinska 
team, Dr. Lasse Folkersen.  
The Advanced Study of Aortic Pathology (ASAP) recruited 221 patients undergoing 
aortic valve surgery at the Karolinska University Hospital, Stockholm Sweden (Sitia, 
Tomasoni et al. 2010). Tissue biopsies were taken from liver, mammary arteries and dilated 
and non-dilated ascending aorta and heart during surgery. The medial and adventitial layers 
of the vascular specimen were isolated by adventicectomy, and incubated with RNAlater 
(Ambion, Austin, Texas, USA) and homogenised for mRNA extraction (Sitia, Tomasoni et al. 
2010). Affymetrix Gene Chip Human Exon 1.0 ST expression arrays were used. Messenger-
RNA expression was evaluated using RNA pre-processing (Luscher and Barton 1997). 
Participants were genotyped using the Illumina Human 610W-Quad Bead array (Ross 1999), 
which included 101 SNPs in the region 200kb up and downstream from the PLA2G2A locus. 
SNPs not covered by the Illumina Human 610W-Quad Bead array were imputed for the 1000 
genome project. Classification by mach1 suggests >0.3 as the lowest threshold for R2. In our 
set this corresponded to ~10% mistakes. Per allele mRNA expression levels were calculated 
on an individual SNP basis for SNPs of interest that were available on the array. 
 
131 
 
2.4.11. Statistics  
 Specific statistical analysis is indicated as appropriate, along with clear 
acknowledgements of who has carried out each analysis. In general the programs used 
throughout the project included;  
 Stata Data Analysis and Statistical Software, which was mainly used for comparing 
genotype data to assess the effect of different genotypes on sPLA2 levels and activity, 
cardiac events and cardiac related disorders. 
IBM SPSS Statistics, which was mainly used to compare genotype effects on 
luciferase activity using results from the luciferase assays. More specifically, statistical 
analysis of luciferase assays was performed using SPSS version 12.0 and an independent 
sample T-test was run to determine the P-value, with a threshold of  P<0.05. 
For the rs11573156 Mendelian randomisation a pre-specified Stata script was 
developed by Jackie Cooper and Michael Holmes to standardise the genetic analysis in the 
collaborating studies. The genotyping was arranged so that the genotype coding was 
directionally consistent and reduced sPLA2 with the addition of the C allele. Traits 
considered not to be normally distributed included sPLA2-IIA mass, sPLA2 activity, carotid 
intima medial thickness (C-IMT), C-reactive protein (CRP), triglyceride and interleukin-6 (IL-
6) concentrations. These traits were log(n) transformed and differences between genotype 
groups were reported as a relative or percentage difference. In order to combat the potential 
for established vascular disease altering the magnitude of genotype-trait association, there 
was limited analysis of associations between genotype and continuous traits to controls in 
retrospective case-control studies. Regarding cohort studies and nested case-control 
studies, all participants were included at recruitment, as variable measurements were made 
prior to clinical events.  
For the PLA2G2A SNP rs3767221 and the PLA2G5 and PLA2G10 meta-analyses 
statistical analysis was carried out by Jackie Cooper and Michael Holmes.  A pre-specified 
Stata script was developed to standardise the genetic analysis in the collaborating studies. A 
trait considered not to be normally distributed was sPLA2 activity. This trait was log(n) 
transformed and differences between genotype groups were reported as a relative or 
percentage difference. In order to combat the potential for established vascular disease 
altering the magnitude of genotype-trait association, there was limited analysis of 
associations between genotype and continuous traits to controls in the retrospective case-
control study. Regarding cohort studies and nested case-control studies, all participants 
were included at recruitment as variable measurements were made prior to clinical events. 
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 Regarding the genotyping results for PLA2G10 SNPs of interest, statistical analysis 
of RFLP and TaqMan genotyping data was analysed by Jackie Cooper using Stata. 
For the ASAP study statistical analysis of microarray expression data was performed 
using R 2.13.0 (Folkersen, Diez et al. 2009). P-values are calculated using a linear additive 
model encoding genotypes numerically. Plotting of location dependent associations was 
performed using the Gene Region Scanversion 1.8.0 (Libby 1995).  
2.5. Meta Analyses Study Populations and Specifications 
 All of the studies populations analysed throughout this thesis correspond to samples 
from European populations. Informed consent was obtained from all participants and 
permissions were granted by all relevant governing bodies where necessary. All additional 
population information is shown in Tables 2.6-2.7.  
2.5.1. Mendelian Randomisation Using PLA2G2A rs11573156 
 To carry out the Mendelian randomisation detailed in Chapter 4, we first had to 
consider how many individuals to include in the meta-analysis to give sufficient power. A 
power calculation was carried out to determine that the numbers involved in the Mendelian 
randomisation were considered great enough to determine a conclusion with high accuracy 
and reliability: The power calculation is described as follows: 
To estimate the power, we used the gene effect on sPLA2 (the per-allele effect was 
to reduce sPLA2-IIA by approximately 0.5 SD) and the observational association (a 1SD 
reduction in sPLA2-IIA mass associated with an OR of CHD of 0.84), we estimated the 
expected effect assuming the observational association was causal - i.e. the per-allele effect 
of sPLA2-IIA should associate with an OR of 0.84^0.5=0.92. Assuming a 10% risk of CVD in 
non-carriers of the variant, the risk would be 9.2% in individuals carrying a variant (assuming 
a causal relationship). We estimated that we would need 15,705 cases in 157,050 to have 
90% power at alpha=0.05. 
Using the values that we have: 19,716 cases (combined total of incident, prevalent 
and recurrent) and 96,523 controls we have a beta value = 0.07 and the power = 1- beta 
=0.93 (93%), where beta value is the likelihood that an experiment will yield a Type II error. 
 Our collaboration incorporated data from 32 studies of 96,523 individuals of 
European descent. Of these studies, 22 were considered to be in general populations, 
including 15 cohorts, 3 nested case-control and 4 case-control studies. There were also 8 
studies carried out in patients with acute coronary syndrome (ACS); 7 cohorts and 1 nested 
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case-control study. A cohort of patients with established vascular disease or risk factors for 
CVD (SMART) and a case-control study of ACS patients undergoing percutaneous coronary 
intervention (PCI) in which the outcome was coronary artery restenosis (GENDER). One 
additional study to these 32, the ASAP study, was not included in the meta-analysis, but was 
used to analyse the PLA2G2A mRNA expression associated with rs11573156. In all 
instances approval from relevant ethical committees was obtained and all analyses unless 
otherwise stated was performed using Stata and led by Dr Michael Holmes. Twenty-eight of 
these studies were used in the final Mendelian randomisation analysis. Table 2.6 gives an 
overview of the studies included and Table 2.7 indicates the relevant CHD and sPLA2 
associated measurements that could be obtained from each study. 
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Footnotes: C-C: case control; ICU: intensive care unit; RCT: randomized clinical trial; X-S: cross sectional. All cohorts were prospective in design.  
 
Table 2.6. The studies included in the MR analysis of rs11573156 with sPLA2-IIA mass/sPLA2 activity and the risk of CHD. The table includes details of the 
study backgrounds. 
Study  Study design Geographical location Sampling frame Participants included Baseline year(s) % Female Age, mean 
(SD) 
STUDIES IN GENERAL POPULATION      
AMC-PAS (Langer and Gawaz 2008) C-C Netherlands Hospital clinic 740 1990-2000 19.00 44.05(3.91) 
BHF-FHS (Lusis 2000) C-C UK Direct media campaign 4521 1998-2003 36.67 50.53(13.90) 
BRHS (Zhang 2008) Cohort UK General practice 3835 1998-2000 0.00 68.74(5.49) 
BWHHS (Zhang 2008) Cohort UK General practice 3405 1999-2001 100.00 68.91(5.49) 
CCHS (Steinberg 1987) Cohort Denmark General population 10375 1991-1994 55.68 56.57(16.26) 
CYPRUS (Lusis, Mar et al. 2004) Cohort Cyprus Mayor’s list 734 2003-2008 52.97 61.27(10.26) 
EAS (Brown and Goldstein 1986) Cohort UK General practices 857 1987 50.64 64.38(5.82) 
EPIC-Netherlands (Brown and Goldstein 1997) Nested C-C Netherlands Existing cohorts 5194 1993-1997 78.11 54.03(10.22) 
EPIC-Norfolk (Lusis 2000) Nested C-C UK General practices 3039 1993-1997 34.65 64.68(7.88) 
GRAPHIC (Berliner and Heinecke 1996) Cohort UK Nuclear families 2024 2003-2005 49.56 39.19(14.48) 
IMPROVE (Badimon, Storey et al. 2011) Cohort Europe Clinic 3236 2004-2005 52.83 64.35(5.17) 
LIFE Heart (Pentikainen, Oorni et al. 2000) C-C Germany Hospital clinic 3128 2006-present 32.83 62.86 (11.52) 
MedStar (Orso, Grandl et al. 2011) Cohort USA Single-centre hospital 1322 2004-2007 54.59 59.76(8.86) 
NPHS-II (Orso, Grandl et al. 2011) Cohort UK General practices 2693 1989-1994 0.00 56.11(3.33) 
PennCath (Libby 1995) C-C USA Single-centre hospital 1516 1998-2003 51.92 59.29(9.69) 
PREVEND (Borissoff, Spronk et al. 2011) Cohort Netherlands Community 8114 1997 50.86 49.05(12.76) 
PROSPER (Ross 1999) RCT UK, Ireland, Netherlands General practices 3991 1997-1999 51.79 75.28 (3.35) 
Rotterdam (Prentice, Paczesny et al. 2010) Cohort Netherlands District participants 5974 1989-1993 59.37 69.38(8.91) 
TPT (Graham 2006) RCT UK General practice 4014 1984-1989 0.00 56.06(6.74) 
UCP (Duscha, Slentz et al. 2005) Nested C-C Netherlands National drug registry 1632 1985-2005 25.49 62.76 (9.64) 
UDACS (Bhupathiraju and Tucker 2011) Cohort UK Clinic 564 2001-2002 41.13 66.73(11.09) 
Whitehall II (Ockene and Miller 1997) Cohort UK Workplace 5018 1985-1988 26.44 43.90(5.93) 
STUDIES IN ACUTE CORONARY SYNDROME PATIENTS     
FAST-MI (Doll and Hill 1966) Cohort France Nationwide ACS 
registry 
973 2005-ongoing 29.19 66.09(13.65) 
GENDEMIP (Gordon, Kannel et al. 1974) Cohort Czech Republic 5 Coronary Units 1432 2006-2009 25.98 57.08(8.62) 
GRACE-France (2004) Cohort France Hospitals 274 2000-2002 20.44 60.13(12.67) 
GRACE-Scotland (Ambrose and Barua 2004) Cohort Scotland Hospital 1488 1999-2009 30.04 64.84 (12.04) 
IHCS (Hawe, Talmud et al. 2003) Nested C-C USA Single hospital 2382 1994-ongoing 29.14 62.99 (12.29) 
KAROLA (Boer, Feskens et al. 1999) Cohort Germany Rehabilitation clinics 1019 1999-2000 15.00 58.93 (7.96) 
MERLIN-TIMI 36 (Pohjola-Sintonen, Rissanen et al. 1998) RCT 17 countries Hospitals 1606 2004-2007 34.10 63.43 (10.81) 
PROVE-IT TIMI 22 (Willer, Sanna et al. 2008) RCT 8 countries Hospitals 2260 2000-2003 22.51 57.48 (11.06) 
OTHER STUDIES        
GENDER (Boer, Feskens et al. 1999) C-C Netherlands Hospital clinic 866 1999-2001 26.00 62.01 (11.09) 
SMART (Hawe, Talmud et al. 2003) Cohort Netherlands Hospital clinic 8297 1996-1998 32.24 56.51(12.42) 
ASAP (Pohjola-Sintonen, Rissanen et al. 1998) Cohort Sweden Hospital clinic 272 2006-2010 28.68 63.54 (12.39) 
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Footnotes: BMI: body mass index; C-IMT: carotid intima medial thickness; CRP: C-reactive protein; HDL-C: high-density lipoprotein cholesterol; IL6: 
interleukin 6; LDL-C: low-density lipoprotein cholesterol; SBP: systolic blood pressure; sPLA2: secretory phospholipase A2; TG: triglycerides; † not included in 
the PLA2G2A-sPLA2 analysis as blood samples were not taken at time of ACS. All measurements undertaken by individual study groups and have been 
previously reported in published data. 
Table 2.7. This table represents the available CHD/sPLA2 relevant biomarker measurements for each included study. 
sPLA2 assays Circulating biomarkers/anthropometric traits 
IIA mass Activity SBP LDL-C HDL-C TG IL6 CRP Glucose BMI C-IMT 
STUDIES IN GENERAL POPULATIONS 
AMC-PAS ● ● ● ● ● ● ● 
BFH-FHS 
BRHS ● ● ● ● ● ● ● ● 
BWHHS ● ● ● ● ● ● ● ● 
CCHS ● ● ● ● ● ● ● 
CYPRUS ● ● ● ● ● ● ● 
EAS ● ● ● ● ● ● ● ● ● 
EPIC-Netherlands ● ● ● ● ● ● ● 
EPIC-Norfolk ● ● ● ● ● ● ● ● 
GRAPHIC ● ● ● ● ● ● ● 
IMPROVE ● ● ● ● ● ● ● ● 
LIFE Heart ● ● ● ● ● ● ● 
MedStar ● ● ● ● 
NPHS-II ● ● ● ● ● ● 
PennCath ● ● ● ● 
PREVEND ● ● ● ● ● ● ● ● 
PROSPER ● ● ● ● ● ● 
Rotterdam ● ● ● ● ● ● 
TPT ● ● 
UCP ● 
UDACS ● ● ● ● ● ● ● ● ● 
Whitehall II ● ● ● ● ● ● ● ● 
STUDIES IN ACUTE CORONARY SYNDROME POPULATIONS 
GENDEMIP ● ● ● ● ● ● ● 
FAST-MI ● ● ● ● ● ● ● 
GRACE-France ● ● ● ● ● ● 
GRACE-Scotland ● ● ● ● ● ● ● ● ● 
IHCS ● ● ● ● ● ● ● 
KAROLA ● † ● ● ● ● ● ● ● ● ● 
MERLIN-TIMI 36 
PROVE-IT TIMI 22 
OTHER STUDIES 
GENDER 
SMART ● 
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Mendelian Randomisation Method 
Data was taken from 28 of 32 studies for the analysis of the association between 
rs11573156 and putative and established cardiovascular risk factors; 21 general population 
studies, 6 ACS cohorts and 1 established vascular disease cohort. This data was used to 
test the associations of PLA2G2A with cardiovascular risk and other co-variables. For these 
continuous traits, per C allele associations of rs11573156 with variables were estimated 
within each study by linear regression analysis. The studies not included here were BFH-
FHS, MERLIN, PROVE-IT, GENDAR and SMART.  
When analysing the associations between rs11573156 and cardiovascular events, 
data was taken from 29 studies including 21 general population studies and 8 ACS patient 
studies. Two additional studies, SMART and GENDER, were also analysed, but could not be 
included due to their patient characteristics or outcome definitions differing from the other 
studies.  
The cardiovascular outcomes were defined as follows: (i) Major Vascular Event 
(MVE) (comprising fatal/non-fatal myocardial infarction or stroke); (ii) non-fatal myocardial 
infarction (ST-segment elevation myocardial infarction or non-ST-segment elevation 
myocardial infarction); (iii) non-fatal stroke (including ischemic or haemorrhagic subtypes), 
and; (iv) fatal myocardial infarction or stroke.  
Studies in general populations were divided into prevalent (events occurring pre-
recruitment) or incident (events occurring during follow-up in individuals previously free from 
MVE). For all ACS studies, all events after recruitment were included and labelled as 
recurrent events. The within-study per C allele association of rs11573156 with MVE was 
estimated using logistic regression. 
For all continuous traits, the results were pooled using a fixed effect (inverse 
variance) meta-analysis and for all clinical traits estimates were pooled using fixed-and 
random-effects meta-analysis. All meta-analysis was stratified by clinical setting and used I2 
to measure heterogeneity (Marenberg, Risch et al. 1994). Assuming the association 
between sPLA2-IIA mass and fatal/non-fatal MI followed a log-linear relationship and was 
free from bias, we estimated the expected effect of the genetic variant on risk of MVE, and 
compared this to that observed outcome.   
PLA2G5 Study Populations Used to Analyse SNPs of Interest 
Based on the initial results from UDACS, I and others in our lab genotyped the 
selected SNPs in up to 11 additional studies, which are listed and detailed in Table 2.8. 
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   There was also limited SNP genotyping data available from MetaboChip genotyping. 
The MetaboChip is a custom Illumina iSelect genotyping array designed to test ~200,000 
SNPs of interest for disease phenotypes such as; metabolic disease and 
atherosclerotic/cardiovascular disease. The content of the chip was chosen based on large 
scale meta-analysis of relevant traits (including up to 100,000 individuals) and of HapMap 
and 1000 Genomes Project SNP content (http://www.sph.umich.edu/csg/kang/MetaboChip/). 
Several MetaboChip studies agreed to contribute genotype data.  
Using the genotyping data available, associations for the identified SNPs with CHD 
risk and known CHD risk factors was studied and additionally the associations between 
these SNPs and sPLA2 activity were studied. We also have access to data from the GWAS 
study; Welcome Trust Case Control Consortium (WTCCC), thanks to Dr. Reecha Sofat who 
is a registered user for WTCCC data. WTCCC is a UK based GWAS, established in 2005 
(Lewington, Clarke et al. 2002). 
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Footnotes: BWHHS: British Women’s Health and Heat Study; Cyprus: Cyprus Study; EPIC: European Prospective Investigation into Cancer and Nutrition; 
GRACE: Global Registry of Acute Coronary Events; IMPROVE: IMPROVE Study; NPHS-II: Northwick park Heart Study; TPT: Thrombosis Prevention Trial; 
UDACS: University College London Diabetes And Cardiovascular Disease Study; Whitehall II: Whitehall II Study. 
Table 2.8. A list of the PLA2G5 tSNPs identified by univariate analysis in UDACS as having potentially significant associations to either total cholesterol or 
LDL levels (CHD risk factors) or sPLA2-IIA mass and the studies that each SNP has been genotyped in. The cohort details for these studies have been 
detailed previously in Table 2.6 and the biomarkers measured in each study have been previously described in Table 2.7.
Study: rs11573185 rs11573248 rs11573203 rs11573191 Genotyped By: 
UDACS (Mason 2011) 
 
       P. Wootton 
EPIC-Norfolk (Jones, Dhamrait et al. 2003) 
 
   M. Guardiola 
GRACE-FRANCE (Kuller and Meilahn 1996)     M. Guardiola 
Edinburgh Artery Study (Willerson and Ridker 2004) 
 
   H.Exeter 
NPHSII (Corson 2009) 
 
   K.Li 
TPT (Andreotti, Porto et al. 2002) 
 
   H.Exeter 
BWHHS (Jain and Ridker 2005) 
 
   MetaboChip 
Whitehall II (Ray, Stein et al. 2002) 
 
   MetaboChip 
Women's Health Initiative (Kimmel, Berlin et al. 2004) 
 
   MetaboChip 
EPIC-Netherlands (Ali, Narayan et al. 2010) 
 
   MetaboChip 
IMPROVE (Kannel and McGee 1979)     H.Exeter 
CYPRUS (Moss, Klein et al. 1991)     H.Exeter 
 
 
 
 
 
 
 
 
  
SNPs Genotyped in Each Study: 
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PLA2G10 Study Populations Used to Analyse SNPs of Interest  
 The studies included in the genotyping analysis are listed in Table 2.9, which also 
gives an overview of the traits measured in each study. Initially all four SNPs were 
genotyped in EPIC-Norfolk and GRACE and, based on these results (6.3.3), rs4003228 was 
additionally genotyped in a further two studies. 
  
 
Table 2.9. The baseline characteristics for EPIC-Norfolk, GRACE-France, UDACS and NPHS-II. The 
cohort details for these studies have been detailed previously in Table 2.6 and the biomarkers 
measured in each study have been previously described in Table 2.7. This table shows which of the 
previously identified PLA2G10 tagging SNPs were genotyped in which of the included studies and 
who was responsible for the genotyping. 
 
 
 
 
 
 
 
 
 
                                                                            SNPs Genotyped                     Genotyped By:   
                                                               rs4003232        rs4003228 rs72546339 rs72546340 
   STUDIES IN GENERAL POPULATIONS  
EPIC-Norfolk (n=3039)                               ●                                     ● ● ●              H.Exeter/M.Gardiola 
 NPHS-II (n=2693)                                                                                ●             H.Exeter/M.Gardiola   
UDACS (n=564)                                                                                   ●                        H.Exeter/M.Gardiola   
STUDIES IN ACUTE CORONARY SYNDROME POPULATIONS  
GRACE-France (n=274)                              ●                                       ● ●          ●              H.Exeter/ M.Gardiola 
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The DRD Cohort 
 The DRD cohort is an in-house volunteer cohort. A small subset of volunteers who 
work at The Rayne Building or live in the surrounding area of London in the UK were invited 
to donate a blood sample for genetic analysis. In all cases baseline data of age at donation 
and gender were taken. Gender was approximately 50% male and 50% female and ages 
ranged between 19 and 65 years old.     
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CHAPTER 3 
Identification of Functional Variants of PLA2G2A 
 
3. Background 
 Secretory PLA2-IIA has been identified as a novel biomarker of CHD in previous 
observational studies (Boekholdt, Keller et al. 2005; Mallat, Steg et al. 2005; Mallat, 
Benessiano et al. 2007; Dutour, Achard et al. 2010) and it has been suggested that this is 
potentially due to its known inflammatory effects playing a role in atherosclerosis and 
inflammation related disease (1.5.7). In order to verify the role of sPLA2-IIA as a causal 
biomarker for atherosclerosis, genetic analysis can be employed. Identification of genetic 
variants that are significantly associated to sPLA2-IIA could be used as genetic instruments 
to test the causality of sPLA2-IIA for atherosclerosis using Mendelian randomisation. This 
approach can be used as a proxy for a randomised control trial (RCT); negating the need to 
find a novel drug against the biomarker and a cohort of patients to test it on before causality 
of the biomarker is established, saving both time and resources. 
3.1. Introduction 
Chapter 1.7.2 describes the identification of six tSNPs across the PLA2G2A gene. Of 
these six SNPs two are shown to have a significant effect on sPLA2-IIA levels; rs11573156 
C>G and r3767221 A>C. The aim of this chapter was to determine if these two SNPs are 
functional and contributing directly to the regulation of levels of sPLA2-IIA, or whether they 
are merely marking a functional variant elsewhere in the gene. Identification of functional 
variants would determine viable genetic instruments for Mendelian randomisation and give a 
greater depth of understanding to the mechanism of sPLA2-IIA. 
For both rs11573156 and rs3767221, research into the characteristics and possible 
effects of these SNPs was carried out using several freely available bioinformatics sources 
(2.2.). In order to confirm whether a SNP is likely to be functional it is beneficial to use these 
bioinformatics tools to obtain known and predicted data about a SNP of interest. This data 
can relate to a huge number of things including; SNP type (missense, synonymous or 
nonsense), SNP position, known and potential transcription factor binding sites, open 
chromatin regions, known and predicted alternate splicing sites, other SNPs in LD, SNP 
conservation, allele frequency and potential microRNA (miRNA) binding sites. Prediction 
algorithms such as MatInspector, which predicts transcription factor binding sites and 
MiRBase, PITA, MiRTar and RegRNA, which predict miRNA binding sites were also used.  
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Transcription factor binding usually occurs in the promoter region and distal parts of 
the 5’UTR (Chatterjee and Pal 2009). Transcription factor proteins binding to a promoter can 
behave as enhancers or repressors to regulate the transcription of a gene. Since the 
promoter region of PLA2G2A has not been conclusively defined, it is possible that 
rs11573156 may affect a transcription factor binding site and it was therefore prudent to use 
the MatInspector tool to investigate this. Micro-RNA binding usually occurs in the 3’UTR and 
regulates the sequence post-transcriptionally, potentially enhancing or repressing levels of 
protein expression. However, there are instances where miRNAs have been shown to bind 
in the 5’UTR and contribute to post-transcriptional regulation (Tsai, Lin et al. 2009). 
Prediction algorithms for miRNA binding were therefore used to examine the regions 
surrounding both rs11573156 (5’UTR) and rs3767221 (3’UTR).   
 Collating bioinformatics data, both known and predicted, about a SNP can allow us to 
predict its potential as a functional SNP and may suggest mechanisms through which the 
SNP could act. This information may help to direct how the investigation of a SNP will 
progress and which techniques will be the most practical for analysing if and how a SNP 
functions to contribute to the actions of the gene and ultimately the protein produced. 
 In order to confirm the potential functionality of rs11573156 and rs3767221 for 
changes in sPLA2-IIA levels and/or sPLA2 activity I employed several techniques. The Dual-
Reporter Luciferase assay (Table 2.1 and 2.4.7) was used in order to measure the change in 
luciferase activity between the common and rare variants of the SNPs of interest. The 
change in luciferase activity is taken as an in vitro replication of the ability of each SNP to 
affect the levels of transcription of the gene. A significant difference in luciferase activity may 
indicate that a SNP is important in the regulation of gene transcription and therefore the 
levels of biomarker produced by the gene. Therefore, genotyping an individual for this SNP 
would suggest whether a person was likely to have increased or decreased sPLA2-levels. 
 Often changes in transcription levels associated with a SNP are due to the change in 
allele altering a transcription factor binding site. Transcription factor proteins bind to DNA at 
specific, recognisable binding sequences and help to regulate transcription. If one variant of 
a SNP is part of a transcription factor binding site, then the other variant of the SNP will 
cause the transcription factor binding site to become unrecognisable and the transcription 
factor will not bind there. EMSA (Table 2.1 and 2.4.8) analysis can be used to detect protein 
binding to a sequence of interest. By isolating a sequence fragment for both the wild type 
and rare alleles of a SNP of interest, I was able to use EMSA analysis to compare protein 
binding between the two alleles. This can be used to support a null difference in luciferase 
assay results between two alleles, by showing no differential protein binding between the 
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same two alleles. However, should the sequence containing one allele have a protein 
binding site not present within the sequence containing the second allele it is likely that there 
is differential transcription factor binding between these variants. Using the bioinformatics 
results for a SNP that shows differential protein binding and taking into account the direction 
of change in luciferase assays between each allele (whether allele with the additional protein 
binding site showed increased or decreased luciferase activity) we can predict potential 
transcription factors that might be differentially binding to the SNP. A supershift EMSA uses 
a known antibody to the suspected binding protein to establish the identity of the 
differentially binding regulatory protein (Tsai, Smider et al. 2012).      
 If differential luciferase activity cannot be associated with a SNP and there is no 
visible difference in protein binding between alleles, it may be that the SNP is acting to 
regulate a gene post-transcriptionally. Post-transcriptional modifications may include miRNA 
binding, which can be predicted by bioinformatics algorithms (Table 2.4 and 2.4.1). It may 
also include alternate splicing of a sequence including a SNP of interest, which would not 
affect transcription levels, but may affect levels of mRNA. In order to determine whether this 
is true for rs11573156 we carried out TaqMan gene expression assays (Table 2.1 and 2.4.9) 
on samples of known genotype to determine any differences in expression associated with 
the SNP. This was compared to TaqMan assay results of the same genotyped samples in an 
area of the gene not considered to be differentially spliced. If a significant difference in 
expression was associated with the SNP of interest in the suspected splice region but no 
difference was seen between the same groups in a different part of the gene, it is likely that 
there is differential splicing in the region of the SNP. To support this data, further mRNA 
expression data was obtained from expression quantitative trait loci (eQTL) studies. These 
genomic loci regulate expression levels of mRNA or proteins. They are mapped using 
standard QTL mapping techniques that test the linkage between variation in expression and 
a genetic polymorphism. In this chapter eQTL data from the ASAP study (described in detail 
in 2.4.10) was used to investigate the potential differential mRNA levels associated with our 
SNP of interest, rs11573156 in several different tissues.  
3.2. Results 
3.2.1. Bioinformatics Study of PLA2G2A   
 PLA2G2A exists in a cluster of PLA2 genes on chromosome 1 (Figure 1.11). The 
gene is usually reverse transcribed and produces the enzyme sPLA2-IIA. The Ensembl 
Genome Browser (release 69) states that PLA2G2A is a known protein coding gene since it 
has been shown to be identical to known cDNAs or proteins from the same species. 
According to the Ensembl Genome Browser and NCBI databases there are 7 known 
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transcripts of the gene and two of these are described as known protein coding (Figure 3.1). 
These transcripts have been confirmed as protein coding since they have been shown to be 
100% identical to an entry in either the Reference Sequence (RefSeq NP) database or the 
Swiss-Port database. The other 5 are described as ‘processed transcripts,’ which lack open 
reading frames and have no protein product (Figure 3.1). This data was collated by manual 
annotation carried out by the Havana group at the Wellcome Trust 
(http://vega.sanger.ac.uk/info/about/man_annotation.html). One of the known protein coding 
transcripts is made up of 5 exons (spliced) and the other of 6 exons (full length). However, 
both transcripts code for a 144 amino acid protein because in both transcripts only 4 exons 
are protein coding, the same 4 exons in both instances. The NCBI database includes the 
RefSeq collection, which is the result of data extraction from International Nucleotide 
Sequence Database Collection (INSDC) submissions, curation, and computation, as well as 
extensive collaboration with authoritative groups. RefSeq quotes the predominant version as 
NCBI ID: NM_000300.3, the longer (6 exon) transcript and NM_001161728.1 as missing one 
of the non-coding 5’UTR exon compared to the dominant transcript, but coding for the same 
protein. This is based on protein sequences derived from translation of the coding 
sequences submitted to public nucleic acid databases. A critical review of all data and peer 
reviewed literature is then carried out in order to annotate these transcripts. In Figure 3.1 the 
coding exons are shown as filled blocks and the non-coding exons are shown as empty 
boxes. 
 The existence of two protein coding transcripts coding for the same 144 amino acid 
protein (sPLA2-IIA), but different mRNAs, suggests alternate splicing of a non-coding exon. 
This may be relevant when investigating the impact of genetic factors on post-transcriptional 
regulation of the levels of sPLA2-IIA produced, depending on whether the transcripts are 
shown to be associated to a genetic polymorphism.  
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PLA2G2A Transcripts 
 
Figure 3.1. PLA2G2A Transcripts. This schematic is based on data from the Ensembl Genome Browser (Release 69) and shows the known transcripts for the 
PLA2G2A gene. Of these, only two transcripts are protein coding. Five have been shown to be non-coding transcripts and classified as not containing an 
open reading frame (Though Ensembl does not specify the length of amino acids that ‘no open reading frame’ constitutes). 
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3.2.2. Bioinformatics Study of rs11573156 
 Data from NCBI and Ensembl confirms that, for the full length PLA2G2A transcript, 
rs11573156 is positioned at chromosome 1:20,306,146, which is in the untranslated exon 2, 
part of the 5’UTR and suspected promoter region of PLA2G2A. The SNP is located 38bp 
from the intron 1-2/exon 2 boundary in the full length transcript. In the alternately spliced 
protein coding transcript this SNP is spliced out. The European genotyping data available 
from HapMap and the 1000 Genomes Project showed that, on the reverse strand of the 
gene, the common allele, C occurs at a frequency of 0.75 and the rare G allele occurs at a 
frequency of 0.25. This SNP is a tagging-SNP in strong linkage disequilibrium (LD) with 
several other PLA2G2A SNPs; With an R2 above 0.7 these SNPs are; rs4744 (synonymous 
coding SNP located at 1:20,304,926), rs2307246 (1:20,304,857, intron 1-2) and rs10732279 
(1:20,305,065, intron 2-3). These LD values were confirmed in both 1000 Genomes Phase 1 
CEU population (Utah residents with Northern and Western European ancestry) and the 
HapMap Project Phase 3 CEU population (again, Utah residents with Northern and Western 
European ancestry), a total population of ~1,500 individuals. Figure 3.2 is an LD heatplot 
using data from the HapMap Release #28 CEU population for PLA2G2A chr:20,301,940–
20,306,426. 
  
Figure 3.2. An LD heatplot showing the D’ linkage disequilibrium between several SNPs of PLA2G2A 
(Chr1: 20,301,940–20,306,426) including rs11573156, rs4744, rs10732279 and rs2307246 (boxed in 
green). Data was taken from the HapMap Project Release #28 and the heatplot was created using 
Haploview version 4.0.  
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According to the MatInspector transcription factor binding prediction tool, there were 
five potential differential transcription factor (TF) binding sites at rs11573156 C>G. This was 
based on a 240bp FASTA sequence taken from Ensembl Genome Browser and 
representing the reverse strand of PLA2G2A. This sequence included rs11573156 at 
position 124. However, the prediction algorithm generated no potential differential TF binding 
site with an anchor site within 5 bases (position 119-129) of the SNP of interest at a 0.95 or 
above matrix similarity (the calculation of similarity between the sequence and the known TF 
binding site sequence). It is therefore unlikely that there is a differential transcription factor 
binding in this region. The only potential differential TF site (matrix similarity = 0.899) was a 
GC-Box factor Sp1/GC site that was present with the rare G allele but not with the common 
C allele and EMSA experiments were carried out to rule this out as a potential differentially 
binding protein (3.3.5.1). 
 MatInspector data comparing rs11573156 C>G is shown below in Table 3.1a and 
Table 3.1b. Only relevant MatInspector matrix matches covering the region of the SNP of 
interest (at position 124) are included in Table 3.1a and 3.1b.  
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Table 3.1a Variant Sequence: rs11573156 C 
Matrix  
Family 
Description Start  
Position 
End  
Position  
Anchor Matrix  
Similarity 
Sequence 
(Core Sequence in Capitals) 
V$NOLF 
Neuron 
specific 
olfactory 
factor 
106 128 117 0.884 ccaaccTCCCagagggagcagct 
V$ZNF01 
C2H2 Zinc 
finger 
transcription 
factors 1 
115 139 127 0.781 cagagggaGCAGctatttaagggga 
 
 
Table 3.1b Variant Sequence: rs11573156 G 
 
Matrix  
Family 
Description Start  
Position 
End  
Position  
Anchor Matrix  
Similarity 
Sequence 
(Core Sequence in Capitals) 
V$EGRF 
EGR/nerve 
growth factor 
induced protein 
C and related 
factors 
113 129 121 0.883 cccagaGGGAggagcta 
V$SP1F GC-Box factors 
SP1/GC 
114 130 122 0.899 ccagagGGAGgagctat 
V$PLAG Pleomorphic 
adenoma gene 
119 141 130 0.886 ggGAGGagctatttaaggggagc 
 
Matrix family: describes the transcription factor family predicted by MatInspector, V$ is the 
abbreviation for vertebrae and the following three letters are an abbreviation for the family of 
transcription factor and the fourth letter in the sequence is either ‘F’= factor or ‘G’= gene. Description: 
A short overview of the potential transcription factor predicted to bind. Start/End Position: Where a 
transcription factor is predicted to begin binding or end binding. Anchor: The anchor position is the 
designated centre point of the matrix sequence. Matrix Similarity: Calculated out of a total of 1. A 
perfect score suggests a total match between a matrix consensus sequence and the input sequence. 
Sequence: Shows the part of the input sequence isolated by the algorithm and predicted to bind a 
transcription factor.   
 
Table 3.1a-3.1b. A 240bp consensus sequence including the SNP rs11573156 at position 124 was 
taken from the Ensembl Genome Browser for input to the MatInspector algorithm. Table (a) shows the 
MatInspector transcription factor prediction algorithm output for the regions including rs11573156 C 
and Table (b) shows the same output for rs11573156 G. 
 
Conversely the UCSC Genome browser data, which includes a detailed map of 
predicted transcription factor binding regions within PLA2G2A, shows no sign of any TF 
binding regions within the vicinity of rs11573156 (Figure 3.3), suggesting the likelihood of the 
predicted Sp1 TF binding site generated by MatInspector truly existing is relatively low. 
Since the UCSC Genome Browser also shows that rs11573156 is not predicted to be in an 
open chromatin region we can also reasonably predict that any functionality associated to 
the SNP is unlikely to be due to differential acetylation or methylation. An additional feature 
of the UCSC Genome Browser is the identification of splicing regions within a gene. The 
position of rs11573156 within PLA2G2A is confirmed by the UCSC Genome Browser to be 
near an alternative splice site, 37bp from the untranslated exon 2 boundary (Figure 3.3).  
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 This is the forward strand but PLA2G2A is reverse transcribed Chr1: 20301924 Chr1: 20306932 
Figure 3.3. Has been reprinted using data from the UCSC Genome Browser for PLA2G2A. The gene is shown on the forward strand but is usually reverse 
transcribed. The full transcript is shown based on data from RefSeq, UniProt. GenBank, CCDS and Comparative Genomics. Spliced ESTs represents Human 
expressed sequence tags (short strands of cDNA used to identify gene transcripts), which have been used to identify potential splice sites within the gene. These are 
shown in black. Layered H3K4Me1 represents data from Encode ChIP sequence assays to show the level of predicted histone 3 and 4 methylation/acetylation. Each 
colour represents a different cell type in which the assay was carried out: Dominant in this schematic, are human mammary epithelial cells (HMEC) (green), and 
human embryonic stem cell line (H1 ES) (yellow). Layered H3K4Me3 shows DNAse hypersensitivity regions are shown in the same cell lines. The ENCODE 
Transcription Factor ChIP-seq data shows the prediction of transcription factors binding to the gene. These are labelled accordingly. The intensity of colour indicated 
the likelihood of true binding. The cells lines represented here are: G/GK=GM12872, A= A549, L= HepG2, HK= HeLa-S3. Finally all the SNPs  
covering the region are indicated by rs number at the bottom. The SNP of interest, rs11573156, is indicated by the vertical red line (http://genome.ucsc.edu/cgi-
bin/hgTracks?position=chr1:20178483-20178983&hgsid=284369053&snp130=pack&hgFind.matches=rs11573156,). The dashed vertical red line represents the 
rs11573156 proxy SNP rs10732279  
150 
 
Alternative splicing may be a mechanism through which this SNP acts to affect 
functionality. Data from the Ensembl Genome Browser supports this idea since one of the 
two non-coding exons at the 5’ end of PLA2G2A is commonly spliced out, causing there to 
be two different protein coding transcripts, which have been previously identified. Evidence 
for this differential splicing can also be found in the ‘supporting evidence’ option for each of 
the protein coding transcripts in Ensembl; ENST00000375111 contains both non-coding 
exons and ENST00000400520 does not contain non-coding exon 2. Data comparing the 
alignment of protein and cDNA sequences to the human genome or by manual curation (by 
the VEGA/Havana group) of human protein, cDNA and EST sequences was used to 
determine and validate the sequences for each transcript. ENST00000375111 has 
supporting protein, DNA and EST evidence and ENST00000400520 has supporting protein 
and cDNA evidence. 
 Rs11573156 is in the same region as the spliced exon. Should this exon splicing 
occur differentially between the rs11573156 variants, this could be an explanation for its 
functionality as the presence or absence of this non-coding exon could contain important 
transcription regulatory elements or miRNA binding sites that are important in the control of 
PLA2G2A transcription (Figure 3.4). 
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 Figure 3.4. Represents an example of alternate splicing. E= Enhancer binding R= Repressor binding. 
The full length transcript includes 5 transcription factors binding and acting as enhancers and 5 
transcription factors binding and acting as repressors. When exon B is alternately spliced out in the 
second transcript two of the repressor binding sites no longer exist and therefore the transcription 
factors do not bind here. The lack of two repressor transcription factors increases transcription 
compared to the full length transcript. If a SNP in this region can be differentially associated with each 
transcript then this SNP will be marking this alternate splicing.  
 
 The chromosomal position of rs11573156 and the surrounding sequence in the 
untranslated exon 2 has been previously analysed in a deletion mapping study, which 
employed Chloramphenicol AcetylTransferase (CAT) assay measurements in a human 
hepatic cell line (HepG2) to compare CAT activity produced by different fragments of the 
supposed promoter region (Olivier, Fan et al. 1994; Fan, Paradon et al. 1997). The region 
including rs11573156 and the untranslated exon 2 was determined to contain a negative 
regulatory region (Olivier, Fan et al. 1994; Paradon, Salvat et al. 1998).  
In order to identify potential miRNA binding sites in the 5’UTR of PLA2G2A, the 
miRNA binding site prediction algorithms described in Table 2.4 and 2.4.1 were used. We 
entered the mRNA sequence for PLA2G2A, NM_000300 into the three genome-wide target 
prediction algorithms that focus outside of the 3’UTR. Using the first algorithm, the 
Probability of Interaction by Target Accessibility (PITA), we searched for possible microRNA 
targets (among 470 human microRNAs) that form 8mers with exon 2. There was one 
Non coding Non coding 
Non coding 
5’UTR/Promoter Region 
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putative miRNA binding site for miR-544 in the region of exon 2, which was in position 96 
and had low conservation between species, making it a less likely functional candidate 
(Table 3.2). In the miRTar algorithm we searched for potential binding sites for 1,104 
miRNAs across the selected region. The parameters included information such as minimum 
free energy of hybridization between microRNAs and their predicted target site (minimum 
free energy (MFE) of <14Kcal/mol) and an alignment score of ≥140 based on structural 
information on the putative hybrid. There were 13 predicted miRNA binding sites for exon 2 
(Table 3.3). The third algorithm, RegRNA, identifies miRNA target sites against an input 
mRNA sequence, which was the RefSeq mRNA ID NM_00300 in our case. As before, we 
used as cut-off points MFEs <14Kcal/mol and an alignment score of ≥140 which are 
estimated from the miRanda algorithm. Results included the 13 miRTar predicted miRNA 
binding sites for exon 2 plus an additional 15 predicted sites (Table 3.4). From the above 
algorithms, which provided overlapping data to a certain extent, we were able to identify 
several potential miRNA binding sites. Absence of the active miRNA binding site, in the case 
of exon skipping, could account for the loss of post-transcriptional repression (Moore, 
Johnston et al. 2011). 
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 Site Predictions; Predict miRNA binding to a single site along the input sequence.  RefSeq; represents the reference sequence database sequence input for 
analysis. Position; anchor base position of the predicted miRNA binding site relative to the input sequence. Seed; the first digit represents the size of the 
miRNA (8mer), the second digit represents the amount of base mismatches predicted and the third digit represents how many GU wobble base pairs exist. 
dGduplex; ∆G free energy score for the DNA duplex. dGopen; ∆G free energy score comparing constrained and non-constrained structures in the sequence. 
ddG; ∆∆G free energy score. The lower this score is the more likely a miRNA is to bind here, As a rule of thumb -10 and below suggests a functional site. 
Table 3.2. Represents the output from the PITA miRNA target site prediction algorithm. We searched for 8-mer targets using the RefSeq NM_000300, 
representing the full length PLA2G2A transcript. Exon 2 lay between position 56-166 of the sequence and so only predicted sites between these positions 
were considered relevant. This left only miR-544 as a potentially relevant miRNA. 
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 Exon Type: AS = alternatively spliced exon CS = constitutively spliced. Target Accessibility; Predicted miRNA binding sites in more accessible parts of the 
DNA sequence are more likely to be accurate. Alignment Score; Score calculated by the MiRanda algorithm- a weighted score of the match and mismatch 
base pairs in the sequence with gap penalties (Higher = more likely to be truly binding). 
Table 3.3. Represents the output from the miRTar miRNA target site prediction algorithm. We searched for 8-mer targets using the RefSeq NM_000300, 
representing the full length PLA2G2A transcript. Parameters of minimum free energy ≤-14Kcal/mol and a Score of ≥140 were used. 
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miRNA ID Location Hybridization MFE Score 
hsa- miR-1224-
5p 
 
144-162 
 
 
-21.2 145 
hsa-miR-1236 159-183 
 
-19.9 143 
hsa-miR-18a* 83-110 
 
-28 143 
hsa-miR-1976 97-116 
 
-20.4 164 
hsa-miR-1976 169-189 
 
-27.7 158 
hsa-miR-19b-1* 102-124 
 
-17.8 148 
hsa-miR-19b-2* 103-124 
 
-15.6 140 
hsa-miR-26b* 106-126 
 
-14.4 141 
hsa-miR-30b* 64-86 
 
-20.9 151 
hsa-miR-3183 150-170 
 
-22.3 146 
hsa-miR-3192 61-87 
 
-24.1 167 
hsa-miR-324-3p 187-206 
 
-21.8 158 
hsa-miR-326 70-89 
 
-16.2 141 
hsa-miR-330-5p 68-89 
 
-16.2 140 
hsa-miR-377* 61-83 
 
-15.3 150 
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hsa-miR-4268 164-184 
 
-18.6 150 
hsa-miR-431* 117-138 
 
-22.3 144 
hsa-miR-4314 71-88 
 
-19.6 146 
hsa-miR-4326 158-184 
 
-18.3 140 
hsa-miR-483-3p 97-118 
 
-20.6 158 
hsa-miR-508-5p 135-157 
 
-18.8 160 
hsa-miR-516a-
3p 
77-94 
 
-20.1 144 
hsa-miR-516b* 77-94 
 
-20.1 144 
hsa-miR-520a-
5p 
135-155 
 
-17.2 140 
hsa-miR-525-5p 133-155 
 
-15.2 146 
hsa-miR-562 83-102 
 
15.3 150 
hsa-miR-637 64-87 
 
-16.7 140 
hsa-miR-92a-1* 54-81 
 
-17.4 151 
hsa-miR-938 85-108 
 
-17.4 141 
 
Table 3.4. Output from RegRNA algorithm for PLA2G2A NM_000300. Results for the region of exon 2 
are shown in the table. Parameters MFE≤ -14Kcal and Score ≥140. Prediction Score is based on the 
MiRanda algorithm. Hybridization = sequence predicted to bind a miRNA. MFE= minimum free 
energy. A lower MFE means an increased chance of binding. The score is weighted on matched and 
mismatched pairs and includes gap penalties. Scores above 140 are considered more likely to 
represent true binding sites.  
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 In summary, 11 miRNAs are predicted to bind to the exon 2 region of PLA2G2A by 
two out of the 3 algorithms used. These are; hsa-mir-1976, hsa-mir-3192, hsa-mir-326, hsa-
mir-330-5p, hsa-mir-4268, hsa-mir-4314, hsa-mir- 483-3p, hsa-mir-508-5p, hsa-mir-520a-p, 
hsa-mir-525-5p, hsa-mir-92a-1. Of these, two miRNAs are predicted to bind in the region of 
rs11573156; hsa-mir-1976 and hsa-483-3p. If rs11573156 genotype is associated with the 
alternate splicing of exon 2 then any miRNA binding here will also be associated with exon 2 
alternate splicing, since the splicing of exon 2 (and rs11573156) would result in the removal 
of the miRNA target seed region.  
3.2.3. Bioinformatics Study of rs3767221 
 Data from NCBI and Ensembl verifies that rs3767221 is positioned at chromosome 
1:20,301,781, which is in the 3’UTR of PLA2G2A. The European genotyping data available 
from the 1000 Genomes Project showed that the common allele, A, occurs at a frequency of 
0.59 and the rare C allele occurs at a frequency of 0.41. The linkage disequilibrium between 
rs3767221 and rs11573156 is quoted as R2 = 0.076 in the 1000 Genomes CEU pilot 1 data, 
which is not significant. However, since rs3767221 is a tagging-SNP it is in strong LD with 
several other SNPs. Those with an R2 above 0.7 are rs10799599, rs2872821, rs2315070, 
rs12023742 and rs12044628 (all of these SNPs lie between PLA2G2A and PLA2G2E) and 
rs1890686 (PLA2G2A 3’UTR). There is no European population HapMap Project data for 
rs3767221 and therefore the Haploview 4.0 heatplot tool cannot be used to generate an LD 
heatplot. Figure 3.5 shows an LD Manhattan style plot generated using the SNAP Pairwise 
LD Plot tool (2.2 Table 2.4), using the following parameters; Regional LD Plot for plot type 
and Text Entry for SNP input; rs3767221 was the input SNP. The R2 value was set to 0.7 
and the 1000 Genomes Pilot 1 CEU dataset was selected. Finally the distance limit input 
was set to 100Kb. 
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 Figure 3.5. An LD Manhattan style plot based on the 1000 Genomes CEU pilot 1 data available 
through the SNAP Pairwise LD program. The SNAP plot tool was used to assess the LD of rs3767221 
with all known SNPs in the region of 100Kb up and downstream of the SNP. The region 
encompassing the SNPs in LD <0.7 with rs11573156 is represented by the two vertical dashed lines. 
Genotyped and imputed SNPs are represented by a diamond shape. The R2 significance value is set 
at 0.7 and represented by a horizontal dashed line. The SNPs in LD above 0.7 are indicated above 
this line. The deeper the shade of red and the larger the size of each diamond, the higher the strength 
of LD with rs3767221. The blue peaks on the plot represents recombination hotspots and the green 
arrows represent different genes. 
 
 Prediction by MatInspector was carried out using a 240 base sequence taken from 
Ensembl Genome Browser including rs3767221 on the reverse strand. Table 3.5a and 3.5b 
show the results from this MatInspector algorithm output that cover the region including 
rs3767221 (position 172). This prediction algorithm suggests the strongest potential 
differential binding to rs3767221 C compared to A is a potential cAMP binding protein site 
with a matrix similarity of over 0.85 in the region of rs3767221 C that is not predicted for 
rs3767221 A. However the anchor base for this binding site is not within 5bp of rs3767221. 
The only prediction with a matrix similarity of over 0.9 and within 5 bases of rs3767221 was 
suggested to be a growth factor independence transcriptional repressor binding to 
rs3767221 A at its anchor position, but not at rs3767221 C.   
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Table 3.5a rs3767221 A 
Matrix  
Family 
Description Start  
Position 
End  
Position  
Anchor Matrix  
Similarity 
Sequence 
(Core Sequence in 
Capitals) 
V$GFI1 
Growth factor 
independence 
transcriptional 
repressor 
165 179 172 0.913 agcAATCattgcact 
V$CAAT 
CCAAT 
binding 
factors 
168 182 175 0.812 tcaaGCAAtcattgc 
V$HOXC HOX-PBX 
complexes 
168 184 176 0.807 gcaatGATTgcttgagc 
 
Table 3.5b rs3767221 C 
Matrix  
Family 
Description Start  
Position 
End  
Position  
Anchor Matrix  
Similarity 
Sequence 
(Core Sequence in 
Capitals) 
V$CREB 
cAMP-
responsive 
element 
binding 
proteins 
156 176 166 0.876 tgaggcTGAAgtgcaaggatt 
V$AHRR 
AHR-arnt 
heterodimers 
and AHR-
related 
factors 
167 191 179 0.775 tgcaaggattGCTTgagctcacaga 
 
Matrix family: describes the transcription factor family predicted by MatInspector, V$ is the 
abbreviation for vertebrae and the following three letters are an abbreviation for the family of 
transcription factor and the fourth letter in the sequence is either ‘F’= factor or ‘G’= gene. Description: 
A short overview of the potential transcription factor predicted to bind. Start/End Position: Where a 
transcription factor is predicted to begin binding or end binding. Anchor: The anchor position is the 
designated centre point of the matrix sequence. 
Matrix Similarity: Calculated out of a total of 1. A perfect score suggests a total match between a 
matrix consensus sequence and the input sequence. Sequence: Shows the part of the input 
sequence isolated by the algorithm and predicted to bind a transcription factor.   
 
Table 3.5a-3.5b. A 240bp consensus sequence including the SNP rs3767221 at position 172 was 
taken from the Ensembl Genome Browser for input to the MatInspector algorithm. Table (a) shows the 
MatInspector transcription factor prediction algorithm output for the regions including rs3767221 A 
and Table (b) shows the same output for rs3767221 C. 
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The UCSC Genome Browser predicts a dense protein binding region in the sequence 
around rs3767221 (Figure 3.6), by in vitro assays and computer based algorithms. This 
region included predicted binding sites for SREBP 1 and sPLA2 interacting transcription 
factors such as p300 (Giandomenico, Simonsson et al. 2003; Ponugoti, Kim et al. 2010) and 
LXR alpha (Trousson, Bernard et al. 2009). The UCSC Genome Browser also reports 
several other known transcription factor binding regions at this site including; RXRA, 
CEBPB, HNF4A and p300, and the Aryl hydrocarbon receptor (AHR). Since transcription 
factors tend to bind to the 5’UTR it is likely that predicted binding sites are in fact for proteins 
other than transcription factors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
161 
 
 This is the forward strand but PLA2G2A is reverse transcribed 
Chr1: 20301924 Chr1: 20306932 
Figure 3.6. Has been reprinted using data from the UCSC Genome Browser for PLA2G2A. The gene is shown on the forward strand but is usually reverse 
transcribed. The full transcript is shown based on data from RefSeq, UniProt. GenBank, CCDS and Comparative Genomics. Spliced ESTs represents Human 
expressed sequence tags (short strands of cDNA used to identify gene transcripts), which have been used to identify potential splice sites within the gene. These are 
shown in black. Layered H3K4Me1 represents data from Encode ChIP sequence assays to show the level of predicted histone 3 and 4 methylation/acetylation. Each 
colour represents a different cell type in which the assay was carried out: Dominant in this schematic, are human mammary epithelial cells (HMEC) (green), and 
human embryonic stem cell line (H1 ES) (yellow). Layered H3K4Me3 shows DNAse hypersensitivity regions are shown in the same cell lines. The  
ENCODE Transcription Factor ChIP-seq data shows the prediction of transcription factors binding to the gene. These are labelled accordingly. The intensity of colour 
indicated the likelihood of true binding. The cells lines represented here are: G/GK=GM12872, A= A549, L= HepG2, HK= HeLa-S3. Finally all the SNPs  
covering the region are indicated by rs number at the bottom. The SNP of interest, rs3767221, is indicated by the vertical red line (http://genome.ucsc.edu/cgi-
bin/hgTracks?position=chr1:20174118-20174618&hgsid=284369053&snp130=pack&hgFind.matches=rs3767221,). 
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 Micro-RNA binding usually occurs in the 3’UTR. The SNP rs3767221 is situated in 
the 3’UTR of PLA2G2A. Should a miRNA bind differentially to the region of rs3767221 this 
SNP could be a post-transcriptional regulator of gene expression. A tentative potential 
miRNA binding site in the region of rs3767221 is hsa-miR-1273g-3p. Interestingly, within the 
recognised binding site for this miRNA; ACCACUGCACUCCAGCCUGAG is a sequence 
similar to the recognised SREBP binding sequence; TCACNCCAC (base pair matches 
highlighted in yellow). This suggests that miRNAs with similar recognised binding sequences 
to transcription factors could be truly binding in the region of UCSC Genome browser 
predicted transcription factor binding in the 3’UTR. Table 3.6 shows the results from 
miRBase. Results returned 935 predicted miRNA binding sites within the 801bp region, 22 of 
which were within 5 bases up or downstream of our SNP of interest (rs3767221 was at 
position 401) and are shown below in Table 3.7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.6 Results for miRBase analysis of a 240bp region the quoted NCBI sequence for rs3767221 
with the SNP located at position 121. The sequence was blasted using the parameters: Mature 
miRNA for search sequences option, search method BLASTN, E-Value cut off set at 10 (this value 
represents the match efficiency between the input sequence and the predicted miRNA sequence, the 
lower the score the higher the match efficiency so an e value of 0 = 100% match), maximum number 
of hits set at 100 and human specific results were selected for. The accessions in the table are for the 
miRBase database details of each miRNA. Query start and end relate to the input sequence position 
matched to a miRNA sequence. Subject start and end refers to the base position of the miRNA 
sequence matched to the input sequence. The score relates to the miRBase algorithm calculation 
weighting matches to mismatches and taking into account gap penalties. The higher the score the 
more likely a prediction is a true miRNA binding sequence. The e value represents the number of 
mismatches between the two sequences. A lower score is better with 0 representing a 100% match 
between sequences. 
Accession ID Query start Query end Subject start Subject end Score Evalue 
MIMAT0005876 hsa-miR-1285-3p 67 87 2 22 87 0.04 
MIMAT0022719 hsa-miR-1285-5p 68 88 1 21 78 0.22 
MIMAT0022286 hsa-miR-5585-3p 143 163 1 21 69 1.3 
MIMAT0015001 hsa-miR-3135a 125 141 6 22 67 1.8 
MIMAT0015090 hsa-miR-1273d 126 142 9 25 67 1.8 
MIMAT0019232 hsa-miR-4423-5p 211 227 6 22 67 1.8 
MIMAT0022285 hsa-miR-5585-5p 140 161 1 22 65 2.7 
MIMAT0022742 hsa-miR-1273g-3p 118 138 1 21 65 2.7 
MIMAT0020602 hsa-miR-1273g-5p 126 143 1 18 63 4 
MIMAT0022708 hsa-miR-584-3p 84 101 3 20 63 4 
MIMAT0005926 hsa-miR-1273a 61 85 1 25 62 4.8 
MIMAT0004952 hsa-miR-665 132 145 3 16 61 5.8 
MIMAT0019049 hsa-miR-4512 66 86 2 22 60 7.1 
MIMAT0019216 hsa-miR-3187-5p 127 147 2 22 60 7.1 
MIMAT0019697 hsa-miR-4639-5p 129 149 2 22 60 7.1 
MIMAT0022473 hsa-miR-5684 78 96 1 19 59 8.6 
MIMAT0025458 hsa-miR-6501-5p 79 97 2 20 59 8.6 
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Gene microRNA Position Seed dGduplex dGopen ddG 
PLA2G2A hsa-miR-944 396  8:1:0 -5.5 -7.06 1.56 
PLA2G2A hsa-miR-522 397  8:1:1 -8.2 -7.06 -1.13 
PLA2G2A hsa-miR-518a-5p 399  8:1:1 -8.81 -7.06 -1.74 
PLA2G2A hsa-miR-527 399  8:1:1 -8.81 -7.06 -1.74 
PLA2G2A hsa-miR-573 399  8:1:1 -8.3 -7.06 -1.23 
PLA2G2A hsa-miR-130b 401  8:0:0 -21.7 -8.64 -13.05 
PLA2G2A hsa-miR-454 401  8:0:0 -19.8 -8.64 -11.15 
PLA2G2A hsa-miR-301b 401  8:0:0 -18.4 -8.64 -9.75 
PLA2G2A hsa-miR-130a 401  8:0:0 -18.12 -8.64 -9.47 
PLA2G2A hsa-miR-512-3p 401  8:1:1 -15.9 -8.64 -7.25 
PLA2G2A hsa-miR-301a 401  8:0:0 -15.5 -8.64 -6.85 
PLA2G2A hsa-miR-372 402  8:1:1 -17.3 -9.66 -7.63 
PLA2G2A hsa-miR-519b-3p 402  8:1:0 -15.56 -9.66 -5.89 
PLA2G2A hsa-miR-519c-3p 402  8:1:0 -13.24 -9.66 -3.57 
PLA2G2A hsa-miR-519a 402  8:1:0 -11.97 -9.66 -2.3 
PLA2G2A hsa-miR-423-5p 403  8:1:1 -14.3 -9.74 -4.55 
PLA2G2A hsa-miR-18b 403  8:1:1 -13.8 -9.74 -4.05 
PLA2G2A hsa-miR-18a 403  8:1:1 -13.6 -9.74 -3.85 
PLA2G2A hsa-miR-1289 403  8:1:1 -10.8 -9.74 -1.05 
PLA2G2A hsa-miR-573 404  8:1:0 -12.1 -10.67 -1.42 
PLA2G2A hsa-miR-203 404  8:1:1 -9.41 -10.67 1.26 
PLA2G2A hsa-miR-138 406  8:1:1 -16.4 -10.76 -5.63 
 
Site Predictions; Predict miRNA binding to a single site along the input sequence.  Gene; represents 
the gene for which the 3’UTR sequence has been selected for input for analysis. Position; anchor 
base position of the predicted miRNA binding site relative to the input sequence: NM_000300. Seed; 
the first digit represents the size of the miRNA (8mer), the second digit represents the amount of base 
mismatches predicted and the third digit represents how many GU wobble base pairs exist. 
dGduplex; ∆G free energy score for the DNA duplex. dGopen; ∆G free energy score comparing 
constrained and non-constrained structures in the sequence. DdG; ∆∆G free energy score. The lower 
this score is the more likely a miRNA is to bind here, as a rule of thumb for the PITA algorithm -10 and 
below suggests a functional site (http://genie.weizmann.ac.il/pubs/mir07/mir07_notes.html). 
Table 3.7. Represents the output from the PITA miRNA target site prediction algorithm. We searched 
for 8-mer targets using the Ensembl SNP tool for the rs3767221 flanking sequence, representing part 
of the 3’UTR PLA2G2A transcript. The SNP rs3767221 lay at position 401 of the sequence and so 
only predicted sites at this position or 5 bases up or downstream were considered relevant.  
 
Bioinformatics tools were also used to check the other previously identified PLA2G2A 
tSNPs to examine if they might influence functional domains, but these results were negative 
and we did not continue to investigate them further. 
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3.2.4. Functional Experiments  
3.2.4.1. Luciferase Assay Results for Analysis of rs11573156 
 The luciferase constructs for rs11573156 C and G were isolated, ligated into a pGL3-
Basic vector and verified as previously described (2.4.7-2.4.7.5). The luciferase assays for 
rs11573156 C and G alleles showed very low expression, being in the order of 1.2 to 1.6 
relative luciferase units, compared to the empty vector alone, with the G allele showing a 
modest 10% higher level (P=0.02) (Figure 3.7). 
 
 
Figure 3.7. The difference in luciferase activity (Relative Light Units) between the C and G alleles of 
rs11573156 normalised to pGL3-Basic. There is no pre-existing promoter in this vector and both 
inserted constructs for C and G variants give very low levels of luciferase compared to the baseline 
measurement of the vector alone. The error bars represent the standard error mean. 
 
3.2.4.2. Luciferase Assay Results for Analysis of rs3767221 
Results from the luciferase assays for rs3767221 A>C are shown in Figure 3.8. A 
significant difference was seen, with the C allele showing ~55% lower luciferase activity 
compared to the T allele (P=<0.0001). Luciferase activity measures for these variants were 
in the order of 27-62 RLU. 
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Figure 3.8. The difference in luciferase activity (Relative Light Units) between the A and C alleles of 
rs3767221 (forward orientation), normalised to pGL3 expression vector. Rs3767221 C (rare) shows a 
55% lower Luc activity compared to the A allele (wild type). The empty pGL3-Basic vector is used as 
a promoter free baseline measurement for transcription. The error bars represent the standard error 
mean. 
 
3.2.5. EMSA Results 
3.2.5.1. EMSA Results for the Analysis of rs11573156 
 Figure 3.9. Shows a standard EMSA for rs11573156. EMSAs specific to either the 
rs11573156 C or G alleles did not show any differential, specific nuclear protein binding. The 
transcription factor binding site prediction algorithm MatInspector identified only Sp1 as a 
putative differential transcription factor binding sites in the 60bp region flanking rs11573156. 
Sp1 protein was therefore used as a potential positive control in rs11573156 EMSA analysis, 
but results showed that a specific Sp1 band was not present for either biotin labelled 
rs11573156 allele. Examination of this region on the UCSC Genome Browser also showed 
an absence of predicted transcription factor binding sites (Figure 3.3). 
 In each EMSA assay sterol regulatory element-binding protein 1 (SREBP 1) was 
used as a positive control as this had been previously optimised for use in an EMSA by 
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members of our lab. I could therefore be satisfied that this protein binding pattern could be 
used to confirm that the EMSA had worked in each instance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. EMSA image of rs11573156 C and G alleles showing no transcription factor binding. Lane 
1 is SREBP 1 positive control that shows specific bands that are competed out with an unlabelled 
SREBP 1 consensus sequence in lane 2. Lanes 3 and 4 show rs11573156 C (wild type) labelled and 
with unlabelled C competitor respectively. There is no specific binding for either. Lanes 5 and 6 
represent rs11573156 G (rare) labelled and with unlabelled G competitor respectively, again with no 
specific binding. Lane 7 represents a second positive control with Sp1 specific binding and in Lane 8, 
labelled Sp1 with unlabelled Sp1 competitor that competes out the specific bands. 
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3.2.5.2. EMSA Results for the Analysis of rs3767221 
An EMSA (Figure 3.10) confirmed differential binding of a nuclear protein between 
the A and C alleles, illustrated by the additional band seen with the biotin-labelled rs3767221 
C, compared to rs3767221 A. This additional band seen with the C variant was competed 
out by the un-biotinylated C probe, suggesting specific binding of a protein in the presence of 
the C allele but not the A allele. The difference in transcription factor binding associated with 
this 3’UTR SNP could influence the rate of transcription and/or mRNA stability, thus affecting 
PLA2G2A expression and levels of sPLA2-IIA. 
  
                                      
 
 
Figure 3.10. Rs3767221 EMSA image showing differential binding between A and C alleles. Lane 1 
shows rs3767221 A. Lane 2 shows rs3767221 A competed with unlabelled rs3767221 A. Lane 3 
shows rs3767221 C. Lane 4 shows rs3767221 C competed with unlabelled rs3767221 C. A specific 
band is seen with the rare (C) variant in Lane 3 compared to the wild type (A) variant in Lane 1. In 
Lane 4, although the competitor reduces the intensity of all bands, only the lower band seen with the 
A allele is competed out completely. 
 
Differential 
band specific 
for G allele 
                      Lane       1              2                     3                 4 
rs
37
67
22
1 
A 
rs
37
67
22
1 
A
 c
om
pe
te
d 
w
ith
  
un
la
be
lle
d 
rs
37
67
22
1 
A 
se
qu
en
ce
 
rs
37
67
22
1 
C
 
rs
37
67
22
1 
C
 c
om
pe
te
d 
w
ith
  
un
la
be
lle
d 
rs
37
67
22
1 
C
 s
eq
ue
nc
e 
168 
 
Coincidently, it was noted that the differentially binding band was a similar size to one 
of the SREBP1 control bands. To investigate this further, rs3767221 C samples were 
competed with SREBP 1. For rs3767221 C, a distinct reduction in the intensity of the band 
was seen, suggesting that an SREBP 1 related protein may be involved in the differential 
binding to the alleles of rs3767221 (Figure 3.11). Though it is unlikely to be SREBP1 
specifically since the known SREBP1 binding sequence does not appear to be present in the 
3’UTR of PLA2G2A.  
            
Figure 3.11. EMSA image for rs3767221; Lane 1: SREBP 1 specific binding as a positive control. 
Lane 2 shows the SREBP1 specific bands competed out by unlabelled SREBP1 consensus 
sequence. Lane 3 and 4 represent rs3767221 A (wild) with (Lane 4) and without (Lane 3) unlabelled A 
competitor with non-specific binding. Lane 5 shows rs3767221 C (rare) specific binding, which is 
competed out with an unlabelled rs3767221 C competitor in lane 6. This confirms differential binding 
between A and C alleles.  Lane 7 shows rs3767221 C competed with unlabelled SREBP 1 and the 
rs3767221 C specific band is much less intense, suggesting SREBP 1 or a related transcription factor 
may bind at rs3767221 C. Lane 8 shows the additional band at rs3767221 G is not competed out by 
non-specific competitor Sp1. 
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3.2.6. TaqMan Gene Expression Results 
3.2.6.1. TaqMan Gene Expression Results for the Analysis of rs11573156 
A total of 67 samples from the DRD cohort (2.5) were genotyped using the TaqMan 
Genotyping Assay System (2.4.6.1) and the results for this are shown below in Figure 3.12. 
The Hardy-Weinberg equation showed no significant difference for this set of results. Semi-
quantitative RT-PCR was then carried out on lymphocyte cell cDNA samples from 12 
individuals of known genotype, across PLA2G2A exons 1 and 2 showed a trend towards 
lower levels in the rs11573156 CG and GG individuals, when compared to the 5 rs11573156 
C homozygotes. The mean expression in the 7 combined rs11573156 CG and GG 
individuals showed ~4.9% lower levels of exon 1 and 2 compared to the homozygous C 
samples (P = 0.09) (Figure 3.13). Unlike exon 2, exons 5-6 are shown by Ensembl and NCBI 
databases to be present in all PLA2G2A transcripts and therefore expression measures for 
exon 5-6 were used as comparison for exon 1-2. For exons 5-6, no genotype effect on 
expression levels was seen (P= 0.54; Figure 3.13). These exon-specific gene expression 
assay results suggest that PLA2G2A exon 1 or 2, but not exons 5 and 6, are differentially 
expressed in a genotype-specific manner according to rs11573156. Each gene expression 
assay is measured relative to an endogenous control, GAPDH (Table 2.3) 
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 Figure 3.12. The TaqMan Genotyping Assay results for rs11573156 in the DRD cohort of 67 samples. 
The autocaller function was used to differentiate between the genotypes. Black squares are NTCs. 
Black crosses are undetermined samples. Blue dots are designated CC common genotype. Green 
dots are designated CG heterozygous genotype. Red dots are designated GG the rare genotype. 
Despite there appearing to be some background noise (as suggested by the spread nature of the No 
Template Control (NTC) samples), the results only become invalid should any of the NTC samples 
record a measurement above the automatically determined thresholds to appear in any of the called 
groups, which none of these NTCs do. 
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Figure 3.13. TaqMan gene expression assay results for rs11573156 C (Green) vs. rs11573156 G carriers (white) expression levels across PLA2G2A exon 1-2 and 
exon 5-6. All assays relative to endogenous control GAPDH. The X axis scale represents ΔCt, the number of amplification cycles required to reach a pre-determined 
threshold of fluorescent signal. Error bars represent the SEM for each result.       = Outlier. The black line through each box represents the median value of each 
dataset. It should be noted that the outliers for rs11573156 CG/GG exon 1-2 are not related to either the CC or the GG genotype specifically. A lower ∆Ct value 
corresponds to increased expression, since less cycles of amplification were required to achieve the manually determined threshold of expression (∆Rn, see 2.4.9. 
Figure 2.9-2.10b). The difference in expression between CC and CG/GG samples for exon 1-2 suggests that individuals with a CC genotype appear to have 
increased PLA2G2A exon 1-2 expression compared to individuals with a CC/GG genotype. There is no difference in expression between the same groups of 
individuals for PLA2G2A exons 5-6 suggesting that there is genotype specific differential expression in the region of PLA2G2A exons 1-2. 
n = 5 n = 7 n = 5 n = 7 
Comparison of Combined TaqMan Gene Expression Assay Repeats for rs11573156 CC and rs11573156 
CG/GG in Exons 1-2 and Exons 5-6: Box Plot Analysis. 
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3.2.7. ASAP Study Gene Expression Analysis  
Bioinformatics Study of rs10732279 
 The SNP rs11573156 was  not present on the Illumina Human 610W-Quad 
Beadarray, so rs10732279 SNP (Figure 3.14) was used as a proxy (R2=0.91 in Europeans, 
HapMap). It is therefore important to establish the likelihood of this SNP being functional 
rather than rs11573156. 
 
Figure 3.14 A schematic of the PLA2G2A gene. The proxy SNP rs11573156 is shown along with 
rs10732279. Rs10732279 is tagged by rs11573156 at R2= 0.91 and used as a proxy for this SNP in 
the ASAP study data since rs11573156 is not available on the Affymetrix Gene Chip. This figure also 
shows that rs10732279 is not present in the suspected alternate splice region where rs11573156 is 
shown.  
 
  The data from Ensembl and NCBI show that rs10732279 is positioned in an intronic 
region of PLA2G2A (NCBI Transcript ID: NM_000300.3). The allele frequencies for 
rs10732279 are A=0.76 and G=0.24 as shown on the NCBI SNP database (European 
population). According to the transcript and SNP data (UCSC and Ensembl), there are no 
known distinguishing features in the intronic region surrounding rs10732279 and it does not 
appear to be near an alternative splice site (Figure 3.3).  
3.2.7.2. ASAP Study Gene Expression Analysis for rs11573156 Proxy 
To examine potential allele-specific expression of PLA2G2A, we analysed PLA2G2A 
mRNA level data from the ASAP study (Folkersen, van't Hooft et al. 2010). Of the tissues 
investigated, liver, mammary arteries, dilated and non-dilated ascending aorta and heart, 
PLA2G2A mRNA was most highly expressed in the aortic adventitia, liver and heart (Figure 
3.15) with the overall allele-specific differential expression of PLA2G2A mRNA was most 
pronounced in the liver (Figure 3.16). This suggests that a SNP or SNPs have the potential 
to regulate sPLA2-IIA expression in a CHD related tissue.    
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The proxy SNP rs10732279 was also the SNP that showed the greatest overall 
differential expression of PLA2G2A and explained 32% of the variance in PLA2G2A mRNA 
(Holmes et al. Submitted). The genotype effect of rs10732279 on PLA2G2A liver mRNA 
showed the strongest differential measurements of all the tissues examined and is presented 
in Figure 3.15; compared to the common A homozygotes, carriers of the rare G allele had 
roughly 25% higher expression of PLA2G2A (P=1.67 x 10-17). Expression of each exon 
compared by rs10732279 alleles was also examined and is shown below in Figure 3.17. 
Exon 2 was shown to be expressed at low levels compared to exons 3-6, suggesting that it 
could be alternately spliced, since it is not detected in as many samples as exon 3-6. 
Additionally, the difference in expression between rs10732279 AA and rs10732279 GG was 
significantly less in exon 2 than in exons 3-6. Again this could suggest that this is due to 
there being less G alleles being expressed in exon 2 since they are usually spliced out, 
whereas the A alleles maintain a regular expression level across all exons (Figure 3.17). 
 
 
Figure 3.15 Expression of PLA2G2A mRNA measured across the tissues of the ASAP study; aorta 
media, aorta adventitia, liver, mammary artery and heart. 
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Figure 3.16. Results from the ASAP Study of the overall differential liver expression of PLA2G2A 
associated with rs10732279 (A>G) genotype. Results in the liver are showed since they are the 
strongest differential measurements regarding rs10732279. Rare G carriers have significantly higher 
total PLA2G2A expression than common A homozygotes (P=1.67 x 10-17). 
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Figure 3.17. The top graph shows ASAP PLA2G2A Expression analysis for different rs10732279 
genotypes. Results from the ASAP study; liver expression levels of exon-specific PLA2G2A probe 
sets stratified by rs10732279 genotype. PLA2G2A is covered by 9 exon-specific probe sets (1 in exon 
2, and two each in exon 3-6)  
 
 The middle figure shows the known protein coding transcripts for PLA2G2A. Known transcribed 
PLA2G2A transcripts showing alternate exon 2 skipping from the UCSC Genome Browser (UCSC 
Genome Browser).  
 
The bottom graph shows PLA2G2A Exon-Specific Expression in the Liver. Results from the ASAP 
study; Liver expression association between exon-specific PLA2G2A probe sets according to 
rs10732279 genotype. The y-axis give the –log10 (p-value) for the PLA2G2A association for 
rs10732279, using an additive model. These values relate to the exon specific absolute expression 
levels shown in the top graph. 
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3.2.7.3. ASAP Study Gene Expression Analysis for rs3767221 
Rs3767221 was not covered on the array nor was there a strong proxy for this SNP. 
However, using the 1000 genomes database Dr. Folkersen was able to impute rs3767221. 
The results predict an association of rs3767221 with PLA2G2A, albeit with less accuracy 
than for rs11573156. The mach1 R2 value was shown to be 0.41. When the differential 
values of PLA2G2A for this imputed SNP were analysed they showed a significant 
association of P=3.6x10-4 (this was weaker than that seen for rs10732279, the proxy for 
rs11573156) with carriers of the common allele (A) showing higher expression compared to 
samples homozygous for the rare allele (C) (Figure 3.18). 
 
 
                         
                  
    
Figure 3.18. Results from the Advanced Study of Aortic Pathology relative to the 1000 Genomes 
Project imputed SNPs for PLA2G2A. The figure shows the predicted overall differential expression 
predicted for rs3767221 (A>C) in the liver. Common A carriers are predicted to have significantly 
higher PLA2G2A expression than rare C homozygotes, P=3.6x10-4. 
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3.3. Discussion 
3.3.1. Rs11573156 C>G as a Functional SNP 
It has been previously reported that the PLA2G2A 5’UTR and potential promoter 
SNP rs11573156 (in the region of the untranslated exon 2) and the 3’UTR SNP rs3767221, 
are independently associated with differences in levels of plasma sPLA2-IIA (Wootton, 
Drenos et al. 2006) and here I show that both influence gene expression by acting through 
different molecular mechanisms.    
The difference in luciferase activity between the rs11573156 C and G constructs is 
modest in comparison to the baseline pGL3 basic measurement and of borderline statistical 
significance. Compared to pGL3 Basic alone (1RLU) the luciferase results were in the order 
of 1.2-1.6 RLU suggesting that this fragment of the promoter does not increase transcription. 
This is potentially explainable considering that the fragment that was analysed includes a 
previously identified negative regulatory region (Olivier, Fan et al. 1994; Fan, Paradon et al. 
1997), and the inhibition of luciferase stimulation by a negative regulatory region in this 
fragment might explain the low luciferase activity measurements that we see. It should be 
noted that the rare (G) variant was introduced into the fragment using site directed 
mutagenesis and therefore both fragments were identical except for this one change in allele 
and therefore changes such as alternate splicing cannot be interpreted through these 
results. Bioinformatics analysis using the transcription factor binding prediction tool, 
MatInspector, indicated no potential, differential transcription factor binding at a matrix 
similarity of <0.95 in the region of rs11573156. A potential differential transcription factor 
binding site for Sp1 at a matrix similarity of <0.90 was predicted, but this was shown not to 
exist by EMSA analysis. Additionally, no predicted transcription factor binding was shown in 
the same region according to the UCSC genome browser. Predicted miRNA binding in the 
region of this SNP was also assessed using several known algorithms. Thus, in order to 
assess all potential transcription factor/miRNA binding in the region of rs11573156, I used 
the chemiluminescent EMSA technique. The lack of mobility shift in the EMSA corroborated 
my theory that there is no differential protein binding associated with this SNP since no 
specific differential protein binding between the rs11573156 C and G variants was seen, 
suggesting no differential protein binding in the region immediately surrounding rs11573156.  
 A clue that the genotype effect might be acting through another mechanism came 
from the observation that exon 2 is not always present in the reported transcripts of the gene 
(Ensembl reference sequence: ENST00000375111 and ENST00000400520). Considering 
the very low levels of luciferase activity in the luciferase experiment, it is likely that a 
negative regulatory element exists in the region of exon 2 in the 5’UTR/promoter region. Fan 
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et al, using deletion mapping of the PLA2G2A promoter in reporter gene assays, identified a 
negative element in the region -1969 to -1624, which incorporates exon 2 (Ensembl Genome 
Browser). When deleted from the full transcript, reporter gene expression increased by 
~400% (Fan, Paradon et al. 1997).  
To assess the relationship between rs11573156 and potential for differential alternate 
splicing, gene expression data was generated and analysed. Gene expression techniques 
analyse differences in mRNA or cDNA expression and therefore take into account post-
transcriptional modifications such as splicing and allows us to see the effects of different 
SNPs and post-transcriptional modifications on gene expression and ultimately, protein 
expression. When PLA2G2A mRNA levels were tested in the limited samples of known 
genotype available to me, I observed that, compared to expression of exons 5 and 6, which 
showed no difference in expression by genotype, there was a non-significant lower levels of 
exons 1 and 2 with G carriers compared to C homozygotes. These results were confirmed 
by the results from the ASAP study. Since  rs11573156 was not available on the ASAP 
arrays,  rs10732279, a proxy for rs11573156  was studied across all the measured tissues 
and in liver was shown to be most significantly associated with a change in PLA2G2A mRNA 
levels with carriers of the rare C allele being significantly associated with increased total 
mRNA expression compared to the common A allele homozygotes in exons 3-6 but, 
importantly, the difference in expression between rs10732279 variants was significantly 
lower for exon 2. This suggests that lower mRNA expression associated with the rare G 
allele occurs with exon 2 due to the splicing out of this exon with this variant, so there is less 
of exon 2 being produced. In turn, the splicing out of exon 2 removes a negative regulatory 
region, thus increasing mRNA expression from all the following exons (3-6), showing an 
overall increase in total PLA2G2A mRNA associated with the rare C allele (Figure 3.17).  
The trend for lower total expression of exon 1 and 2 seen with the rare G allele 
carriers compared to the C allele homozygotes in the TaqMan gene expression experiments 
therefore supports this data and theory, again suggesting that exon 2 could potentially be 
spliced out differentially with this allele and samples where exon 2 is spliced out will express 
lower mRNA in the exon 2 region. This splicing out of exon 2 would remove the negative 
regulatory region in this exon and would result in an increase of overall mRNA expression 
from exons 3-6, ultimately contributing to the regulation of sPLA2-IIA mass and sPLA2 
activity which we know to be differentially associated with this allele from previous 
observational data (Wootton, Drenos et al. 2006). The TaqMan gene expression analysis 
that I carried out had limited power, since the sample of healthy lab volunteers was very 
small. I was also cautious of the fact that the TaqMan results were all at very high ∆CT 
values, suggesting that the assays were not very efficient. Therefore these results were used 
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as only a guide to indicate whether there might be a need for further testing. However, when 
taken together with the ASAP study, these results implied that, in the presence of the rare G 
allele, exon 2 was expressed less well, suggesting that it was preferentially skipped in the 
presence of the rare allele. 
Rs10732279, which showed the most significant association with PLA2G2A 
expression in the ASAP study, is intronic and is not in close proximity to any predicted 
functional sites (UCSC Genome Browser). However our SNP of interest, rs11573156, for 
which it acted as a proxy, is in very close proximity (37bp) to a known exon skipping site 
(beginning at chr1:20306884).  
To examine the possibility that rs11573156 is only marking the true functional SNP in 
linkage disequilibrium, the LD between rs11573156 and all known exon-boundary SNPs was 
examined using the 1000 Genomes data and the SNAP Pairwise LD program. There was no 
other genotyped variant at those positions showing LD with rs11573156 above an R2 
threshold of 0.7 paired. 
3.3.2. Rs3767221 A>C as a Functional SNP 
 There is strong evidence to suggest that rs3767221 A>C in the 3’UTR of PLA2G2A is 
also functional. The rare allele was shown to be associated with reduced sPLA2-IIA mass 
compared to the wild type in observational studies (Wootton, Drenos et al. 2006). In this 
instance we have shown that this is likely to be due to differential protein binding between 
the wild type and rare variant, with a binding site created by the presence of the rare G 
allele. Lower luciferase activity was associated with the rare C variant, seemingly replicating 
the data from the observational studies that showed the rare C allele homozygotes to be 
associated with significantly lower sPLA2-IIA mass compared with the wild type A allele 
homozygotes in a per allele pattern. Additionally, EMSA analysis showed a specific protein 
bound differentially to the rare C allele fragment compared to the wild type A allele. 
Coincidentally, the migration of a specific band seen with rs3767221 C appeared to 
correspond partially to one of those of the SREBP 1 positive control, used for all EMSA 
work. Competition of the C allele with SREBP 1 unlabelled consensus sequence resulted in 
lower intensity of the specific band, which I attempted to confirm by supershift assay. 
However, I was unable to confirm SREBP 1 binding using a supershift, due to an inability to 
optimise the assay with the required thesis submission time frame. As previously shown, 
prediction by MatInspector suggests a potential cAMP binding protein site in the region of 
rs3767221 C that is not predicted for rs3767221 A and cAMP is known to effect human 
sterol regulation, including SREBP1 binding (Lu and Shyy 2006) and to play a role in sPLA2-
IIA transcription regulation (Touqui and Alaoui-El-Azher 2001). The UCSC Genome Browser 
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identifies a dense potential transcription factor binding region in the sequence around 
rs3767221, which included SREBP1 and sPLA2 interacting transcription factors such as 
p300 (Giandomenico, Simonsson et al. 2003)  and LXR alpha (Trousson, Bernard et al. 
2009). Additionally the miRBase algorithm predicted a binding site in the region of 
rs3767221 and this binding site contains part of a known SREBP consensus sequence. 
Therefore, it may be that the protein binding differentially in the EMSA is related to SREBP, 
but further experiments must be carried out to confirm this.  
Considering both the observational and luciferase assay results we can predict that 
the protein binding in this position in the 3’UTR of PLA2G2A is an inhibitor, which would 
correlate with the comparatively low luciferase activity and sPLA2-IIA mass associated with 
this SNP. Further experiments are needed to clarify the specificity of the protein beyond 
doubt and to identify the protein binding to this site.  
 Several likely potential miRNA binding sites were predicted by the miRNA prediction 
algorithms miRBase and PITA and the differential protein complex seen in the EMSA could 
also relate to a type of post-transcriptional modification such as an miRNA or a member of 
the ribonucleoprotein family, which are known to modify genes post-transcriptionally, by pre-
mRNA splicing (Chaudhury, Hussey et al. 2011) and have been associated to phospholipid 
mechanisms in the cell (Maraldi, Mazzotti et al. 1992). Again, further investigation into what 
the differential protein complex is needs to be carried out. 
Observational studies show higher sPLA2-IIA levels associated with the A variant 
compared to the C variant and this is concordant with the higher luciferase activity seen with 
the A allele and the higher PLA2G2A expression associated with A allele carriers predicted 
by the ASAP study, so we predict that the protein binding to this region in C allele carriers, 
would act as a repressor. 
3.4. Summary of Findings 
3.4.1. Summary of the Potential Functionality of rs11573156 
These results provide strong evidence to suggest that rs11573156 is a functional 
SNP affecting the expression of PLA2G2A. The potential mechanism of action of 
rs11573156 is differential splicing of exon 2, where the rare G allele is associated with the 
splicing out of the untranslated exon 2 and creates a truncated 5-exon transcript from the 
dominant 6-exon transcript. This seems to affect the rate of transcription of sPLA2-IIA, 
potentially through the loss of a negative regulatory mechanism shown to be in this region. 
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3.4.2. Summary of the Potential Functionality of rs3767221 
 The data accumulated here also suggests that rs3767221 A>C is potentially 
functional SNP. However, this SNP appears to act through a mechanism of differential 
regulatory protein binding. 
3.5. Conclusion 
The major aim of this part of the study was to determine the functionality of these two 
SNPs in tissues relevant to CHD, with a view to validate their use as robust genetic 
instruments to be used in Mendelian Randomization (MR) analysis. The MR approach uses 
a genetic variant to validate the causal relationship between a biomarker and outcome, in 
this case sPLA2-IIA and CHD, by examining the relationship of the SNP with both biomarker 
and outcome and testing the concordance of effects (Hingorani and Humphries 2005). 
 The functional analysis of rs11573156 and rs3767221 showed both SNPs to have 
functional relationships regarding sPLA2-IIA mass and/or sPLA2 activity. Since rs11573156 
appears to have the most significant association with sPLA2-IIA mass (Wootton, Arora et al. 
2007) and activity (EPIC-Norfolk) we took this SNP forward to use for a Mendelian 
randomisation (MR) analysis in order to assess whether the relationship seen between 
sPLA2-IIA mass and CHD (Boekholdt, Keller et al. 2005; Mallat, Benessiano et al. 2007) is 
likely to be causal.   
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CHAPTER 4 
Using Genetics to Test the Causality of sPLA2-IIA 
for CHD: A Mendelian Randomisation Approach 
 
4. Background 
The Mendelian randomisation data presented in this chapter is a result of a large 
collaboration of 32 studies. Thanks and credit is given to all of the Principal Investigators of 
each study and to all who worked on the genotyping and statistical analysis for each study. A 
list of Principal Investigators is provided in the acknowledgements section (p6). 
4.1. Introduction 
4.1.1. Formation of the sPLA2-IIA Mendelian Randomisation Study 
 In Chapters 1 and 3 data from previous studies were examined and showed 
encouraging evidence supporting the hypothesis that there is causative role for sPLA2-IIA in 
CHD. The studies included both mechanistic analyses in animals (Ishimoto, Yamada et al. 
2003; Webb, Bostrom et al. 2003; Tietge, Pratico et al. 2005; Bostrom, Boyanovsky et al. 
2007; Koenig, Vossen et al. 2009) and observational studies in humans (Pruzanski, 
Keystone et al. 1988; Boekholdt, Keller et al. 2005; Mallat, Steg et al. 2005; Mallat, 
Benessiano et al. 2007; Koenig, Vossen et al. 2009; Oorni and Kovanen 2009). However, 
despite these promising findings it is not possible to definitively model a human disease 
process in animal models, and observational studies are susceptible to confounding and 
reverse causation. 
 In order to fully answer the question of the causation of sPLA2-IIA in the 
development of CHD, it is therefore necessary to take a different approach and this could 
also result in a better evaluation of the significance of sPLA2-IIA as a therapeutic target in 
CHD prevention. The approach used for this chapter took advantage of the rs11573156 C>G 
variant in the sPLA2-IIA encoding gene (PLA2G2A), that I had previously identified as a 
functional SNP (Chapter 3) and before that had been shown to be significantly associated 
with sPLA2-IIA mass (Wootton, Drenos et al. 2006). Using this SNP as a natural model of 
differential sPLA2-IIA mass/ sPLA2 activity the Mendelian randomisation principle was 
applied (Davey Smith and Ebrahim 2003). This variation is considered to be specific and un-
confounded for the evaluation of the validity of sPLA2-IIA as a therapeutic target for the 
prevention of CHD. The concept of Mendelian randomisation and some examples of where it 
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could have been relevant and where it has been used successfully are explained in Chapter 
1.7.3.  
4.1.2. The Effects of sPLA2-IIA Levels/sPLA2 Activity on Cardiovascular Risk Traits 
 There is a chance that sPLA2-IIA mass and sPLA2 activity act to effect CHD risk 
through actions on a known confounder. In order assess this and to establish what traits 
should be adjusted for in the analysis of rs11573156 with risk of CHD, analysis was carried 
out in the EPIC-Norfolk population (a populations described previously in 2.5.1) to show how 
increasing tertiles of sPLA2-IIA mass and sPLA2 activity effect known cardiovascular risk 
factors (4.2.2 Table 4.5A-B). 
 The cross-sectional association between log sPLA2-IIA mass and log sPLA2 enzyme 
activity was evaluated with the following traits: age, body mass index (BMI), C-reactive 
protein (CRP), systolic blood pressure (SBP), diastolic blood pressure (DBP), high density 
lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides 
(TG), apolipoprotein A1, apolipoprotein B, gender, type 2 diabetes (T2D) and smoking 
status. The tertiles of sPLA2-IIA mass and sPLA2 enzyme activity were created by dividing 
the population into 3 equal parts by either sPLA2-IIA mass or sPLA2 activity measures, with 
tertile 1 representative of the lowest measurements and tertile 3 the highest measurements. 
The mean and standard deviation (SD) for continuous traits and proportion of cases for 
binary traits for each tertile were calculated and tabulated. For sPLA2 activity; tertile 1 = 1.7-
4.0 nmol/min/ml, tertile 2 = 4.0-4.9 nmol/min/ml and tertile 3 = 4.9-23.1 nmol/min/ml (Table 
4.5A). For sPLA2-IIA mass; tertile 1 = 0.4-6.8 ng/ml, tertile 2 = 6.8-11.3 ng/ml and tertile 3 = 
11.3-114.5 ng/ml (Table 4.5B). Next, a univariate linear and logistic regression analyses was 
completed for continuous and binary traits, respectively, using log(n) transformed sPLA2 IIA 
mass and sPLA2 enzyme activity as the explanatory (independent) variables. All analysis 
was carried out using Stata v11 (2.4.11). 
4.1.3. Varespladib Literature Study 
 The known sPLA2 inhibitor, varespladib, was undergoing Phase III trials 
simultaneously with this Mendelian randomisation analysis was being undertaken and it was 
therefore important to compare the effects of the drug with the effect of the genetic 
instrument, rs11573156 C>G in order to contextualise the MR findings. According to the 
PRISMA guidelines (2.4.1) and using the search parameters outlined in 2.4.1 I was able to 
run a search that resulted in 4 primary human dose-response studies for varespladib (Figure 
4.1). The four human based randomised trials identified (Table 4.1), totalled 1,300 
participants (Rosenson, Hislop et al. 2009; Dzavik, Lavi et al. 2010; Rosenson, Hislop et al. 
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2010; Rosenson, Elliott et al. 2011). To compare the effect of the PLA2G2A SNP on sPLA2-
IIA mass and sPLA2 enzyme activity in relation to pharmacological modification, I identified 
four randomized trials of the sPLA2 inhibitor varespladib in a total of 1,300 individuals. A 
meta-regression of dose-finding studies indicated varespladib treatment produced a dose-
dependent reduction in sPLA2-IIA mass (P for meta-regression=0.06). The most frequently 
studied dose of varespladib (500mg/day) reduced sPLA2-IIA mass by an average of 78% 
(95%CI: 62%, 94%). This effect is equivalent to approximately twice the effect seen for each 
C allele of rs11573156. The effect of varespladib on sPLA2 enzyme activity was not reported 
in clinical trials since baseline activity was reported to be beneath the lower limit of 
quantification of the assay. No trial reported the effect of varespladib on sPLA2-III, V or X 
mass.  
Varespladib showed a strong association with sPLA2-IIA mass. However, data 
extracted from these studies suggested no significant effects could be seen in the reduction 
of primary CHD risk and minimal effects were on secondary risk of heart disease (Rosenson 
and Gelb 2009; Dzavik, Lavi et al. 2010; Rosenson, Hislop et al. 2010; Rosenson, Elliott et 
al. 2011). This has been underpinned by the recent, premature termination of the phase III 
RCT, VISTA-16 (Nicholls, Cavender et al. 2011) due to reasons of futility. The outcome of 
this large scale MR analysis is therefore timely for helping to put the failure of this inhibitor 
trial into context. 
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 Figure 4.1. This flow diagram provided by PRISMA shows the process of the PRISMA guided analysis of varespladib randomised control trials. The pre-
determined parameters resulted in 105 studies originally, which was narrowed down to 4 specific included studies by following the PRISMA guidelines for 
inclusion, demonstrated in the form of a flow diagram (http://www.prisma-statement.org/statement.htm). 
186 
 
  
 
 
 
 
 
 
 
 
 
 
 
Table 4.1. Results from PRISMA guided analysis of varespladib randomised control trial studies. The table shows the design of each of the 4 trials identified 
from the literature search using the PRISMA guidelines (February 2012).  
  
Trial name RCT 
phase 
Years 
conducted 
Clinical 
setting 
Primary end-point Age,  
mean 
(SD) 
Sex, 
% female 
Number 
randomised 
Varespladib dose,  
mg/day (dosing 
frequency per day) 
Trial 
duration, 
months 
FRANCIS-
ACS 
(Rosenson, 
Hislop et 
al. 2010) 
IIB 2008-2010 ACS Change in LDL-C from 
baseline to 8 weeks 
59.05 
(10.5) 
25.3 625 500 
(once) 
6 
PLASMA 
(Rosenson, 
Hislop et 
al. 2009) 
II 2007 Stable CHD Change in sPLA2 
concentration or 
activity from baseline 
to 8 weeks  
62 (11) 24 393 50/100/250/500  
(twice) 
2 
PLASMA 2 
(Rosenson, 
Elliott et 
al. 2011) 
II 2007 Stable CHD Change in sPLA2 
concentration from 
baseline to 8 weeks 
64 (12) 11 138 250/500 
(once) 
2 
SPIDER-PCI 
(Dzavik, 
Lavi et al. 
2010) 
II 2007-2009 Stable CHD 
patients 
undergoing 
elective PCI 
Elevation of cardiac 
enzymes (CK-MB,  
Troponin I) up to 24h 
PCI 
63.4 (9.9) 12.5 144 500 
(twice) 
1 
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4.1.4. Identifying the Strongest Genetic Instrument 
As presented in Chapter 3, two functional SNPs were identified in PLA2G2A; 
rs11573156 C>G and rs3767221 A>C. The SNP rs11573156 was chosen as the genetic 
instrument after investigation by genotyping in 5 studies with sPLA2-IIA mass and sPLA2 
activity measures; including EPIC-Norfolk, GRACE-France, GRACE-Scotland, UDACS and 
FAST-MI (Populations defined in 2.5.1 Table 2.6) found evidence in favour of rs11573156 
C>G being the stronger genetic instrument for the purposes of Mendelian randomisation 
analysis (results shown below in 4.2.1). The statistical methods used to determine this are 
described in 2.4.11. For each of the 5 studies, per C allele associations of each SNP with 
sPLA2-IIA mass and sPLA2 activity were calculated. 
4.2. Results 
4.2.1. Rs11573156 C>G the Strongest and Most Specific Genetic Instrument 
The initial identification of rs11573156 C>G, along with 5 other tSNPs, showed 
significant association with sPLA2-IIA mass (Wootton, Drenos et al. 2006) in a Type II 
diabetes cohort, the University College London Diabetes and Cardiovascular Disease Study 
(UDACS) (Defined previously in Table 2.6 and Table 2.7).  Further analysis of these 6 SNPs 
led to rs11573156 and rs3767221 being identified as the most highly associated with sPLA2-
IIA mass and subsequently these two SNPs were genotyped in two additional studies. The 
European Prospective Investigation of Cancer (EPIC-Norfolk) (Day, Oakes et al. 1999) is a 
nested case-control prospective study based on 3,039 individuals sampled from general 
practices in Norfolk, England and the Global Registry of Acute Coronary Events (GRACE)-
France is a study of 275 acute coronary syndrome (ACS) patients recruited from hospitals in 
France (Both of these studies are summarized in Table 2.6 and Table 2.7) (Investigators 
2001). Both studies have measures for sPLA2-IIA mass and sPLA2 activity. The Hardy-
Weinberg Equilibrium test for each SNP in each study is shown in Figure 4.2A-D.The 
baseline measurements for EPIC-Norfolk and GRACE France are shown in Table 4.3, 
categorised by prospective CHD cases and controls for EPIC-Norfolk and as acute coronary 
syndrome cases for GRACE. Additionally the association of genotype with all measured 
intermediate covariates is shown for both rs11573156 and rs3767221 in Table 4.4A-B.  
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 SNP  EPIC-Norfolk GRACE-France 
N sPLA2 activity sPLA2-IIA mass MAF N sPLA2 activity sPLA2-IIA mass MAF 
rs3767221 
11 
 
12 
 
22 
 
P value 
(trend) 
 
P value2 
1214 
 
1450 
 
523 
 
4.45 [3.85-5.22] 
 
4.40 [3.85-5.15] 
 
4.32 [3.81-4.97] 
 
0.06 
 
 
0.21 
10.10 [6.80-16.05] 
 
8.60 [5.90-12.90] 
 
6.90 [5.10-9.10] 
 
7.91x10-41 
 
 
1.43x10-47 
0.39 101 
 
127 
 
48 
 
2.00 [1.50-2.70] 
 
2.00 [1.40-2.90] 
 
1.80 [1.20-3.30] 
 
0.50 
 
 
0.36 
3.62 [2.15-8.67] 
3.42 [1.66-5.71] 
1.84 [1.13-3.18] 
0.0003062 
 
0.0017 
0.40 
rs11573156 
11 
 
12 
 
22 
 
P value 
(trend) 
 
P value2 
1834 
 
1046 
 
159 
 
 
4.33 [3.78-5.04] 
 
4.47 [3.90-5.23] 
 
4.56 [3.91-5.39] 
 
0.00004132 
 
 
0.0002 
6.80 [5.08-9.0] 
12.00 [8.74-16.47] 
16.10 [10.94-23.73] 
1.08x10-170 
 
7.82x10-193 
0.22 178 
 
88 
 
9 
 
 
1.85 [1.20-2.80] 
 
2.00 [1.50-3.20] 
 
2.80 [1.50-2.80] 
 
0.03 
 
 
0.07 
2.26 [1.37-4.24] 
4.35 [2.61-1.25] 
7.30 [4.66-18.84] 
2.27x10-8 
 
2.48x10-6 
0.19 
All results are represented as median (IQR). 11: homozygotes for the common allele; 12: heterozygotes; 22: homozygotes for the rare allele. 
1 unadjusted p values. 
2 age, gender and CHD adjusted p value. 
 
Table 4.2. Shows the results of genotyping the PLA2G2A functional SNPs rs3767221A>C and rs11573156 C>G in the Epic Norfolk and GRACE France 
cohorts and their related associations with sPLA2 activity and sPLA2-IIA mass. The results show that rs11573156 has a stronger association to sPLA2 
activity and sPLA2-IIA mass in both cohorts. 
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NTC= No template control; Undetermined = uncalled samples; 11 = homozygous for common allele; 12 = heterozygous; 22= homozygous for rare allele. 
Figure 4.2A. The Hardy-Weinberg Equilibrium equation for rs11573156 C>G in                            Figure 4.2B. The Hardy-Weinberg Equilibrium equation for rs3767221 A>C in 
EPIC-Norfolk. There is no significant difference between observed and expected values.            GRACE France. There is no significant difference between observed and            
                                                                                                                                                        expected values. 
Stats for a 2-allele polymorphism       
SNP = rs11573156 C>G      
  Observed    
  rs11573156 rs11573156 rs11573156     
Genotypes 11 12 22 Total   
Frequency 1834 1046 159 3039   
        
  P Q p+q    
  0.776 0.224 1.000    
        
  Expected    
  rs11573156 rs11573156 rs11573156     
Genotypes 11 12 22 Total   
Frequency 1828.1 1057.9 153.1 3039.0   
        
  Chi^2 test and level of significance 
  O E (o-e)^2/e Chi^2 Sig level 
  1834 1828.1 0.0    
  1046 1057.9 0.1    
  159 153.1 0.2    
     0.384 0.5353 
     Not sig at 1 df   
Notes:                                                                                                                                                        
NTC = 72      
Undetermined = 287     
Stats for a 2-allele polymorphism       
SNP = rs11573156 C>G     
  Observed    
  rs11573156 rs11573156 rs11573156     
Genotypes 11 12 22 Total   
Frequency 178 88 9 275   
        
  P Q p+q    
  0.807 0.193 1.000    
        
  Expected    
  rs11573156 rs11573156 rs11573156     
Genotypes 11 12 22 Total   
Frequency 179.2 85.6 10.2 275.0   
        
  Chi^2 test and level of significance 
  O E (o-e)^2/e Chi^2 Sig level 
  178 179.2 0.0    
  88 85.6 0.1    
  9 10.2 0.1    
     0.222 0.6378 
     Not sig at 1 df   
Notes:                                                                                                                                                          
NTC = 106     
Undetermined = 3     
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NTC= No Template Control; Undetermined = sample not called for genotype; 11= homozygous for the common allele; 12= heterozygous; 22= homozygous for the rare allele 
 
Figure 4.2C. The Hardy-Weinberg Equilibrium equation for rs3767221 A>C in                          Figure 4.2D. The Hardy-Weinberg Equilibrium equation for rs3767221 A>C in 
EPIC-Norfolk. There is no significant difference between observed and                                   GRACE France. There is no significant difference between observed and            
expected values.                                                                                                                        expected values. 
 
Stats for a 2-allele polymorphism       
SNP = rs3767221 A>C      
  Observed    
  rs3767221  rs3767221  rs3767221      
Genotypes 11 12 22 Total   
Frequency 1239 1480 499 3218   
        
  P q p+q    
  0.615 0.385 1.000    
        
  Expected    
  rs3767221  rs3767221  rs3767221      
Genotypes 11 12 22 Total   
Frequency 1217.0 1523.9 477.0 3218.0   
        
  Chi^2 test and level of significance 
  O E (o-e)^2/e Chi^2 Sig 
level 
  1239 1217.0 0.4    
  1480 1523.9 1.3    
  499 477.0 1.0    
     2.672 0.1021 
     Not sig at 1 df   
Notes:                                                                                                                                                            
NTC = 72      
Undetermined = 166     
Stats for a 2-allele polymorphism       
SNP = rs3767221       
  Observed    
  rs3767221  rs3767221  rs3767221      
Genotypes 11 12 22 Total   
Frequency 101 127 48 276   
        
  p q p+q    
  0.596 0.404 1.000    
        
  Expected    
  rs3767221  rs3767221  rs3767221      
Genotypes 11 12 22 Total   
Frequency 98.0 132.9 45.0 276.0   
        
  Chi^2 test and level of significance 
  O E (o-e)^2/e Chi^2 Sig level 
  101 98.0 0.1    
  127 132.9 0.3    
  48 45.0 0.2    
     0.546 0.4600 
     Not sig at 1 df   
Notes:                                                                                                                                                         
NTC = 106     
Undetermined = 2     
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All EPIC Norfolk results are geometric mean (approx sd) except CRP, which is median (IQR). Sd = standard deviation 
Table 4.3. Baseline measurements for the EPIC Norfolk and GRACE France cohorts. The measurements for EPIC-Norfolk are categorised by cases of CHD 
versus controls with adjustment for age and sex. The measurements for GRACE-France represent data from ACS patients. 
 
 
 
 
Variable Controls n=2237 Cases n=1138 P value Variable Mean (sd) 
Age (years) 
BMI (kg/m2) 
% Males (n) 
SBP (mm Hg) 
DBP (mm Hg) 
Cholesterol (mmol/L) 
TG (mmol/L) 
CRP (mg/L) 
sPLA2 mass (ng/mL) 
sPLA2 activity (nmol/min/mL) 
64.80 (7.70) 
26.10 (3.40) 
63.10 (1411) 
137.90 (17.60) 
82.90 (10.90) 
6.17 (1.11) 
1.66 (0.83) 
1.57 (1.83) 
8.72 (5.19) 
4.36 (1.05) 
65.00 (7.90) 
27.00 (3.70) 
63.70 (725) 
142.70 (18.80) 
85.00 (11.90) 
6.40 (1.21) 
1.94 (0.96) 
2.35 (2.75) 
10.00 (6.18) 
4.69 (1.22) 
0.54 
2.96x10-13 
0.72 
9.93x10-13 
2.78x10-7 
1.34x10-7 
3.46x10-17 
8.66x10-21 
5.75x10-10 
1.53x10-15 
Age (years) 
BMI (kg/m2) 
SBP (mm Hg) 
DBP (mm Hg) 
Cholesterol (mmol/L) 
CRP (mg/L) 
sPLA2 mass (ng/mL) 
sPLA2 activity 
(nmol/min/mL) 
58.70 (13.00) 
26.00 (4.40) 
135.00 (26.00) 
76.90 (16.10) 
5.30 (1.30) 
11.40 (13.80) 
3.68 (4.22) 
3.09 (1.17)  
                                        EPIC-Norfolk                                                                                                                GRACE-France (n=276) 
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rs3767221 N BMI (kg/m2) SBP (mm Hg) DBP (mm Hg) CHOL (mmol/L) TG (mmol/L) LDL (mmol/L) HDL (mmol/L) CRP (mg/L) LpPLA2 (U/L) 
11 
12 
22 
P value 
1214 
1450 
523 
26.5 (3.5) 
26.3 (3.5) 
26.5 (3.5) 
0.64 
139.4 (18.0) 
139.7 (18.1) 
139.0 (18.1) 
0.73 
83.6 (11.1) 
83.9 (11.5) 
83.2 (10.9) 
0.95 
6.25 (1.14) 
6.26 (1.18) 
6.19 (1.11) 
0.30 
1.78 (0.91) 
1.73 (0.87) 
1.73 (0.86) 
0.31 
4.07 (1.00) 
4.10 (1.03) 
4.00 (0.98) 
0.30 
1.27 (0.36) 
1.29 (0.36) 
1.29 (0.38) 
0.39 
1.6 (0.8-3.5) 
1.8 (0.8-4.0) 
1.8 (0.8-3.9) 
0.13 
49.4 (15.9) 
49.5 (15.6) 
48.6 (15.7) 
0.61 
rs11573156 N BMI (kg/m2) SBP (mm Hg) DBP (mm Hg) CHOL (mmol/L) TG (mmol/L) LDL (mmol/L) HDL (mmol/L) CRP (mg/L) LpPLA2 (U/L) 
11 
12 
22 
P value 
1834 
1046 
159 
26.4 (3.5) 
26.4 (3.5) 
26.4 (3.1) 
0.64 
138.9 (18.0) 
140.1 (18.2) 
141.5 (19.5) 
0.02 
83.4 (11.1) 
84.0 (11.4) 
85.3 (12.3) 
0.03 
6.23 (1.15) 
6.24 (1.18) 
6.19 (1.06) 
0.78 
1.75 (0.88) 
1.73 (0.87) 
1.76 (0.85) 
0.67 
4.06 (1.01) 
4.08 (1.05) 
4.02 (0.88) 
0.82 
1.28 (0.36) 
1.28 (0.36) 
1.25 (0.38) 
0.35 
1.7 (0.8-3.8) 
1.8 (0.8-3.9) 
1.4 (0.7-2.9) 
0.03 
49.3 (15.9) 
49.2 (15.8) 
50.6 (15.5) 
0.63 
All results are geometric mean (approx sd) except CRP, which is median (IQR) 
Age and gender adjusted p values. 
 
Table 4.4A. The Intermediate trait measurements of the Epic-Norfolk case/control cohort categorised by SNP genotype for the PLA2G2A SNPs rs11573156 
C>G and rs3767221 A>C 
 
 
 
 
 
 
 
 
 
 
 
 
EPIC-Norfolk Intermediate Traits By Genotype: 
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rs3767221 BMI (kg/m2) SBP (mm Hg) DBP (mm Hg) CHOL (mmol/L) LDL (mmol/L) CRP (mg/L) 
11 (n=101) 
12 (n=127) 
22 (n=48) 
P value 
26.9 (4.4) 46 
25.6 (4.2) 55 
25.5 (2.8) 13 
 
134.7 (24.7) 89 
138.4 (25.5) 107 
127.1 (24.1) 37 
0.32 
78.4 (14.4) 89 
77.5 (17.4) 107 
74.8 (13.0) 37 
0.29 
5.16 (1.09) 42 
5.25 (1.31) 53 
5.72 (1.00) 17 
0.20 
3.17 (0.96) 41 
3.11(1.27) 47 
3.78 (0.94) 17 
0.18 
10.4 (3-23.3) 101 
8.7 (3-17.8) 126 
9.2 (3.1-21.2) 48 
0.95 
rs11573156 BMI (kg/m2) SBP (mm Hg) DBP (mm Hg) CHOL (mmol/L) LDL (mmol/L) CRP (mg/L) 
11 (n=178) 
12 (n=88) 
22 (n=9) 
P value 
26.2 (4.5) 77 
26.1 (3.7) 36 
26.3 (7.5) 2 
 
134.5 (24.2) 157 
135.3 (27.9) 68 
145.0 (17.0) 7 
0.70 
78.3 (14.6) 157 
75.0 (18.0) 68 
81.2 (11.2) 7 
0.34 
5.32 (1.18) 77 
5.27 (1.22) 32 
4.83 (1.53) 4 
0.58 
3.27 (1.16) 72 
3.20 (1.07) 30 
2.92 (1.36) 4 
0.64 
9.2 (3-18) 177 
10.4 (3.2-22.5) 88 
5.5 (3-20.9) 9 
0.72 
                        
                        All results are geometric mean (approx sd) except CRP, which is median (IQR). Followed by Age and gender adjusted p values. 
 
 
Table 4.4B The Intermediate trait measurements of the GRACE-France acute coronary syndrome cohort categorised by SNP genotype for the PLA2G2A 
SNPs rs11573156 C>G and rs3767221 A>C.
GRACE-France Intermediate Traits By Genotype: 
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Upon analysis of the genotyped EPIC-Norfolk and GRACE-France cohorts I 
determined rs11573156 C>G as the most likely candidate for a strong genetic instrument to 
be used in Mendelian randomisation to study the role of sPLA2-IIA in the causation of 
cardiovascular events. The results showed rs11573156 to have a significantly strong 
association to both sPLA2-IIA mass (P=1.08x10-170) and sPLA2 activity (P=4x10-5). The SNP 
was also confirmed as a functional SNP as described by the functional analysis in Chapter 
3. 
Parallel to the genotyping of EPIC-Norfolk and GRACE-France, another French ACS 
cohort, FAST-MI was being genotyped for, among other SNPs, rs11573156 C>G. This 
genotyping and analysis was carried out by Dr Tabbassome Simon (APHP, Hôpital Saint 
Antoine, Department of Pharmacology – URC-EST; UPMC University, Site Saint Antoine, 
Department of Pharmacology) in a cohort of 973 individuals recruited from a nationwide ACS 
registry in France. The data indicated that rs11573156 C>G had the strongest association to 
sPLA2 activity and sPLA2-IIA mass. GRACE-Scotland has measures for both sPLA2-IIA 
mass and sPLA2 activity in 1,488 individuals with ACS, recruited from hospitals in Scotland. 
Again, genotyping data from this study has shown rs11573156 to be significantly associated 
to sPLA2-IIA mass and sPLA2 activity. Figure 4.3. gives an overview of this initial 
observational data. This analysis was carried out using Stata v11 and calculates the change 
in sPLA2-IIA mass and sPLA2 activity dependent on rs11573156 genotype. Figure 4.3 
represents pooled meta-analysis estimates of the association between PLA2G2A 
rs11573156 with (A) sPLA2-IIA mass and (B) sPLA2 activity, separated by study setting into 
general populations (EPIC-Norfolk, UDACS) and acute coronary syndrome (GRACE-
Scotland, GRACE-France, FAST-MI). The numbers in brackets represent the number of 
studies, participants, and between-study heterogeneity (measured by I2). 
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Figure 4.3. Schematic representations of rs11573156 C>G association with sPLA2-IIA mass and 
sPLA2 activity, based on 3 ACS studies; GRACE-France, GRACE-Scotland and FAST-MI (red) and 2 
population based studies, UDACS and EPIC-Norfolk (blue). (A) Represents the association of the 
SNP with sPLA2-IIA mass (B) Represents the association of the SNP with sPLA2 Activity. Numbers in 
brackets represent the number of studies, participants, and between-study heterogeneity (measured 
by I2) (Holmes et al. Submitted). 
 
 I requested some further analysis of the SNP in the ASAP cohort, which was carried 
out by Dr Lasse Folkersen as described in Chapter 3. The results suggested that PLA2G2A 
was most strongly expressed in the liver, aortic adventitia and heart tissues (Figure 3.15). 
PLA2G2A was additionally shown to have the highest total relative expression across the 
gene compared to PLA2G5 or PLA2G10 (log10 expression = 0.9 in PLA2G2A compared to 
0.8 and 0.45 in PLA2G5 and PLA2G10 respectively). PLA2G2A mRNA was also seen to be 
differentially expressed at much higher levels than both PLA2G5 and PLA2G10 mRNA 
(Figure 4.4 A, B and C) in the liver. PLA2G2A SNPs showed no differential expression of 
PLA2G5 or PLA2G10.  
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 rs10732279 
(P=1.67x10
-17
)  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4A-C. Relative mRNA levels of PLA2 Genes of interest associated with SNPs 
across these genes in a per allele model, measured in the tissue samples of the ASAP 
cohort. Results presented as Manhattan plots. (A) Relative mRNA levels in PLA2G2A (B) 
Relative mRNA levels in PLA2G5 (C) Relative mRNA levels in PLA2G10 (Holmes et al. 
Submitted).  
 
 As indicated in Figure 4.4A, the SNP that is clearly most strongly associated with 
PLA2G2A mRNA levels in the liver is rs10732279 (P=8.71x10-19). This is the rs11573156 
proxy SNP that was identified in Chapter 3 due to the strong LD between rs10732279 and 
rs11573156 (R2=0.91 in European HapMap release 21). Since rs10732279 showed no 
association with either PLA2G5 (P=0.04) or PLA2G10 (P=0.88), the specificity of this SNP 
as a genetic instrument for the sPLA2-IIA isoform was confirmed.    
 As well as being a highly specific genetic instrument, data from the ASAP study 
showed (via its proxy, rs10732279) that rs11573156 explains 32% of PLA2G2A mRNA 
variability and these results have been replicated in an external data source of 206 
transplant donor liver samples (P=4.76x10-8) (Innocenti, Cooper et al. 2011).  
   (A) (B) (C) 
Base pair position (Chr1) 
-lo
g1
0 
(P
) 
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4.2.2. Results for Observational Analysis of sPLA2-IIA and Myocardial Infarction 
 Five studies (EPIC-Norfolk, UDACS, GRACE-France, GRACE-Scotland and FAST-
MI), have sPLA2-IIA mass measurements, sPLA2 activity measurements, or both and 
rs11573156 was genotyped in each of these. Figure 4.2A and 4.2B show the genotyping 
data for EPIC-Norfolk and GRACE-France. The genotyping data for GRACE-Scotland and 
UDACS are shown below in Figure 4.5 and 4.6. The genotyping for FAST-MI was completed 
by one of the collaborating groups and I do not have access to the primary data. Initial 
analysis was for associations between sPLA2-IIA mass, sPLA2 activity and several 
cardiovascular risk factors in EPIC-Norfolk (Table 4.5A and Table 4.5B). These results 
showed that sPLA2-IIA mass and sPLA2 enzyme activity were associated with several 
established and emerging cardiovascular risk factors in the general population represented 
by EPIC-Norfolk. Generally an adjustment for cardiovascular risk factors reduced the 
association between sPLA2-IIA mass and sPLA2 enzyme activity with incident MI in the 
general population, though the association remained following multivariate adjustment.  
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Stats for a 2-allele polymorphism       
                                                                                                        
SNP = 
 
rs11573156 C>G 
    
   Observed    
  rs11573156 rs11573156 rs11573156     
Genotypes 11 12 22 Total   
Frequency 1011 554 87 1652   
        
  p Q p+q    
  0.780 0.220 1    
        
  Expected    
  rs11573156 rs11573156 rs11573156     
Genotypes 11 12 22 Total   
Frequency 1004.2 567.6 80.2 1652   
        
  Chi^2 test and level of significance 
  O E (o-e)^2/e Chi^2 Sig 
level 
  1011 1004.2 0.0    
  554 567.6 0.3    
  87 80.2 0.6    
     0.948 0.3304 
     Not sig at 1 df   
Notes:                                                                                                                                                           
 NTC = 38     
 Undetermined = 37    
     
 
NTC = No template control; Undetermined = Genotype call not assigned to sample; 11= homozygous for the common allele; 12 = heterozygous; 22= homozygous 
for the rare allele. 
 
Figure 4.5. The Hardy-Weinberg Equilibrium equation for rs11573156 C>G in GRACE Scotland. There is no significant difference between observed and expected values at 1 
degree of freedom.      
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NTC = No template control; Undetermined = Genotype call not assigned to sample; 11= homozygous for the common allele; 12 = heterozygous; 22= homozygous 
for the rare allele. 
 
Figure 4.6. The Hardy-Weinberg Equilibrium equation for rs11573156 C>G in UDACS. There is no significant difference between observed and expected values at 1 degree of 
freedom.     
Stats for a 2-allele polymorphism       
SNP = rs11573156      
  Observed    
  rs11573156 rs11573156 rs11573156     
Genotypes 11 12 22 Total   
Frequency 357 183 24 564   
        
  P q p+q    
  0.795 0.205 1.000    
        
  Expected    
  rs11573156 rs11573156 rs11573156     
Genotypes 11 12 22 Total   
Frequency 356.7 183.7 23.7 564.0   
        
  Chi^2 test and level of significance 
  O E (o-e)^2/e Chi^2 Sig 
level 
  357 356.7 0.0    
  183 183.7 0.0    
  24 23.7 0.0    
     0.008 0.9285 
     Not sig at 1 df   
Notes:                                                                                                                                                          
NTC = 44      
Undetermined = 31     
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Tertile (min-max, nmol/min/ml) of sPLA2 activity 
 1 (1.7-4.0) 2 (4.0-4.9) 3 (4.9-23.1)  
Continuous traits N Mean SD N Mean SD N Mean SD P value § 
Age (yrs.) 1107 64.19 7.84 1107 64.54 7.89 1107 65.80 7.48 7.17x10-07 
BMI (kg/m2) 1107 26.02 3.44 1106 26.61 3.75 1104 27.32 3.71 1.00x10-15 
CRP* (mg/dl) 1086 0.41 1.2 1087 0.53 1.16 1090 0.83 1.14 1.87x10-16 
Systolic BP (mmHg) 1103 138.62 18.33 1105 139.76 18.13 1106 143.71 18.01 7.46x10-10 
Diastolic BP (mmHg) 1103 83.22 11.34 1105 83.88 11.02 1106 86.03 11.69 2.57x10-07 
HDL-C (mmol/l) 1088 1.38 0.4 1070 1.35 0.4 980 1.28 0.38 2.99x10-08 
LDL-C (mmol/l) 1088 3.93 0.94 1070 4.14 0.99 981 4.37 1.1 4.26x10-21 
TG* (mol/l) 1091 0.29 0.39 1093 0.52 0.44 1092 0.87 0.5 5.40x10-168 
Apolipoprotein A1 (mg/dl) 976 159.74 28.98 956 160.62 29.45 955 159.18 29.93 0.94 
Apolipoprotein B (mg/dl) 1038 120.49 26.91 1024 130.77 29.12 993 146.7 35.2 5.61x10-72 
Binary traits N Proportion SD N Proportion SD N Proportion SD P value ᶲ 
Female sex (%) 1107 33.06 0.47 1107 35.95 0.48 1107 41.73 0.49 1.27x10-05 
T2D (%) 1107 2.62 0.16 1105 4.43 0.21 1106 3.35 0.18 0.10 
Ever smoker (%) 1095 60.00 0.49 1098 59.56 0.49 1092 67.58 0.47 2.42x10-04 
 
Footnotes Abbreviations: BMI: body mass index; CRP: C-reactive protein; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein 
cholesterol; T2D: type 2 diabetes 
* log-transformed (units do not apply); § derived from univariate linear regression using log sPLA2 activity as the independent variable; ᶲ derived from 
univariate logistic regression using log sPLA2 activity as the independent variable.  
Table 4.5A. The association between tertiles of sPLA2 activity and traditional cardiovascular risk factors in 3,371 individuals in EPIC-Norfolk (Holmes et al. 
Submitted). 
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 Tertile (min-max, ng/ml) of sPLA2-IIA mass  
 1 (0.4-6.8) 2 (6.8-11.3) 3 (11.3-114.5)  
Continuous traits N Mean SD N Mean SD N Mean SD P value § 
Age (yrs.) 1125 63.51 8.24 1124 64.93 7.59 1122 66.07 7.17 1.10x10-17 
BMI (kg/m2) 1125 26.20 3.28 1120 26.69 3.66 1122 27.03 3.99 5.46x10-09 
CRP* (mg/dl) 1100 0.22 1.05 1108 0.53 1.15 1104 1.01 1.21 1.67x10-74 
Systolic BP (mmHg) 1122 139.54 17.85 1122 140.63 17.64 1120 141.83 19.21 4.36x10-03 
Diastolic BP (mmHg) 1122 84.13 11.08 1122 84.49 11.20 1120 84.51 11.99 0.69 
HDL-C (mmol/l) 1073 1.31 0.38 1051 1.35 0.40 1059 1.36 0.40 0.03 
LDL-C (mmol/l) 1073 4.05 0.98 1052 4.17 1.03 1059 4.20 1.05 0.01 
TG* (mol/l) 1114 0.57 0.50 1106 0.56 0.51 1105 0.55 0.51 0.06 
Apolipoprotein A1 (mg/dl) 977 156.23 28.26 972 160.14 28.58 972 163.27 31.02 9.03x10-06 
Apolipoprotein B (mg/dl) 1029 129.79 32.28 1024 133.38 31.28 1038 134.31 33.42 0.07 
Binary traits N Proportion SD N Proportion SD N Proportion SD P value ᶲ 
Female sex (%) 1125 21.33 40.98 1124 35.68 47.93 1122 53.21 49.92 8.94x10-59 
T2D (%) 1124 3.20 17.62 1123 3.03 17.14 1120 4.11 19.85 0.06 
Ever smoker (%) 1116 62.01 48.56 1106 62.30 48.49 1113 62.80 48.35 0.78 
 
Footnotes Abbreviations: BMI: body mass index; CRP: C-reactive protein; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein 
cholesterol; T2D: type 2 diabetes 
* log-transformed (units do not apply); § derived from univariate linear regression using log sPLA2-IIA as the independent variable; ᶲ derived from univariate 
logistic regression using log sPLA2-IIA as the independent variable. 
 
Table 4.5B. The association between tertiles of sPLA2-IIA mass and traditional cardiovascular risk factors in 3,371 individuals in EPIC-Norfolk (Holmes et al. 
Submitted).
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Analysis of the relationship between sPLA2-IIA mass (Figure 4.7A) and sPLA2 
activity with incident/non-fatal myocardial infarction risk was examined by creating frequency 
distribution plots (4.6A-B) using Stata v11, which showed that both relationships followed a 
log-linear association and the likelihood ratio test P-value to support a quadratic over a linear 
model was 0.77 for sPLA2-IIA mass and 0.90 for sPLA2 activity. A similar association was 
identified between sPLA2-IIA mass with recurrent fatal/non-fatal myocardial infarction events 
in subjects with ACS in the combined GRACE-France and GRACE-Scotland cohorts (Figure 
4.7B). After adjustment for multiple variables including age, sex, smoking, blood pressure 
and LDL-cholesterol, the odds ratio (OR) per one standard deviation (SD) reduction of 
sPLA2-IIA mass and sPLA2 activity with incident fatal/nonfatal myocardial infarction was 
0.84 (95%CI: 0.77,0.91) and 0.86 (95%CI: 0.79, 0.94), respectively. The log odds of CHD 
and associated 95% confidence intervals were derived from a predicted linear model.  
 
  
Figure 4.7. The frequency distribution of sPLA2-IIA mass in: (A) a general population study (EPIC-
Norfolk); and (B): two ACS cohorts (GRACE-France and GRACE-Scotland), with a risk of (A) incident 
and (B) recurrent fatal/non-fatal myocardial infarction (red and green lines derived from predicted 
linear model adjusted for age and sex). Black dashed vertical lines represent the mean sPLA2-IIA 
mass per genotype (Holmes et al. Submitted). 
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4.2.3. Mendelian Randomisation Results: rs11573156 and Cardiovascular Outcomes 
 The studies used for Mendelian randomisation analysis are described in 2.5 in Table 
2.6. and Table 2.7. Of these studies I genotyped IMPROVE, TPT, CYPRUS, NPHSII and 
EAS by TaqMan genotyping, a total of 11,534 samples. I also analysed this data using the 
Hardy Weinberg equilibrium and found none of the results were significant at 1 degree of 
freedom and that there was no significant difference in the allele frequencies across all of 
these studies. 
Major vascular events (MVE) were categorised based on the outcomes described by 
each study, which were then standardised to fatal/nonfatal MI or stroke. For incident MVE 
(fatal/nonfatal MI or stroke) association with rs11573156, in 13 population studies comprising 
8,021 incident MVE in 56,359 individuals, the summary per C allele OR was 1.02 (95%CI: 
0.98, 1.06). The summary OR for individual outcomes were: incident nonfatal myocardial 
infarction, 1.04 (95%CI: 0.98, 1.10); incident nonfatal stroke, 1.00 (95%CI: 0.93, 1.07) and 
incident fatal myocardial infarction/stroke, 1.01 (95%CI: 0.93, 1.10) (Figure 4.8). These 
results were adjusted for age, sex, CRP, SBP, BMI, smoking status, T2D, TG and LDL-
cholesterol. A power calculation justifying the population numbers used in these meta-
analyses studies is described in 2.5.1. 
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 Figure 4.8. Meta-analysis pooled estimates of association between rs11573156 and major vascular 
events (including individual components) stratified by clinical setting into general populations and ACS 
patients. Adjusted for age, sex, CRP, SBP, BMI, smoking status, T2D, TG and LDL. Each plot 
represents the rs11573156 per C allele OR, with genotype grouping arranged to mimic the effects of 
pharmacological lowering of sPLA2-IIA so that if sPLA2-IIA mass were to reduce risk of 
cardiovascular events the OR should be less than one. In this instance MVE= fatal/nonfatal 
myocardial infarction or stroke. I2 represents the percentage heterogeneity across the meta-analysis. 
 
For prevalent MVE (MI or stroke) association with rs11573156, in 16 population 
studies comprising 9,722 prevalent MVE in 57,330 individuals, the summary per C allele OR 
was 1.01 (95%CI: 0.97, 1.06). The summary OR for individual outcomes were: prevalent 
myocardial infarction, 1.01 (95%CI: 0.97, 1.06); prevalent stroke, 1.02 (95%CI: 0.92, 1.12) 
(Figure 4.8).  
The association between rs11573156 and recurrent cardiovascular events in patients 
with acute coronary syndrome was assessed in 8 studies (1,973 recurrent MVE in 11,434 
participants with ACS). Results showed a summary per C allele OR for rs11573156 with 
recurrent MVE (fatal/nonfatal MI or stroke) of 0.95 (95%CI: 0.87, 1.02). The summary OR for 
individual components were: nonfatal MI 0.95 (95%CI: 0.84, 1.06); nonfatal stroke 0.88 
(95%CI: 0.69, 1.14), and; fatal MI/stroke 0.96 (95%CI: 0.85, 1.08). These findings were 
consistent in a random-effects meta-analysis (Figure 4.8). 
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Additionally, in the study set in patients with established vascular disease or high 
cardiovascular risk (SMART), the per C allele OR of rs11573156 with recurrent MVE 
(fatal/nonfatal MI or stroke) was 0.92 (95%CI: 0.80, 1.07). For the study set in patients with 
ACS and undergoing PCI, the per C allele OR of rs11573156 with coronary artery restenosis 
was OR 1.04 (95%CI: 0.82, 1.31). 
In order to draw a definitive conclusion from the Mendelian randomisation, the 
observed effects odds ratios (as seen above) had to be compared with the expected 
outcome. The expected association between rs11573156 and incident cardiovascular events 
was calculated assuming a causal relationship between circulating sPLA2-IIA mass and 
sPLA2 activity with fatal/nonfatal myocardial infarction. We estimated the expected per C 
allele OR of rs11573156 with fatal/nonfatal MI events. For sPLA2-IIA mass, the expected 
genetic association was OR 0.88 (95%CI: 0.82, 0.94) in general populations, with a similar 
outcome predicted for ACS studies. Compared to the observed associations, using 
rs11573156, for either sPLA2 activity or sPLA2-IIA mass with fatal/nonfatal myocardial 
infarction, the expected associations showed very little overlap in all study settings (Figure 
4.9).  
 
 
 
Figure 4.9. Observed and expected genetic effects of rs11573156 on major vascular events assuming 
unbiased associations of sPLA2-IIA mass and sPLA2 activity on fatal/nonfatal myocardial infarction in 
(A) general population (incident events); (B) ACS patients (recurrent events). The expected genetic 
effects were estimated twice, first for sPLA2-IIA mass and then sPLA2 activity. For each of the 
expected effects, the effect of the rs11573156 variant on sPLA2-IIA mass and sPLA2 activity was 
used, as well as the effect of sPLA2-IIA mass and sPLA2 activity on fatal/nonfatal MI. The observed 
genetic effects are derived from the per C allele association of rs11573156 with major vascular events 
(comprising fatal/nonfatal MI or stroke). 
A B 
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4.3. Discussion 
 The aim of this chapter was to try and accurately classify the causal role of sPLA2-IIA 
on cardiovascular events using a genetic approach. This process would also allow us to 
evaluate the worth of sPLA2 inhibition as a specific therapeutic target for decreasing the risk 
of cardiovascular disease. The PLA2G2A functional SNP that I identified in Chapter 3, 
rs11573156, was shown to have a large effect on circulating sPLA2-IIA mass and a 
significant, albeit more modest, effect on sPLA2 activity, proving it a strong genetic 
instrument for the evaluation of the role of sPLA2 in disease. No association was found 
between rs11573156 and prevalent, incident or recurrent myocardial infarction or stroke, 
which strongly suggests that earlier observation associations between sPLA2-IIA mass and 
cardiovascular events are due to residual confounding or reverse causality. This is 
supported by the results seen in Table 45A and 45B, which show that several known 
cardiovascular risk factors are significantly associated with increasing tertiles of sPLA2 
activity and sPLA2-IIA mass. Adjustments for these biomarkers weakens the significance of 
the effect of sPLA2 on CHD risk, suggesting that sPLA2 may act through one or more of 
these confounding biomarkers to effect the risk of CHD. The results from the 5 studies 
originally genotyped for rs11573156 did show a significant association between the SNP and 
CHD after adjustment, however the loss of this significant association in an much larger 
meta-analysis leads back to these original results and an increased likelihood that sPLA2 
acts through reverse causation or one of the known CHD risk markers that the SNP was 
shown to be associated with. 
The sPLA2 specific inhibitor, varespladib, has been developed in the last several 
years by Anthera Pharmaceuticals, who hoped to use the drug in conjunction with 
atorvastatin to decrease the risk of secondary cardiac events in patients with acute coronary 
syndrome. The phase III study VISTA-16 was set up, due for completion in 2012, which 
looked to recruit 6,500 ACS patients across Europe and the USA (Nicholls, Cavender et al. 
2011). The data has major clinical impact since the VISTA-16 trial (Nicholls, Cavender et al. 
2011) (http://investor.anthera.com/releasedetail.cfm?ReleaseID=656340) was prematurely 
halted due to efficacy issues. The 6,500 ACS patients were to be randomised between 
placebo and a 500mg/day dose of varespladib for 16 weeks. The primary combined end-
point was cardiovascular death, nonfatal myocardial infarction, nonfatal stroke or 
documented unstable angina. Design issues included the relatively brief duration of therapy 
and the low number of subjects, which may have explained the lack of benefit from the drug. 
However, this genetic data now suggests that in reality sPLA2-IIA is highly unlikely to be a 
valid therapeutic target for the prevention of primary or secondary cardiovascular events and 
this is therefore the likely reason for the lack of benefit seen with varespladib.  
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Varespladib is known to inhibit 3 forms of sPLA2 enzyme, IIA, V and X. However, the 
IC50 values for the drug show it to be most effective at reducing sPLA2-IIA in mice and 
human atherosclerotic plaques (IC50 9nM compared to 77nM and 15nM for groups V and X 
respectively) (Fraser, Hislop et al. 2009). The drug was shown to reduce sPLA2-IIA mass by 
78% (Rosenson, Elliott et al. 2011) and thus my SNP of interest appears to be the strongest 
single candidate that could be used for this type of analysis. The results of our large scale 
meta-analysis showed null associations between rs11573156 C>G and all CHD/CVD related 
traits, with the only significant associations were between the SNP and sPLA2-IIA 
mass/sPLA2 activity. The MR results using rs11573156 suggest that differential sPLA2-IIA 
levels are not causally associated with CHD and the differential levels of sPLA2-IIA 
associated with changes in CHD seen in observational studies are more likely as a product 
of the onset of CHD.  
 Since the SNP that I identified for use as a genetic instrument was specific to 
PLA2G2A, we saw a very strong and specific association between the SNP and sPLA2-IIA 
mass and a less strong association with sPLA2 activity, which also includes sPLA2-V and 
sPLA2-X in its measurement, suggesting that the sPLA2 isoforms, sPLA2-V and X may 
make significant contributions to sPLA2 activity even with lower measures of sPLA2-IIA. The 
sPLA2-V and X isoforms and their potential effects are explored in greater detail in Chapter 
5 and 6. 
 The fact that the analysis carried out here does not cover the sPLA2-V or sPLA2-X 
isoforms is a limitation, since we cannot exclude the possibility that there is a causal role for 
one of these isoforms for cardiovascular events. A further limitation is the smaller number of 
subjects in the ACS set studies, meaning that there was less power to exclude a small 
association with myocardial infarction or stroke if it were real, as demonstrated by the small 
overlap of the expected and observed estimates for sPLA2-IIA mass and sPLA2 activity with 
CVD in an ACS setting. However, comparing individuals homozygous for the rs11573156 C 
allele to those homozygous for the G allele resulted in a comparable reduction in sPLA2-IIA 
mass to the effect of 500mg/day varespladib, and also showed no association with incident 
or recurrent MVE, suggesting that the lack of efficacy of varespladib for the reduction of 
recurrent MVE is a true result. A final limitation for this chapter is that there was not data 
from a common set of participants with measures of sPLA2 and cardiovascular disease, as 
is often the case with large-scale meta-analyses of Mendelian randomization studies (Minelli, 
Thompson et al. 2004). However, in this study, we identified a very strong association 
between rs11573156 and sPLA2-IIA in the subset of studies with measures of sPLA2-IIA, 
reducing the risk of measurement error in this stage. 
208 
 
As previously acknowledged the genetic instrument I identified is specific for sPLA2-
IIA and although meta-analysis was more than sufficiently powered, there were a much 
smaller proportion of studies examining secondary cardiac events. Therefore my prediction 
would be that varespladib and similar sPLA2 inhibitors will have no effect on either primary 
or secondary heart disease, but further studies into the effects on secondary events and the 
particular contributions of sPLA2-V and X will be necessary.  
The independent risk factor status of sPLA2-IIA seen in the early observational and 
in vitro studies was thus not reflected by the studies shown in this thesis, suggesting that 
sPLA2-IIA is merely a marker for atherosclerosis, perhaps acting through a confounding 
known cardiovascular risk trait as suggested by the results in Table 45A-B, or through 
reverse causation, but it does not appear to be directly causal. 
4.4. Conclusion 
 This collaboration has yielded a large-scale Mendelian randomisation study that does 
not support the hypothesis that sPLA2-IIA mass is causally linked to cardiovascular events 
or that it is a viable drug-target for cardiovascular prevention. The parallel between these 
genetic findings and the lack of efficacy of the sPLA2 inhibitor, varespladib, seen in the 
VISTA-16 trial supports the use of this genetic approach earlier in drug development, as this 
may help to prioritise the best drug targets to follow in human randomised trials and this in 
turn could save a lot of time and money that is often wasted due to late-stage drug failure. 
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CHAPTER 5 
The Potential Contribution of sPLA2-V to sPLA2 
activity and Risk of CHD 
 
5.1. Introduction 
5.1.1.   Background: sPLA2 Isoenzyme Analysis 
Past research has shown that the sPLA2 group of enzymes are classified together 
due to a range of structural similarities as described in Chapter 1. As well as their common 
ability to hydrolyse the sn-2 ester bonds of phospholipids the sPLA2 enzymes generally 
have comparable low molecular weights (~14kDa), similar secretory mechanisms, a 
histidine/calcium dependency and are generally rich in disulphide bonds (Six and Dennis 
2000; Masuda, Murakami et al. 2005; Lambeau and Gelb 2008). However, the enzymes are 
defined individually by the subtle differences in each protein structure that lead to distinctions 
in the mechanism and efficiency of phospholipid hydrolysis for each enzyme. These 
structural changes often relate to differences in the overall charge of each enzyme 
(Lambeau and Gelb 2008). It has also been proved by immunohistochemical staining that 
each enzyme has a different expression profile in different tissues, suggesting alternative 
roles for each isoenzyme (Masuda, Murakami et al. 2005; Lambeau and Gelb 2008). These 
differences highlight the importance of trying to interpret the contribution of each individual 
isoenzyme to sPLA2 activity and ultimately to diseases such as heart disease. The results 
presented in Chapter 4 have shown that sPLA2-IIA is highly unlikely to contribute to the 
onset of CHD, but since the MR analysis that was carried out in Chapter 4 did not give us a 
true indication of the potential causal contributions of other isoenzymes, such as sPLA2-V, to 
CHD it was important to establish whether sPLA2-V could potentially have an independent 
causal association with CHD (5.1.2- 5.1.5) and, if so, to begin the process of identifying 
potentially functional SNPs in these genes to be used as instruments for MR as with 
rs11573156 for PLA2G2A (Chapter 3 and Chapter 4). Further to this, examining the 
potential contribution of each PLA2 gene expression pattern to sPLA2 activity was important 
in order to present a clearer picture of how these enzymes might interact and what the 
potential significance of sPLA2 inhibition could be depending on the contribution of each 
protein.  
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5.1.2. Comparing sPLA2-V and sPLA2-IIA 
 As I have previously discussed, sPLA2-IIA and sPLA2-V share many common 
features and the genes PLA2G2A and PLA2G5 are transcribed in opposite directions in a 
cluster on chromosome 1, only 90kb apart (Chapter 1, Figure 1.11). I hoped to use genetic 
analysis of SNPs in the PLA2G5 gene to help to explain the differing functional roles played 
by sPLA2-V and sPLA2-IIA in sPLA2 activity and in CHD. (Tischfield, Xia et al. 1996; 
Wootton, Arora et al. 2007).  
A deficiency in any individual sPLA2 enzyme can affect total sPLA2 activity in 
different ways and often in a tissue dependent manner (Murakami, Taketomi et al. 2011). 
This may indicate distinct functional roles for sPLA2-IIA and sPLA2-V and since these 
potential enzyme deficiencies could affect activity to different magnitudes, in different tissues 
depending on which isoenzyme is depleted, it is reasonable to assume that sPLA2-V could 
have different effects in diseases such as atherosclerosis compared to sPLA2-IIA. However 
there is also some evidence that suggests that a deficiency in one could be partially 
compensated for by the presence of the other, suggesting that these enzymes may work 
reciprocally (Sawada, Murakami et al. 1999) and one of the aims of this thesis was to try and 
identify what the distinct roles for each enzyme might be.  
5.1.3. The Potential Contribution of sPLA2-V to sPLA2 Activity 
 Since the fluorometric assay used to measure sPLA2 activity is inclusive of three 
sPLA2 isoforms; groups IIA, V and X, research has so far been unable to successfully 
identify the individual contributions of each of these enzymes to sPLA2 activity and this may 
be important when determining the contributions of each isoform to diseases such as CHD.  
As documented previously, sPLA2-V has around 20 times higher potency towards 
common phospholipids compared to sPLA2-IIA due to their different structural elements and 
charges (Lambeau and Gelb 2008). These differences mean that while both group IIA and 
group V enzymatic properties include proteoglycan binding and the release of arachidonate 
through a Heparan Sulphate proteoglycan (HSPG) shuttling pathway, only group V has the 
ability to additionally release arachidonate through the external plasma membrane pathway 
(Figure 1.12), albeit to a lesser extent than through the HSPG pathway (Murakami and Kudo 
2003). The increased potency of sPLA2-V compared to sPLA2-IIA could suggest that group 
V may contribute more to overall sPLA2 activity, however sPLA2-IIA levels are significantly 
higher than the other sPLA2 isoforms, which may be more important than potency in a 
natural physiological state (Lambeau and Gelb 2008). When studying the contributions of 
each enzyme to sPLA2 activity it is important to take into account where each enzyme is 
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expressed, since differential expression patterns exist for each isoform in each tissue 
dependent on the circumstances (e.g. healthy versus diseased tissue) (Chapter 1.5).  
5.1.4. Investigating the Contribution of sPLA2-V to CHD Risk 
 Chapter 1.5.7 explores the potential role of sPLA2-V in CHD risk and discusses 
evidence from in vitro and in vivo studies to support these claims. Chapter 1.7.2 goes on to 
identify a study (Wootton, Arora et al. 2007) that has previously isolated 7 tagging-SNPS that 
span the gene (1.7.2 Table 1.3 and Figure 1.13). A further SNP of interest was identified by 
analysis carried out by Dr Lasse Folkersen in the ASAP study. In this instance an eQTL with 
the strongest differential association with PLA2G5 mRNA was identified as the variant 
rs525380 (Figure 5.1). In this chapter I describe some of the expression patterns of PLA2G5 
and related tagging-SNPs to attempt to provide useful insights into the tissue distribution of 
PLA2G5 expression and to use genetics to examine any associations between PLA2G5 
variations, sPLA2 activity and risk of CHD/CHD traits in a small meta-analysis setting. 
 
 
 
 
 
 
 
 
Figure 5.1. A schematic of the PLA2G5 gene and the 7 tSNPs originally identified (Wootton, Arora et 
al. 2007) as well as the SNP identified by eQTL data as significantly differentially associated with 
PLA2G5 mRNA, rs525380 A>C. Schematic reprinted from (Wootton, Arora et al. 2007). The region 
spanned here is from the upstream 5’UTR SNP rs11573185 to downstream 3’UTR SNP rs622450, 
since these were the most extremely located preciously identified tSNPs; Chr1: 20,395,401-
20,419,340. 
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rs640022 
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5.1.5 SNP Selection 
 The SNPs selected from the study by Wootton et al. for further analysis included; 
rs11573185 C>A, rs11573191 A>G, r11573203 G indel and rs11573248 TA indel. These 4 
SNPs had been shown by adjusted univariate analysis in UDACS to be significantly 
associated with cholesterol (a known CHD biomarker) and sPLA2-IIA levels (Table 5.1) 
(Wootton, Arora et al. 2007). The SNP rs11573185 was the only SNP from this group 
available on the ASAP array. Since this SNP was also shown to be associated with sPLA2-
IIA levels, it was taken forward for further analysis in the ASAP study. The SNPs rs11573248 
and rs11573203 may warrant further genotyping since there is very little known genotyping 
data for these SNPs.  
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 Table 5.1. Adjusted and unadjusted univariate analysis for significant associations found with four PLA2G5 tSNPs identified in the 2007 study by Wootton et 
al. with sPLA2-IIA mass and the known CHD biomarker, LDL-cholesterol. The analysis is based on genotyping data for each SNP in the UDAC Study 
(previously defined in 2.5) 
SNP/Genotype: N log sPLA2-IIA Mass (ng/ml) P value unadjusted P value adjusted* P value adjusted** LDL-C (mmol/l)*** P value unadjusted P value adjusted* P value adjusted** 
                    
rs11573185 11 105 2.76       2.85       
rs11573185 12 244 3.22       2.7       
rs11573185 22 155 3.32 0.10 0.06 0.04 2.58 0.08 0.01 0.02 
                    
rs11573191 11 347 3.36       2.62       
rs11573191 12 146 2.90       2.88       
rs11573191 22 14 1.93 0.004 0.004 0.002 2.79 0.02 0.01 0.02 
                    
rs11573203 11 261 3.39       2.58       
rs11573203 12 190 3.05       2.80       
rs11573203 22 39 2.33 0.006 0.008 0.007 2.92 0.02 0.007 0.01 
                    
rs11573248 11 210 3.01       2.84       
rs11573248 12 227 3.17       2.64       
rs11573248 22 69 3.78 0.08 0.05 0.02 2.46 0.007 0.0003 0.0005 
                    
* = adjusted for age, gender, CHD status and statin use        
**= adjusted for age, gender, CHD status, CRP and statin use        
***= square root 
transformed         
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 Bioinformatics of tSNPs 
A detailed bioinformatics analysis was carried out for both rs11573185 and rs525380. 
Considering the other three tSNPs identified along with rs11573185, analysis from the 
UCSC Genome Browser showed that only rs11573248 could potentially be functional since it 
exists in an area of DNA hypersensitivity and in a potential transcription factor binding region 
(Figure 5.6). Further genotyping analysis of this SNP may be useful to investigate the 
relationship between sPLA2-V and sPLA2-IIA as this was also the tSNP with the most 
significant differential association to sPLA2-IIA levels (Wootton, Arora et al. 2007). 
Additionally the SNP rs525380 (Figure 5.1) was identified as a potential SNP of 
interest from initial ASAP study analysis (Figure 5.7) since it showed the highest association 
with differential PLA2G5 mRNA in the aortic adventitia. Based on these results rs525380 
was analysed further and genotyping has been completed in EPIC-Norfolk with additional 
genotyping data from WTCCC. Analysis in this study was carried out by Dr Reecha Sofat. 
Due to their inclusion in the ASAP arrays, rs11573185 and rs525380 are considered the 
‘lead’ SNPs in this results chapter. 
5.2. Results 
5.2.1. Bioinformatics Analysis 
5.2.1.1. Bioinformatics Analysis of PLA2G5 
According to the Ensembl Genome Browser and NCBI databases there are 8 known 
transcripts of the gene but only one of these is protein coding. The protein coding transcript 
is made up of 5 exons in total, 4 coding and 1 non-coding (Figure 1.13 and Figure 5.1). This 
transcript codes for a 138 amino acid protein. There is supporting evidence for this transcript 
being protein coding including protein evidence, EST evidence and cDNA copy evidence. 
The additional 7 transcripts are identified by Ensembl as non-coding since they do not 
contain an open reading frame. Supporting evidence for these transcripts includes cDNA 
and EST but not protein evidence.   
5.2.1.2. Bioinformatics Analysis of the Lead tSNP rs11573185 C>A 
Data from NCBI and Ensembl verified that rs11573185 C>A was positioned at 
chromosome 1:20,395,401 which is in the region immediately upstream of the 5’UTR of 
PLA2G5 (Figure 5.2). The genotyping data for Europeans available from HapMap release 
#28 and the 1000 Genomes Project showed that the rare A allele occurs at a frequency of 
0.47. Since this SNP is a tagging-SNP it is in strong LD (D’) with several other SNPs; Figure 
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5.3 is an LD heat plot representing PLA2G5 and HapMap release #28 genotyped SNPs, 
including rs11573185. The higher the intensity of red, the higher the D’ LD score is between 
2 SNPs. Where acknowledged, the R2 values appear as numbers in each block. As is shown 
on the LD map, rs11573185 exists in a region of high D’ with its surrounding SNPs from 
Chr1: 20,394,713-20,395,868 (Figure 5.3). However, as shown in Figure 5.4, taken from the 
SNAP pairwise LD plotting tool using the 1000 Genomes Pilot 1 data, this SNP does not 
have significant R2 (R2 <0.7) with any known SNPs across PLA2G2A and PLA2G5 in this 
database. This is probably due to the fact that the 1000 Genomes Pilot 1 data is a subset of 
the HapMap CEU data and therefore includes less individuals from the same sample and 
less power to show LD between SNPs. The CEU population for both samples (1000 
Genomes Pilot 1 and HapMap release #28) are based on Utah residents with Northern and 
Western European ancestry from the CEPH collection. The 1000 Genomes population is 
based on 60 of the HapMap genotyped individuals and the HapMap population is based on 
226 genotyped individuals. 
Figure 5.2. Shows the location of rs11573185 upstream of the 5’UTR of PLA2G5 within the 90Kb 
shared region between PLA2G2A and PLA2G5. Hatched boxes represent non-coding exons. Filled 
boxes represent coding exons. The arrows on exons indicate the direction of transcription for each 
gene (reverse transcription for PLA2G2A and forward transcription for PLA2G5). The figure is based 
on the genomic sequence NC_000001 on chromosome 1 and data from the Ensembl Genome 
Browser. 
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Figure 5.3. An LD Heatplot created using Haploview version (4.1) and genotyping data from HapMap Phase 2 and 3. This data included the tSNP rs11573185 and this SNP is 
indicated in a green box. The darker the shade of red in a square linking two SNPs, the higher the D’ LD between these SNPs. Where possible the R2 value is indicated by 
number (%) inside the relevant square. The tSNPs cover the whole PLA2G5 region including upstream and downstream of the UTR, where SNPs are still classified as PLA2G5 
and not as intergenic. The SNP rs11573185 exists upstream of the 5’UTR, which begins at Chr1:20,396,714. 
Chr1: 20,394,713 Chr1: 20,418,207 
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Figure 5.4. An LD Manhattan style plot based on the 1000 Genomes CEU pilot 1 data available 
through the SNAP Pairwise LD program. The SNAP plot tool was used to assess the LD of 
rs11573185 with all known SNPs in the region of 120Kb upstream (as far as the OTUD3 gene) and 
185Kb downstream (as far as the UBXN10  gene) of the SNP, which covers the whole PLA2 gene 
cluster. The location of rs11573185 is represented by the vertical dashed line. Genotyped and 
imputed SNPs are represented by a diamond shape. The R2 significance value is set at 0.7 and 
represented by a horizontal dashed line. The SNPs in LD above 0.7 are indicated above this line. The 
deeper the shade of red and the larger the size of each diamond, the stronger the LD with 
rs11573185. The blue peaks on the plot represent recombination hotspots and the green arrows 
represent different genes. The measure of LD calculated as R2 is indicated by Y axis values. 
 
 The UCSC Genome Browser identifies no potential transcription factor binding region 
in the sequence immediately around rs11573185 (Figure 5.6). Additionally, it does not 
appear near a known splicing region, or in a DNA hypersensitive region. This data suggests 
that if any associations are seen between rs11573185 and either sPLA2, CHD or CHD risk 
factor measures, it is more likely to be due to a SNP that rs11573185 is tagging as opposed 
to directly due to this SNP. This may be a previously defined SNP in LD with rs11573185 or 
it is possible that a true functional SNP has not been genotyped yet, or is in a region 
unrelated to the PLA2 cluster. 
 
 20,246,502     20,301,925 20,209,006 20,395,401 20,512,578  
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5.2.1.3. Bioinformatics Analysis of rs525380 A>C 
Data from NCBI and Ensembl verifies that rs525380 A>C is positioned at 
chromosome 1:20,409,374, which is positioned 1,939bp upstream of the intron 1/exon 2 
boundary of PLA2G5. The genotyping data in Europeans available from HapMap and the 
1000 Genomes Project puts the minor allele frequency at 0.44-0.49 (A). This SNP, was 
identified as significantly associated with PLA2G5 mRNA expression in the ASAP study 
(Figure 5.7). According to the data from both HapMap European and 1000 genomes 
European genotyping data this SNP tags rs576352 (PLA2G5 intron 1 Chr1: 20,397,157) 
rs513246 (PLA2G5 intron 1, Chr1:20,398,043) and rs656110 (PLA2G5 intron 1, 
Chr1:20,397,240). An LD plot with rs525380 as the SNP of interest shows a significant 
threshold for R2 at 0.7 and is shown in Figure 5.5, taken from the SNAP pairwise LD plotting 
tool. This plot covers PLA2G2A, PLA2G5 and other PLA2 cluster SNPs. The CEU 
population for both samples (1000 Genomes Pilot 1 and HapMap release #28) are based on 
Utah residents with Northern and Western European ancestry from the CEPH collection. The 
1000 Genomes population is based on 60 of the HapMap genotyped individuals and the 
HapMap population is based on 226 genotyped individuals. 
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 Figure 5.5. An LD Manhattan style plot based on the 1000 Genomes CEU pilot 1 data available 
through the SNAP Pairwise LD program. The SNAP plot tool was used to assess the LD of rs525380 
with all known SNPs in the region of 500Kb upstream and 500Kb downstream of the SNP. The region 
that includes SNPs in LD <0.7 with rs525380 are represented by the vertical dashed lines. Genotyped 
and imputed SNPs are represented by a diamond shape. The R2 significance value is set at 0.7 and 
represented by a horizontal dashed line. The SNPs in LD above 0.7 are indicated above this line. The 
deeper the shade of red and the larger the size of each diamond, the higher the strength of LD with 
rs525380. The blue peaks on the plot represent recombination hotspots and the green arrows 
represent different genes. 
  
When rs525380 was input to the UCSC Genome Browser no potential transcription 
factor binding regions could be identified in the sequence immediately around the SNP 
(Figure 5.6). Additionally, it does not appear near a known splicing region, or in a DNA 
hypersensitive region. This data suggests that if any associations are seen between 
rs525380 and either sPLA2, CHD or CHD risk factor measures, it is more likely to be due to 
a SNP that rs525380 is tagging as opposed to directly due to this SNP. 
 
 
20,246,502     20,301,925 20,209,006 20,395,401 20,512,578 
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5.2.2. PLA2G5 mRNA Expression in the ASAP Study 
PLA2G5 mRNA expression across all the tissues included in the ASAP study 
(mammary artery, liver, aorta media, aorta adventitia and heart) was characterised by the 
analysis of all 123 PLA2G5 SNPs covered by the array, covering a large portion of the gene. 
The Manhattan plot style Figure 5.6 indicates which SNPs were associated with the 
strongest differential mRNA expression and in which tissues by colour coding. The data 
showed that the strongest expression of PLA2G5 mRNA was most significantly associated 
with SNPs in the aortic adventitia (aqua) and liver (blue). The SNP rs525380 was the SNP 
with the single strongest significant association with differential PLA2G5 mRNA levels as 
indicated in Figure 5.7 as the highest point on the Manhattan plot. This association is 
measured in the aorta adventitia. However, as shown previously, across all 5 tissues in the 
ASAP study the strongest association between rs525380 and PLA2G5 mRNA levels is 
rs11573185 
Chr1: 
20,395,401 
rs525380 
Chr1: 
20,409,374 
Figure 5.6. Has been reprinted using data from the UCSC Genome Browser for PLA2G2A. The gene is shown 
on the forward strand. The protein coding transcript is shown based on data from RefSeq, UniProt. GenBank, 
CCDS and Comparative Genomics. Spliced ESTs represents Human expressed sequence tags (short strands 
of cDNA used to identify gene transcripts), which have been used to identify potential splice sites within the 
gene. These are shown in black. Layered H3K4Me1 represents data from Encode ChIP sequence assays to 
show the level of predicted histone 3 and 4 methylation/acetylation. Each colour represents a different cell type 
in which the assay was carried out. Layered H3K4Me3 shows DNAse hypersensitivity regions are shown in the 
same cell lines. The ENCODE Transcription Factor ChIP-seq data shows the prediction of transcription factors 
binding to the gene. These are labelled accordingly. The intensity of colour indicated the likelihood of true 
binding. Finally all the SNPs covering the region are indicated by rs number at the bottom. The SNPs of 
interest, rs11573185 and rs525380, are indicated by the vertical red line and the vertical black line respectively 
and the SNP rs11573248 is indicated by the vertical aqua line (UCSC Genome Browser) 
(http://genome.ucsc.edu/cgibin/hgTracks?position=chr1:202802420280743&hgsid=282534055&snp130=pack
&hgFind.matches=rs11573248) (http://genome.ucsc.edu/cgi-bin/hgTracks). 
rs11573248 
Chr1: 
20,407,905-
20,407,906 
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comparatively lower than the strongest SNP association with PLA2G2A mRNA (as shown in 
Figure 4.4).  
Figure 5.7. A Manhattan plot style figure to show the expression of PLA2G5 mRNA associated with 
SNPs across the tissues included in the ASAP study. The strongest single association is seen with 
the SNP rs525380 A>C in the aorta adventitia. The black horizontal line above the scale represents 
the position of PLA2G5. 
Both rs11573185 and rs525380 were analysed using the arrays of the ASAP study. 
Analysis was performed to assess the levels of both these SNPs across the tissues included 
in the study; mammary artery, aorta media, aorta adventitia, liver and heart, thus allowing us 
to identify if there is likely differential expression between the rs11573185 or rs525380 
Relative PLA2G5 mRNA Expression Associations Per-
Allele for SNPs Across the ASAP Array 
rs525380  Mammary Artery
 Liver
 Aorta Media
 Aorta Adventitia
 Heart 
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variants in cardiovascular related tissues such as the aortic adventitia, aortic media, heart 
and liver. The results showed that the SNP rs11573185 was associated with the highest 
levels PLA2G5 mRNA most highly in the aortic adventitia, but was associated with the least 
mRNA expression in the aorta media and in heart tissue (Figure 5.8). Further analysis 
showed there to be no significant per allele difference in mRNA expression across the aortic 
adventitia for rs11573185 (P=0.08), suggesting that this SNP is not functional regarding 
PLA2G5 mRNA expression in this tissue (Figure 5.9). Regarding rs525380, Figure 5.10 
shows that the most significant association of differential expression of PLA2G5 mRNA with 
rs525380 is in the mammary artery, the aortic media and the aortic adventitia. Figures 
5.11A, 5.11B and 5.11C show the per allele effect of rs525380 on mRNA expression of 
PLA2G5 in these tissues with the most significant association seen with the aorta adventitia 
(5.05x10-6) (Figure 5.10).  
 
 
Figure 5.8. Differential PLA2G5 mRNA expression associated with rs11573185 C>A across all ASAP 
measured tissues in a per allele additive model. Differential expression was most significantly 
associated with this SNP in aorta adventitia and least significantly associated in the heart. 
223 
 
                          
Figure 5.9. The per C allele effect of rs11573185 C>A on PLA2G5 mRNA expression across the aorta 
adventitia based on measurements from the ASAP study. The figure shows the effect of each 
additional C allele increases mRNA expression in this tissue.   
 
 
Figure 5.10. Shows the association of rs525380 A>C with differential mRNA expression levels of 
PLA2G5 in a per allele additive model. Differential expression is most significantly associated with this 
SNP in aorta adventitia and least significantly associated in heart. 
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                                 a                                                                b                                                                c 
 
Figure 5.11a Results from the ASAP study showing the rs525380 A>C differential expression association with PLA2G5 mRNA in the mammary artery. Per C 
allele there is a reduction in mRNA expression. Figure 5.11b Results from the ASAP study showing the rs525380 A>C differential expression association with 
PLA2G5 mRNA in the aorta media. Per C allele there is a reduction in mRNA expression. Figure 5.11c Results from the ASAP study showing the rs525380 
differential expression association with PLA2G5 mRNA in the aorta adventitia. Per C allele there is a reduction in mRNA expression.  
5.05x10-6 
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5.2.3. Association of PLA2G5 SNPs with PLA2G2A mRNA Levels. 
 The original data for rs11573185 (Wootton, Arora et al. 2007) shown in Table 5.1 and  
results from my meta-analysis (Figure 5.18 and Figure 5.21) suggest that the PLA2G5 SNPs 
rs11573185 and rs525380 (among others), are significantly associated with sPLA2-IIA levels 
I asked Dr Folkersen for data relating to the relative differential expression of PLA2G2A 
mRNA associated with either of these SNPs for me to analyse in order to prove these 
associations and discount confounding or lack of assay specificity as a cause for these 
outcomes (Figure 5.12a and 5.12b).  
 
 
Figure 5.12 a and b show the relative expression of PLA2G2A mRNA and PLA2G5 mRNA with the 
PLA2G5 SNPs; rs11573185 (a) and rs525380 (b) across the 5 tissues of the ASAP study; mammary 
artery, liver, aorta media, aorta adventitia and heart. Both SNPs appear to be associated with 
PLA2G2A mRNA suggesting some cross regulation between PLA2G2A and PLA2G5. 
(a) 
(b) 
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I then analysed further data provided Dr Folkersen (Figures 5.13a and 5.13b) to 
confirm that both rs11573185 and rs525380 had significant per-allele associations with 
PLA2G2A mRNA in the liver, suggesting perhaps that PLA2G2A and PLA2G5 are co-
regulated. A per C allele increase in PLA2G2A mRNA is seen with r525380 A>C and a per C 
allele decrease in PLA2G2A mRNA is seen with rs11573185 A>C.  
            (a)                                                        (b) 
                                                                          
                                                      
Figure 5.13. Shows the per allele differential PLA2G2A mRNA expression patterns associated with (a) 
rs11573185 A>C and (b) rs525380 A>C in the liver. Both PLA2G5 SNPs appear to be significantly 
associated with PLA2G2A suggesting some shared regulation between these two genes.  
 
5.2.4. Combined Meta-Analysis Data for rs11573185 
Following the identification of four tSNPs of interest in the UDAC study (Wootton, 
Arora et al. 2007), further genotyping analysis was carried out for each SNP in several 
additional studies (Table 5.2). No significant associations remained between total cholesterol 
and any of the selected SNPs and although there was a borderline significant association 
seen between LDL-cholesterol and rs11573203, this measure was only across 3 studies and 
the association appears to be driven solely by the UDACS cohort, thus suggesting that this 
is an anomalous result. None of the selected SNPs showed significant associations with 
sPLA2 activity or with total CHD in these additional studies. Table 5.2 gives an overview of 
relevant SNP/biomarker associations across the studies indicated and previously described 
in Table 2.6. A further in depth analysis for rs11573185 is presented in more detail in Figures 
5.14-5.19. All analysis was adjusted for age and gender. Since the four tSNPs shown here 
were shown by Wootton et al. (Wootton, Arora et al. 2007) to have significant associations 
ASAP Liver 
Gene: PLA2G2A 
SNP: rs525380 
Distribution: 32AA//120AC//59CC 
AA-AC-CC P value = 0.00144 
ASAP Liver 
Gene: PLA2G2A 
SNP: rs11573185 
Distribution: 63AA//100AC//47CC 
AA-AC-CC P value = 7.68x10-7 
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with both sPLA2-IIA mass and cholesterol, which is a known CHD biomarker, the results in 
Table 5.2 are relative to sPLA2-IIA mass, sPLA2 activity and both LDL and HDL cholesterol 
where these measures were possible. The association of each SNP with CHD across all 
genotyped studies is also shown in order to assess the potential likelihood that sPLA2-V is 
causal for CHD. The data from these studies should be considered as a preliminary meta-
analysis. In order to confirm the data as accurate, further genotyping should be carried out to 
increase the power of the meta-analysis in both the general population and ACS study 
settings. 
*Numbers in brackets represent the % of genotype calls made where results are available 
**HWE = Hardy Weinberg Equilibrium. A tick represents that all studies genotyped for the SNP were 
within the HWE and not significantly different at 1 degree of freedom where data is available. 
Table 5.2. A small initial meta-analysis showing the associations of non-lead PLA2G5 tSNPs; 
rs11573248, rs11573203 and rs11573191 with relevant sPLA2 and CHD biomarkers. Yellow boxes 
indicates a significant association (P<0.05) (EPIC = EPIC-Norfolk, EPIC-NL= EPIC Netherlands). 
SNP: Biomarker/Trait: Studies Genotyped*: P Value: Notes: HWE** 
rs11573185 LDL-cholesterol NPHSII (95), EPIC (98), EAS (94), 
CYPRUS (97), BWHHS,WHII, EPIC-NL 
0.41   
 HDL Cholesterol NPHSII (95), EPIC (98), EAS (94), 
CYPRUS (97), BWHHS,WHII, EPIC-NL 
0.50   
 sPLA2-IIA Levels EPIC (98), UDACS (98) 3.35x10-38   
 sPLA2 Activity EPIC (98) 0.29   
 CHD NPHSII (95), EPIC (98), TPT (96), EAS 
(94), CYPRUS (97), BWHHS, WHII, 
EPIC-NL 
0.06   
 
rs11573248 LDL-cholesterol NPHSII (98), EPIC (95), EAS (98), 
CYPRUS (98), BWHHS 
0.82   
 HDL Cholesterol NPHSII (98), EPIC (95), EAS (98), 
CYPRUS (98), BWHHS 
0.18   
 sPLA2-IIA Levels EPIC (95), UDACS (98) 1.36x10-40   
 sPLA2 Activity EPIC (95) 0.15   
 CHD NPHSII (98), EPIC (95), TPT (95), 
IMPROVE, EAS (98), CYPRUS (98) 
0.11   
 
rs11573191 LDL-cholesterol NPHSII (98), EPIC (97), UDACS (99), 
GRACE 
0.42   
 HDL Cholesterol NPHSII (98), EPIC (97), GRACE 0.75   
 sPLA2-IIA Levels EPIC (97), UDACS (99), GRACE 4.66x10-7   
 sPLA2 Activity EPIC (97), GRACE 0.87   
 CHD NPHSII (98), EPIC (97), UDACS (99), 
GRACE 
0.51   
rs11573203 LDL-cholesterol NPHSII (97), UDACS (96), GRACE 0.03 UDACS Driven  
 HDL Cholesterol NPHSII (97), UDACS (96) 0.13   
 sPLA2-IIA Levels UDACS (96), GRACE 0.01   
 sPLA2 Activity GRACE 0.93   
 CHD NPHSII (97), UDACS (96), GRACE 0.79   
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 Figure 5.14. Adjusted Meta-analysis shows the association between LDL-cholesterol and 
rs11573185. ES = Effect Size. EPIC = EPIC-Norfolk, EPIC-NL = EPIC Netherlands studies. All 
studies defined previously in Table 2.6 
 
Figure 5.15. Adjusted Meta-analysis shows the association between HDL cholesterol and 
rs11573185. ES = Effect Size. EPIC = EPIC-Norfolk, EPIC-NL = EPIC Netherlands studies. All 
studies defined previously in Table 2.6 
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Figure 5.16. Adjusted Meta-analysis shows the association between (log) triglycerides and 
rs11573185. ES = Effect Size. EPIC = EPIC-Norfolk, EPIC-NL = EPIC Netherlands studies. All 
studies defined previously in Table 2.11 
Figure 5.17. Adjusted Meta-analysis shows the association between CHD and rs11573185. OR = 
Odds Ratio. EPIC = EPIC-Norfolk, EPIC-NL = EPIC Netherlands studies. All studies defined 
previously in Table 2.6 
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Figure 5.18. Adjusted Meta-analysis shows the association between sPLA2-IIA mass and 
rs11573185. ES = Effect Size. EPIC = EPIC-Norfolk. All studies defined previously in Table 2.11 
Figure 5.19. Adjusted analysis shows the association between sPLA2-activity and rs11573185. ES = 
Effect Size. EPIC = EPIC-Norfolk. This study was defined previously in Table 2.6 
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5.2.5. Combined Meta-Analysis Data for rs525380 
The SNP rs525380, selected for further analysis due to its high per-SNP differential 
association with PLA2G5 mRNA levels in the ASAP study was genotyped in EPIC-Norfolk. 
These data were added to the genotype data from the GWAS study, WTCCC. The results 
regarding the associations between rs525380, CHD, sPLA2-IIA mass and sPLA2 activity, 
are shown below (Figure 5.20-5.21).  
Figure 5.20. The per allele association of rs525380 with CHD. OR = Odds Ratio. EPIC = EPIC-
Norfolk. All studies defined previously in Table 2.6. 
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Figure 5.21. The association of rs525380 with sPLA2-IIA mass. ES = Effect Size. This study was 
previously defined in Table 2.6 
Figure 5.22. The association of rs525380 with sPLA2 activity. ES= Effect Size. This study was 
previously defined in Table 2.6 
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5.3. Discussion 
The original tSNP selection and analysis in UDACS showed the associations of 
several tSNPs covering approximately 92% of the variance of the gene PLA2G5 (Wootton, 
Arora et al. 2007). From this univariate analysis four SNPs; rs11573185 C>A, rs11573191 
A>G, rs11573203 G indel and rs11573248 TA indel, were identified as having a potentially 
significant association with the CHD related biomarker, cholesterol and being significantly 
associated with sPLA2-IIA levels. These SNPs were genotyped in additional studies by me 
and others in my lab to try and establish whether these effects could be replicated. 
Data from the meta-analysis indicated that none of the SNPs maintained a significant 
association with cholesterol and although rs11573203 showed a borderline significant 
association with LDL-cholesterol levels (P=0.03), these results were only inclusive of 3 and 2 
relatively small cohorts respectively and in both instances the association was driven by the 
small UDACS cohort alone, suggesting that these may be anomalous results. Additionally, 
when taking into account the Bonferroni Effect it is unlikely that these results will remain 
significant. 
 Analysis of these tSNPs with sPLA2-IIA levels and sPLA2 activity showed that all 
SNPs were significantly associated with sPLA2-IIA levels, with a per rare allele increase 
seen with rs11573248 (P=1.36x10-40) and a per rare allele decrease seen with rs11573185 
(P=2.35x10-38) being the most significant associations. However none of the SNPs were 
significantly associated with sPLA2 activity and none showed a significant association with 
CHD. 
Regarding rs525380 A>C, the SNP selected from the ASAP study results as having 
the most significant differential effect on PLA2G5 mRNA expression (in the aortic adventitia), 
genotyping analysis in the EPIC-Norfolk and WTCCC studies showed no significant 
associations with either sPLA2 activity or CHD, though there was a significant association 
between rs525380 and sPLA2-IIA levels (P=7.74x10-7). There is no reported significant LD 
between any of these genotyped SNPs.  
The results from the meta-analysis suggest that there is no causal association 
between sPLA2-V and CHD or CHD related traits with any PLA2G5 SNP analysed in this 
chapter. These results suggest sPLA2-V is likely to be an inflammatory marker of 
atherosclerosis, but not causally associated. The presence of sPLA2-V in plaque tissues 
(Jonsson-Rylander, Lundin et al. 2008) is therefore most likely to be due to reverse 
causation. However, the power of these results is relatively low due to limited studies and is 
being increased in order to confirm these findings. 
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Regarding the potential contribution of sPLA2-V to total sPLA2 activity, analysis of 
the results from the meta-analysis show no significant association between any of the 
genotyped PLA2G5 SNPs and sPLA2-activity. Even in these relatively small cohorts, an 
effect on sPLA2 activity was seen with PLA2G2A SNPs (Chapter 4), therefore it seems 
unlikely that a stronger effect will be seen with any of the PLA2G5 SNPs, even in a larger 
cohort. This suggests that the contribution of sPLA2-V to sPLA2 activity could be less than 
the contribution made by sPLA2-IIA in CHD relevant tissues, including the liver (where some 
sPLA2 isoenzymes are expressed to move into the circulation).  
The ASAP study represents a significant portion of the gene PLA2G5. Both available 
SNPs of interest (rs11573185 and rs525380) were shown to be associated with differential 
PLA2G5 mRNA expression in the aortic adventitia. However, rs11573185 was not 
significantly associated (P=0.08) whereas rs525380 was the single strongest association of 
a SNP with differential PLA2G5 mRNA expression in this tissue (P=5.50x10-6), suggesting 
that rs525380 is strongly associated with differential sPLA2-V activity, but that rs11573185 
may be less so. This supports the idea that rs525380 is strongly associated with differential 
sPLA2-V activity. However, since rs525380 was not shown to be significantly associated 
with total sPLA2 activity in the meta-analysis perhaps sPLA2-V does not contribute as 
strongly to overall sPLA2 activity measures compared to sPLA2-IIA in these CHD-related 
tissues in the circulation. Analysing selected SNPs of PLA2G5 showed that the strongest 
overall differential expression was consistently in the aortic adventitia and liver, indicating 
that sPLA2-V is most highly expressed in these tissues, however when compared to the 
PLA2G2A SNPs, reported in Chapter 3, the highest expression levels of PLA2G5 are 
approximately third as high as those of PLA2G2A (-log10 (P) values of 17.5 for PLA2G2A 
and 5.5 for PLA2G5). This suggests that the relative levels of sPLA2-IIA are considerably 
higher than sPLA2-V in CHD related tissues, as has been previously shown (Lambeau and 
Gelb 2008). Since data in this chapter shows sPLA2-V levels are comparatively lower and 
no association is seen with sPLA2 activity in these tissues and in the circulation, the 20 
times higher potency associated with sPLA2-V compared to sPLA2-IIA in vitro and in animal 
models may not be significant in normal human physiological conditions for these tissues 
and in the circulation. These results also show that the associations of PLA2G2A and 
PLA2G5 SNPs with mRNA expression are different depending on the tissue. PLA2G2A 
differential mRNA expression is seen most frequently and strongly in the liver, but for 
PLA2G5 it is mostly in the aortic adventitia, suggesting that individual isoenzyme 
contributions to sPLA2 activity are potentially tissue dependent and based on expression 
patterns (Lambeau and Gelb 2008). Therefore, perhaps it is more likely that sPLA2 
isoenzyme contributions to sPLA2 activity are flexible rather than fixed, depending on the 
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environment and type of tissue being studied. However, it should be noted that the power of 
the meta-analysis results is low due to the small number of studies included and is being 
increased in order to confirm the findings regarding sPLA2 activity. Also, as there are 
currently no specific ELISAs available to measure the levels of sPLA2-V or the specific 
contributions of each isoenzyme to total sPLA2 activity it is uncertain that this interpretation 
of the sPLA2-IIA and sPLA2-V contributions to activity is true. Results from the ASAP study 
analysing each SNP individually suggests there is an overlap between some of the PLA2G5 
associated SNPs and PLA2G2A mRNA expression in the liver, and significant meta-analysis 
associations have been shown with both rs11573185 and rs525380 (as well as the 
additional tSNPs rs11573191, rs11573203 and rs11573248) and sPLA2-IIA levels. These 
findings appear to add weight to the argument that sPLA2-IIA and sPLA2-V may be able to 
partially compensate for and independently regulate each other to a certain degree, despite 
their mechanistic differences (Sawada, Murakami et al. 1999). This may be unique to these 
enzymes, but could possibly be a feature of the whole PLA2 gene-cluster on chromosome 1 
and a potentially important continuation of this work would be to analyse the relationships of 
all the genes in this cluster and identify both the co-operative and independent activities 
between them. This overlap in regulation amongst these genes may also go some way to 
explaining why it is has been, thus far, so difficult to create an assay to measure the 
individual activity of each enzyme in the serum, since, in the case of sPLA2-IIA and sPLA2-
V, the regulation and expression of these enzymes may be more tightly linked than first 
thought. It may be that the effects seen here are due to the functional effects of another SNP 
in high LD with rs11573185 or rs525380 within the 90kb, shared promoter region between 
PLA2G2A and PLA2G5 (potentially the true functional SNP may not yet be genotyped, since 
I have been unable to identify any SNPs in high LD with rs11573185 in either the HapMap or 
1000 Genomes databases). Other SNPs in this region that are not genotyped may not yet 
have been identified as specific for either gene. This shared promoter region and potential 
co-regulation between PLA2G2A and PLA2G5 suggests that the tissue dependent 
expression patterns of each sPLA2 isoform may reflect the best suited enzyme for each 
individual tissue and yet the structural similarities between sPLA2-IIA and sPLA2-V mean 
that in each instance, should the isoform of choice be absent or degraded for some reason 
in a particular tissue, the second sPLA2 isoform could at least partially compensate for it. A 
definitive conclusion regarding these associations cannot be confirmed until the power of the 
meta-analysis is increased and, therefore, the association is tested more robustly. It is 
however also possible that the associations of these two PLA2G5 SNPs with PLA2G2A 
mRNA expression could have a potentially confounding effect on the results in this chapter. 
For example, because sPLA2-V also alters sPLA2-IIA mRNA and data in Chapter 4 
suggests that sPLA2-IIA is not causal for CHD, the null association between sPLA2-IIA with 
236 
CHD may dilute the effect of sPLA2-V on CHD towards null and result in negative 
confounding. 
Although rs525380 appears to be a reasonable candidate gene to use in MR 
analysis, this must be confirmed by functional work, similar to what has been presented in 
Chapter 3 to test whether it is functional or tags a truly functional SNP. We must also 
consider the problem of potential confounding by sPLA2-IIA levels and how this can be 
assessed and overcome.  
A limitation of this study is that the tSNPs selected were chosen in 2007 and this 
selection method has now been updated by more advanced algorithms that are much more 
accurate at identifying tSNPs. Additionally, advances such as the completion of the 1000 
genomes database have also improved our ability to identify SNPs of interest. Therefore it 
may be that there are other useful potential candidate SNPs for MR analysis besides those 
presented in this chapter. 
5.4. Conclusion 
Based on the results shown in this chapter, I cannot conclusively identify whether 
sPLA2-V contributes significantly to sPLA2-activity compared to sPLA2-IIA in CHD related 
tissues using this genetic approach. Regarding the small meta-analysis I would suggest that 
rs11573185 (associated with sPLA2-IIA levels) and rs525380 (associated with PLA2G5 
mRNA expression) as well as rs11573203 (borderline association with LDL and triglycerides) 
and rs11573248 (associated with sPLA2-IIA levels) should be genotyped in additional 
studies, as increasing the power of the meta analysis will allow us to be confident in making 
a true conclusion. It may also be prudent to further explore the relationships between all of 
the genes identified as part of the PLA2 cluster on chromosome 1 to best interpret how they 
may partially share regulatory mechanisms.  
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CHAPTER 6 
The Potential Contribution of sPLA2-X to sPLA2 
Activity 
6.1. Introduction 
6.1.1. sPLA2-X Background 
Previous investigation of all the mammalian sPLA2s has shown that sPLA2-X 
exhibits the strongest PC-hydrolysing activity (Karabina, Brocheriou et al. 2006). This is 
potentially important when evaluating the contribution of this enzyme to both overall sPLA2 
activity and CHD risk. Chapter 1.5 gives an overview of sPLA2-X and explores how sPLA2-X 
differs from sPLA2-IIA and sPLA2-V. The gene for sPLA2-X is PLA2G10 which exists at 
chromosome 16p13.1-p12, not as part of the PLA2 gene cluster on chromosome 1.  
In this Chapter I used genotyping data from a small meta-analysis and eQTL data 
from the ASAP study to explore the potential contribution of sPLA2-X to total sPLA2 activity 
and to test the possibility that sPLA2-X acts as a causal biomarker for CHD. Identification of 
potential functional SNPs allowed me to assess whether any of these variations have 
significant associations to sPLA2-IIA mass, sPLA2 activity or CHD, by genotyping across 
several studies previously identified (2.5). The eQTL data from the ASAP study then allowed 
me to analyse how PLA2G10 mRNA levels compare to both PLA2G2A and PLA2G5 mRNA 
expression in CHD related tissues such as liver, aorta adventitia, aorta media and heart. 
This suggests what the potential contribution of sPLA2-X might be to total sPLA2 activity.  
6.1.2. Identifying Tagging-SNPs of Interest 
As described in 1.7.2, 10 tSNPs were identified by the STRAM algorithm and three of 
these SNPs with an MAF >5% were selected for further analysis by genotyping in both 
EPIC-Norfolk and GRACE-France: rs72546340, rs72546339 and rs4003232. A further tSNP, 
the C-SNP rs4003228 (R38C) was identified in the published literature (Gora, Perret et al. 
2009), and was also included in my analysis despite a low reported MAF of ~3%. There is 
ambiguous mapping of rs4003228 in the bioinformatics databases I used to analyse these 
SNPs, due to a lack of genotyping information in relevant CEU populations. The SNP has, 
however, been mapped in published literature (Gora, Perret et al. 2009). The PLA2G10 gene 
was screened by this group using the genomic sequences retrieved from public depositories 
and performed using genomic DNA from 62 unrelated MI patients selected from the ECTIM 
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study (http://www.genecanvas.org). Researchers used polymerase chain reaction (PCR) and 
direct sequencing, to examine 1 kb of the promoter, all of the exonic sequences and their 
corresponding flanking intronic sequences, as well as 1 kb of the 3′UTR downstream of the 
codon stop. The sequences were aligned and analysed with the SeqScape software 
(Applied Biosystems) to determine the potential polymorphisms. The genotyping of the 
polymorphisms were carried out using a modified RFLP method or TaqMan 5′ nuclease 
assays. Details of the polymorphisms and genotyping conditions is described in detail on the 
group’s website web site (http://www.genecanvas.org, genes: PLA2G10). 
6.2. Results 
6.2.1. Bioinformatics Analysis of PLA2G10 
Data from the Ensembl Genome Browser confirms that PLA2G10 is located at 
16:14,766,405-14,788,523. The gene is reverse transcribed and encodes the enzyme 
sPLA2-X. According to the Ensembl Genome Browser and NCBI databases there are 2 
known transcripts of the gene and one of these codes for the normal protein. The second is 
subject to nonsense mediated decay, where a premature stop codon is recognized and 
undergoes a decay process preventing the sequence from translating a normal protein. 
Evidence for this is presented by the Ensembl Genebuild and Havana Projects including 
protein, EST, and cDNA sequence data in support of both the full length and nonsense 
medicated decay transcripts for PLA2G210. 
The protein coding transcript is made up of 4 exons (Figure 6.1a). This transcript 
codes for a 165 amino acid protein. The nonsense-mediated decay truncated transcript 
(Figure 6.1b) is 587bp, producing a 130 amino acid protein.  
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Figure 6.1a. PLA2G10 coding transcript (Ensembl Transcript ID: ENST00000438167) for normal protein. This schematic is taken from the 
Ensembl Genome Browser. The boxes indicate exons and the solid line represents introns. 
Figure 6.1b. PLA2G10 transcript subject to nonsense-mediated decay (Ensembl Transcript ID: ENST00000567462) for truncated protein. This 
schematic is taken from the Ensembl Genome Browser. The boxes indicate exons and the solid line represents introns. 
PLA2G10 
3’ 
5’ 
3’ 
5’ 
PLA2G10 
Chr16: 14,766,405 Chr16: 14,788,526 
Chr16: 14,766,538 Chr16: 14,788,133 
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6.2.2. Results from EPIC-Norfolk and GRACE-France 
Tables 6.1, 6.2 and 6.3 show the associations between the four selected SNPs and 
sPLA2-IIA mass in EPIC-Norfolk and GRACE-France, sPLA2 activity in EPIC-Norfolk and 
GRACE-France and CHD in EPIC-Norfolk respectively. Only rs4003228 shows a significant 
association with any trait, exhibiting a significant association with sPLA2 activity in the 
GRACE-France cohort. All genotyping completed in EPIC-Norfolk and GRACE-France 
complied with the Hardy Weinberg Equilibrium (not significantly different at 1 degree of 
freedom). 
All results are represented as geometric mean (approximate SD) 11: homozygotes for the common 
allele; 12: heterozygotes; 22: homozygotes for the rare allele. 1 unadjusted P values for trend. 2 age 
and gender adjusted P value for trend. 
Table 6.1. Associations between rs4003228, rs4003232, rs72546339 and rs72546340 variants and 
the trait, sPLA2 activity in the case:control nested cohort EPIC-Norfolk and the ACS cohort GRACE-
France.  
PLA2G10 
        SNP      Genotype 
EPIC GRACE 
N 
sPLA2 activity 
geometric mean 
(approximate SD) MAF N 
sPLA2 activity 
geometric mean 
(approximate 
SD) 
MAF 
rs72546340 (G>C) GG 
GC 
CC 
P value (trend)1 
P value2 
2955 
171 
9 
4.47 (1.12) 
4.56 (1.08) 
4.18 (0.69) 
0.53 
0.52 
0.03 297 
16 
3.10 (1.13) 
3.48 (1.20) 
0.23 
0.25 
0.05 
rs72546339 (C>A) CC 
CA 
AA 
P value (trend)1 
P value2 
2901 
279 
13 
4.47 (1.13) 
4.45 (1.04) 
4.37 (0.99) 
0.74 
0.79 
0.04 294 
23 
3.14 (1.16) 
2.97 (1.03) 
0.51 
0.90 
0.03 
rs4003228 (R38C) CC 
CT 
TT 
P value1 
P value2 
2151 
90 
1 
4.47 (1.12) 
CT+TT:4.42 (0.97) 
   0.66 
0.59 
0.02 301 
15 
0 
3.17 (1.12) 
2.47 (1.30) 
-- 
0.01 
0.005 
0.02 
rs4003232 
(C indel) 
TT 
TC 
CC 
P value (trend)1 
P value2 
1460 
760 
110 
4.47 (1.06) 
4.49 (1.19) 
4.54 (1.22) 
0.52 
0.52 
0.21 141 
100 
22 
3.17 (1.21) 
3.10 (1.05) 
3.02 (1.21) 
0.52 
0.60 
0.27 
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         PLA2G10 
SNP            Genotype 
EPIC GRACE 
    N 
sPLA2-IIA mass 
geometric mean 
(approximate SD)       N 
sPLA2-IIA mass 
geometric mean 
(approximate SD) 
rs72546340 11 
12 
22 
P value (trend)1
P value2 
2955 
171 
9 
8.60 [5.96-13.12] 
8.30 [6.30-14.6] 
7.00 [4.40-8.09] 
0.65 
0.65 
297 
16 
2.97 [1.62-6.52] 
2.50 [1.74-13.76] 
0.68 
0.61 
rs72546339 11 
12 
22 
P value (trend)1
P value2 
2901 
279 
13 
8.60 [6.00-13.390] 
8.50 [5.950-12.60] 
10.20 [7.80-12.70] 
0.91 
0.60 
294 
23 
2.79 [1.59-7.08] 
4.27 [1.94-5.76] 
0.36 
0.19 
rs4003228 11 
12 
22 
P value (trend)1
P value2 
2151 
90 
8.40 [5.90-12.80] 
8.00 [5.30-12.80] 
0.59 
0.46 
301 
15 
2.97 [1.65-6.78] 
2.95 [1.54-6.21] 
0.91 
0.97 
rs4003232 11 
12 
22 
P value (trend)1
P value2 
1460 
760 
110 
8.60 [6.00-13.10] 
8.20 [5.70-12.40] 
7.90 [5.40-11.60] 
0.11 
0.12 
141 
100 
 22 
3.48 [1.73-6.99] 
2.63 [1.60-7.69] 
2.40 [1.35-4.97] 
0.21 
0.45 
All results are represented as median (IQR). 11: homozygotes for the common allele; 12: 
heterozygotes; 22: homozygotes for the rare allele. 1 unadjusted P values. 2 age, gender and CHD 
adjusted P value. 
Table 6.2. Associations between rs4003228, rs4003232, rs72546339 and rs72546340 variations and 
the trait, sPLA2-IIA Mass in the nested case:control cohort EPIC-Norfolk and the ACS cohort GRACE-
France. 
PLA2G10 SNP Genotype Freq in controls Freq in cases OR (95% CI)* 
rs72546340 (303G>C) GG 
GC+CC 
P value 
1977 (94.4) 
117 (5.6) 
978 (94.0) 
63 (6.1) 
1.00 
1.09 (0.79-1.49) 
0.60 
rs72546339 (264C>A) CC 
CA 
AA 
P value 
1942 (91.4) 
175 (8.2) 
8 (0.4) 
959 (89.8) 
104 (9.7) 
5 (0.5) 
1.00 
1.20 (0.93-1.55) 
1.27 (0.41-3.88) 
0.15 
rs4003228 (R38C) CC 
CT+TT 
P value 
1201 (96.00) 
50 (4.00) 
950 (96.00) 
40  (4.00) 
1.00 
1.01 (0.66-1.54) 
0.98 
rs4003232 (T-123/in1C) TT 
TC 
CC 
P value  
813 (62.40) 
422 (32.40) 
67 (5.20) 
647 (62.90) 
338 (32.90) 
43 (4.20) 
1.00 
1.01 (0.85-1.20) 
0.79 (0.53-1.17) 
0.51 
*age and gender adjusted odds ratio
Table 6.3. Associations between rs4003228, rs4003232, rs72546339 and rs72546340 and CHD in 
the nested case:control cohort EPIC-Norfolk. 
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6.2.3. Bioinformatics Analysis of rs4003228 (R38C) 
The results above in 6.2.2 show only rs4003228 to have any associations with the 
traits of interest. Therefore rs4003228 was taken forward as the lead SNP to be examined in 
more depth. When analysing rs4003228 G>A (R38C), there is a certain amount of ambiguity 
since, like some other PLA2G10 SNPs, it has been mapped to four different positions 
according to the Ensembl Genome Browser, the UCSC Genome Browser, and the 1000 
Genomes database. These are; Chr16:14,771,169, chr16:15,452,850, chr16:16,492,437 and 
chr16:18,407,169. None of these databases definitively explain why there are 4 known SNP 
locations, but there is some suggestion that it could be due to multiple submissions of the 
SNP location from different sources that have analysed different transcripts of the gene or 
that there are additional transcripts of the genes besides those defined by supporting 
evidence that we already recognise (Figure 6.1a and 6.1b) which would cause the SNP to be 
mapped differently relative to the length of each transcript. The issue of multiple locations for 
this SNP is complicated due to a lack of genotyping in the populations of interest, CEU 
HapMap release #28 and 1000 Genomes pilot 1 or phase 1 data and the generally limited 
genotype data that is available (only 4 individuals across all databases). However, previous 
data have mapped rs4003228 R38C as described in 6.1.2. Results showed the SNP to be 
mapped to exon 2 of PLA2G10, at position Chr16: 14,691,989. The minor allele frequency 
was low at 3% and predicted by the analysis of the SIPLAC (n= 312) and AtheroGene 
(n=1,303) studies this is supported by data from my completed EPIC-Norfolk and GRACE-
France genotyping, which showed the frequency of the SNP to be ~4%. However, this is still 
a very small combined Caucasian population (Gora, Perret et al. 2009).  
6.2.4. Meta-Analysis for rs4003228 (R38C) 
In order to assess the value of rs4003228 as a functional SNP that is differentially 
associated with sPLA2 activity and as a useful tool to analyse the relationship of sPLA2-X 
with CHD risk, Dr Montse Guardiola and I genotyped the variant in two additional studies, 
making up a small meta-analysis of 4 studies, 3 general population and 1 ACS cohort. The 
AtheroGene and SIPLAC results were then also combined for analysis of any associations 
between rs4003228 and CHD. 
After adjustment for multiple variables including age, sex and smoking, the effect size 
(ES) for rs4003228 with (log) sPLA2-IIA mass was -0.019 (95% CI: -0.134, 0.095) (P=0.74), 
i.e. showing no significant association with mass (Figure 6.2). Likewise with (log) sPLA2 
activity the effect size was shown to be non-significant at -0.022 (95% CI: -0.074, 0.030) 
(P=0.42) (Figure 6.3). These data suggest that despite the functional analysis of previous 
studies (Gora, Perret et al. 2009) showing that sPLA2-X activity is affected by this SNP in 
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vitro, the SNP does not manifest itself at a significant level to be relevant in this small scale 
meta-analysis. This is potentially due to the low MAF of this SNP (3%) in the general 
population. 
Figure 6.2. The association of PLA2G10 SNP rs4003228 with sPLA2-IIA Mass. ES= Effect size. 
Studies have been previously defined (Table 2.6) 
(n=274) 
(n=3,039) 
(n=564) 
SNP 
rs4003228 
Log(n) sPLA2-IIA Mass 
N = 3,877 
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Figure 6.3. The association of PLA2G10 SNP rs4003228 with sPLA2 Activity. ES= Effect size. Studies 
have been previously defined (Table 2.6) 
Regarding disease (binary) associations, rs4003228 showed no association with 
CHD. After adjustment for age and gender, the odds ratio (OR) for the association of 
rs4003228 with CHD was 1.20 (95% CI: 0.89, 1.62) (P=0.24) (Figure 6.4). GRACE-France 
was not included in CHD measures since all events in this study are recurrent and may skew 
the data.  
(n=3,039) 
(n=274) 
SNP 
Study 
rs4003228 
Log(n) sPLA2 Activity 
N = 3,313 
245 
 Figure 6.4. The association between PLA2G10 SNP rs4003228 and CHD. OR = Odds ratio. 
Studies previously defined (Table 2.6). 
 
6.2.5. PLA2G10 mRNA Expression in the ASAP Study 
 The analysis I requested and analysed from Dr Folkersen regarding the expression 
of PLA2G10 mRNA in various tissues showed that values were low in comparison to 
PLA2G2A (Figure 6.5 compared to Figure 4.4A) in these tissues. None of our selected SNPs 
of interest were present on the ASAP arrays and a limitation of these results is that only a 
small number of PLA2G10 specific SNPs (13) were available on the array. However, this 
data does suggest that PLA2G10 mRNA does not appear to be differentially expressed by 
any other PLA2 related SNPs, suggesting that there is no potential for co-regulation between 
PLA2G10 and other PLA2 genes as we saw for PLA2G2A and PLA2G5 in Chapter 5. 
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Figure 6.5. Relative expression levels of PLA2G10 mRNA in various tissues of the ASAP study 
(Indicated by colour key). No SNPs appear to be significantly associated with differential PLA2G10 
mRNA. 
6.3. Discussion 
In order to begin to examine the contribution of sPLA2-X to the composite measure 
of sPLA2 activity and its potential contribution to CHD risk I took a two-pronged approach, 
first assessing a SNP previously identified as potentially affecting sPLA2-X in a small meta-
analysis for any associations between sPLA2 activity and, potentially, CHD and then using 
data I had requested from the ASAP study to examine the mRNA expression of PLA2G10 in 
several tissues. 
 The second transcript of PLA2G10 identified by the Ensembl Genome Browser, 
indicates that nonsense mediated decay prevents the sequence from fully translating. The 
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variation thought to cause this premature stop codon is rs76137801C>G. The prediction 
algorithm websites SIFT and Polyphen predict that the change causes a residue change 
from R>G and is ‘deleterious’ and ‘probably damaging’ respectively. This SNP was not in the 
list of polymorphisms identified as being of interest relative to sPLA2-X (Gora, Perret et al. 
2009) (STRAM) that I used to select my sPLA2-X analysis instrument and an interesting 
follow up to this chapter could be to genotype this SNP and observe its effect on the 
expression of sPLA2-X in different individuals and whether there is an association with this 
SNP that could perhaps explain low levels of PLA2G10 mRNA expression detected in the 
ASAP study. 
The results from the ASAP eQTL analysis show the expression of PLA2G10 across 
all the examined tissues is very low and no single PLA2G10 SNP on the array had a 
significant association with differential mRNA expression. This fits with data from previous 
studies showing sPLA2-X to be less frequently expressed than sPLA2-IIA and V in tissues 
such as the heart and liver (Kudo and Murakami 2002). The increased potency of sPLA2-X 
suggests that this enzyme should perhaps contribute strongly to total sPLA2 activity. 
However, the results from the ASAP study suggest that the protein levels expressed in these 
tissues would be so low that they are almost undetectable and despite the around 20 times 
higher potency of sPLA2-X compared to sPLA2-IIA, these low levels would very likely 
prevent any significant contribution to overall sPLA2 activity. This data cannot, however, give 
us any indication of the PLA2G10 mRNA expression levels in tissues not measured by the 
ASAP study. Previous studies suggest that sPLA2-X is most strongly expressed in tissues 
other than those measured in the ASAP study, for example in the airways (Hallstrand, Chi et 
al. 2007; Henderson, Chi et al. 2007) and testes (Escoffier, Jemel et al. 2010). I think that 
this data supports the theory that individual isoenzyme contributions to sPLA2 activity are 
likely to be tissue dependent depending on the specific tissue requirements and the 
immediate environment.  
 Regarding the meta-analysis results, none of the previously identified SNPs showed 
significant associations with sPLA2 activity measures, suggesting that either these SNPs are 
not significantly associated with sPLA2-X or that sPLA2-X is not contributing strongly to total 
sPLA2 activity. A limitation of our study is that the STRAM method used to select PLA2G10 
SNPs of interest may now be outdated by technology such as genome wide association 
studies and therefore there are potentially better candidate SNPs available. However, we 
also took into account data from other groups previous studies (Gora, Perret et al. 2009) and 
their SNP selection and were still unable to show a significant association between sPLA2 
activity and a sPLA2-X related SNP. 
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 It is possible that sPLA2-X is expressed due to induction as part of the inflammatory 
response. This would help to explain why there is no association seen between sPLA2-X 
related SNPs and CHD, since PLA2G10 appears not to be expressed at high levels in the 
normal artery, but is identified as being present in the atherosclerotic plaque (Hanasaki, 
Yamada et al. 2002; Murakami and Kudo 2003), suggesting that it is not causal for CHD but 
is initiated as part of the inflammatory response associated with atherosclerosis (Ross 
1999).  
This lead SNP, rs4003228 R38C was identified as potentially having an effect on 
sPLA2-X activity in vitro and therefore CHD in the study by Gora et al (Gora, Perret et al. 
2009). The functional analysis of this SNP suggests that the synonymous arginine to 
cysteine change at codon 38 has a very significant impact on sPLA2-X activity in vitro with 
the extra cysteine residue causing ~95% decrease in sPLA2-X protein in COS cell 
supernatant and ~85% decrease in COS cell lysate. However, this SNP did not show any 
association to CHD risk in either the AtheroGene or SIPLAC studies. In order to try and 
establish whether this SNP has an effect on sPLA2 activity in human serum or on CHD risk 
we genotyped it in a further 4 studies and, as discussed above, this small combined meta-
analysis resulted in no significant associations with either sPLA2-IIA mass or sPLA2 activity 
as well as showing no significant association with CHD. The meta-analysis is not highly 
powered and the low minor allele frequency of the SNP (3-4%) suggests that a larger cohort 
would need to be established before any firm conclusions can be drawn about this SNP 
regarding sPLA2-X activity and therefore whether it is a useful genetic instrument for further 
MR studies to investigate the role of sPLA2-X in CHD. However, from these results, we can 
see that although the SNP is shown to have a significant effect in vitro (Gora, Perret et al. 
2009), it does not appear to affect sPLA2 activity in vivo, suggesting that perhaps the SNP is 
not having an impact in the general population due to its low frequency, or that the SNP is 
significantly associated to sPLA2-X activity, but that sPLA2-X is generally not well expressed 
and does not contribute significantly to sPLA2 activity in organs such as the heart and liver, 
despite its potency. This would mean that regardless of a significant association with group 
X sPLA2 activity, the association between the SNP and total sPLA2 activity would be low. 
This would also fit with the evidence that sPLA2-X is expressed at low levels in these tissues 
compared to other sPLA2 isoforms (Kudo and Murakami 2002). The low power of the study 
is a limitation and a larger study would need to be conducted to increase the power of these 
findings. Unfortunately, due to time constraints, I was unable to follow up this initial meta-
analysis, but strongly suggest additional work to further validate these results. 
As to other potential variants that could affect sPLA2-X activity, these have proved 
difficult to identify due to ambiguous mapping to chromosomal positions and a subsequent 
249 
lack of known genotyping or functional data. Again future work should consider the potential 
of other PLA2G10 SNPs as better instruments (with higher MAFs) to study the effects of 
sPLA2-X on CHD risk and its contribution to overall sPLA2 activity, perhaps identified 
through platforms such as GWAS. 
PLA2G10 is not part of the PLA2 cluster on chromosome 1 and thus does not 
contribute to any potential co-regulation between the cluster genes, despite structural 
similarities with these enzymes (Murakami and Kudo 2003). Transgenic mice over-
expressing pla2g10 die neonatally due to severe lung pathology, suggesting a role for 
sPLA2-X over-expression in inflammatory airway diseases (Curfs, Ghesquiere et al. 2008). 
The previously identified expression pattern for sPLA2-X does not include cardiac or arterial 
tissues, suggesting that the enzyme does not play a role in atherosclerosis, however, 
sPLA2-X is present in blood leukocytes as part of the body’s natural defence system and 
has been shown by immunohistochemistry to exist in atherosclerotic plaques (Curfs, 
Ghesquiere et al. 2008). However, unlike sPLA2-IIA and V it only appears to be present in 
circulation rather than localised in normal arteries, suggesting it is more likely to be part of 
the on-going inflammatory process that perpetuates the progress of an atherosclerotic 
plaque, rather than contributing to atherosclerotic plaque initiation. 
In summary, the data we have collected in this chapter suggests that sPLA2-X, 
despite its potency, contributes minimally to overall sPLA2 activity in CHD related tissues 
and is not associated with CHD risk, but further analysis must be carried out in order to 
assess and verify how representative these data are in larger populations. 
250 
CHAPTER 7 
Discussion 
7.1. General Discussion 
The burden of coronary heart disease, as outlined in Chapter 1, has become a 
global problem to overcome as the number one cause of death. This is in spite of significant 
improvements in medical management (Liu, Maniadakis et al. 2002) and since the incidence 
of deaths by CVD is predicted to rise to between 6.2 million and 8.2 million by the year 2030 
(Mathers and Loncar 2006) the importance of identifying CVD contributing factors to identify 
potential novel therapies is vital and relevant. Chapter 1 describes a small portion of the 
large number of CVD risk factors that have been previously identified. Of these it seems that 
family history is still considered to be one of the strongest independent risk factors (Lusis, 
Mar et al. 2004) and this implies that there is a strong cause for continuing to investigate the 
genetic contribution to CVD. To date, research into the genetics of heart disease has yielded 
only a small number of variants to explain a minimal portion of disease heritability (Manolio 
2010). Additionally these variants add very little to the classical risk stratification techniques 
(Drenos, Whittaker et al. 2007; Humphries, Drenos et al. 2010). This leaves us with plenty of 
scope for identifying gene variations associated with genes encoding enzymes that have 
been previously identified as relevant to CVD.  This will help us to understand the true 
contribution of these enzymes to the disease and, potentially, the heritability of CVD, using 
the ever improving genomic technologies and novel insights into the 3.1 billion base pairs 
that make up the human genome. As an example, I present data throughout this thesis to 
analyse the role of the suspected CVD risk factor, secretory phospholipase A2. In this 
chapter I hope to summarize the roles of different experimental techniques (7.1.1- 7.1.4 and 
7.1.6) in medical research and show how Mendelian randomisation (MR) and expression 
quantitative trait loci (eQTL) analysis could generate relevant data that cannot be 
conclusively derived from other techniques (7.11-7.13), which may be important when 
developing an inhibitor drug (7.1.5). The remainder of the chapter (7.2) is an overview of the 
data presented in the results chapters and a discussion of its value in determining the 
contribution of 3 sPLA2 isoenzymes to total sPLA2 activity and the potential of each of these 
enzymes to contribute to CHD, including results from both MR and eQTL analysis.  
7.1.1. Observational Data 
Observational studies are useful research tools to predict how changes in a particular 
biomarker could affect a disease outcome. An observational study is an analysis of a group 
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of individuals that measures relevant biomarkers and observes numbers of disease events in 
a natural setting without any kind of experimental intervention (Mann 2003; Ligthelm, Borzi et 
al. 2007). The sample can then be separated into cases and controls dependent on whether 
an event was observed or not. These two groups can then be compared to see if there is 
any significant difference in supposed causal biomarkers between the groups, allowing one 
to conclude whether this biomarker will causally affect the event outcome. Observational 
studies are often used when it is considered to be unethical to carry out a randomised 
control trial (RCT) to analyse an association (Ligthelm, Borzi et al. 2007). If it is considered 
to be unethical to randomly allocate an intervention (or not) to a group of people then an 
observational study provides an opportunity to study the link in a natural setting. This type of 
study can also be used in a situation where it is not possible to carry out a blind RCT or if an 
RCT is impractical. The benefits of this kind of study are that they are inexpensive and there 
is a much better potential for recruiting high numbers, which can mean a better prediction of 
rare or adverse events. (Black 1996; Ligthelm, Borzi et al. 2007). The major downside is that 
observational studies are subject to confounding, for example by another risk factor for the 
disease (lifestyle or otherwise) and reverse causation, where the true causality of a 
supposed intervention is masked by its association with another risk factor, or the fact that 
changes in the supposed intervention are actually as a result of the outcome rather than the 
other way around. Additionally there is no formal randomisation so there is a higher potential 
for bias and if the data has not been collected for the purpose of analysing the biomarker of 
interest it is possible that not all of the relevant measurements have been taken (Ligthelm, 
Borzi et al. 2007). In this way observational studies may generate false positive results. This 
can be problematic since drug design and RCT initiation are often based on these results 
and this is expensive and time consuming. 
 The observational data described throughout this thesis strongly suggests that 
sPLA2 could play a causal role for CHD. However, further analysis has shown that this is 
unlikely and sPLA2s are more likely to be markers of disease, induced by the prolonged 
inflammatory response associated with CHD. This study highlights the importance of 
observational data to identify potential biomarkers, but also the need for closer inspection of 
these relationships before they are taken forward as novel disease intervention pathways.       
7.1.2. Animal (in vivo) Models  
 Animal models can be an excellent tool to study the relationship between a 
suspected risk factor and a disease outcome in a living model. In particular, regarding the 
sPLA2 effects in CHD, which has been reviewed in this thesis, mouse models of 
atherosclerosis are the most widely used to study the potential effects of sPLA2 proteins 
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(Ghesquiere, Gijbels et al. 2005; Getz and Reardon 2012). Mouse models are relatively 
cheap and easy to keep and feed and their rate of reproduction and litter sizes make it 
possible to interbreed them and examine differences in particular groups relatively quickly 
and in large numbers. It is also reasonably easy to genetically manipulate a mouse model to 
suit the specific purposes of a study (Getz and Reardon 2012) with the creation of knockout, 
knock-down and transgenic mice. The disadvantages lie in the incongruities between the 
mouse and human forms of atherosclerosis and sPLA2 distribution. For example; mice do 
not naturally present with coronary lesions and the lesions that do develop (mostly in the 
aortic root) are of limited complexity compared to human lesions and distributed differently. 
The mouse model only represents atherogenesis, not late stage unstable atherosclerosis. 
There is limited tissue to study, due to the small size of the model and wild-type mice are 
generally fairly atherosclerosis resistant, in part due to their innate monotypic HDL, 
increasing their cardio-protectiveness (Getz and Reardon 2012). Specifically considering 
sPLA2, there is a reasonably strong homology between human and mouse genes (USCS 
genome browser) (Tischfield, Xia et al. 1996). However, the most frequently used mouse 
model when researching sPLA2 is the C57/BL6J model, which is a natural knockout model 
for sPLA2-IIA and has been frequently crossed with known atherosclerosis inducing mouse 
models such as Apoe-/- and Ldlr-/- to assess the effects of the lack of sPLA2-IIA in C57/BL6 
compared to wild-type models (Ghesquiere, Gijbels et al. 2005; Boyanovsky, Zack et al. 
2009). This model has also been useful for breeding a transgenic mouse to express human 
sPLA2-IIA, which allowed researchers to analyse the impact of human sPLA2-IIA without the 
overlap of murine sPLA2-IIA confounding the results. It is important to remember that, while 
mouse models provide excellent background data, which is often comparable to humans, the 
disease pathway has significant differences and although sPLA2-IIA can  be redundant with 
no obvious side-effects in a natural knock-out mouse model, the same may not be true in 
humans (Rosengren, Peilot et al. 2006). Additionally the manipulation of genetics and diet 
within mouse models does not necessarily mimic the natural setting of humans. (Fraser, 
Hislop et al. 2009).       
7.1.3. In vitro Analysis 
Unlike animal modelling, in vitro analysis is not carried out in living organisms. 
Components of an organism are isolated and analysed using a variety of experimental 
techniques. The benefit of this is that human tissues and fluids can be used for analysis. 
Tissue samples taken from relevant organs as well as blood and saliva samples are 
regularly used to isolate DNA or mRNA for measurement and comparison. In Chapter 3 
DNA extracted from blood samples was used in an array of functional techniques including 
EMSA, Luciferase assays and gene expression. The ASAP study utilised tissue biopsies to 
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take measurements of mRNA expression and tissue biopsies are also used for 
immunohistochemistry. In vitro analysis is an excellent way to assess potential biological 
pathways and associations in a human model. However, in vitro work is not carried out in a 
living and active organism and results from isolated samples may not truly reflect the way 
things interact in a complex living organism. Additionally, in vitro experiments often require 
the use of vector, which may add to potential confounding. 
A strong, combined body of concurrent evidence from in vitro, in vivo and 
observational data will provide a solid background on which to make a reasonable 
conclusion about the likely contribution of a biomarker to disease.     
7.1.4. Mendelian Randomisation 
Mendelian randomisation (MR) analysis has the ability to be a key bridging step 
between observational results and an RCT. The concept of MR is simply that a genetic 
variant that is known to be independently associated with a biomarker of interest can be 
used to prove the causality of this biomarker in disease (Katan 1986; Davey Smith 2007; 
Sheehan, Didelez et al. 2008). Alleles are randomly consigned during meiosis and are 
therefore not subject to reverse causation (Sheehan, Didelez et al. 2008). If a variant is 
independently associated with naturally different biomarker levels compared to the wild-type 
it can be considered a candidate for use in MR analysis. Additionally, all other biomarker 
measurements should be evenly and randomly distributed between carriers of the variant 
and non-carriers, which will prevent confounding by other risk factors. If large enough 
numbers can be recruited, we can compare measurements of a disease outcome of interest 
between carriers and non-carriers. If a significant difference in incidence of disease is 
detected between these groups we can be sure that it is due to the difference in biomarker 
levels attributed to the variant and it is therefore likely that the biomarker is causal for 
disease. If the rate of incidence is not significantly different between the two groups, then the 
biomarker affected by the variant is not causally associated with disease (Sheehan, Didelez 
et al. 2008). MR has been previously considered as a natural RCT, where the two randomly 
assigned groups are carriers of the variant and non-carriers instead of placebo and drug and 
are compared for differences in outcome in the same way (Hingorani and Humphries 2005). 
Biomarkers of interest are generally selected based on observational data showing a 
significant association between the biomarker and a disease outcome (Sheehan, Didelez et 
al. 2008). 
For a genetic variant to be acceptable as an instrument of MR it must fulfil several 
requirements. First it must be shown to have an independent effect on the biomarker of 
interest, preferably covering as much of the genetic variance for the biomarker as possible. It 
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must also be shown not to be associated to any known confounders. Finally, the genetic 
variant must be independent of disease outcome for known confounders after adjustment 
(Katan 1986; Sheehan, Didelez et al. 2008). 
In brief, MR uses a genetic variant to validate the causal relationship between a 
biomarker and outcome by examining the relationship of the SNP with both biomarker and 
outcome and testing the concordance of effects, comparing the observed and expected 
values (Katan 1986; Sheehan, Didelez et al. 2008).  
The limitations of MR can be listed broadly in two categories. Firstly, an inability of a 
genetic variant to fully meet the criteria set out above for the ideal genetic instrument, which 
may bias a demonstrated causal effect. For example if the variant only explains a small 
percentage of the variance of the biomarker. In the case of PLA2G2A and rs11573156, the 
SNP explained ~32% of the variance of PLA2G2A mRNA expression and therefore was a 
very strong instrument. Secondly, extra distributional assumptions are often made when 
undertaking statistical analysis in MR and these may skew results regarding the magnitude 
of an effect (though not the presence of the effect itself), for example; considering binary 
variable outcomes, under typically applied mathematical models, such as logistic regression, 
conventional linearity is not satisfied. Consequentially, estimations made in the all-linear 
case should not really be applied to binary outcome data, despite it sometimes being 
advocated (Sheehan, Didelez et al. 2008).   
Despite these limitations, MR is considered to be a reliable and informative analytical 
technique to add to the profile of data from observational, animal and in vitro studies. It is 
less expensive and less time consuming than drug design and RCT and gives a more 
accurate indication of the causality of a biomarker than observational data alone. 
Additionally, with the advent of chip technology where large studies are genotyped for many 
different SNPs we have large numbers of samples to pool quickly and efficiently. Therefore, 
it should perhaps be considered a useful practice to carry out an MR analysis before moving 
on to drug design and RCT, saving valuable time and resources (Hingorani and Humphries 
2005). Examples of successful applications of MR analysis are numerous. For instance, 
regarding heart disease as an outcome, fibrinogen genetic instruments G-455A and C-148T 
were used to show that fibrinogen association with CHD is probably due to reverse 
causation or confounding (Smith, Harbord et al. 2005; Keavney, Danesh et al. 2006), but 
homocysteine variant MTHFR C677T showed MR evidence consistent with a causal role for 
homocysteine in stroke (Casas, Bautista et al. 2005). 
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7.1.5. Inhibitor Drug Design 
 Designing molecules to inhibit pathways related to biomarkers known to be causal for 
a disease is an important step to potentially preventing a disease outcome. Once designed, 
drugs undergo extensive efficacy and safety testing, which start (as we have seen above) 
with in vitro data and animal model testing. The supposed gold standard test of a drug is a 
large randomised control trial (RCT) in humans. Many inhibitor molecules are designed 
based on data from observational studies alone and tested in vitro and in animal models, 
which may yield positive results regarding the inhibition of the causal biomarker and 
decreased incidence of disease. However, these molecules sometimes generate 
disappointing results when used in large scale RCTs and, at times, the premature cessation 
of an RCT has happened due to increased undesirable side effects or even mortality seen 
with the drug. When a drug trial is terminated early for these reasons it is important to 
understand whether it is due to an off target effect of the molecule itself, suggesting that a 
different class of drugs working on the same biomarker may not have the same side-effects 
and remain a useful novel therapeutic molecule, or if the inhibition of the pathway is the 
cause of the side-effect, in which case the inhibition of this biomarker can no longer be 
considered as a novel intervention since any drug designed to inhibit this pathway would 
cause the same side-effect. A lot of time and resources could be saved if we attempted to 
answer these questions before they arise and MR is an excellent tool to predict whether a 
change in biomarker levels is naturally associated with any undesirable side-effects. There 
are several examples where MR has been useful in this way. As described in Chapter 1.7.3.  
7.1.6. ASAP Study: The Value of Expression Quantitative Trait Loci (eQTLs) 
 Expression quantitative trait loci (eQTLs) are defined as genomic loci that are 
associated with the regulation of gene transcription or gene expression. Static eQTLs are 
considered to remain constant across all tissues and dynamic eQTLs are tissue dependent. 
An eQTL can also be cis (occurring and acting on the gene of interest) or trans (acting on a 
proximal gene, often on the same chromosome, (Damerval, Maurice et al. 1994; Petretto, 
Mangion et al. 2006). 
 Results from the ASAP study (Folkersen, van't Hooft et al. 2010) were presented in 
this thesis. The gene and SNP specific eQTL data measured mRNA and gave us excellent 
evidence to substantiate our findings about the interactions and contributions of each sPLA2 
isoform to sPLA2 activity. We could also use these eQTLs as additional proof that the 
sPLA2-IIA functional SNP that we selected as a genetic instrument for MR in Chapter 3 and 
Chapter 4 was truly regulatory for mRNA expression.   
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 7.2. Overall Summary of Results 
Phospholipases including secretory phospholipase had been observed to be 
significantly associated with CHD, specifically atherosclerosis. Common genetic variants for 
the genes that code for these enzymes can be used for techniques such as Mendelian 
randomisation in order to determine whether an increase in secretory phospholipases 
contributes causally to the onset of atherosclerosis, or is a result of reverse causation or 
confounding and thus a marker of disease. In this thesis one of the aims was to identify 
common genetic variants to genotype in numerous prospective and case control studies. 
These studies were in both general populations and acute coronary syndrome settings. The 
results from these studies were used in order to improve the current understanding of the 
role of secretory phospholipases in the development of CHD and clarify the suitability of 
sPLA2s as potential therapeutic targets. It was also an aim to investigate the genetics of 
sPLA2-IIA, V and X in order to improve the understanding of how these enzymes interact 
with and compensate for each other as well as the individual contributions of each enzyme 
to overall sPLA2 activity. 
Refining these aims further, the main focus of this thesis has been to try and identify 
the true role of sPLA2-IIA in the risk of CHD through the analysis of common variants within 
the sPLA2-IIA coding gene, PLA2G2A. However, a small follow-up section has been 
dedicated to the potential contributions of sPLA2-V and sPLA2-X to sPLA2 activity and CHD 
risk.  
I believe that I successfully identified two truly functional variants within PLA2G2A, 
rs11573156 C>G and rs3767221 T>G and used rs11573156 as a genetic instrument to 
show conclusively in a Mendelian randomisation of over 30 studies that sPLA2-IIA is not 
causal for CHD, but merely a marker of the disease. Assessing the contributions of each 
enzyme to sPLA2 activity was carried out by studying the expression analysis of each gene 
in different tissues in the ASAP study and the results of several meta-analyses along with 
previously published data regarding the potential differential contributions of each SNP. I 
think several conclusions can be drawn from this combination of data. The contribution of 
sPLA2 isoenzymes to total sPLA2 activity appears to be tissue and environment dependent 
(i.e. where the tissue is situated). Previous data has shown that sPLA2-X is most highly 
expressed in thymus, spleen and peripheral blood leukocytes (Curfs, Ghesquiere et al. 
2008). Data from the ASAP study that shows that SNPs were associated with consistently 
low levels of PLA2G10 mRNA across all the tissues measured in the study, which did not 
include thymus, spleen or blood leukocytes. Figure 7.1 shows the overall mRNA expression 
for each gene probeset, which consists of a set of probes designed to measure the mRNA 
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expression of each exon of each gene (PLA2G2A, PLA2G5 and PLA2G10) across all the 
tissues of the study. The results show that the probeset with the highest mRNA expression 
across these tissues was PLA2G2A and then PLA2G5. The probeset covering PLA2G10 
mRNA expression was so low across these tissues that it was barely measurable. It should 
be noted that a slight flaw of this study was the low SNP coverage for PLA2G10 compared 
to PLA2G2A and PLA2G5, which could potentially confound the mRNA expression results.  
Figure 7.1 Shows the PLA2 mRNA relative expression values across all PLA2 isoform probesets used 
in the ASAP study. PLA2G2A covers 101 SNPs, PLA2G5 covers 123 SNPs and PLA2G10 covers 13 
SNPs. 
Despite the low SNP coverage for PLA2G10, these results are further validated by 
previous data that has shown PLA2G2A and PLA2G5 to be most highly expressed in several 
of the tissues covered by ASAP (Crowl, Stoller et al. 1991; Murakami and Kudo 1999; 
All probesets below this line are 
considered to be low expression 
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Masuda, Murakami et al. 2005), suggesting that PLA2G10 mRNA is truly the least 
expressed in the tissues across this study. Considering the results from the meta-analysis 
studies the SNPs associated with sPLA2 activity levels were localized to the PLA2G2A 
gene. This suggests that sPLA2-IIA has the strongest contributions to sPLA2 activity, with 
the PLA2G2A SNP rs11573156 showing the strongest overall association. The PLA2G5 
SNP rs525380 showed the strongest association with PLA2G5 mRNA suggesting that it 
should have a strong association with sPLA2-V activity. The lack of a significant association 
between this SNP and overall sPLA2 activity therefore suggests that sPLA2-V does not 
contribute as significantly to overall sPLA2 activity compared to sPLA2-IIA. None of the 
PLA2G10 SNPs were significantly associated with sPLA2 activity. (Curfs, Ghesquiere et al. 
2008; Lambeau and Gelb 2008). The IC50 values for each enzyme considering the drug 
varespladib in humans were  quoted as 9nM for sPLA2-IIA, 15nM for sPLA2-X and 77nM for 
sPLA2-V, which explains the ability of the drug to significantly lower sPLA2-IIA levels and to 
lower sPLA2 activity to immeasurably low levels (Fraser, Hislop et al. 2009). These values fit 
nicely with the rank order potency amongst human sPLA2 to kill Gram-positive bacteria in 
vitro; sPLA2-IIA > sPLA2-X> sPLA2-V (Lambeau and Gelb 2008). It seems, therefore, that in 
circulation the contribution of each enzyme to activity is likely to be in the same order; 
sPLA2-IIA>sPLA2-X>sPLA2-V, but in tissues local to the heart and in the liver it seems more 
likely to be sPLA2-IIA>sPLA2-V>sPLA2-X, with sPLA2-IIA and sPLA2-V potentially having a 
confounding effect on the magnitude of each enzymes individual effect. The increased levels 
of sPLA2-IIA and its strong proteoglycan binding ability (Mallat, Lambeau et al. 2010) appear 
to give this enzyme an increased contribution to sPLA2 activity compared to the high 
potency of sPLA2-X (Lambeau and Gelb 2008). Considering sPLA2-V, this enzyme appears 
to contribute less to circulating sPLA2 activity levels, but is likely to be expressed more 
highly in specific tissues. Again, it is important to recognise the possibility that sPLA2-IIA and 
sPLA2-V expression are co-regulated and inherited, and this may be confounding. The 
specific expression and localization of these two enzymes is different, perhaps because only 
one of these enzymes is truly required in any given tissue based on the slight differences 
between them that have been described previously. Therefore, should there be a deficiency 
in the regular enzyme in that tissue it may be that a certain level of compensation by the 
other enzyme could occur. The fact that these two genes are closely linked (Tischfield, Xia et 
al. 1996) may therefore make sPLA2-V less important in contributing to circulating sPLA2-
activity, but more highly expressed and therefore potentially important in, for example, the 
tissues and cells of human airways (Masuda, Murakami et al. 2005). Data from ASAP and 
previous tissue expression data suggest that, regarding the onset of atherosclerosis, the two 
enzymes most likely to contribute to sPLA2-activity in CHD related tissues are sPLA2-IIA 
and sPLA2-V as these enzymes are found in normal arteries and cardiac tissue as well as in 
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circulation (Crowl, Stoller et al. 1991; Murakami and Kudo 1999; Masuda, Murakami et al. 
2005). Since the gene PLA2G2A appears to have the greatest contribution to sPLA2 activity, 
sPLA2-IIA would be the most essential enzyme to inhibit if sPLA2 was causally linked to 
CHD. However, as concluded in Chapter 4, this enzyme is highly unlikely to contribute the 
onset of CHD, suggesting that none of these PLA2 isoenzymes is likely to be causal 
regarding primary CHD. When considering secondary CHD, past evidence has suggested 
that all 3 enzymes have been detected in atherosclerotic lesions when over-expressed in 
transgenic models (Hurt-Camejo, Andersen et al. 1997; Karabina, Brocheriou et al. 2006; 
Bostrom, Boyanovsky et al. 2007) and in human atherosclerotic lesions (Elinder, Dumitrescu 
et al. 1997; Sartipy, Johansen et al. 2000; Karabina, Brocheriou et al. 2006; Rosengren, 
Peilot et al. 2006; Kimura-Matsumoto, Ishikawa et al. 2008) and this suggests that sPLA2 
enzymes could be part of the perpetual inflammatory reaction associated with 
atherosclerosis, contributing to driving the upregulation of further inflammatory enzymes and 
thus becoming a marker of atherosclerosis. However, I feel that further genetic investigation 
of SNPs related to PLA2G5 and PLA2G10 is necessary in the case of secondary events. 
Recently Anthera terminated the Phase III trial of varespladib, an sPLA2 inhibitor, early due 
to concerns about lack of efficacy 
(http://investor.anthera.com/releasedetail.cfm?ReleaseID=656340). The drug is reported to 
inhibit all three isoforms, sPLA2-IIA, V and X, and a lack of efficacy of this inhibitory drug 
adds to the suggestion that the presence of these enzymes in atherosclerotic lesions is 
merely as a marker and not associated causally to secondary cardiac events (Anthera, 
2012). The trial was due to recruit 6,500 high-risk ACS patients across 15 countries in the 
USA and Europe and was to test a combination therapy of varespladib methyl (500mg once 
daily) with atorvastatin. The primary end-point was the effect on major adverse coronary 
events such as cardiovascular death, unstable angina, myocardial infarction or stroke 
(Nicholls, Cavender et al. 2011). Our large scale MR analysis presented in Chapter 4 of this 
thesis was conducted at the same time and results suggest that sPLA2 falls into the same 
category as CRP, where the independent effect seen in observational studies and early 
positive in vitro and in vivo results (Snyder, Bach et al. 1999; Fraser, Hislop et al. 2009) for 
the drug are not reflected in the MR study, which shows no significant association between 
increased sPLA2-IIA and incidence of CHD. Based on the MR analysis it seems likely that 
sPLA2-IIA inhibition will not decrease CHD incidence, regardless of the class of molecule 
used. Had this data been available prior to sPLA2 inhibitor design, perhaps more robust 
initial testing of the sPLA2/CHD relationship would have been undertaken, saving time and 
resources for the pharmaceutical industry. I feel that the work in Chapter 4 shows how 
Mendelian randomisation could be used to predict causality and potentially be of significant 
practical use to drug companies in this way. 
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7.2.1. Limitations 
            Like all scientific research this thesis encountered limitations and several are of note. 
The assay used to measure sPLA2 activity in all of the observational studies dealt with in 
this thesis is inclusive of all three sPLA2 isoforms; sPLA2-IIA, sPLA2-V and sPLA2-X. At this 
time there are no reliable assays able to measure each individual isoform (Mallat, Steg et al. 
2005). Additionally there is an assay for sPLA2-IIA levels, but there is no ELISA available to 
measure either sPLA2-V or -X (Mallat, Steg et al. 2005). This makes it incredibly difficult to 
assess the contributions of each enzyme individually and ultimately determine whether any 
one enzyme is more likely to contribute to total sPLA2 activity or CHD. 
There was significant difficulty genotyping the PLA2G10 SNPs rs4003228 and 
rs4003232. Originally I attempted to genotype these SNPs using TaqMan genotyping 
specific assays (40x), but these assays failed to work. Standard RFLP techniques were then 
employed to genotype these SNPs in several studies, but unfortunately accurate genotyping 
was still unattainable. Eventually I carried out a nested PCR prior to RFLP, which was very 
time consuming and led to less studies being genotyped and thus a lower powered meta-
analysis including these SNPs.   
The majority of the SNPs assessed throughout this thesis were identified as SNPs of 
interest or tagging-SNPs in previously published studies. It is possible that the SNP 
identification techniques used in these studies have now become outdated or that new SNPs 
have been identified and genotyped since their publication and this suggests that we cannot 
be entirely sure that these are the best candidate SNPs for investigation. However, the 
addition of the eQTL data from the ASAP study has taken away some of this uncertainty and 
allowed us to validate several of the SNPs as being potentially functional.     
Regarding the EMSA analysis in Chapter 3 relating to rs3767221 A>C, I was unable 
to produce a supershift EMSA due to time constraints, which would have distinguished the 
protein binding differentially in the region of the rare C allele and proved specific, differential 
binding occurred here. This would also give a more significant insight into the potential 
biological mechanism at work here. 
7.3. Conclusions and Further Work  
 In conclusion, based on the results documented in this thesis, I think that it is likely 
that sPLA2-IIA has the biggest contribution to circulating sPLA2 activity, though the rank 
order of contributions from each enzyme is likely to change in a tissue dependent manner 
perhaps due to the differing mechanisms of each enzyme producing variable activity in 
different tissues. The genes encoding sPLA2-IIA and sPLA2-V may be partially co-regulated 
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and display high linkage. It is therefore possible that these enzymes have a certain amount 
of overlap and compensatory behaviour for each other. Regarding CHD, a comprehensive 
Mendelian randomisation analysis of sPLA2-IIA using the functional SNP rs11573156 
showed that this enzyme was unlikely to be causal for CHD. Since sPLA2-X is not 
expressed in normal arteries and both sPLA2-V and sPLA2-X appear to contribute less to 
circulatory sPLA2 activity it is also unlikely that these enzymes are individually associated 
with the onset of CHD. 
 In order to confirm these conclusions, further analysis should be carried out. 
Functionality of SNPs for sPLA2-V and sPLA2-X should be confirmed and then genotyped in 
significantly powered meta-analyses so that Mendelian randomisation analyses can be 
carried out and compared to that of sPLA2-IIA and examined regarding CHD/CHD related 
disorders. It may also be important to further assess the co-regulation between the genes of 
the PLA2 cluster on chromosome 1 to further explore the impact of this on each individual 
enzyme and the overall actions of the cluster. Additionally, several other sPLA2 genes occur 
outside the chromosome 1 cluster, like PLA2G10 and it would be useful to find out more 
about these. To this end, investigations into the genes PLA2G3 and PLA21B are already 
underway.  
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